_unit_id,_created_at,_canary,_id,_started_at,_channel,_trust,_worker_id,_country,_region,_city,_ip,b1,b2,confirmids1,confirmids2,e1,e2,factor1,factor2,firstfactor,saveselectionids1,saveselectionids2,secondfactor,sentence,wordid1,wordid2,orig_b1,orig_b2,orig_e1,orig_e2,expertdecision,relation,sent_id,orig_sentence,term1,term2
503545370,7/16/2014 20:33:34,,1324463618,7/16/2014 20:33:21,instagc,1,18531561,CAN,ON,Mississauga,99.229.185.45,44,18,,,62,39,HYPOPARATHYROIDISM,KEARNS-SAYRE SYNDROME,HYPOPARATHYROIDISM,44,18-25-31,KEARNS SAYRE SYNDROME,Two patients with Kearns-Sayre Syndrome and hypoparathyroidism were treated with alfacalcidol (1a-OH D3) and total serum calcium concentration remained within normal range for a long period.,44,18 25 31,44,18,62,39,-1,RO-has_manifestation,906308,Two patients with Kearns-Sayre Syndrome and hypoparathyroidism were treated with alfacalcidol (1a-OH D3) and total serum calcium concentration remained within normal range for a long period,hypoparathyroidism,Kearns-Sayre Syndrome
503545370,7/16/2014 20:41:01,,1324466689,7/16/2014 20:40:42,clixsense,1,24896327,GBR,V2,Glasgow,94.2.231.4,44,18,,,62,39,HYPOPARATHYROIDISM,KEARNS-SAYRE SYNDROME,HYPOPARATHYROIDISM,44,18-25-31,KEARNS SAYRE SYNDROME,Two patients with Kearns-Sayre Syndrome and hypoparathyroidism were treated with alfacalcidol (1a-OH D3) and total serum calcium concentration remained within normal range for a long period.,44,18 25 31,44,18,62,39,-1,RO-has_manifestation,906308,Two patients with Kearns-Sayre Syndrome and hypoparathyroidism were treated with alfacalcidol (1a-OH D3) and total serum calcium concentration remained within normal range for a long period,hypoparathyroidism,Kearns-Sayre Syndrome
503545370,7/16/2014 20:41:41,,1324466973,7/16/2014 20:41:40,coinworker,1,28394550,USA,PA,Marcus Hook,71.175.96.184,44,18,,,62,39,HYPOPARATHYROIDISM,KEARNS-SAYRE SYNDROME,Sayre Syndrome and HYPOPARATHYROIDISM were treated with,25-31-40-44-63-68-76,0-4-13-18-25-31-40-44-63,Two patients with KEARNS SAYRE SYNDROME and hypoparathyroidism were,Two patients with Kearns-Sayre Syndrome and hypoparathyroidism were treated with alfacalcidol (1a-OH D3) and total serum calcium concentration remained within normal range for a long period.,44,18 25 31,44,18,62,39,-1,RO-has_manifestation,906308,Two patients with Kearns-Sayre Syndrome and hypoparathyroidism were treated with alfacalcidol (1a-OH D3) and total serum calcium concentration remained within normal range for a long period,hypoparathyroidism,Kearns-Sayre Syndrome
503545370,7/16/2014 20:41:51,,1324467032,7/16/2014 20:39:55,instagc,1,19636746,USA,NY,Andover,192.182.216.225,44,18,,,62,39,HYPOPARATHYROIDISM,KEARNS-SAYRE SYNDROME,HYPOPARATHYROIDISM,44,18-25-31,KEARNS SAYRE SYNDROME,Two patients with Kearns-Sayre Syndrome and hypoparathyroidism were treated with alfacalcidol (1a-OH D3) and total serum calcium concentration remained within normal range for a long period.,44,18 25 31,44,18,62,39,-1,RO-has_manifestation,906308,Two patients with Kearns-Sayre Syndrome and hypoparathyroidism were treated with alfacalcidol (1a-OH D3) and total serum calcium concentration remained within normal range for a long period,hypoparathyroidism,Kearns-Sayre Syndrome
503545370,7/16/2014 20:41:53,,1324467042,7/16/2014 20:41:40,clixsense,1,20614047,USA,MO,Maryville,174.32.162.147,44,18,,,62,39,HYPOPARATHYROIDISM,KEARNS-SAYRE SYNDROME,Sayre Syndrome and HYPOPARATHYROIDISM were treated with,25-31-40-44-63-68-76,0-4-13-18-25-31-40-44-63,Two patients with KEARNS SAYRE SYNDROME and hypoparathyroidism were,Two patients with Kearns-Sayre Syndrome and hypoparathyroidism were treated with alfacalcidol (1a-OH D3) and total serum calcium concentration remained within normal range for a long period.,44,18 25 31,44,18,62,39,-1,RO-has_manifestation,906308,Two patients with Kearns-Sayre Syndrome and hypoparathyroidism were treated with alfacalcidol (1a-OH D3) and total serum calcium concentration remained within normal range for a long period,hypoparathyroidism,Kearns-Sayre Syndrome
503545370,7/16/2014 20:43:05,,1324467451,7/16/2014 20:43:03,bitcoinget,1,24792414,USA,"","",166.181.81.55,44,18,,,62,39,HYPOPARATHYROIDISM,KEARNS-SAYRE SYNDROME,Sayre Syndrome and HYPOPARATHYROIDISM were treated with,25-31-40-44-63-68-76,0-4-13-18-25-31-40-44-63,Two patients with KEARNS SAYRE SYNDROME and hypoparathyroidism were,Two patients with Kearns-Sayre Syndrome and hypoparathyroidism were treated with alfacalcidol (1a-OH D3) and total serum calcium concentration remained within normal range for a long period.,44,18 25 31,44,18,62,39,-1,RO-has_manifestation,906308,Two patients with Kearns-Sayre Syndrome and hypoparathyroidism were treated with alfacalcidol (1a-OH D3) and total serum calcium concentration remained within normal range for a long period,hypoparathyroidism,Kearns-Sayre Syndrome
503545370,7/16/2014 20:44:09,,1324467817,7/16/2014 20:43:56,instagc,1,13763729,USA,"","",75.182.89.225,44,18,,,62,39,HYPOPARATHYROIDISM,KEARNS-SAYRE SYNDROME,HYPOPARATHYROIDISM,44,18-25-31,KEARNS SAYRE SYNDROME,Two patients with Kearns-Sayre Syndrome and hypoparathyroidism were treated with alfacalcidol (1a-OH D3) and total serum calcium concentration remained within normal range for a long period.,44,18 25 31,44,18,62,39,-1,RO-has_manifestation,906308,Two patients with Kearns-Sayre Syndrome and hypoparathyroidism were treated with alfacalcidol (1a-OH D3) and total serum calcium concentration remained within normal range for a long period,hypoparathyroidism,Kearns-Sayre Syndrome
503545370,7/16/2014 20:47:45,,1324469390,7/16/2014 20:47:23,clixsense,1,16827630,GBR,A7,Birmingham,86.146.169.103,44,18,,,62,39,HYPOPARATHYROIDISM,KEARNS-SAYRE SYNDROME,HYPOPARATHYROIDISM,44,18-25-31,KEARNS SAYRE SYNDROME,Two patients with Kearns-Sayre Syndrome and hypoparathyroidism were treated with alfacalcidol (1a-OH D3) and total serum calcium concentration remained within normal range for a long period.,44,18 25 31,44,18,62,39,-1,RO-has_manifestation,906308,Two patients with Kearns-Sayre Syndrome and hypoparathyroidism were treated with alfacalcidol (1a-OH D3) and total serum calcium concentration remained within normal range for a long period,hypoparathyroidism,Kearns-Sayre Syndrome
503545370,7/16/2014 20:48:02,,1324469505,7/16/2014 20:47:41,prodege,1,9997387,USA,CO,Colorado Springs,75.70.112.31,44,18,,,62,39,HYPOPARATHYROIDISM,KEARNS-SAYRE SYNDROME,HYPOPARATHYROIDISM,44,18-25-31,KEARNS SAYRE SYNDROME,Two patients with Kearns-Sayre Syndrome and hypoparathyroidism were treated with alfacalcidol (1a-OH D3) and total serum calcium concentration remained within normal range for a long period.,44,18 25 31,44,18,62,39,-1,RO-has_manifestation,906308,Two patients with Kearns-Sayre Syndrome and hypoparathyroidism were treated with alfacalcidol (1a-OH D3) and total serum calcium concentration remained within normal range for a long period,hypoparathyroidism,Kearns-Sayre Syndrome
503545370,7/16/2014 20:48:31,,1324469732,7/16/2014 20:48:15,prodege,1,28255346,GBR,L9,Sheffield,2.125.183.137,44,18,,,62,39,HYPOPARATHYROIDISM,KEARNS-SAYRE SYNDROME,HYPOPARATHYROIDISM,44,18-25-31,KEARNS SAYRE SYNDROME,Two patients with Kearns-Sayre Syndrome and hypoparathyroidism were treated with alfacalcidol (1a-OH D3) and total serum calcium concentration remained within normal range for a long period.,44,18 25 31,44,18,62,39,-1,RO-has_manifestation,906308,Two patients with Kearns-Sayre Syndrome and hypoparathyroidism were treated with alfacalcidol (1a-OH D3) and total serum calcium concentration remained within normal range for a long period,hypoparathyroidism,Kearns-Sayre Syndrome
503545371,7/16/2014 20:38:33,,1324465595,7/16/2014 20:38:22,clixsense,1,27871219,NLD,07,Amsterdam,87.210.207.223,84,13,,,91,23,CANDIDA,CANDIDEMIA,CANDIDA,84,13,CANDIDEMIA,Treatment of candidemia is more complicated because of the changing epidemiology of Candida and introduction of newer antifungal agents.,84,13,84,13,91,23,1,RO-has_causative_agent,903897,Treatment of candidemia is more complicated because of the changing epidemiology of Candida and introduction of newer antifungal agents,Candida,candidemia
503545371,7/16/2014 20:39:20,,1324465996,7/16/2014 20:39:14,clixsense,1,6610277,CAN,ON,Oshawa,174.117.79.122,84,13,,,91,23,CANDIDA,CANDIDEMIA,changing epidemiology of CANDIDA and introduction,59-68-81-84-92-96,0-10-13-24-27-32,Treatment of CANDIDEMIA is more complicated,Treatment of candidemia is more complicated because of the changing epidemiology of Candida and introduction of newer antifungal agents.,84,13,84,13,91,23,1,RO-has_causative_agent,903897,Treatment of candidemia is more complicated because of the changing epidemiology of Candida and introduction of newer antifungal agents,Candida,candidemia
503545371,7/16/2014 20:42:55,,1324467372,7/16/2014 20:42:53,bitcoinget,1.0,24792414,USA,"","",166.181.81.55,84,13,,,91,23,CANDIDA,CANDIDEMIA,changing epidemiology of CANDIDA and introduction of,59-68-81-84-92-96-109,0-10-13-24-27-32,Treatment of CANDIDEMIA is more complicated,Treatment of candidemia is more complicated because of the changing epidemiology of Candida and introduction of newer antifungal agents.,84,13,84,13,91,23,1,RO-has_causative_agent,903897,Treatment of candidemia is more complicated because of the changing epidemiology of Candida and introduction of newer antifungal agents,Candida,candidemia
503545371,7/16/2014 20:45:31,,1324468355,7/16/2014 20:45:20,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,84,13,,,91,23,CANDIDA,CANDIDEMIA,CANDIDA,84,13,CANDIDEMIA,Treatment of candidemia is more complicated because of the changing epidemiology of Candida and introduction of newer antifungal agents.,84,13,84,13,91,23,1,RO-has_causative_agent,903897,Treatment of candidemia is more complicated because of the changing epidemiology of Candida and introduction of newer antifungal agents,Candida,candidemia
503545371,7/16/2014 20:47:36,,1324469313,7/16/2014 20:47:21,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,84,13,,,91,23,CANDIDA,CANDIDEMIA,epidemiology of CANDIDA,68-81-84,13,CANDIDEMIA,Treatment of candidemia is more complicated because of the changing epidemiology of Candida and introduction of newer antifungal agents.,84,13,84,13,91,23,1,RO-has_causative_agent,903897,Treatment of candidemia is more complicated because of the changing epidemiology of Candida and introduction of newer antifungal agents,Candida,candidemia
503545371,7/16/2014 20:49:36,,1324470264,7/16/2014 20:49:09,eup_slw,1,28011002,CAN,MB,Winnipeg,24.77.44.140,84,13,,,91,23,CANDIDA,CANDIDEMIA,candidemia CANDIDA,84-13,13,CANDIDEMIA,Treatment of candidemia is more complicated because of the changing epidemiology of Candida and introduction of newer antifungal agents.,84,13,84,13,91,23,1,RO-has_causative_agent,903897,Treatment of candidemia is more complicated because of the changing epidemiology of Candida and introduction of newer antifungal agents,Candida,candidemia
503545371,7/16/2014 20:50:06,,1324470455,7/16/2014 20:49:48,clixsense,1,27793793,GBR,C5,Chester,151.230.27.155,84,13,,,91,23,CANDIDA,CANDIDEMIA,CANDIDA,84,13,CANDIDEMIA,Treatment of candidemia is more complicated because of the changing epidemiology of Candida and introduction of newer antifungal agents.,84,13,84,13,91,23,1,RO-has_causative_agent,903897,Treatment of candidemia is more complicated because of the changing epidemiology of Candida and introduction of newer antifungal agents,Candida,candidemia
503545371,7/16/2014 20:50:39,,1324470627,7/16/2014 20:50:11,prodege,1.0,9997387,USA,CO,Colorado Springs,75.70.112.31,84,13,,,91,23,CANDIDA,CANDIDEMIA,CANDIDA,84,13,CANDIDEMIA,Treatment of candidemia is more complicated because of the changing epidemiology of Candida and introduction of newer antifungal agents.,84,13,84,13,91,23,1,RO-has_causative_agent,903897,Treatment of candidemia is more complicated because of the changing epidemiology of Candida and introduction of newer antifungal agents,Candida,candidemia
503545371,7/16/2014 20:52:01,,1324471166,7/16/2014 20:51:37,prodege,1,4968858,USA,CA,Corona,99.44.120.153,84,13,,,91,23,CANDIDA,CANDIDEMIA,CANDIDA,84,13,CANDIDEMIA,Treatment of candidemia is more complicated because of the changing epidemiology of Candida and introduction of newer antifungal agents.,84,13,84,13,91,23,1,RO-has_causative_agent,903897,Treatment of candidemia is more complicated because of the changing epidemiology of Candida and introduction of newer antifungal agents,Candida,candidemia
503545371,7/16/2014 20:52:33,,1324471459,7/16/2014 20:52:19,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,84,13,,,91,23,CANDIDA,CANDIDEMIA,CANDIDA,84,13,CANDIDEMIA,Treatment of candidemia is more complicated because of the changing epidemiology of Candida and introduction of newer antifungal agents.,84,13,84,13,91,23,1,RO-has_causative_agent,903897,Treatment of candidemia is more complicated because of the changing epidemiology of Candida and introduction of newer antifungal agents,Candida,candidemia
503545372,7/16/2014 20:35:14,,1324464273,7/16/2014 20:34:59,elite,1,28503042,USA,NJ,Woodbridge,54.191.150.115,70,0,,,78,20,MECONIUM,MECONIUM PERITONITIS,MECONIUM,70,0-9,MECONIUM PERITONITIS,Meconium peritonitis occasionally occurs as a localized collection of meconium contained in a cyst made of fibrous granulation tissue.,70,0 9,70,0,78,20,-1,RO-has_causative_agent,903841,Meconium peritonitis occasionally occurs as a localized collection of meconium contained in a cyst made of fibrous granulation tissue,meconium,Meconium peritonitis
503545372,7/16/2014 20:39:14,,1324465952,7/16/2014 20:39:02,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,70,0,,,78,20,MECONIUM,MECONIUM PERITONITIS,MECONIUM,70,0-9,MECONIUM PERITONITIS,Meconium peritonitis occasionally occurs as a localized collection of meconium contained in a cyst made of fibrous granulation tissue.,70,0 9,70,0,78,20,-1,RO-has_causative_agent,903841,Meconium peritonitis occasionally occurs as a localized collection of meconium contained in a cyst made of fibrous granulation tissue,meconium,Meconium peritonitis
503545372,7/16/2014 20:40:15,,1324466340,7/16/2014 20:40:03,tremorgames,1,24449707,CAN,QC,Laval,96.21.249.72,70,0,,,78,20,MECONIUM,MECONIUM PERITONITIS,MECONIUM,70,0-9,MECONIUM PERITONITIS,Meconium peritonitis occasionally occurs as a localized collection of meconium contained in a cyst made of fibrous granulation tissue.,70,0 9,70,0,78,20,-1,RO-has_causative_agent,903841,Meconium peritonitis occasionally occurs as a localized collection of meconium contained in a cyst made of fibrous granulation tissue,meconium,Meconium peritonitis
503545372,7/16/2014 20:40:44,,1324466578,7/16/2014 20:39:01,prodege,1.0,9997387,USA,CO,Colorado Springs,75.70.112.31,70,0,,,78,20,MECONIUM,MECONIUM PERITONITIS,Meconium peritonitis MECONIUM,0-9-70,0-9,MECONIUM PERITONITIS,Meconium peritonitis occasionally occurs as a localized collection of meconium contained in a cyst made of fibrous granulation tissue.,70,0 9,70,0,78,20,-1,RO-has_causative_agent,903841,Meconium peritonitis occasionally occurs as a localized collection of meconium contained in a cyst made of fibrous granulation tissue,meconium,Meconium peritonitis
503545372,7/16/2014 20:40:55,,1324466646,7/16/2014 20:40:23,coinworker,1.0,28394550,USA,PA,Marcus Hook,71.175.96.184,70,0,,,78,20,MECONIUM,MECONIUM PERITONITIS,localized collection of MECONIUM contained in a,46-56-67-70-79-89-92,0-9-21-34-41,MECONIUM PERITONITIS occasionally occurs as,Meconium peritonitis occasionally occurs as a localized collection of meconium contained in a cyst made of fibrous granulation tissue.,70,0 9,70,0,78,20,-1,RO-has_causative_agent,903841,Meconium peritonitis occasionally occurs as a localized collection of meconium contained in a cyst made of fibrous granulation tissue,meconium,Meconium peritonitis
503545372,7/16/2014 20:41:43,,1324466982,7/16/2014 20:40:30,bitcoinget,1.0,24792414,USA,"","",166.181.81.55,70,0,,,78,20,MECONIUM,MECONIUM PERITONITIS,MECONIUM,70,0-9,MECONIUM PERITONITIS,Meconium peritonitis occasionally occurs as a localized collection of meconium contained in a cyst made of fibrous granulation tissue.,70,0 9,70,0,78,20,-1,RO-has_causative_agent,903841,Meconium peritonitis occasionally occurs as a localized collection of meconium contained in a cyst made of fibrous granulation tissue,meconium,Meconium peritonitis
503545372,7/16/2014 20:46:10,,1324468677,7/16/2014 20:45:56,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,70,0,,,78,20,MECONIUM,MECONIUM PERITONITIS,localized collection of MECONIUM contained in a,46-56-67-70-79-89-92,0-9-21-34-41,MECONIUM PERITONITIS occasionally occurs as,Meconium peritonitis occasionally occurs as a localized collection of meconium contained in a cyst made of fibrous granulation tissue.,70,0 9,70,0,78,20,-1,RO-has_causative_agent,903841,Meconium peritonitis occasionally occurs as a localized collection of meconium contained in a cyst made of fibrous granulation tissue,meconium,Meconium peritonitis
503545372,7/16/2014 20:46:38,,1324468886,7/16/2014 20:46:34,prodege,1,26325260,GBR,"","",79.64.25.64,70,0,,,78,20,MECONIUM,MECONIUM PERITONITIS,localized collection of MECONIUM contained in a,46-56-67-70-79-89-92,0-9-21-34-41,MECONIUM PERITONITIS occasionally occurs as,Meconium peritonitis occasionally occurs as a localized collection of meconium contained in a cyst made of fibrous granulation tissue.,70,0 9,70,0,78,20,-1,RO-has_causative_agent,903841,Meconium peritonitis occasionally occurs as a localized collection of meconium contained in a cyst made of fibrous granulation tissue,meconium,Meconium peritonitis
503545372,7/16/2014 20:46:42,,1324468899,7/16/2014 20:46:27,clixsense,1,19803139,NLD,06,Veldhoven,212.61.84.196,70,0,,,78,20,MECONIUM,MECONIUM PERITONITIS,MECONIUM,70,0-9,MECONIUM PERITONITIS,Meconium peritonitis occasionally occurs as a localized collection of meconium contained in a cyst made of fibrous granulation tissue.,70,0 9,70,0,78,20,-1,RO-has_causative_agent,903841,Meconium peritonitis occasionally occurs as a localized collection of meconium contained in a cyst made of fibrous granulation tissue,meconium,Meconium peritonitis
503545372,7/16/2014 20:47:14,,1324469151,7/16/2014 20:46:54,prodege,1,22360212,GBR,I1,Luton,82.6.41.191,70,0,,,78,20,MECONIUM,MECONIUM PERITONITIS,MECONIUM,70,0-9,MECONIUM PERITONITIS,Meconium peritonitis occasionally occurs as a localized collection of meconium contained in a cyst made of fibrous granulation tissue.,70,0 9,70,0,78,20,-1,RO-has_causative_agent,903841,Meconium peritonitis occasionally occurs as a localized collection of meconium contained in a cyst made of fibrous granulation tissue,meconium,Meconium peritonitis
503545373,7/16/2014 20:36:37,,1324464901,7/16/2014 20:36:21,clixsense,1.0,24896327,GBR,V2,Glasgow,94.2.231.4,17,65,,,33,87,FACIAL ASYMMETRY,FACIAL HEMIHYPERTROPHY,"FACIAL ASYMMETRY,",17-24,65-72,FACIAL HEMIHYPERTROPHY.,"All cases showed facial asymmetry, one of them exhibiting marked facial hemihypertrophy.",17 24,65 72,17,65,33,87,-1,RO-has_manifestation,906208,"All cases showed facial asymmetry, one of them exhibiting marked facial hemihypertrophy",facial asymmetry,facial hemihypertrophy
503545373,7/16/2014 20:43:42,,1324467657,7/16/2014 20:43:40,bitcoinget,1.0,24792414,USA,"","",166.181.81.55,17,65,,,33,87,FACIAL ASYMMETRY,FACIAL HEMIHYPERTROPHY,"All cases showed FACIAL ASYMMETRY, one of them",0-4-10-17-24-35-39-42,42-47-58-65-72,them exhibiting marked FACIAL HEMIHYPERTROPHY.,"All cases showed facial asymmetry, one of them exhibiting marked facial hemihypertrophy.",17 24,65 72,17,65,33,87,-1,RO-has_manifestation,906208,"All cases showed facial asymmetry, one of them exhibiting marked facial hemihypertrophy",facial asymmetry,facial hemihypertrophy
503545373,7/16/2014 20:46:35,,1324468867,7/16/2014 20:46:23,instagc,1.0,13763729,USA,"","",75.182.89.225,17,65,,,33,87,FACIAL ASYMMETRY,FACIAL HEMIHYPERTROPHY,"FACIAL ASYMMETRY,",17-24,65-72,FACIAL HEMIHYPERTROPHY.,"All cases showed facial asymmetry, one of them exhibiting marked facial hemihypertrophy.",17 24,65 72,17,65,33,87,-1,RO-has_manifestation,906208,"All cases showed facial asymmetry, one of them exhibiting marked facial hemihypertrophy",facial asymmetry,facial hemihypertrophy
503545373,7/16/2014 20:46:58,,1324469023,7/16/2014 20:46:56,prodege,1.0,26325260,GBR,"","",79.64.25.64,17,65,,,33,87,FACIAL ASYMMETRY,FACIAL HEMIHYPERTROPHY,"All cases showed FACIAL ASYMMETRY, one of them",0-4-10-17-24-35-39-42,42-47-58-65-72,them exhibiting marked FACIAL HEMIHYPERTROPHY.,"All cases showed facial asymmetry, one of them exhibiting marked facial hemihypertrophy.",17 24,65 72,17,65,33,87,-1,RO-has_manifestation,906208,"All cases showed facial asymmetry, one of them exhibiting marked facial hemihypertrophy",facial asymmetry,facial hemihypertrophy
503545373,7/16/2014 20:47:20,,1324469187,7/16/2014 20:47:11,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,17,65,,,33,87,FACIAL ASYMMETRY,FACIAL HEMIHYPERTROPHY,"FACIAL ASYMMETRY,",17-24,65-72,FACIAL HEMIHYPERTROPHY.,"All cases showed facial asymmetry, one of them exhibiting marked facial hemihypertrophy.",17 24,65 72,17,65,33,87,-1,RO-has_manifestation,906208,"All cases showed facial asymmetry, one of them exhibiting marked facial hemihypertrophy",facial asymmetry,facial hemihypertrophy
503545373,7/16/2014 20:47:44,,1324469392,7/16/2014 20:47:35,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,17,65,,,33,87,FACIAL ASYMMETRY,FACIAL HEMIHYPERTROPHY,"All cases showed FACIAL ASYMMETRY, one of them",0-4-10-17-24-35-39-42,42-47-58-65-72,them exhibiting marked FACIAL HEMIHYPERTROPHY.,"All cases showed facial asymmetry, one of them exhibiting marked facial hemihypertrophy.",17 24,65 72,17,65,33,87,-1,RO-has_manifestation,906208,"All cases showed facial asymmetry, one of them exhibiting marked facial hemihypertrophy",facial asymmetry,facial hemihypertrophy
503545373,7/16/2014 20:48:39,,1324469828,7/16/2014 20:48:20,prodege,1.0,9997387,USA,CO,Colorado Springs,75.70.112.31,17,65,,,33,87,FACIAL ASYMMETRY,FACIAL HEMIHYPERTROPHY,"FACIAL ASYMMETRY,",17-24,65-72,FACIAL HEMIHYPERTROPHY.,"All cases showed facial asymmetry, one of them exhibiting marked facial hemihypertrophy.",17 24,65 72,17,65,33,87,-1,RO-has_manifestation,906208,"All cases showed facial asymmetry, one of them exhibiting marked facial hemihypertrophy",facial asymmetry,facial hemihypertrophy
503545373,7/16/2014 20:49:06,,1324470042,7/16/2014 20:48:48,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,17,65,,,33,87,FACIAL ASYMMETRY,FACIAL HEMIHYPERTROPHY,"FACIAL ASYMMETRY,",17-24,65-72,FACIAL HEMIHYPERTROPHY.,"All cases showed facial asymmetry, one of them exhibiting marked facial hemihypertrophy.",17 24,65 72,17,65,33,87,-1,RO-has_manifestation,906208,"All cases showed facial asymmetry, one of them exhibiting marked facial hemihypertrophy",facial asymmetry,facial hemihypertrophy
503545373,7/16/2014 20:50:47,,1324470706,7/16/2014 20:48:23,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,17,65,,,33,87,FACIAL ASYMMETRY,FACIAL HEMIHYPERTROPHY,"FACIAL ASYMMETRY,",17-24,65-72,FACIAL HEMIHYPERTROPHY.,"All cases showed facial asymmetry, one of them exhibiting marked facial hemihypertrophy.",17 24,65 72,17,65,33,87,-1,RO-has_manifestation,906208,"All cases showed facial asymmetry, one of them exhibiting marked facial hemihypertrophy",facial asymmetry,facial hemihypertrophy
503545373,7/16/2014 20:50:59,,1324470780,7/16/2014 20:50:25,prodege,1.0,22360212,GBR,I1,Luton,82.6.41.191,17,65,,,33,87,FACIAL ASYMMETRY,FACIAL HEMIHYPERTROPHY,"FACIAL ASYMMETRY,",17-24,65-72,FACIAL HEMIHYPERTROPHY.,"All cases showed facial asymmetry, one of them exhibiting marked facial hemihypertrophy.",17 24,65 72,17,65,33,87,-1,RO-has_manifestation,906208,"All cases showed facial asymmetry, one of them exhibiting marked facial hemihypertrophy",facial asymmetry,facial hemihypertrophy
503545374,7/16/2014 20:36:07,,1324464654,7/16/2014 20:35:56,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,109,83,,,126,89,ALLERGIC RHINITIS,ATOPIC,ALLERGIC RHINITIS,109-118,83-90,"ATOPIC history,","About one third of patients have a history of asthma, and up to one half have some atopic history, including allergic rhinitis and nasal polyps.",109 118,83,109,83,126,89,-1,RO-cause_of,900011,"About one third of patients have a history of asthma, and up to one half have some atopic history, including allergic rhinitis and nasal polyps",allergic rhinitis,atopic
503545374,7/16/2014 20:36:34,,1324464864,7/16/2014 20:36:18,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,109,83,,,126,89,ALLERGIC RHINITIS,ATOPIC,ALLERGIC RHINITIS,109-118,83-90,"ATOPIC history,","About one third of patients have a history of asthma, and up to one half have some atopic history, including allergic rhinitis and nasal polyps.",109 118,83,109,83,126,89,-1,RO-cause_of,900011,"About one third of patients have a history of asthma, and up to one half have some atopic history, including allergic rhinitis and nasal polyps",allergic rhinitis,atopic
503545374,7/16/2014 20:40:09,,1324466301,7/16/2014 20:39:29,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,109,83,,,126,89,ALLERGIC RHINITIS,ATOPIC,ALLERGIC RHINITIS,109-118,83-90,"ATOPIC history,","About one third of patients have a history of asthma, and up to one half have some atopic history, including allergic rhinitis and nasal polyps.",109 118,83,109,83,126,89,-1,RO-cause_of,900011,"About one third of patients have a history of asthma, and up to one half have some atopic history, including allergic rhinitis and nasal polyps",allergic rhinitis,atopic
503545374,7/16/2014 20:41:29,,1324466858,7/16/2014 20:41:22,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,109,83,,,126,89,ALLERGIC RHINITIS,ATOPIC,ALLERGIC RHINITIS,109-118,83-90,"ATOPIC history,","About one third of patients have a history of asthma, and up to one half have some atopic history, including allergic rhinitis and nasal polyps.",109 118,83,109,83,126,89,-1,RO-cause_of,900011,"About one third of patients have a history of asthma, and up to one half have some atopic history, including allergic rhinitis and nasal polyps",allergic rhinitis,atopic
503545374,7/16/2014 20:43:01,,1324467421,7/16/2014 20:42:59,bitcoinget,1.0,24792414,USA,"","",166.181.81.55,109,83,,,126,89,ALLERGIC RHINITIS,ATOPIC,"atopic history, including ALLERGIC RHINITIS and nasal polyps.",83-90-99-109-118-127-131-137,68-73-78-83-90-99-109,"half have some ATOPIC history, including allergic","About one third of patients have a history of asthma, and up to one half have some atopic history, including allergic rhinitis and nasal polyps.",109 118,83,109,83,126,89,-1,RO-cause_of,900011,"About one third of patients have a history of asthma, and up to one half have some atopic history, including allergic rhinitis and nasal polyps",allergic rhinitis,atopic
503545374,7/16/2014 20:44:41,,1324468036,7/16/2014 20:44:26,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,109,83,,,126,89,ALLERGIC RHINITIS,ATOPIC,ALLERGIC RHINITIS,109-118,83-90,"ATOPIC history,","About one third of patients have a history of asthma, and up to one half have some atopic history, including allergic rhinitis and nasal polyps.",109 118,83,109,83,126,89,-1,RO-cause_of,900011,"About one third of patients have a history of asthma, and up to one half have some atopic history, including allergic rhinitis and nasal polyps",allergic rhinitis,atopic
503545374,7/16/2014 20:47:55,,1324469449,7/16/2014 20:47:41,instagc,1.0,13763729,USA,"","",75.182.89.225,109,83,,,126,89,ALLERGIC RHINITIS,ATOPIC,ALLERGIC RHINITIS,109-118,83-90,"ATOPIC history,","About one third of patients have a history of asthma, and up to one half have some atopic history, including allergic rhinitis and nasal polyps.",109 118,83,109,83,126,89,-1,RO-cause_of,900011,"About one third of patients have a history of asthma, and up to one half have some atopic history, including allergic rhinitis and nasal polyps",allergic rhinitis,atopic
503545374,7/16/2014 20:48:14,,1324469626,7/16/2014 20:47:55,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,109,83,,,126,89,ALLERGIC RHINITIS,ATOPIC,ALLERGIC RHINITIS,109-118,83,ATOPIC,"About one third of patients have a history of asthma, and up to one half have some atopic history, including allergic rhinitis and nasal polyps.",109 118,83,109,83,126,89,-1,RO-cause_of,900011,"About one third of patients have a history of asthma, and up to one half have some atopic history, including allergic rhinitis and nasal polyps",allergic rhinitis,atopic
503545374,7/16/2014 20:48:26,,1324469716,7/16/2014 20:48:01,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,109,83,,,126,89,ALLERGIC RHINITIS,ATOPIC,ALLERGIC RHINITIS,109-118,83,ATOPIC,"About one third of patients have a history of asthma, and up to one half have some atopic history, including allergic rhinitis and nasal polyps.",109 118,83,109,83,126,89,-1,RO-cause_of,900011,"About one third of patients have a history of asthma, and up to one half have some atopic history, including allergic rhinitis and nasal polyps",allergic rhinitis,atopic
503545374,7/16/2014 20:49:03,,1324470020,7/16/2014 20:48:40,prodege,1.0,9997387,USA,CO,Colorado Springs,75.70.112.31,109,83,,,126,89,ALLERGIC RHINITIS,ATOPIC,ALLERGIC RHINITIS,109-118,83,ATOPIC,"About one third of patients have a history of asthma, and up to one half have some atopic history, including allergic rhinitis and nasal polyps.",109 118,83,109,83,126,89,-1,RO-cause_of,900011,"About one third of patients have a history of asthma, and up to one half have some atopic history, including allergic rhinitis and nasal polyps",allergic rhinitis,atopic
503545375,7/16/2014 20:36:02,,1324464637,7/16/2014 20:35:49,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,104,95,,,118,100,MILD DYSPLASIA,GROUP,MILD DYSPLASIA,104-109,95-101-104-109,GROUP of mild dysplasia,The morphometric evaluation revealed that the number of AgNORs and nuclear area increased from group of mild dysplasia to invasive cancer.,104 109,95,104,95,118,100,-1,RO-disease_has_finding,901828,The morphometric evaluation revealed that the number of AgNORs and nuclear area increased from group of mild dysplasia to invasive cancer,mild dysplasia,group
503545375,7/16/2014 20:36:35,,1324464887,7/16/2014 20:36:18,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,104,95,,,118,100,MILD DYSPLASIA,GROUP,MILD DYSPLASIA,104-109,95,GROUP,The morphometric evaluation revealed that the number of AgNORs and nuclear area increased from group of mild dysplasia to invasive cancer.,104 109,95,104,95,118,100,-1,RO-disease_has_finding,901828,The morphometric evaluation revealed that the number of AgNORs and nuclear area increased from group of mild dysplasia to invasive cancer,mild dysplasia,group
503545375,7/16/2014 20:38:07,,1324465449,7/16/2014 20:37:49,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,104,95,,,118,100,MILD DYSPLASIA,GROUP,MILD DYSPLASIA,104-109,95,GROUP,The morphometric evaluation revealed that the number of AgNORs and nuclear area increased from group of mild dysplasia to invasive cancer.,104 109,95,104,95,118,100,-1,RO-disease_has_finding,901828,The morphometric evaluation revealed that the number of AgNORs and nuclear area increased from group of mild dysplasia to invasive cancer,mild dysplasia,group
503545375,7/16/2014 20:38:17,,1324465509,7/16/2014 20:38:01,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,104,95,,,118,100,MILD DYSPLASIA,GROUP,MILD DYSPLASIA,104-109,95-101-104-109,GROUP of mild dysplasia,The morphometric evaluation revealed that the number of AgNORs and nuclear area increased from group of mild dysplasia to invasive cancer.,104 109,95,104,95,118,100,-1,RO-disease_has_finding,901828,The morphometric evaluation revealed that the number of AgNORs and nuclear area increased from group of mild dysplasia to invasive cancer,mild dysplasia,group
503545375,7/16/2014 20:39:07,,1324465878,7/16/2014 20:38:51,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,104,95,,,118,100,MILD DYSPLASIA,GROUP,MILD DYSPLASIA,104-109,95-101-104-109,GROUP of mild dysplasia,The morphometric evaluation revealed that the number of AgNORs and nuclear area increased from group of mild dysplasia to invasive cancer.,104 109,95,104,95,118,100,-1,RO-disease_has_finding,901828,The morphometric evaluation revealed that the number of AgNORs and nuclear area increased from group of mild dysplasia to invasive cancer,mild dysplasia,group
503545375,7/16/2014 20:39:33,,1324466084,7/16/2014 20:37:27,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,104,95,,,118,100,MILD DYSPLASIA,GROUP,MILD DYSPLASIA,104-109,95-101-104-109,GROUP of mild dysplasia,The morphometric evaluation revealed that the number of AgNORs and nuclear area increased from group of mild dysplasia to invasive cancer.,104 109,95,104,95,118,100,-1,RO-disease_has_finding,901828,The morphometric evaluation revealed that the number of AgNORs and nuclear area increased from group of mild dysplasia to invasive cancer,mild dysplasia,group
503545375,7/16/2014 20:39:36,,1324466096,7/16/2014 20:39:18,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,104,95,,,118,100,MILD DYSPLASIA,GROUP,MILD DYSPLASIA,104-109,75-80-95-104-109,area increased GROUP mild dysplasia,The morphometric evaluation revealed that the number of AgNORs and nuclear area increased from group of mild dysplasia to invasive cancer.,104 109,95,104,95,118,100,-1,RO-disease_has_finding,901828,The morphometric evaluation revealed that the number of AgNORs and nuclear area increased from group of mild dysplasia to invasive cancer,mild dysplasia,group
503545375,7/16/2014 20:42:21,,1324467170,7/16/2014 20:42:18,coinworker,1.0,28394550,USA,PA,Marcus Hook,71.175.96.184,104,95,,,118,100,MILD DYSPLASIA,GROUP,from group of MILD DYSPLASIA to invasive cancer.,90-95-101-104-109-119-122-131,75-80-90-95-101-104-109,area increased from GROUP of mild dysplasia,The morphometric evaluation revealed that the number of AgNORs and nuclear area increased from group of mild dysplasia to invasive cancer.,104 109,95,104,95,118,100,-1,RO-disease_has_finding,901828,The morphometric evaluation revealed that the number of AgNORs and nuclear area increased from group of mild dysplasia to invasive cancer,mild dysplasia,group
503545375,7/16/2014 20:42:25,,1324467214,7/16/2014 20:41:44,eup_slw,1.0,28011002,CAN,MB,Winnipeg,24.77.44.140,104,95,,,118,100,MILD DYSPLASIA,GROUP,MILD DYSPLASIA,104-109,4-17-95,morphometric evaluation GROUP,The morphometric evaluation revealed that the number of AgNORs and nuclear area increased from group of mild dysplasia to invasive cancer.,104 109,95,104,95,118,100,-1,RO-disease_has_finding,901828,The morphometric evaluation revealed that the number of AgNORs and nuclear area increased from group of mild dysplasia to invasive cancer,mild dysplasia,group
503545375,7/16/2014 20:42:40,,1324467285,7/16/2014 20:42:38,bitcoinget,1.0,24792414,USA,"","",166.181.81.55,104,95,,,118,100,MILD DYSPLASIA,GROUP,from group of MILD DYSPLASIA to invasive cancer.,90-95-101-104-109-119-122-131,75-80-90-95-101-104-109,area increased from GROUP of mild dysplasia,The morphometric evaluation revealed that the number of AgNORs and nuclear area increased from group of mild dysplasia to invasive cancer.,104 109,95,104,95,118,100,-1,RO-disease_has_finding,901828,The morphometric evaluation revealed that the number of AgNORs and nuclear area increased from group of mild dysplasia to invasive cancer,mild dysplasia,group
503545376,7/16/2014 20:35:22,,1324464328,7/16/2014 20:35:06,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,141,97,,,154,106,ENDOMETRIOSIS,NAFARELIN,ENDOMETRIOSIS.,141,91-97,nasal NAFARELIN,"1]  Henzl MR, Corson SL, Moghissi K, Buttram VC, Berqvist C, Jacobson J. Administration of nasal nafarelin as compared with oral danazol for endometriosis.",141,97,141,97,154,106,1,RO-may_treat,907593,"1]  Henzl MR, Corson SL, Moghissi K, Buttram VC, Berqvist C, Jacobson J. Administration of nasal nafarelin as compared with oral danazol for endometriosis",endometriosis,nafarelin
503545376,7/16/2014 20:37:51,,1324465350,7/16/2014 20:37:34,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,141,97,,,154,106,ENDOMETRIOSIS,NAFARELIN,ENDOMETRIOSIS.,141,91-97,nasal NAFARELIN,"1]  Henzl MR, Corson SL, Moghissi K, Buttram VC, Berqvist C, Jacobson J. Administration of nasal nafarelin as compared with oral danazol for endometriosis.",141,97,141,97,154,106,1,RO-may_treat,907593,"1]  Henzl MR, Corson SL, Moghissi K, Buttram VC, Berqvist C, Jacobson J. Administration of nasal nafarelin as compared with oral danazol for endometriosis",endometriosis,nafarelin
503545376,7/16/2014 20:39:38,,1324466101,7/16/2014 20:39:16,clixsense,1.0,24896327,GBR,V2,Glasgow,94.2.231.4,141,97,,,154,106,ENDOMETRIOSIS,NAFARELIN,ENDOMETRIOSIS.,141,97,NAFARELIN,"1]  Henzl MR, Corson SL, Moghissi K, Buttram VC, Berqvist C, Jacobson J. Administration of nasal nafarelin as compared with oral danazol for endometriosis.",141,97,141,97,154,106,1,RO-may_treat,907593,"1]  Henzl MR, Corson SL, Moghissi K, Buttram VC, Berqvist C, Jacobson J. Administration of nasal nafarelin as compared with oral danazol for endometriosis",endometriosis,nafarelin
503545376,7/16/2014 20:41:04,,1324466707,7/16/2014 20:40:45,prodege,1.0,9997387,USA,CO,Colorado Springs,75.70.112.31,141,97,,,154,106,ENDOMETRIOSIS,NAFARELIN,ENDOMETRIOSIS.,141,91-97,nasal NAFARELIN,"1]  Henzl MR, Corson SL, Moghissi K, Buttram VC, Berqvist C, Jacobson J. Administration of nasal nafarelin as compared with oral danazol for endometriosis.",141,97,141,97,154,106,1,RO-may_treat,907593,"1]  Henzl MR, Corson SL, Moghissi K, Buttram VC, Berqvist C, Jacobson J. Administration of nasal nafarelin as compared with oral danazol for endometriosis",endometriosis,nafarelin
503545376,7/16/2014 20:42:08,,1324467127,7/16/2014 20:42:06,coinworker,1.0,28394550,USA,PA,Marcus Hook,71.175.96.184,141,97,,,154,106,ENDOMETRIOSIS,NAFARELIN,oral danazol for ENDOMETRIOSIS.,124-129-137-141,73-88-91-97-107-110-119,Administration of nasal NAFARELIN as compared with,"1]  Henzl MR, Corson SL, Moghissi K, Buttram VC, Berqvist C, Jacobson J. Administration of nasal nafarelin as compared with oral danazol for endometriosis.",141,97,141,97,154,106,1,RO-may_treat,907593,"1]  Henzl MR, Corson SL, Moghissi K, Buttram VC, Berqvist C, Jacobson J. Administration of nasal nafarelin as compared with oral danazol for endometriosis",endometriosis,nafarelin
503545376,7/16/2014 20:42:58,,1324467394,7/16/2014 20:42:56,bitcoinget,1.0,24792414,USA,"","",166.181.81.55,141,97,,,154,106,ENDOMETRIOSIS,NAFARELIN,oral danazol for ENDOMETRIOSIS.,124-129-137-141,73-88-91-97-107-110-119,Administration of nasal NAFARELIN as compared with,"1]  Henzl MR, Corson SL, Moghissi K, Buttram VC, Berqvist C, Jacobson J. Administration of nasal nafarelin as compared with oral danazol for endometriosis.",141,97,141,97,154,106,1,RO-may_treat,907593,"1]  Henzl MR, Corson SL, Moghissi K, Buttram VC, Berqvist C, Jacobson J. Administration of nasal nafarelin as compared with oral danazol for endometriosis",endometriosis,nafarelin
503545376,7/16/2014 20:47:26,,1324469240,7/16/2014 20:47:23,prodege,1.0,26325260,GBR,"","",79.64.25.64,141,97,,,154,106,ENDOMETRIOSIS,NAFARELIN,oral danazol for ENDOMETRIOSIS.,124-129-137-141,73-88-91-97-107-110-119,Administration of nasal NAFARELIN as compared with,"1]  Henzl MR, Corson SL, Moghissi K, Buttram VC, Berqvist C, Jacobson J. Administration of nasal nafarelin as compared with oral danazol for endometriosis.",141,97,141,97,154,106,1,RO-may_treat,907593,"1]  Henzl MR, Corson SL, Moghissi K, Buttram VC, Berqvist C, Jacobson J. Administration of nasal nafarelin as compared with oral danazol for endometriosis",endometriosis,nafarelin
503545376,7/16/2014 20:49:06,,1324470038,7/16/2014 20:48:51,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,141,97,,,154,106,ENDOMETRIOSIS,NAFARELIN,ENDOMETRIOSIS.,141,97,NAFARELIN,"1]  Henzl MR, Corson SL, Moghissi K, Buttram VC, Berqvist C, Jacobson J. Administration of nasal nafarelin as compared with oral danazol for endometriosis.",141,97,141,97,154,106,1,RO-may_treat,907593,"1]  Henzl MR, Corson SL, Moghissi K, Buttram VC, Berqvist C, Jacobson J. Administration of nasal nafarelin as compared with oral danazol for endometriosis",endometriosis,nafarelin
503545376,7/16/2014 20:49:53,,1324470404,7/16/2014 20:49:28,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,141,97,,,154,106,ENDOMETRIOSIS,NAFARELIN,ENDOMETRIOSIS.,141,97-91,nasal NAFARELIN,"1]  Henzl MR, Corson SL, Moghissi K, Buttram VC, Berqvist C, Jacobson J. Administration of nasal nafarelin as compared with oral danazol for endometriosis.",141,97,141,97,154,106,1,RO-may_treat,907593,"1]  Henzl MR, Corson SL, Moghissi K, Buttram VC, Berqvist C, Jacobson J. Administration of nasal nafarelin as compared with oral danazol for endometriosis",endometriosis,nafarelin
503545376,7/16/2014 20:52:16,,1324471288,7/16/2014 20:51:50,prodege,1.0,22360212,GBR,I1,Luton,82.6.41.191,141,97,,,154,106,ENDOMETRIOSIS,NAFARELIN,ENDOMETRIOSIS.,141,91-97,nasal NAFARELIN,"1]  Henzl MR, Corson SL, Moghissi K, Buttram VC, Berqvist C, Jacobson J. Administration of nasal nafarelin as compared with oral danazol for endometriosis.",141,97,141,97,154,106,1,RO-may_treat,907593,"1]  Henzl MR, Corson SL, Moghissi K, Buttram VC, Berqvist C, Jacobson J. Administration of nasal nafarelin as compared with oral danazol for endometriosis",endometriosis,nafarelin
503545377,7/16/2014 20:34:43,,1324464087,7/16/2014 20:34:24,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,309,262,,,334,271,SEBACEOUS DIFFERENTIATION,SEBACEOMA,"basal cell carcinoma with SEBACEOUS DIFFERENTIATION,",283-289-294-304-309-319,262,"SEBACEOMA,","The authors studied the immunohistochemical expression of T antigen in 45 skin biopsy and excisional specimens obtained from the archives of their dermatopathology laboratories, including 8 cases of sebaceous carcinoma, 15 cases of sebaceous adenoma, 9 cases of sebaceoma, 1 case of basal cell carcinoma with sebaceous differentiation, and 12 cases of basal cell carcinoma with cytologic atypia.",309 319,262,309,262,334,271,-1,RO-disease_has_finding,901921,"The authors studied the immunohistochemical expression of T antigen in 45 skin biopsy and excisional specimens obtained from the archives of their dermatopathology laboratories, including 8 cases of sebaceous carcinoma, 15 cases of sebaceous adenoma, 9 cases of sebaceoma, 1 case of basal cell carcinoma with sebaceous differentiation, and 12 cases of basal cell carcinoma with cytologic atypia",sebaceous differentiation,sebaceoma
503545377,7/16/2014 20:35:53,,1324464575,7/16/2014 20:34:20,eup_slw,1.0,28011002,CAN,MB,Winnipeg,24.77.44.140,309,262,,,334,271,SEBACEOUS DIFFERENTIATION,SEBACEOMA,"sebaceous adenoma, sebaceoma, SEBACEOUS DIFFERENTIATION,",232-242-309-319-262,199-209-262-309,"sebaceous carcinoma, SEBACEOMA, sebaceous","The authors studied the immunohistochemical expression of T antigen in 45 skin biopsy and excisional specimens obtained from the archives of their dermatopathology laboratories, including 8 cases of sebaceous carcinoma, 15 cases of sebaceous adenoma, 9 cases of sebaceoma, 1 case of basal cell carcinoma with sebaceous differentiation, and 12 cases of basal cell carcinoma with cytologic atypia.",309 319,262,309,262,334,271,-1,RO-disease_has_finding,901921,"The authors studied the immunohistochemical expression of T antigen in 45 skin biopsy and excisional specimens obtained from the archives of their dermatopathology laboratories, including 8 cases of sebaceous carcinoma, 15 cases of sebaceous adenoma, 9 cases of sebaceoma, 1 case of basal cell carcinoma with sebaceous differentiation, and 12 cases of basal cell carcinoma with cytologic atypia",sebaceous differentiation,sebaceoma
503545377,7/16/2014 20:37:48,,1324465313,7/16/2014 20:37:33,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,309,262,,,334,271,SEBACEOUS DIFFERENTIATION,SEBACEOMA,"SEBACEOUS DIFFERENTIATION,",309-319,262,"SEBACEOMA,","The authors studied the immunohistochemical expression of T antigen in 45 skin biopsy and excisional specimens obtained from the archives of their dermatopathology laboratories, including 8 cases of sebaceous carcinoma, 15 cases of sebaceous adenoma, 9 cases of sebaceoma, 1 case of basal cell carcinoma with sebaceous differentiation, and 12 cases of basal cell carcinoma with cytologic atypia.",309 319,262,309,262,334,271,-1,RO-disease_has_finding,901921,"The authors studied the immunohistochemical expression of T antigen in 45 skin biopsy and excisional specimens obtained from the archives of their dermatopathology laboratories, including 8 cases of sebaceous carcinoma, 15 cases of sebaceous adenoma, 9 cases of sebaceoma, 1 case of basal cell carcinoma with sebaceous differentiation, and 12 cases of basal cell carcinoma with cytologic atypia",sebaceous differentiation,sebaceoma
503545377,7/16/2014 20:39:38,,1324466111,7/16/2014 20:39:07,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,309,262,,,334,271,SEBACEOUS DIFFERENTIATION,SEBACEOMA,"SEBACEOUS DIFFERENTIATION,",309-319,262,"SEBACEOMA,","The authors studied the immunohistochemical expression of T antigen in 45 skin biopsy and excisional specimens obtained from the archives of their dermatopathology laboratories, including 8 cases of sebaceous carcinoma, 15 cases of sebaceous adenoma, 9 cases of sebaceoma, 1 case of basal cell carcinoma with sebaceous differentiation, and 12 cases of basal cell carcinoma with cytologic atypia.",309 319,262,309,262,334,271,-1,RO-disease_has_finding,901921,"The authors studied the immunohistochemical expression of T antigen in 45 skin biopsy and excisional specimens obtained from the archives of their dermatopathology laboratories, including 8 cases of sebaceous carcinoma, 15 cases of sebaceous adenoma, 9 cases of sebaceoma, 1 case of basal cell carcinoma with sebaceous differentiation, and 12 cases of basal cell carcinoma with cytologic atypia",sebaceous differentiation,sebaceoma
503545377,7/16/2014 20:41:31,,1324466871,7/16/2014 20:41:03,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,309,262,,,334,271,SEBACEOUS DIFFERENTIATION,SEBACEOMA,"SEBACEOUS DIFFERENTIATION,",309-319,262,"SEBACEOMA,","The authors studied the immunohistochemical expression of T antigen in 45 skin biopsy and excisional specimens obtained from the archives of their dermatopathology laboratories, including 8 cases of sebaceous carcinoma, 15 cases of sebaceous adenoma, 9 cases of sebaceoma, 1 case of basal cell carcinoma with sebaceous differentiation, and 12 cases of basal cell carcinoma with cytologic atypia.",309 319,262,309,262,334,271,-1,RO-disease_has_finding,901921,"The authors studied the immunohistochemical expression of T antigen in 45 skin biopsy and excisional specimens obtained from the archives of their dermatopathology laboratories, including 8 cases of sebaceous carcinoma, 15 cases of sebaceous adenoma, 9 cases of sebaceoma, 1 case of basal cell carcinoma with sebaceous differentiation, and 12 cases of basal cell carcinoma with cytologic atypia",sebaceous differentiation,sebaceoma
503545377,7/16/2014 20:43:58,,1324467735,7/16/2014 20:43:47,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,309,262,,,334,271,SEBACEOUS DIFFERENTIATION,SEBACEOMA,"cell carcinoma with SEBACEOUS DIFFERENTIATION, and 12 cases",289-294-304-309-319-336-340-343,251-253-259-262-273-275-280,"9 cases of SEBACEOMA, 1 case of","The authors studied the immunohistochemical expression of T antigen in 45 skin biopsy and excisional specimens obtained from the archives of their dermatopathology laboratories, including 8 cases of sebaceous carcinoma, 15 cases of sebaceous adenoma, 9 cases of sebaceoma, 1 case of basal cell carcinoma with sebaceous differentiation, and 12 cases of basal cell carcinoma with cytologic atypia.",309 319,262,309,262,334,271,-1,RO-disease_has_finding,901921,"The authors studied the immunohistochemical expression of T antigen in 45 skin biopsy and excisional specimens obtained from the archives of their dermatopathology laboratories, including 8 cases of sebaceous carcinoma, 15 cases of sebaceous adenoma, 9 cases of sebaceoma, 1 case of basal cell carcinoma with sebaceous differentiation, and 12 cases of basal cell carcinoma with cytologic atypia",sebaceous differentiation,sebaceoma
503545377,7/16/2014 20:46:04,,1324468597,7/16/2014 20:46:01,prodege,1.0,26325260,GBR,"","",79.64.25.64,309,262,,,334,271,SEBACEOUS DIFFERENTIATION,SEBACEOMA,"cell carcinoma with SEBACEOUS DIFFERENTIATION, and 12 cases",289-294-304-309-319-336-340-343,251-253-259-262-273-275-280,"9 cases of SEBACEOMA, 1 case of","The authors studied the immunohistochemical expression of T antigen in 45 skin biopsy and excisional specimens obtained from the archives of their dermatopathology laboratories, including 8 cases of sebaceous carcinoma, 15 cases of sebaceous adenoma, 9 cases of sebaceoma, 1 case of basal cell carcinoma with sebaceous differentiation, and 12 cases of basal cell carcinoma with cytologic atypia.",309 319,262,309,262,334,271,-1,RO-disease_has_finding,901921,"The authors studied the immunohistochemical expression of T antigen in 45 skin biopsy and excisional specimens obtained from the archives of their dermatopathology laboratories, including 8 cases of sebaceous carcinoma, 15 cases of sebaceous adenoma, 9 cases of sebaceoma, 1 case of basal cell carcinoma with sebaceous differentiation, and 12 cases of basal cell carcinoma with cytologic atypia",sebaceous differentiation,sebaceoma
503545377,7/16/2014 20:46:22,,1324468765,7/16/2014 20:46:08,instagc,1.0,13763729,USA,"","",75.182.89.225,309,262,,,334,271,SEBACEOUS DIFFERENTIATION,SEBACEOMA,"SEBACEOUS DIFFERENTIATION,",309-319,262,"SEBACEOMA,","The authors studied the immunohistochemical expression of T antigen in 45 skin biopsy and excisional specimens obtained from the archives of their dermatopathology laboratories, including 8 cases of sebaceous carcinoma, 15 cases of sebaceous adenoma, 9 cases of sebaceoma, 1 case of basal cell carcinoma with sebaceous differentiation, and 12 cases of basal cell carcinoma with cytologic atypia.",309 319,262,309,262,334,271,-1,RO-disease_has_finding,901921,"The authors studied the immunohistochemical expression of T antigen in 45 skin biopsy and excisional specimens obtained from the archives of their dermatopathology laboratories, including 8 cases of sebaceous carcinoma, 15 cases of sebaceous adenoma, 9 cases of sebaceoma, 1 case of basal cell carcinoma with sebaceous differentiation, and 12 cases of basal cell carcinoma with cytologic atypia",sebaceous differentiation,sebaceoma
503545377,7/16/2014 20:50:06,,1324470456,7/16/2014 20:49:34,prodege,1.0,22360212,GBR,I1,Luton,82.6.41.191,309,262,,,334,271,SEBACEOUS DIFFERENTIATION,SEBACEOMA,"SEBACEOUS DIFFERENTIATION,",309-319,262,"SEBACEOMA,","The authors studied the immunohistochemical expression of T antigen in 45 skin biopsy and excisional specimens obtained from the archives of their dermatopathology laboratories, including 8 cases of sebaceous carcinoma, 15 cases of sebaceous adenoma, 9 cases of sebaceoma, 1 case of basal cell carcinoma with sebaceous differentiation, and 12 cases of basal cell carcinoma with cytologic atypia.",309 319,262,309,262,334,271,-1,RO-disease_has_finding,901921,"The authors studied the immunohistochemical expression of T antigen in 45 skin biopsy and excisional specimens obtained from the archives of their dermatopathology laboratories, including 8 cases of sebaceous carcinoma, 15 cases of sebaceous adenoma, 9 cases of sebaceoma, 1 case of basal cell carcinoma with sebaceous differentiation, and 12 cases of basal cell carcinoma with cytologic atypia",sebaceous differentiation,sebaceoma
503545377,7/16/2014 20:51:48,,1324471099,7/16/2014 20:51:36,prodege,1.0,9997387,USA,CO,Colorado Springs,75.70.112.31,309,262,,,334,271,SEBACEOUS DIFFERENTIATION,SEBACEOMA,"SEBACEOUS DIFFERENTIATION,",309-319,262,"SEBACEOMA,","The authors studied the immunohistochemical expression of T antigen in 45 skin biopsy and excisional specimens obtained from the archives of their dermatopathology laboratories, including 8 cases of sebaceous carcinoma, 15 cases of sebaceous adenoma, 9 cases of sebaceoma, 1 case of basal cell carcinoma with sebaceous differentiation, and 12 cases of basal cell carcinoma with cytologic atypia.",309 319,262,309,262,334,271,-1,RO-disease_has_finding,901921,"The authors studied the immunohistochemical expression of T antigen in 45 skin biopsy and excisional specimens obtained from the archives of their dermatopathology laboratories, including 8 cases of sebaceous carcinoma, 15 cases of sebaceous adenoma, 9 cases of sebaceoma, 1 case of basal cell carcinoma with sebaceous differentiation, and 12 cases of basal cell carcinoma with cytologic atypia",sebaceous differentiation,sebaceoma
503545378,7/16/2014 20:33:12,,1324463499,7/16/2014 20:33:01,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,95,141,,,109,164,CRANIAL NERVES,CRANIAL NERVE DISORDERS,CRANIAL NERVES,95-103,141-149-155,CRANIAL NERVE DISORDERS,PERIPHERAL NERVOUS SYSTEM DISORDERS  INTRODUCTION  The peripheral nervous system refers to the cranial nerves (see  Neuro-ophthalmologic and Cranial Nerve Disorders ) and spinal nerves from their origin to their end.,95 103,141 149 155,95,141,109,164,1,RO-disease_has_primary_anatomic_site,902415,PERIPHERAL NERVOUS SYSTEM DISORDERS  INTRODUCTION  The peripheral nervous system refers to the cranial nerves (see  Neuro-ophthalmologic and Cranial Nerve Disorders ) and spinal nerves from their origin to their end,cranial nerves,Cranial Nerve Disorders
503545378,7/16/2014 20:35:46,,1324464503,7/16/2014 20:35:17,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,95,141,,,109,164,CRANIAL NERVES,CRANIAL NERVE DISORDERS,CRANIAL NERVES,95-103,116-122-137-141-149-155,Neuro ophthalmologic and CRANIAL NERVE DISORDERS,PERIPHERAL NERVOUS SYSTEM DISORDERS  INTRODUCTION  The peripheral nervous system refers to the cranial nerves (see  Neuro-ophthalmologic and Cranial Nerve Disorders ) and spinal nerves from their origin to their end.,95 103,141 149 155,95,141,109,164,1,RO-disease_has_primary_anatomic_site,902415,PERIPHERAL NERVOUS SYSTEM DISORDERS  INTRODUCTION  The peripheral nervous system refers to the cranial nerves (see  Neuro-ophthalmologic and Cranial Nerve Disorders ) and spinal nerves from their origin to their end,cranial nerves,Cranial Nerve Disorders
503545378,7/16/2014 20:37:31,,1324465231,7/16/2014 20:37:22,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,95,141,,,109,164,CRANIAL NERVES,CRANIAL NERVE DISORDERS,CRANIAL NERVES,95-103,141-149-155,CRANIAL NERVE DISORDERS,PERIPHERAL NERVOUS SYSTEM DISORDERS  INTRODUCTION  The peripheral nervous system refers to the cranial nerves (see  Neuro-ophthalmologic and Cranial Nerve Disorders ) and spinal nerves from their origin to their end.,95 103,141 149 155,95,141,109,164,1,RO-disease_has_primary_anatomic_site,902415,PERIPHERAL NERVOUS SYSTEM DISORDERS  INTRODUCTION  The peripheral nervous system refers to the cranial nerves (see  Neuro-ophthalmologic and Cranial Nerve Disorders ) and spinal nerves from their origin to their end,cranial nerves,Cranial Nerve Disorders
503545378,7/16/2014 20:40:29,,1324466431,7/16/2014 20:39:50,eup_slw,1.0,28011002,CAN,MB,Winnipeg,24.77.44.140,95,141,,,109,164,CRANIAL NERVES,CRANIAL NERVE DISORDERS,CRANIAL NERVES Neuro ophthalmologic,95-103-116-122,116-141-149-155-122,Neuro ophthalmologic CRANIAL NERVE DISORDERS,PERIPHERAL NERVOUS SYSTEM DISORDERS  INTRODUCTION  The peripheral nervous system refers to the cranial nerves (see  Neuro-ophthalmologic and Cranial Nerve Disorders ) and spinal nerves from their origin to their end.,95 103,141 149 155,95,141,109,164,1,RO-disease_has_primary_anatomic_site,902415,PERIPHERAL NERVOUS SYSTEM DISORDERS  INTRODUCTION  The peripheral nervous system refers to the cranial nerves (see  Neuro-ophthalmologic and Cranial Nerve Disorders ) and spinal nerves from their origin to their end,cranial nerves,Cranial Nerve Disorders
503545378,7/16/2014 20:40:54,,1324466636,7/16/2014 20:40:38,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,95,141,,,109,164,CRANIAL NERVES,CRANIAL NERVE DISORDERS,CRANIAL NERVES,95-103,141-149-155,CRANIAL NERVE DISORDERS,PERIPHERAL NERVOUS SYSTEM DISORDERS  INTRODUCTION  The peripheral nervous system refers to the cranial nerves (see  Neuro-ophthalmologic and Cranial Nerve Disorders ) and spinal nerves from their origin to their end.,95 103,141 149 155,95,141,109,164,1,RO-disease_has_primary_anatomic_site,902415,PERIPHERAL NERVOUS SYSTEM DISORDERS  INTRODUCTION  The peripheral nervous system refers to the cranial nerves (see  Neuro-ophthalmologic and Cranial Nerve Disorders ) and spinal nerves from their origin to their end,cranial nerves,Cranial Nerve Disorders
503545378,7/16/2014 20:42:14,,1324467151,7/16/2014 20:41:58,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,95,141,,,109,164,CRANIAL NERVES,CRANIAL NERVE DISORDERS,CRANIAL NERVES,95-103,141-149-155,CRANIAL NERVE DISORDERS,PERIPHERAL NERVOUS SYSTEM DISORDERS  INTRODUCTION  The peripheral nervous system refers to the cranial nerves (see  Neuro-ophthalmologic and Cranial Nerve Disorders ) and spinal nerves from their origin to their end.,95 103,141 149 155,95,141,109,164,1,RO-disease_has_primary_anatomic_site,902415,PERIPHERAL NERVOUS SYSTEM DISORDERS  INTRODUCTION  The peripheral nervous system refers to the cranial nerves (see  Neuro-ophthalmologic and Cranial Nerve Disorders ) and spinal nerves from their origin to their end,cranial nerves,Cranial Nerve Disorders
503545378,7/16/2014 20:42:33,,1324467272,7/16/2014 20:42:08,clixsense,1.0,24896327,GBR,V2,Glasgow,94.2.231.4,95,141,,,109,164,CRANIAL NERVES,CRANIAL NERVE DISORDERS,CRANIAL NERVES,95-103,141-149-155,CRANIAL NERVE DISORDERS,PERIPHERAL NERVOUS SYSTEM DISORDERS  INTRODUCTION  The peripheral nervous system refers to the cranial nerves (see  Neuro-ophthalmologic and Cranial Nerve Disorders ) and spinal nerves from their origin to their end.,95 103,141 149 155,95,141,109,164,1,RO-disease_has_primary_anatomic_site,902415,PERIPHERAL NERVOUS SYSTEM DISORDERS  INTRODUCTION  The peripheral nervous system refers to the cranial nerves (see  Neuro-ophthalmologic and Cranial Nerve Disorders ) and spinal nerves from their origin to their end,cranial nerves,Cranial Nerve Disorders
503545378,7/16/2014 20:43:12,,1324467490,7/16/2014 20:43:10,bitcoinget,1.0,24792414,USA,"","",166.181.81.55,95,141,,,109,164,CRANIAL NERVES,CRANIAL NERVE DISORDERS,refers to the CRANIAL NERVES Neuro ophthalmologic,81-88-91-95-103-116-122,116-122-137-141-149-155-167-171-178,Neuro ophthalmologic and CRANIAL NERVE DISORDERS and spinal nerves,PERIPHERAL NERVOUS SYSTEM DISORDERS  INTRODUCTION  The peripheral nervous system refers to the cranial nerves (see  Neuro-ophthalmologic and Cranial Nerve Disorders ) and spinal nerves from their origin to their end.,95 103,141 149 155,95,141,109,164,1,RO-disease_has_primary_anatomic_site,902415,PERIPHERAL NERVOUS SYSTEM DISORDERS  INTRODUCTION  The peripheral nervous system refers to the cranial nerves (see  Neuro-ophthalmologic and Cranial Nerve Disorders ) and spinal nerves from their origin to their end,cranial nerves,Cranial Nerve Disorders
503545378,7/16/2014 20:43:37,,1324467623,7/16/2014 20:43:23,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,95,141,,,109,164,CRANIAL NERVES,CRANIAL NERVE DISORDERS,CRANIAL NERVES,95-103,116-122-137-141-149-155,Neuro ophthalmologic and CRANIAL NERVE DISORDERS,PERIPHERAL NERVOUS SYSTEM DISORDERS  INTRODUCTION  The peripheral nervous system refers to the cranial nerves (see  Neuro-ophthalmologic and Cranial Nerve Disorders ) and spinal nerves from their origin to their end.,95 103,141 149 155,95,141,109,164,1,RO-disease_has_primary_anatomic_site,902415,PERIPHERAL NERVOUS SYSTEM DISORDERS  INTRODUCTION  The peripheral nervous system refers to the cranial nerves (see  Neuro-ophthalmologic and Cranial Nerve Disorders ) and spinal nerves from their origin to their end,cranial nerves,Cranial Nerve Disorders
503545378,7/16/2014 20:44:18,,1324467854,7/16/2014 20:43:56,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,95,141,,,109,164,CRANIAL NERVES,CRANIAL NERVE DISORDERS,CRANIAL NERVES,95-103,141-149-155,CRANIAL NERVE DISORDERS,PERIPHERAL NERVOUS SYSTEM DISORDERS  INTRODUCTION  The peripheral nervous system refers to the cranial nerves (see  Neuro-ophthalmologic and Cranial Nerve Disorders ) and spinal nerves from their origin to their end.,95 103,141 149 155,95,141,109,164,1,RO-disease_has_primary_anatomic_site,902415,PERIPHERAL NERVOUS SYSTEM DISORDERS  INTRODUCTION  The peripheral nervous system refers to the cranial nerves (see  Neuro-ophthalmologic and Cranial Nerve Disorders ) and spinal nerves from their origin to their end,cranial nerves,Cranial Nerve Disorders
503545379,7/16/2014 20:33:02,,1324463448,7/16/2014 20:32:10,clixsense,1.0,24896327,GBR,V2,Glasgow,94.2.231.4,85,152,,,107,176,VISCERAL LEISHMANIASIS,LIPOSOMAL AMPHOTERICIN B,VISCERAL LEISHMANIASIS,85-94,152-162-175,LIPOSOMAL AMPHOTERICIN B,"This report is of the successful treatment of a patient with multiply drug-resistant visceral leishmaniasis with a commercially prepared formulation of liposomal amphotericin B (L-AmB) ('AmBisome', Vestar, San Dimas, California, USA.",85 94,152 162 175,85,152,107,176,1,RO-may_treat,908300,"This report is of the successful treatment of a patient with multiply drug-resistant visceral leishmaniasis with a commercially prepared formulation of liposomal amphotericin B (L-AmB) ('AmBisome', Vestar, San Dimas, California, USA",visceral leishmaniasis,liposomal amphotericin B
503545379,7/16/2014 20:38:10,,1324465452,7/16/2014 20:38:08,clixsense,1.0,6610277,CAN,ON,Oshawa,174.117.79.122,85,152,,,107,176,VISCERAL LEISHMANIASIS,LIPOSOMAL AMPHOTERICIN B,multiply drug resistant VISCERAL LEISHMANIASIS with a commercially,61-70-75-85-94-108-113-115,128-137-149-152-162-175-180,prepared formulation of LIPOSOMAL AMPHOTERICIN B AmB),"This report is of the successful treatment of a patient with multiply drug-resistant visceral leishmaniasis with a commercially prepared formulation of liposomal amphotericin B (L-AmB) ('AmBisome', Vestar, San Dimas, California, USA.",85 94,152 162 175,85,152,107,176,1,RO-may_treat,908300,"This report is of the successful treatment of a patient with multiply drug-resistant visceral leishmaniasis with a commercially prepared formulation of liposomal amphotericin B (L-AmB) ('AmBisome', Vestar, San Dimas, California, USA",visceral leishmaniasis,liposomal amphotericin B
503545379,7/16/2014 20:38:58,,1324465836,7/16/2014 20:38:44,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,85,152,,,107,176,VISCERAL LEISHMANIASIS,LIPOSOMAL AMPHOTERICIN B,drug resistant VISCERAL LEISHMANIASIS,70-75-85-94,152-162-175-180-177,LIPOSOMAL AMPHOTERICIN B (L AmB),"This report is of the successful treatment of a patient with multiply drug-resistant visceral leishmaniasis with a commercially prepared formulation of liposomal amphotericin B (L-AmB) ('AmBisome', Vestar, San Dimas, California, USA.",85 94,152 162 175,85,152,107,176,1,RO-may_treat,908300,"This report is of the successful treatment of a patient with multiply drug-resistant visceral leishmaniasis with a commercially prepared formulation of liposomal amphotericin B (L-AmB) ('AmBisome', Vestar, San Dimas, California, USA",visceral leishmaniasis,liposomal amphotericin B
503545379,7/16/2014 20:39:54,,1324466230,7/16/2014 20:39:35,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,85,152,,,107,176,VISCERAL LEISHMANIASIS,LIPOSOMAL AMPHOTERICIN B,drug resistant VISCERAL LEISHMANIASIS,70-75-85-94,152-162-175,LIPOSOMAL AMPHOTERICIN B,"This report is of the successful treatment of a patient with multiply drug-resistant visceral leishmaniasis with a commercially prepared formulation of liposomal amphotericin B (L-AmB) ('AmBisome', Vestar, San Dimas, California, USA.",85 94,152 162 175,85,152,107,176,1,RO-may_treat,908300,"This report is of the successful treatment of a patient with multiply drug-resistant visceral leishmaniasis with a commercially prepared formulation of liposomal amphotericin B (L-AmB) ('AmBisome', Vestar, San Dimas, California, USA",visceral leishmaniasis,liposomal amphotericin B
503545379,7/16/2014 20:40:11,,1324466313,7/16/2014 20:39:58,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,85,152,,,107,176,VISCERAL LEISHMANIASIS,LIPOSOMAL AMPHOTERICIN B,VISCERAL LEISHMANIASIS,85-94,152-162-175-177-179-180,LIPOSOMAL AMPHOTERICIN B (L - AmB),"This report is of the successful treatment of a patient with multiply drug-resistant visceral leishmaniasis with a commercially prepared formulation of liposomal amphotericin B (L-AmB) ('AmBisome', Vestar, San Dimas, California, USA.",85 94,152 162 175,85,152,107,176,1,RO-may_treat,908300,"This report is of the successful treatment of a patient with multiply drug-resistant visceral leishmaniasis with a commercially prepared formulation of liposomal amphotericin B (L-AmB) ('AmBisome', Vestar, San Dimas, California, USA",visceral leishmaniasis,liposomal amphotericin B
503545379,7/16/2014 20:41:06,,1324466714,7/16/2014 20:41:02,coinworker,1.0,28394550,USA,PA,Marcus Hook,71.175.96.184,85,152,,,107,176,VISCERAL LEISHMANIASIS,LIPOSOMAL AMPHOTERICIN B,multiply drug resistant VISCERAL LEISHMANIASIS with a commercially,61-70-75-85-94-108-113-115,128-137-149-152-162-175-180,prepared formulation of LIPOSOMAL AMPHOTERICIN B AmB),"This report is of the successful treatment of a patient with multiply drug-resistant visceral leishmaniasis with a commercially prepared formulation of liposomal amphotericin B (L-AmB) ('AmBisome', Vestar, San Dimas, California, USA.",85 94,152 162 175,85,152,107,176,1,RO-may_treat,908300,"This report is of the successful treatment of a patient with multiply drug-resistant visceral leishmaniasis with a commercially prepared formulation of liposomal amphotericin B (L-AmB) ('AmBisome', Vestar, San Dimas, California, USA",visceral leishmaniasis,liposomal amphotericin B
503545379,7/16/2014 20:41:39,,1324466941,7/16/2014 20:41:13,prodege,1.0,22360212,GBR,I1,Luton,82.6.41.191,85,152,,,107,176,VISCERAL LEISHMANIASIS,LIPOSOMAL AMPHOTERICIN B,drug resistant VISCERAL LEISHMANIASIS,70-75-85-94,152-162-175,LIPOSOMAL AMPHOTERICIN B,"This report is of the successful treatment of a patient with multiply drug-resistant visceral leishmaniasis with a commercially prepared formulation of liposomal amphotericin B (L-AmB) ('AmBisome', Vestar, San Dimas, California, USA.",85 94,152 162 175,85,152,107,176,1,RO-may_treat,908300,"This report is of the successful treatment of a patient with multiply drug-resistant visceral leishmaniasis with a commercially prepared formulation of liposomal amphotericin B (L-AmB) ('AmBisome', Vestar, San Dimas, California, USA",visceral leishmaniasis,liposomal amphotericin B
503545379,7/16/2014 20:41:50,,1324467025,7/16/2014 20:41:40,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,85,152,,,107,176,VISCERAL LEISHMANIASIS,LIPOSOMAL AMPHOTERICIN B,drug - resistant VISCERAL LEISHMANIASIS,70-74-75-85-94,152-162-175,LIPOSOMAL AMPHOTERICIN B,"This report is of the successful treatment of a patient with multiply drug-resistant visceral leishmaniasis with a commercially prepared formulation of liposomal amphotericin B (L-AmB) ('AmBisome', Vestar, San Dimas, California, USA.",85 94,152 162 175,85,152,107,176,1,RO-may_treat,908300,"This report is of the successful treatment of a patient with multiply drug-resistant visceral leishmaniasis with a commercially prepared formulation of liposomal amphotericin B (L-AmB) ('AmBisome', Vestar, San Dimas, California, USA",visceral leishmaniasis,liposomal amphotericin B
503545379,7/16/2014 20:45:05,,1324468166,7/16/2014 20:44:51,instagc,1.0,13763729,USA,"","",75.182.89.225,85,152,,,107,176,VISCERAL LEISHMANIASIS,LIPOSOMAL AMPHOTERICIN B,VISCERAL LEISHMANIASIS,85-94,152-162-175,LIPOSOMAL AMPHOTERICIN B,"This report is of the successful treatment of a patient with multiply drug-resistant visceral leishmaniasis with a commercially prepared formulation of liposomal amphotericin B (L-AmB) ('AmBisome', Vestar, San Dimas, California, USA.",85 94,152 162 175,85,152,107,176,1,RO-may_treat,908300,"This report is of the successful treatment of a patient with multiply drug-resistant visceral leishmaniasis with a commercially prepared formulation of liposomal amphotericin B (L-AmB) ('AmBisome', Vestar, San Dimas, California, USA",visceral leishmaniasis,liposomal amphotericin B
503545379,7/16/2014 20:45:16,,1324468264,7/16/2014 20:44:59,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,85,152,,,107,176,VISCERAL LEISHMANIASIS,LIPOSOMAL AMPHOTERICIN B,VISCERAL LEISHMANIASIS,85-94,152-162-175,LIPOSOMAL AMPHOTERICIN B,"This report is of the successful treatment of a patient with multiply drug-resistant visceral leishmaniasis with a commercially prepared formulation of liposomal amphotericin B (L-AmB) ('AmBisome', Vestar, San Dimas, California, USA.",85 94,152 162 175,85,152,107,176,1,RO-may_treat,908300,"This report is of the successful treatment of a patient with multiply drug-resistant visceral leishmaniasis with a commercially prepared formulation of liposomal amphotericin B (L-AmB) ('AmBisome', Vestar, San Dimas, California, USA",visceral leishmaniasis,liposomal amphotericin B
503545380,7/16/2014 20:37:14,,1324465145,7/16/2014 20:36:50,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,150,171,,,167,177,ATOPIC DERMATITIS,ATOPIC,ATOPIC DERMATITIS,150-157,171-178-185,"ATOPIC winter feet,","When comparing 1% hydrocortisone in a stabilized 10% urea cream with 0.1% betamethasone 17-valerate cream in a double-blind study on 49 patients with atopic dermatitis or atopic winter feet, betamethasone cream was found to be the most potent.",150 157,171,150,171,167,177,-1,RO-cause_of,900231,"When comparing 1% hydrocortisone in a stabilized 10% urea cream with 0.1% betamethasone 17-valerate cream in a double-blind study on 49 patients with atopic dermatitis or atopic winter feet, betamethasone cream was found to be the most potent",atopic dermatitis,atopic
503545380,7/16/2014 20:39:15,,1324465957,7/16/2014 20:38:42,clixsense,1.0,24896327,GBR,V2,Glasgow,94.2.231.4,150,171,,,167,177,ATOPIC DERMATITIS,ATOPIC,ATOPIC DERMATITIS,150-157,171-191,ATOPIC betamethasone,"When comparing 1% hydrocortisone in a stabilized 10% urea cream with 0.1% betamethasone 17-valerate cream in a double-blind study on 49 patients with atopic dermatitis or atopic winter feet, betamethasone cream was found to be the most potent.",150 157,171,150,171,167,177,-1,RO-cause_of,900231,"When comparing 1% hydrocortisone in a stabilized 10% urea cream with 0.1% betamethasone 17-valerate cream in a double-blind study on 49 patients with atopic dermatitis or atopic winter feet, betamethasone cream was found to be the most potent",atopic dermatitis,atopic
503545380,7/16/2014 20:39:23,,1324466047,7/16/2014 20:39:20,clixsense,1.0,6610277,CAN,ON,Oshawa,174.117.79.122,150,171,,,167,177,ATOPIC DERMATITIS,ATOPIC,49 patients with ATOPIC DERMATITIS or atopic winter,133-136-145-150-157-168-171-178,150-157-168-171-178-185-191,"atopic dermatitis or ATOPIC winter feet, betamethasone","When comparing 1% hydrocortisone in a stabilized 10% urea cream with 0.1% betamethasone 17-valerate cream in a double-blind study on 49 patients with atopic dermatitis or atopic winter feet, betamethasone cream was found to be the most potent.",150 157,171,150,171,167,177,-1,RO-cause_of,900231,"When comparing 1% hydrocortisone in a stabilized 10% urea cream with 0.1% betamethasone 17-valerate cream in a double-blind study on 49 patients with atopic dermatitis or atopic winter feet, betamethasone cream was found to be the most potent",atopic dermatitis,atopic
503545380,7/16/2014 20:42:10,,1324467120,7/16/2014 20:41:51,instagc,1.0,13763729,USA,"","",75.182.89.225,150,171,,,167,177,ATOPIC DERMATITIS,ATOPIC,ATOPIC DERMATITIS,150-157,171,ATOPIC,"When comparing 1% hydrocortisone in a stabilized 10% urea cream with 0.1% betamethasone 17-valerate cream in a double-blind study on 49 patients with atopic dermatitis or atopic winter feet, betamethasone cream was found to be the most potent.",150 157,171,150,171,167,177,-1,RO-cause_of,900231,"When comparing 1% hydrocortisone in a stabilized 10% urea cream with 0.1% betamethasone 17-valerate cream in a double-blind study on 49 patients with atopic dermatitis or atopic winter feet, betamethasone cream was found to be the most potent",atopic dermatitis,atopic
503545380,7/16/2014 20:44:51,,1324468090,7/16/2014 20:43:09,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,150,171,,,167,177,ATOPIC DERMATITIS,ATOPIC,ATOPIC DERMATITIS,150-157,171-178-185,"ATOPIC winter feet,","When comparing 1% hydrocortisone in a stabilized 10% urea cream with 0.1% betamethasone 17-valerate cream in a double-blind study on 49 patients with atopic dermatitis or atopic winter feet, betamethasone cream was found to be the most potent.",150 157,171,150,171,167,177,-1,RO-cause_of,900231,"When comparing 1% hydrocortisone in a stabilized 10% urea cream with 0.1% betamethasone 17-valerate cream in a double-blind study on 49 patients with atopic dermatitis or atopic winter feet, betamethasone cream was found to be the most potent",atopic dermatitis,atopic
503545380,7/16/2014 20:45:39,,1324468408,7/16/2014 20:45:35,prodege,1.0,26325260,GBR,"","",79.64.25.64,150,171,,,167,177,ATOPIC DERMATITIS,ATOPIC,49 patients with ATOPIC DERMATITIS or atopic winter,133-136-145-150-157-168-171-178,150-157-168-171-178-185-191,"atopic dermatitis or ATOPIC winter feet, betamethasone","When comparing 1% hydrocortisone in a stabilized 10% urea cream with 0.1% betamethasone 17-valerate cream in a double-blind study on 49 patients with atopic dermatitis or atopic winter feet, betamethasone cream was found to be the most potent.",150 157,171,150,171,167,177,-1,RO-cause_of,900231,"When comparing 1% hydrocortisone in a stabilized 10% urea cream with 0.1% betamethasone 17-valerate cream in a double-blind study on 49 patients with atopic dermatitis or atopic winter feet, betamethasone cream was found to be the most potent",atopic dermatitis,atopic
503545380,7/16/2014 20:45:41,,1324468420,7/16/2014 20:45:32,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,150,171,,,167,177,ATOPIC DERMATITIS,ATOPIC,49 patients with ATOPIC DERMATITIS or atopic winter,133-136-145-150-157-168-171-178,150-157-168-171-178-185-191,"atopic dermatitis or ATOPIC winter feet, betamethasone","When comparing 1% hydrocortisone in a stabilized 10% urea cream with 0.1% betamethasone 17-valerate cream in a double-blind study on 49 patients with atopic dermatitis or atopic winter feet, betamethasone cream was found to be the most potent.",150 157,171,150,171,167,177,-1,RO-cause_of,900231,"When comparing 1% hydrocortisone in a stabilized 10% urea cream with 0.1% betamethasone 17-valerate cream in a double-blind study on 49 patients with atopic dermatitis or atopic winter feet, betamethasone cream was found to be the most potent",atopic dermatitis,atopic
503545380,7/16/2014 20:46:33,,1324468859,7/16/2014 20:46:07,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,150,171,,,167,177,ATOPIC DERMATITIS,ATOPIC,ATOPIC DERMATITIS,150-157,171,ATOPIC,"When comparing 1% hydrocortisone in a stabilized 10% urea cream with 0.1% betamethasone 17-valerate cream in a double-blind study on 49 patients with atopic dermatitis or atopic winter feet, betamethasone cream was found to be the most potent.",150 157,171,150,171,167,177,-1,RO-cause_of,900231,"When comparing 1% hydrocortisone in a stabilized 10% urea cream with 0.1% betamethasone 17-valerate cream in a double-blind study on 49 patients with atopic dermatitis or atopic winter feet, betamethasone cream was found to be the most potent",atopic dermatitis,atopic
503545380,7/16/2014 20:46:55,,1324469001,7/16/2014 20:46:45,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,150,171,,,167,177,ATOPIC DERMATITIS,ATOPIC,ATOPIC DERMATITIS,150-157,171,ATOPIC,"When comparing 1% hydrocortisone in a stabilized 10% urea cream with 0.1% betamethasone 17-valerate cream in a double-blind study on 49 patients with atopic dermatitis or atopic winter feet, betamethasone cream was found to be the most potent.",150 157,171,150,171,167,177,-1,RO-cause_of,900231,"When comparing 1% hydrocortisone in a stabilized 10% urea cream with 0.1% betamethasone 17-valerate cream in a double-blind study on 49 patients with atopic dermatitis or atopic winter feet, betamethasone cream was found to be the most potent",atopic dermatitis,atopic
503545380,7/16/2014 20:50:56,,1324470761,7/16/2014 20:50:41,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,150,171,,,167,177,ATOPIC DERMATITIS,ATOPIC,ATOPIC DERMATITIS,150-157,171-178-185,"ATOPIC winter feet,","When comparing 1% hydrocortisone in a stabilized 10% urea cream with 0.1% betamethasone 17-valerate cream in a double-blind study on 49 patients with atopic dermatitis or atopic winter feet, betamethasone cream was found to be the most potent.",150 157,171,150,171,167,177,-1,RO-cause_of,900231,"When comparing 1% hydrocortisone in a stabilized 10% urea cream with 0.1% betamethasone 17-valerate cream in a double-blind study on 49 patients with atopic dermatitis or atopic winter feet, betamethasone cream was found to be the most potent",atopic dermatitis,atopic
503545381,7/16/2014 20:34:17,,1324463913,7/16/2014 20:33:53,clixsense,1.0,24896327,GBR,V2,Glasgow,94.2.231.4,385,353,,,393,361,SEIZURES,EPILEPSY,"myoclonic astatic SEIZURES,",367-377-385,353-362-367-377,EPILEPSY with myoclonic astatic,"PET scans were normal in all five children with typical de novo Lennox-Gastaut syndrome but showed cortical metabolic abnormalities in three out of four with atypical de novo Lennox-Gastaut syndrome, five out of six with Lennox-Gastaut syndrome following infantile spasms, six out of eight with severe myoclonic epilepsy in infancy, one out of two with epilepsy with myoclonic-astatic seizures, and four out of six with an unclassified epileptic encephalopathy.",385,353,385,353,393,361,-1,RO-has_definitional_manifestation,904941,"PET scans were normal in all five children with typical de novo Lennox-Gastaut syndrome but showed cortical metabolic abnormalities in three out of four with atypical de novo Lennox-Gastaut syndrome, five out of six with Lennox-Gastaut syndrome following infantile spasms, six out of eight with severe myoclonic epilepsy in infancy, one out of two with epilepsy with myoclonic-astatic seizures, and four out of six with an unclassified epileptic encephalopathy",seizures,epilepsy
503545381,7/16/2014 20:36:01,,1324464629,7/16/2014 20:35:47,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,385,353,,,393,361,SEIZURES,EPILEPSY,"SEIZURES,",385,353,EPILEPSY,"PET scans were normal in all five children with typical de novo Lennox-Gastaut syndrome but showed cortical metabolic abnormalities in three out of four with atypical de novo Lennox-Gastaut syndrome, five out of six with Lennox-Gastaut syndrome following infantile spasms, six out of eight with severe myoclonic epilepsy in infancy, one out of two with epilepsy with myoclonic-astatic seizures, and four out of six with an unclassified epileptic encephalopathy.",385,353,385,353,393,361,-1,RO-has_definitional_manifestation,904941,"PET scans were normal in all five children with typical de novo Lennox-Gastaut syndrome but showed cortical metabolic abnormalities in three out of four with atypical de novo Lennox-Gastaut syndrome, five out of six with Lennox-Gastaut syndrome following infantile spasms, six out of eight with severe myoclonic epilepsy in infancy, one out of two with epilepsy with myoclonic-astatic seizures, and four out of six with an unclassified epileptic encephalopathy",seizures,epilepsy
503545381,7/16/2014 20:37:41,,1324465272,7/16/2014 20:37:25,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,385,353,,,393,361,SEIZURES,EPILEPSY,"myoclonic astatic SEIZURES,",367-377-385,353,EPILEPSY,"PET scans were normal in all five children with typical de novo Lennox-Gastaut syndrome but showed cortical metabolic abnormalities in three out of four with atypical de novo Lennox-Gastaut syndrome, five out of six with Lennox-Gastaut syndrome following infantile spasms, six out of eight with severe myoclonic epilepsy in infancy, one out of two with epilepsy with myoclonic-astatic seizures, and four out of six with an unclassified epileptic encephalopathy.",385,353,385,353,393,361,-1,RO-has_definitional_manifestation,904941,"PET scans were normal in all five children with typical de novo Lennox-Gastaut syndrome but showed cortical metabolic abnormalities in three out of four with atypical de novo Lennox-Gastaut syndrome, five out of six with Lennox-Gastaut syndrome following infantile spasms, six out of eight with severe myoclonic epilepsy in infancy, one out of two with epilepsy with myoclonic-astatic seizures, and four out of six with an unclassified epileptic encephalopathy",seizures,epilepsy
503545381,7/16/2014 20:37:46,,1324465310,7/16/2014 20:37:45,clixsense,1.0,6610277,CAN,ON,Oshawa,174.117.79.122,385,353,,,393,361,SEIZURES,EPILEPSY,"with myoclonic astatic SEIZURES, and four out",362-367-377-385-395-399-404,341-344-348-353-362-367-377,of two with EPILEPSY with myoclonic astatic,"PET scans were normal in all five children with typical de novo Lennox-Gastaut syndrome but showed cortical metabolic abnormalities in three out of four with atypical de novo Lennox-Gastaut syndrome, five out of six with Lennox-Gastaut syndrome following infantile spasms, six out of eight with severe myoclonic epilepsy in infancy, one out of two with epilepsy with myoclonic-astatic seizures, and four out of six with an unclassified epileptic encephalopathy.",385,353,385,353,393,361,-1,RO-has_definitional_manifestation,904941,"PET scans were normal in all five children with typical de novo Lennox-Gastaut syndrome but showed cortical metabolic abnormalities in three out of four with atypical de novo Lennox-Gastaut syndrome, five out of six with Lennox-Gastaut syndrome following infantile spasms, six out of eight with severe myoclonic epilepsy in infancy, one out of two with epilepsy with myoclonic-astatic seizures, and four out of six with an unclassified epileptic encephalopathy",seizures,epilepsy
503545381,7/16/2014 20:38:46,,1324465719,7/16/2014 20:38:27,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,385,353,,,393,361,SEIZURES,EPILEPSY,"myoclonic astatic SEIZURES,",367-377-385,353-362-367-377-385,"EPILEPSY with myoclonic astatic seizures,","PET scans were normal in all five children with typical de novo Lennox-Gastaut syndrome but showed cortical metabolic abnormalities in three out of four with atypical de novo Lennox-Gastaut syndrome, five out of six with Lennox-Gastaut syndrome following infantile spasms, six out of eight with severe myoclonic epilepsy in infancy, one out of two with epilepsy with myoclonic-astatic seizures, and four out of six with an unclassified epileptic encephalopathy.",385,353,385,353,393,361,-1,RO-has_definitional_manifestation,904941,"PET scans were normal in all five children with typical de novo Lennox-Gastaut syndrome but showed cortical metabolic abnormalities in three out of four with atypical de novo Lennox-Gastaut syndrome, five out of six with Lennox-Gastaut syndrome following infantile spasms, six out of eight with severe myoclonic epilepsy in infancy, one out of two with epilepsy with myoclonic-astatic seizures, and four out of six with an unclassified epileptic encephalopathy",seizures,epilepsy
503545381,7/16/2014 20:42:36,,1324467273,7/16/2014 20:42:33,bitcoinget,1.0,24792414,USA,"","",166.181.81.55,385,353,,,393,361,SEIZURES,EPILEPSY,"with myoclonic astatic SEIZURES, and four out",362-367-377-385-395-399-404,341-344-348-353-362-367-377,of two with EPILEPSY with myoclonic astatic,"PET scans were normal in all five children with typical de novo Lennox-Gastaut syndrome but showed cortical metabolic abnormalities in three out of four with atypical de novo Lennox-Gastaut syndrome, five out of six with Lennox-Gastaut syndrome following infantile spasms, six out of eight with severe myoclonic epilepsy in infancy, one out of two with epilepsy with myoclonic-astatic seizures, and four out of six with an unclassified epileptic encephalopathy.",385,353,385,353,393,361,-1,RO-has_definitional_manifestation,904941,"PET scans were normal in all five children with typical de novo Lennox-Gastaut syndrome but showed cortical metabolic abnormalities in three out of four with atypical de novo Lennox-Gastaut syndrome, five out of six with Lennox-Gastaut syndrome following infantile spasms, six out of eight with severe myoclonic epilepsy in infancy, one out of two with epilepsy with myoclonic-astatic seizures, and four out of six with an unclassified epileptic encephalopathy",seizures,epilepsy
503545381,7/16/2014 20:47:18,,1324469162,7/16/2014 20:47:14,prodege,1.0,26325260,GBR,"","",79.64.25.64,385,353,,,393,361,SEIZURES,EPILEPSY,"with myoclonic astatic SEIZURES, and four out",362-367-377-385-395-399-404,341-344-348-353-362-367-377,of two with EPILEPSY with myoclonic astatic,"PET scans were normal in all five children with typical de novo Lennox-Gastaut syndrome but showed cortical metabolic abnormalities in three out of four with atypical de novo Lennox-Gastaut syndrome, five out of six with Lennox-Gastaut syndrome following infantile spasms, six out of eight with severe myoclonic epilepsy in infancy, one out of two with epilepsy with myoclonic-astatic seizures, and four out of six with an unclassified epileptic encephalopathy.",385,353,385,353,393,361,-1,RO-has_definitional_manifestation,904941,"PET scans were normal in all five children with typical de novo Lennox-Gastaut syndrome but showed cortical metabolic abnormalities in three out of four with atypical de novo Lennox-Gastaut syndrome, five out of six with Lennox-Gastaut syndrome following infantile spasms, six out of eight with severe myoclonic epilepsy in infancy, one out of two with epilepsy with myoclonic-astatic seizures, and four out of six with an unclassified epileptic encephalopathy",seizures,epilepsy
503545381,7/16/2014 20:47:20,,1324469166,7/16/2014 20:46:59,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,385,353,,,393,361,SEIZURES,EPILEPSY,"myoclonic astatic SEIZURES,",367-377-385,353,EPILEPSY,"PET scans were normal in all five children with typical de novo Lennox-Gastaut syndrome but showed cortical metabolic abnormalities in three out of four with atypical de novo Lennox-Gastaut syndrome, five out of six with Lennox-Gastaut syndrome following infantile spasms, six out of eight with severe myoclonic epilepsy in infancy, one out of two with epilepsy with myoclonic-astatic seizures, and four out of six with an unclassified epileptic encephalopathy.",385,353,385,353,393,361,-1,RO-has_definitional_manifestation,904941,"PET scans were normal in all five children with typical de novo Lennox-Gastaut syndrome but showed cortical metabolic abnormalities in three out of four with atypical de novo Lennox-Gastaut syndrome, five out of six with Lennox-Gastaut syndrome following infantile spasms, six out of eight with severe myoclonic epilepsy in infancy, one out of two with epilepsy with myoclonic-astatic seizures, and four out of six with an unclassified epileptic encephalopathy",seizures,epilepsy
503545381,7/16/2014 20:47:19,,1324469171,7/16/2014 20:47:00,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,385,353,,,393,361,SEIZURES,EPILEPSY,"SEIZURES,",385,353,EPILEPSY,"PET scans were normal in all five children with typical de novo Lennox-Gastaut syndrome but showed cortical metabolic abnormalities in three out of four with atypical de novo Lennox-Gastaut syndrome, five out of six with Lennox-Gastaut syndrome following infantile spasms, six out of eight with severe myoclonic epilepsy in infancy, one out of two with epilepsy with myoclonic-astatic seizures, and four out of six with an unclassified epileptic encephalopathy.",385,353,385,353,393,361,-1,RO-has_definitional_manifestation,904941,"PET scans were normal in all five children with typical de novo Lennox-Gastaut syndrome but showed cortical metabolic abnormalities in three out of four with atypical de novo Lennox-Gastaut syndrome, five out of six with Lennox-Gastaut syndrome following infantile spasms, six out of eight with severe myoclonic epilepsy in infancy, one out of two with epilepsy with myoclonic-astatic seizures, and four out of six with an unclassified epileptic encephalopathy",seizures,epilepsy
503545381,7/16/2014 20:47:59,,1324469475,7/16/2014 20:47:28,eup_slw,1.0,28011002,CAN,MB,Winnipeg,24.77.44.140,385,353,,,393,361,SEIZURES,EPILEPSY,"SEIZURES, epileptic encephalopathy.",385-436-446,353-446-436,EPILEPSY epileptic encephalopathy.,"PET scans were normal in all five children with typical de novo Lennox-Gastaut syndrome but showed cortical metabolic abnormalities in three out of four with atypical de novo Lennox-Gastaut syndrome, five out of six with Lennox-Gastaut syndrome following infantile spasms, six out of eight with severe myoclonic epilepsy in infancy, one out of two with epilepsy with myoclonic-astatic seizures, and four out of six with an unclassified epileptic encephalopathy.",385,353,385,353,393,361,-1,RO-has_definitional_manifestation,904941,"PET scans were normal in all five children with typical de novo Lennox-Gastaut syndrome but showed cortical metabolic abnormalities in three out of four with atypical de novo Lennox-Gastaut syndrome, five out of six with Lennox-Gastaut syndrome following infantile spasms, six out of eight with severe myoclonic epilepsy in infancy, one out of two with epilepsy with myoclonic-astatic seizures, and four out of six with an unclassified epileptic encephalopathy",seizures,epilepsy
503545382,7/16/2014 20:35:54,,1324464588,7/16/2014 20:35:42,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,34,98,,,42,106,SEIZURES,EPILEPSY,SEIZURES,34,85-89-98,pre existing EPILEPSY,There was no reported increase in seizures after starting melatonin in children with pre-existing epilepsy and no new-onset seizures.,34,98,34,98,42,106,-1,RO-has_definitional_manifestation,904689,There was no reported increase in seizures after starting melatonin in children with pre-existing epilepsy and no new-onset seizures,seizures,epilepsy
503545382,7/16/2014 20:38:44,,1324465692,7/16/2014 20:38:42,clixsense,1.0,6610277,CAN,ON,Oshawa,174.117.79.122,34,98,,,42,106,SEIZURES,EPILEPSY,reported increase in SEIZURES after starting melatonin,13-22-31-34-43-49-58,80-85-89-98-107-111-114,with pre existing EPILEPSY and no new,There was no reported increase in seizures after starting melatonin in children with pre-existing epilepsy and no new-onset seizures.,34,98,34,98,42,106,-1,RO-has_definitional_manifestation,904689,There was no reported increase in seizures after starting melatonin in children with pre-existing epilepsy and no new-onset seizures,seizures,epilepsy
503545382,7/16/2014 20:40:01,,1324466264,7/16/2014 20:39:39,clixsense,1.0,24896327,GBR,V2,Glasgow,94.2.231.4,34,98,,,42,106,SEIZURES,EPILEPSY,SEIZURES,34,98,EPILEPSY,There was no reported increase in seizures after starting melatonin in children with pre-existing epilepsy and no new-onset seizures.,34,98,34,98,42,106,-1,RO-has_definitional_manifestation,904689,There was no reported increase in seizures after starting melatonin in children with pre-existing epilepsy and no new-onset seizures,seizures,epilepsy
503545382,7/16/2014 20:41:01,,1324466687,7/16/2014 20:40:29,eup_slw,1.0,28011002,CAN,MB,Winnipeg,24.77.44.140,34,98,,,42,106,SEIZURES,EPILEPSY,SEIZURES epilepsy,34-98,98-34,seizures EPILEPSY,There was no reported increase in seizures after starting melatonin in children with pre-existing epilepsy and no new-onset seizures.,34,98,34,98,42,106,-1,RO-has_definitional_manifestation,904689,There was no reported increase in seizures after starting melatonin in children with pre-existing epilepsy and no new-onset seizures,seizures,epilepsy
503545382,7/16/2014 20:41:01,,1324466690,7/16/2014 20:40:55,coinworker,1.0,28394550,USA,PA,Marcus Hook,71.175.96.184,34,98,,,42,106,SEIZURES,EPILEPSY,reported increase in SEIZURES after starting melatonin,13-22-31-34-43-49-58,80-85-89-98-107-111-114,with pre existing EPILEPSY and no new,There was no reported increase in seizures after starting melatonin in children with pre-existing epilepsy and no new-onset seizures.,34,98,34,98,42,106,-1,RO-has_definitional_manifestation,904689,There was no reported increase in seizures after starting melatonin in children with pre-existing epilepsy and no new-onset seizures,seizures,epilepsy
503545382,7/16/2014 20:41:36,,1324466932,7/16/2014 20:41:24,instagc,1.0,13763729,USA,"","",75.182.89.225,34,98,,,42,106,SEIZURES,EPILEPSY,SEIZURES,34,85-89-98,pre existing EPILEPSY,There was no reported increase in seizures after starting melatonin in children with pre-existing epilepsy and no new-onset seizures.,34,98,34,98,42,106,-1,RO-has_definitional_manifestation,904689,There was no reported increase in seizures after starting melatonin in children with pre-existing epilepsy and no new-onset seizures,seizures,epilepsy
503545382,7/16/2014 20:41:41,,1324466964,7/16/2014 20:41:31,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,34,98,,,42,106,SEIZURES,EPILEPSY,SEIZURES,34,85-89-98,pre existing EPILEPSY,There was no reported increase in seizures after starting melatonin in children with pre-existing epilepsy and no new-onset seizures.,34,98,34,98,42,106,-1,RO-has_definitional_manifestation,904689,There was no reported increase in seizures after starting melatonin in children with pre-existing epilepsy and no new-onset seizures,seizures,epilepsy
503545382,7/16/2014 20:44:25,,1324467943,7/16/2014 20:44:05,prodege,1.0,26325260,GBR,"","",79.64.25.64,34,98,,,42,106,SEIZURES,EPILEPSY,reported increase in SEIZURES after starting melatonin,13-22-31-34-43-49-58,80-85-89-98-107-111-114,with pre existing EPILEPSY and no new,There was no reported increase in seizures after starting melatonin in children with pre-existing epilepsy and no new-onset seizures.,34,98,34,98,42,106,-1,RO-has_definitional_manifestation,904689,There was no reported increase in seizures after starting melatonin in children with pre-existing epilepsy and no new-onset seizures,seizures,epilepsy
503545382,7/16/2014 20:46:30,,1324468814,7/16/2014 20:46:08,prodege,1.0,22360212,GBR,I1,Luton,82.6.41.191,34,98,,,42,106,SEIZURES,EPILEPSY,SEIZURES,34,98,EPILEPSY,There was no reported increase in seizures after starting melatonin in children with pre-existing epilepsy and no new-onset seizures.,34,98,34,98,42,106,-1,RO-has_definitional_manifestation,904689,There was no reported increase in seizures after starting melatonin in children with pre-existing epilepsy and no new-onset seizures,seizures,epilepsy
503545382,7/16/2014 20:48:01,,1324469518,7/16/2014 20:47:52,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,34,98,,,42,106,SEIZURES,EPILEPSY,reported increase in SEIZURES after starting melatonin,13-22-31-34-43-49-58,80-85-89-98-107-111-114,with pre existing EPILEPSY and no new,There was no reported increase in seizures after starting melatonin in children with pre-existing epilepsy and no new-onset seizures.,34,98,34,98,42,106,-1,RO-has_definitional_manifestation,904689,There was no reported increase in seizures after starting melatonin in children with pre-existing epilepsy and no new-onset seizures,seizures,epilepsy
503545383,7/16/2014 20:37:24,,1324465198,7/16/2014 20:37:18,clixsense,1.0,6610277,CAN,ON,Oshawa,174.117.79.122,163,89,,,182,93,TORSADES DE POINTES,HERG,arrhythmias known as TORSADES DE POINTES.,142-154-160-163-172-175,75-83-88-95-98-109,related gene (HERG) is considered the,Unintended inhibition of the cardiac potassium channel human ether-a-go-go-related gene (hERG) is considered the main culprit in drug-induced arrhythmias known as torsades de pointes.,163 172 175,,163,89,182,93,-1,RO-has_manifestation,906446,Unintended inhibition of the cardiac potassium channel human ether-a-go-go-related gene (hERG) is considered the main culprit in drug-induced arrhythmias known as torsades de pointes,torsades de pointes,hERG
503545383,7/16/2014 20:39:56,,1324466247,7/16/2014 20:39:32,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,163,89,,,182,93,TORSADES DE POINTES,HERG,TORSADES DE POINTES.,163-172-175,61-66-67-68-69-71-72-74-75-83-88,ether - a - go - go - related gene (HERG),Unintended inhibition of the cardiac potassium channel human ether-a-go-go-related gene (hERG) is considered the main culprit in drug-induced arrhythmias known as torsades de pointes.,163 172 175,,163,89,182,93,-1,RO-has_manifestation,906446,Unintended inhibition of the cardiac potassium channel human ether-a-go-go-related gene (hERG) is considered the main culprit in drug-induced arrhythmias known as torsades de pointes,torsades de pointes,hERG
503545383,7/16/2014 20:42:42,,1324467296,7/16/2014 20:42:19,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,163,89,,,182,93,TORSADES DE POINTES,HERG,TORSADES DE POINTES.,163-172-175,88,(HERG),Unintended inhibition of the cardiac potassium channel human ether-a-go-go-related gene (hERG) is considered the main culprit in drug-induced arrhythmias known as torsades de pointes.,163 172 175,,163,89,182,93,-1,RO-has_manifestation,906446,Unintended inhibition of the cardiac potassium channel human ether-a-go-go-related gene (hERG) is considered the main culprit in drug-induced arrhythmias known as torsades de pointes,torsades de pointes,hERG
503545383,7/16/2014 20:43:03,,1324467441,7/16/2014 20:42:54,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,163,89,,,182,93,TORSADES DE POINTES,HERG,arrhythmias known as TORSADES DE POINTES.,142-154-160-163-172-175,75-83-88-95-98-109,related gene (HERG) is considered the,Unintended inhibition of the cardiac potassium channel human ether-a-go-go-related gene (hERG) is considered the main culprit in drug-induced arrhythmias known as torsades de pointes.,163 172 175,,163,89,182,93,-1,RO-has_manifestation,906446,Unintended inhibition of the cardiac potassium channel human ether-a-go-go-related gene (hERG) is considered the main culprit in drug-induced arrhythmias known as torsades de pointes,torsades de pointes,hERG
503545383,7/16/2014 20:43:16,,1324467497,7/16/2014 20:42:56,clixsense,1.0,24896327,GBR,V2,Glasgow,94.2.231.4,163,89,,,182,93,TORSADES DE POINTES,HERG,TORSADES DE POINTES.,163-172-175,75-83-88,related gene (HERG),Unintended inhibition of the cardiac potassium channel human ether-a-go-go-related gene (hERG) is considered the main culprit in drug-induced arrhythmias known as torsades de pointes.,163 172 175,,163,89,182,93,-1,RO-has_manifestation,906446,Unintended inhibition of the cardiac potassium channel human ether-a-go-go-related gene (hERG) is considered the main culprit in drug-induced arrhythmias known as torsades de pointes,torsades de pointes,hERG
503545383,7/16/2014 20:44:01,,1324467760,7/16/2014 20:43:46,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,163,89,,,182,93,TORSADES DE POINTES,HERG,TORSADES DE POINTES.,163-172-175,,,Unintended inhibition of the cardiac potassium channel human ether-a-go-go-related gene (hERG) is considered the main culprit in drug-induced arrhythmias known as torsades de pointes.,163 172 175,,163,89,182,93,-1,RO-has_manifestation,906446,Unintended inhibition of the cardiac potassium channel human ether-a-go-go-related gene (hERG) is considered the main culprit in drug-induced arrhythmias known as torsades de pointes,torsades de pointes,hERG
503545383,7/16/2014 20:46:58,,1324469038,7/16/2014 20:46:28,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,163,89,,,182,93,TORSADES DE POINTES,HERG,TORSADES DE POINTES.,163-172-175,55-61-67-69-71-72-75-83-88,human ether a go - go related gene (HERG),Unintended inhibition of the cardiac potassium channel human ether-a-go-go-related gene (hERG) is considered the main culprit in drug-induced arrhythmias known as torsades de pointes.,163 172 175,,163,89,182,93,-1,RO-has_manifestation,906446,Unintended inhibition of the cardiac potassium channel human ether-a-go-go-related gene (hERG) is considered the main culprit in drug-induced arrhythmias known as torsades de pointes,torsades de pointes,hERG
503545383,7/16/2014 20:50:02,,1324470446,7/16/2014 20:48:18,prodege,1.0,4968858,USA,CA,Corona,99.44.120.153,163,89,,,182,93,TORSADES DE POINTES,HERG,TORSADES DE POINTES.,163-172-175,0-11-22-25-29-37-47-88,Unintended inhibition of the cardiac potassium channel (HERG),Unintended inhibition of the cardiac potassium channel human ether-a-go-go-related gene (hERG) is considered the main culprit in drug-induced arrhythmias known as torsades de pointes.,163 172 175,,163,89,182,93,-1,RO-has_manifestation,906446,Unintended inhibition of the cardiac potassium channel human ether-a-go-go-related gene (hERG) is considered the main culprit in drug-induced arrhythmias known as torsades de pointes,torsades de pointes,hERG
503545383,7/16/2014 20:51:35,,1324471023,7/16/2014 20:51:14,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,163,89,,,182,93,TORSADES DE POINTES,HERG,TORSADES DE POINTES.,163-172-175,55-61-66-67-69-72-75-83-88,human ether - a go go related gene (HERG),Unintended inhibition of the cardiac potassium channel human ether-a-go-go-related gene (hERG) is considered the main culprit in drug-induced arrhythmias known as torsades de pointes.,163 172 175,,163,89,182,93,-1,RO-has_manifestation,906446,Unintended inhibition of the cardiac potassium channel human ether-a-go-go-related gene (hERG) is considered the main culprit in drug-induced arrhythmias known as torsades de pointes,torsades de pointes,hERG
503545383,7/16/2014 20:53:42,,1324471867,7/16/2014 20:52:48,eup_slw,1.0,28011002,CAN,MB,Winnipeg,24.77.44.140,163,89,,,182,93,TORSADES DE POINTES,HERG,arrhythmias TORSADES DE POINTES.,163-172-175-142,88,(HERG),Unintended inhibition of the cardiac potassium channel human ether-a-go-go-related gene (hERG) is considered the main culprit in drug-induced arrhythmias known as torsades de pointes.,163 172 175,,163,89,182,93,-1,RO-has_manifestation,906446,Unintended inhibition of the cardiac potassium channel human ether-a-go-go-related gene (hERG) is considered the main culprit in drug-induced arrhythmias known as torsades de pointes,torsades de pointes,hERG
503545384,7/16/2014 20:37:31,,1324465228,7/16/2014 20:37:29,clixsense,1.0,6610277,CAN,ON,Oshawa,174.117.79.122,80,112,,,89,146,DYSPLASIA,CERVICAL INTRAEPITHELIAL NEOPLASIA,made in the DYSPLASIA carcinoma in situ,68-73-76-80-90-100-103,100-103-108-112-121-137-153-170,"in situ and CERVICAL INTRAEPITHELIAL NEOPLASIA classifications, CIN1","The Bethesda System eliminates two diagnostic distinctions that are made in the dysplasia/carcinoma in situ and cervical intraepithelial neoplasia (CIN) classifications, CIN1 vs koilocytotic atypia and CIN2 vs CIN3, and maintains three others, negative vs ASQUS, ASQUS vs koilocytotic atypia, and CIN1 vs CIN2.",80,112 121 137,80,112,89,146,-1,RO-disease_has_finding,901520,"The Bethesda System eliminates two diagnostic distinctions that are made in the dysplasia/carcinoma in situ and cervical intraepithelial neoplasia (CIN) classifications, CIN1 vs koilocytotic atypia and CIN2 vs CIN3, and maintains three others, negative vs ASQUS, ASQUS vs koilocytotic atypia, and CIN1 vs CIN2",dysplasia,cervical intraepithelial neoplasia
503545384,7/16/2014 20:38:41,,1324465677,7/16/2014 20:38:18,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,80,112,,,89,146,DYSPLASIA,CERVICAL INTRAEPITHELIAL NEOPLASIA,DYSPLASIA carcinoma,80-90,112-121-137-153-147,"CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN) classifications,","The Bethesda System eliminates two diagnostic distinctions that are made in the dysplasia/carcinoma in situ and cervical intraepithelial neoplasia (CIN) classifications, CIN1 vs koilocytotic atypia and CIN2 vs CIN3, and maintains three others, negative vs ASQUS, ASQUS vs koilocytotic atypia, and CIN1 vs CIN2.",80,112 121 137,80,112,89,146,-1,RO-disease_has_finding,901520,"The Bethesda System eliminates two diagnostic distinctions that are made in the dysplasia/carcinoma in situ and cervical intraepithelial neoplasia (CIN) classifications, CIN1 vs koilocytotic atypia and CIN2 vs CIN3, and maintains three others, negative vs ASQUS, ASQUS vs koilocytotic atypia, and CIN1 vs CIN2",dysplasia,cervical intraepithelial neoplasia
503545384,7/16/2014 20:42:23,,1324467187,7/16/2014 20:42:21,coinworker,1.0,28394550,USA,PA,Marcus Hook,71.175.96.184,80,112,,,89,146,DYSPLASIA,CERVICAL INTRAEPITHELIAL NEOPLASIA,made in the DYSPLASIA carcinoma in situ,68-73-76-80-90-100-103,100-103-108-112-121-137-153-170,"in situ and CERVICAL INTRAEPITHELIAL NEOPLASIA classifications, CIN1","The Bethesda System eliminates two diagnostic distinctions that are made in the dysplasia/carcinoma in situ and cervical intraepithelial neoplasia (CIN) classifications, CIN1 vs koilocytotic atypia and CIN2 vs CIN3, and maintains three others, negative vs ASQUS, ASQUS vs koilocytotic atypia, and CIN1 vs CIN2.",80,112 121 137,80,112,89,146,-1,RO-disease_has_finding,901520,"The Bethesda System eliminates two diagnostic distinctions that are made in the dysplasia/carcinoma in situ and cervical intraepithelial neoplasia (CIN) classifications, CIN1 vs koilocytotic atypia and CIN2 vs CIN3, and maintains three others, negative vs ASQUS, ASQUS vs koilocytotic atypia, and CIN1 vs CIN2",dysplasia,cervical intraepithelial neoplasia
503545384,7/16/2014 20:42:49,,1324467334,7/16/2014 20:42:39,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,80,112,,,89,146,DYSPLASIA,CERVICAL INTRAEPITHELIAL NEOPLASIA,made in the DYSPLASIA carcinoma in situ,68-73-76-80-90-100-103,100-103-108-112-121-137-153-170,"in situ and CERVICAL INTRAEPITHELIAL NEOPLASIA classifications, CIN1","The Bethesda System eliminates two diagnostic distinctions that are made in the dysplasia/carcinoma in situ and cervical intraepithelial neoplasia (CIN) classifications, CIN1 vs koilocytotic atypia and CIN2 vs CIN3, and maintains three others, negative vs ASQUS, ASQUS vs koilocytotic atypia, and CIN1 vs CIN2.",80,112 121 137,80,112,89,146,-1,RO-disease_has_finding,901520,"The Bethesda System eliminates two diagnostic distinctions that are made in the dysplasia/carcinoma in situ and cervical intraepithelial neoplasia (CIN) classifications, CIN1 vs koilocytotic atypia and CIN2 vs CIN3, and maintains three others, negative vs ASQUS, ASQUS vs koilocytotic atypia, and CIN1 vs CIN2",dysplasia,cervical intraepithelial neoplasia
503545384,7/16/2014 20:43:09,,1324467472,7/16/2014 20:43:07,bitcoinget,1.0,24792414,USA,"","",166.181.81.55,80,112,,,89,146,DYSPLASIA,CERVICAL INTRAEPITHELIAL NEOPLASIA,made in the DYSPLASIA carcinoma in situ,68-73-76-80-90-100-103,100-103-108-112-121-137-153-170,"in situ and CERVICAL INTRAEPITHELIAL NEOPLASIA classifications, CIN1","The Bethesda System eliminates two diagnostic distinctions that are made in the dysplasia/carcinoma in situ and cervical intraepithelial neoplasia (CIN) classifications, CIN1 vs koilocytotic atypia and CIN2 vs CIN3, and maintains three others, negative vs ASQUS, ASQUS vs koilocytotic atypia, and CIN1 vs CIN2.",80,112 121 137,80,112,89,146,-1,RO-disease_has_finding,901520,"The Bethesda System eliminates two diagnostic distinctions that are made in the dysplasia/carcinoma in situ and cervical intraepithelial neoplasia (CIN) classifications, CIN1 vs koilocytotic atypia and CIN2 vs CIN3, and maintains three others, negative vs ASQUS, ASQUS vs koilocytotic atypia, and CIN1 vs CIN2",dysplasia,cervical intraepithelial neoplasia
503545384,7/16/2014 20:46:53,,1324469011,7/16/2014 20:46:08,eup_slw,1.0,28011002,CAN,MB,Winnipeg,24.77.44.140,80,112,,,89,146,DYSPLASIA,CERVICAL INTRAEPITHELIAL NEOPLASIA,DYSPLASIA,80,112-121-137-147-170-178-191-202-210,"CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN) CIN1 koilocytotic atypia CIN2 CIN3,","The Bethesda System eliminates two diagnostic distinctions that are made in the dysplasia/carcinoma in situ and cervical intraepithelial neoplasia (CIN) classifications, CIN1 vs koilocytotic atypia and CIN2 vs CIN3, and maintains three others, negative vs ASQUS, ASQUS vs koilocytotic atypia, and CIN1 vs CIN2.",80,112 121 137,80,112,89,146,-1,RO-disease_has_finding,901520,"The Bethesda System eliminates two diagnostic distinctions that are made in the dysplasia/carcinoma in situ and cervical intraepithelial neoplasia (CIN) classifications, CIN1 vs koilocytotic atypia and CIN2 vs CIN3, and maintains three others, negative vs ASQUS, ASQUS vs koilocytotic atypia, and CIN1 vs CIN2",dysplasia,cervical intraepithelial neoplasia
503545384,7/16/2014 20:47:41,,1324469337,7/16/2014 20:47:15,prodege,1.0,22360212,GBR,I1,Luton,82.6.41.191,80,112,,,89,146,DYSPLASIA,CERVICAL INTRAEPITHELIAL NEOPLASIA,DYSPLASIA,80,112-121-137,CERVICAL INTRAEPITHELIAL NEOPLASIA,"The Bethesda System eliminates two diagnostic distinctions that are made in the dysplasia/carcinoma in situ and cervical intraepithelial neoplasia (CIN) classifications, CIN1 vs koilocytotic atypia and CIN2 vs CIN3, and maintains three others, negative vs ASQUS, ASQUS vs koilocytotic atypia, and CIN1 vs CIN2.",80,112 121 137,80,112,89,146,-1,RO-disease_has_finding,901520,"The Bethesda System eliminates two diagnostic distinctions that are made in the dysplasia/carcinoma in situ and cervical intraepithelial neoplasia (CIN) classifications, CIN1 vs koilocytotic atypia and CIN2 vs CIN3, and maintains three others, negative vs ASQUS, ASQUS vs koilocytotic atypia, and CIN1 vs CIN2",dysplasia,cervical intraepithelial neoplasia
503545384,7/16/2014 20:49:26,,1324470176,7/16/2014 20:49:08,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,80,112,,,89,146,DYSPLASIA,CERVICAL INTRAEPITHELIAL NEOPLASIA,DYSPLASIA carcinoma in situ,80-90-100-103,112-121-137-147-153,"CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN) classifications,","The Bethesda System eliminates two diagnostic distinctions that are made in the dysplasia/carcinoma in situ and cervical intraepithelial neoplasia (CIN) classifications, CIN1 vs koilocytotic atypia and CIN2 vs CIN3, and maintains three others, negative vs ASQUS, ASQUS vs koilocytotic atypia, and CIN1 vs CIN2.",80,112 121 137,80,112,89,146,-1,RO-disease_has_finding,901520,"The Bethesda System eliminates two diagnostic distinctions that are made in the dysplasia/carcinoma in situ and cervical intraepithelial neoplasia (CIN) classifications, CIN1 vs koilocytotic atypia and CIN2 vs CIN3, and maintains three others, negative vs ASQUS, ASQUS vs koilocytotic atypia, and CIN1 vs CIN2",dysplasia,cervical intraepithelial neoplasia
503545384,7/16/2014 20:53:29,,1324471787,7/16/2014 20:53:10,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,80,112,,,89,146,DYSPLASIA,CERVICAL INTRAEPITHELIAL NEOPLASIA,DYSPLASIA carcinoma,80-90,112-121-137-147,CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN),"The Bethesda System eliminates two diagnostic distinctions that are made in the dysplasia/carcinoma in situ and cervical intraepithelial neoplasia (CIN) classifications, CIN1 vs koilocytotic atypia and CIN2 vs CIN3, and maintains three others, negative vs ASQUS, ASQUS vs koilocytotic atypia, and CIN1 vs CIN2.",80,112 121 137,80,112,89,146,-1,RO-disease_has_finding,901520,"The Bethesda System eliminates two diagnostic distinctions that are made in the dysplasia/carcinoma in situ and cervical intraepithelial neoplasia (CIN) classifications, CIN1 vs koilocytotic atypia and CIN2 vs CIN3, and maintains three others, negative vs ASQUS, ASQUS vs koilocytotic atypia, and CIN1 vs CIN2",dysplasia,cervical intraepithelial neoplasia
503545384,7/16/2014 20:53:44,,1324471886,7/16/2014 20:53:15,prodege,1.0,4968858,USA,CA,Corona,99.44.120.153,80,112,,,89,146,DYSPLASIA,CERVICAL INTRAEPITHELIAL NEOPLASIA,DYSPLASIA,80,112-121-137,CERVICAL INTRAEPITHELIAL NEOPLASIA,"The Bethesda System eliminates two diagnostic distinctions that are made in the dysplasia/carcinoma in situ and cervical intraepithelial neoplasia (CIN) classifications, CIN1 vs koilocytotic atypia and CIN2 vs CIN3, and maintains three others, negative vs ASQUS, ASQUS vs koilocytotic atypia, and CIN1 vs CIN2.",80,112 121 137,80,112,89,146,-1,RO-disease_has_finding,901520,"The Bethesda System eliminates two diagnostic distinctions that are made in the dysplasia/carcinoma in situ and cervical intraepithelial neoplasia (CIN) classifications, CIN1 vs koilocytotic atypia and CIN2 vs CIN3, and maintains three others, negative vs ASQUS, ASQUS vs koilocytotic atypia, and CIN1 vs CIN2",dysplasia,cervical intraepithelial neoplasia
503545385,7/16/2014 20:32:56,,1324463430,7/16/2014 20:32:27,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,101,69,,,121,79,RENAL CELL CARCINOMA,INTERFERON,advanced RENAL CELL CARCINOMA.,92-101-107-112,69-80,INTERFERON therapy,"Abdi EA, Nguyen GK, Ludwig RN et al. Pulmonary sarcoidosis following interferon therapy for advanced renal cell carcinoma.",101 107 112,69,101,69,121,79,1,RO-may_treat,907579,"Abdi EA, Nguyen GK, Ludwig RN et al. Pulmonary sarcoidosis following interferon therapy for advanced renal cell carcinoma",renal cell carcinoma,interferon
503545385,7/16/2014 20:34:58,,1324464177,7/16/2014 20:34:38,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,101,69,,,121,79,RENAL CELL CARCINOMA,INTERFERON,advanced RENAL CELL CARCINOMA.,101-107-112-92,69-80,INTERFERON therapy,"Abdi EA, Nguyen GK, Ludwig RN et al. Pulmonary sarcoidosis following interferon therapy for advanced renal cell carcinoma.",101 107 112,69,101,69,121,79,1,RO-may_treat,907579,"Abdi EA, Nguyen GK, Ludwig RN et al. Pulmonary sarcoidosis following interferon therapy for advanced renal cell carcinoma",renal cell carcinoma,interferon
503545385,7/16/2014 20:35:36,,1324464444,7/16/2014 20:35:18,clixsense,1.0,24896327,GBR,V2,Glasgow,94.2.231.4,101,69,,,121,79,RENAL CELL CARCINOMA,INTERFERON,RENAL CELL CARCINOMA.,101-107-112,69-80,INTERFERON therapy,"Abdi EA, Nguyen GK, Ludwig RN et al. Pulmonary sarcoidosis following interferon therapy for advanced renal cell carcinoma.",101 107 112,69,101,69,121,79,1,RO-may_treat,907579,"Abdi EA, Nguyen GK, Ludwig RN et al. Pulmonary sarcoidosis following interferon therapy for advanced renal cell carcinoma",renal cell carcinoma,interferon
503545385,7/16/2014 20:38:03,,1324465417,7/16/2014 20:38:01,clixsense,1.0,6610277,CAN,ON,Oshawa,174.117.79.122,101,69,,,121,79,RENAL CELL CARCINOMA,INTERFERON,therapy for advanced RENAL CELL CARCINOMA.,80-88-92-101-107-112,37-47-59-69-80-88-92,Pulmonary sarcoidosis following INTERFERON therapy for advanced,"Abdi EA, Nguyen GK, Ludwig RN et al. Pulmonary sarcoidosis following interferon therapy for advanced renal cell carcinoma.",101 107 112,69,101,69,121,79,1,RO-may_treat,907579,"Abdi EA, Nguyen GK, Ludwig RN et al. Pulmonary sarcoidosis following interferon therapy for advanced renal cell carcinoma",renal cell carcinoma,interferon
503545385,7/16/2014 20:42:21,,1324467176,7/16/2014 20:42:14,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,101,69,,,121,79,RENAL CELL CARCINOMA,INTERFERON,therapy for advanced RENAL CELL CARCINOMA.,80-88-92-101-107-112,37-47-59-69-80-88-92,Pulmonary sarcoidosis following INTERFERON therapy for advanced,"Abdi EA, Nguyen GK, Ludwig RN et al. Pulmonary sarcoidosis following interferon therapy for advanced renal cell carcinoma.",101 107 112,69,101,69,121,79,1,RO-may_treat,907579,"Abdi EA, Nguyen GK, Ludwig RN et al. Pulmonary sarcoidosis following interferon therapy for advanced renal cell carcinoma",renal cell carcinoma,interferon
503545385,7/16/2014 20:42:29,,1324467241,7/16/2014 20:42:27,coinworker,1.0,28394550,USA,PA,Marcus Hook,71.175.96.184,101,69,,,121,79,RENAL CELL CARCINOMA,INTERFERON,therapy for advanced RENAL CELL CARCINOMA.,80-88-92-101-107-112,37-47-59-69-80-88-92,Pulmonary sarcoidosis following INTERFERON therapy for advanced,"Abdi EA, Nguyen GK, Ludwig RN et al. Pulmonary sarcoidosis following interferon therapy for advanced renal cell carcinoma.",101 107 112,69,101,69,121,79,1,RO-may_treat,907579,"Abdi EA, Nguyen GK, Ludwig RN et al. Pulmonary sarcoidosis following interferon therapy for advanced renal cell carcinoma",renal cell carcinoma,interferon
503545385,7/16/2014 20:43:24,,1324467543,7/16/2014 20:43:10,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,101,69,,,121,79,RENAL CELL CARCINOMA,INTERFERON,RENAL CELL CARCINOMA.,101-107-112,69-80,INTERFERON therapy,"Abdi EA, Nguyen GK, Ludwig RN et al. Pulmonary sarcoidosis following interferon therapy for advanced renal cell carcinoma.",101 107 112,69,101,69,121,79,1,RO-may_treat,907579,"Abdi EA, Nguyen GK, Ludwig RN et al. Pulmonary sarcoidosis following interferon therapy for advanced renal cell carcinoma",renal cell carcinoma,interferon
503545385,7/16/2014 20:44:50,,1324468089,7/16/2014 20:44:39,instagc,1.0,13763729,USA,"","",75.182.89.225,101,69,,,121,79,RENAL CELL CARCINOMA,INTERFERON,advanced RENAL CELL CARCINOMA.,92-101-107-112,69-80,INTERFERON therapy,"Abdi EA, Nguyen GK, Ludwig RN et al. Pulmonary sarcoidosis following interferon therapy for advanced renal cell carcinoma.",101 107 112,69,101,69,121,79,1,RO-may_treat,907579,"Abdi EA, Nguyen GK, Ludwig RN et al. Pulmonary sarcoidosis following interferon therapy for advanced renal cell carcinoma",renal cell carcinoma,interferon
503545385,7/16/2014 20:45:04,,1324468164,7/16/2014 20:44:43,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,101,69,,,121,79,RENAL CELL CARCINOMA,INTERFERON,RENAL CELL CARCINOMA.,101-107-112,69,INTERFERON,"Abdi EA, Nguyen GK, Ludwig RN et al. Pulmonary sarcoidosis following interferon therapy for advanced renal cell carcinoma.",101 107 112,69,101,69,121,79,1,RO-may_treat,907579,"Abdi EA, Nguyen GK, Ludwig RN et al. Pulmonary sarcoidosis following interferon therapy for advanced renal cell carcinoma",renal cell carcinoma,interferon
503545385,7/16/2014 20:46:29,,1324468784,7/16/2014 20:46:25,prodege,1.0,26325260,GBR,"","",79.64.25.64,101,69,,,121,79,RENAL CELL CARCINOMA,INTERFERON,therapy for advanced RENAL CELL CARCINOMA.,80-88-92-101-107-112,37-47-59-69-80-88-92,Pulmonary sarcoidosis following INTERFERON therapy for advanced,"Abdi EA, Nguyen GK, Ludwig RN et al. Pulmonary sarcoidosis following interferon therapy for advanced renal cell carcinoma.",101 107 112,69,101,69,121,79,1,RO-may_treat,907579,"Abdi EA, Nguyen GK, Ludwig RN et al. Pulmonary sarcoidosis following interferon therapy for advanced renal cell carcinoma",renal cell carcinoma,interferon
503545386,7/16/2014 20:37:26,,1324465201,7/16/2014 20:36:59,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,101,49,,,110,62,DYSPLASIA,FLAT ADENOMAS,high grade DYSPLASIA,90-95-101,49-54,FLAT ADENOMAS,"Compared with polypoid adenomas of similar size, flat adenomas show a higher frequency of high-grade dysplasia and rapid submucosal invasion.",101,49 54,101,49,110,62,1,RO-disease_has_finding,901798,"Compared with polypoid adenomas of similar size, flat adenomas show a higher frequency of high-grade dysplasia and rapid submucosal invasion",dysplasia,flat adenomas
503545386,7/16/2014 20:37:51,,1324465325,7/16/2014 20:36:49,eup_slw,1.0,28011002,CAN,MB,Winnipeg,24.77.44.140,101,49,,,110,62,DYSPLASIA,FLAT ADENOMAS,polypoid adenomas DYSPLASIA,14-101-23,49-54-101,FLAT ADENOMAS dysplasia,"Compared with polypoid adenomas of similar size, flat adenomas show a higher frequency of high-grade dysplasia and rapid submucosal invasion.",101,49 54,101,49,110,62,1,RO-disease_has_finding,901798,"Compared with polypoid adenomas of similar size, flat adenomas show a higher frequency of high-grade dysplasia and rapid submucosal invasion",dysplasia,flat adenomas
503545386,7/16/2014 20:38:26,,1324465567,7/16/2014 20:38:18,clixsense,1.0,6610277,CAN,ON,Oshawa,174.117.79.122,101,49,,,110,62,DYSPLASIA,FLAT ADENOMAS,of high grade DYSPLASIA and rapid submucosal,87-90-95-101-111-115-121,49-54-63-68-70,FLAT ADENOMAS show a higher,"Compared with polypoid adenomas of similar size, flat adenomas show a higher frequency of high-grade dysplasia and rapid submucosal invasion.",101,49 54,101,49,110,62,1,RO-disease_has_finding,901798,"Compared with polypoid adenomas of similar size, flat adenomas show a higher frequency of high-grade dysplasia and rapid submucosal invasion",dysplasia,flat adenomas
503545386,7/16/2014 20:40:46,,1324466580,7/16/2014 20:40:22,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,101,49,,,110,62,DYSPLASIA,FLAT ADENOMAS,DYSPLASIA,101,49-54,FLAT ADENOMAS,"Compared with polypoid adenomas of similar size, flat adenomas show a higher frequency of high-grade dysplasia and rapid submucosal invasion.",101,49 54,101,49,110,62,1,RO-disease_has_finding,901798,"Compared with polypoid adenomas of similar size, flat adenomas show a higher frequency of high-grade dysplasia and rapid submucosal invasion",dysplasia,flat adenomas
503545386,7/16/2014 20:43:09,,1324467479,7/16/2014 20:42:57,instagc,1.0,13763729,USA,"","",75.182.89.225,101,49,,,110,62,DYSPLASIA,FLAT ADENOMAS,high grade DYSPLASIA,90-95-101,49-54,FLAT ADENOMAS,"Compared with polypoid adenomas of similar size, flat adenomas show a higher frequency of high-grade dysplasia and rapid submucosal invasion.",101,49 54,101,49,110,62,1,RO-disease_has_finding,901798,"Compared with polypoid adenomas of similar size, flat adenomas show a higher frequency of high-grade dysplasia and rapid submucosal invasion",dysplasia,flat adenomas
503545386,7/16/2014 20:45:33,,1324468371,7/16/2014 20:45:17,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,101,49,,,110,62,DYSPLASIA,FLAT ADENOMAS,DYSPLASIA,101,49-54,FLAT ADENOMAS,"Compared with polypoid adenomas of similar size, flat adenomas show a higher frequency of high-grade dysplasia and rapid submucosal invasion.",101,49 54,101,49,110,62,1,RO-disease_has_finding,901798,"Compared with polypoid adenomas of similar size, flat adenomas show a higher frequency of high-grade dysplasia and rapid submucosal invasion",dysplasia,flat adenomas
503545386,7/16/2014 20:46:16,,1324468708,7/16/2014 20:45:55,prodege,1.0,9997387,USA,CO,Colorado Springs,75.70.112.31,101,49,,,110,62,DYSPLASIA,FLAT ADENOMAS,flat adenomas DYSPLASIA,49-54-101,49-54-101,FLAT ADENOMAS dysplasia,"Compared with polypoid adenomas of similar size, flat adenomas show a higher frequency of high-grade dysplasia and rapid submucosal invasion.",101,49 54,101,49,110,62,1,RO-disease_has_finding,901798,"Compared with polypoid adenomas of similar size, flat adenomas show a higher frequency of high-grade dysplasia and rapid submucosal invasion",dysplasia,flat adenomas
503545386,7/16/2014 20:46:31,,1324468828,7/16/2014 20:46:19,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,101,49,,,110,62,DYSPLASIA,FLAT ADENOMAS,DYSPLASIA,101,49-54,FLAT ADENOMAS,"Compared with polypoid adenomas of similar size, flat adenomas show a higher frequency of high-grade dysplasia and rapid submucosal invasion.",101,49 54,101,49,110,62,1,RO-disease_has_finding,901798,"Compared with polypoid adenomas of similar size, flat adenomas show a higher frequency of high-grade dysplasia and rapid submucosal invasion",dysplasia,flat adenomas
503545386,7/16/2014 20:51:36,,1324471035,7/16/2014 20:50:52,prodege,1.0,4968858,USA,CA,Corona,99.44.120.153,101,49,,,110,62,DYSPLASIA,FLAT ADENOMAS,high grade DYSPLASIA,90-95-101,49-54,FLAT ADENOMAS,"Compared with polypoid adenomas of similar size, flat adenomas show a higher frequency of high-grade dysplasia and rapid submucosal invasion.",101,49 54,101,49,110,62,1,RO-disease_has_finding,901798,"Compared with polypoid adenomas of similar size, flat adenomas show a higher frequency of high-grade dysplasia and rapid submucosal invasion",dysplasia,flat adenomas
503545386,7/16/2014 20:52:34,,1324471483,7/16/2014 20:52:14,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,101,49,,,110,62,DYSPLASIA,FLAT ADENOMAS,high grade DYSPLASIA,90-95-101,49-54,FLAT ADENOMAS,"Compared with polypoid adenomas of similar size, flat adenomas show a higher frequency of high-grade dysplasia and rapid submucosal invasion.",101,49 54,101,49,110,62,1,RO-disease_has_finding,901798,"Compared with polypoid adenomas of similar size, flat adenomas show a higher frequency of high-grade dysplasia and rapid submucosal invasion",dysplasia,flat adenomas
503545387,7/16/2014 20:33:52,,1324463764,7/16/2014 20:33:37,clixsense,1.0,24896327,GBR,V2,Glasgow,94.2.231.4,46,0,,,63,16,DIABETES MELLITUS,WOLFRAM SYNDROME,"DIABETES MELLITUS,",46-55,0-8,WOLFRAM SYNDROME,"Wolfram syndrome (WS), an infrequent cause of diabetes mellitus, derives its name from the physician who first reported the combination of juvenile-onset diabetes mellitus and optic atrophy.",46 55,0 8,46,0,63,16,1,RO-has_manifestation,906470,"Wolfram syndrome (WS), an infrequent cause of diabetes mellitus, derives its name from the physician who first reported the combination of juvenile-onset diabetes mellitus and optic atrophy",diabetes mellitus,Wolfram syndrome
503545387,7/16/2014 20:36:47,,1324464946,7/16/2014 20:35:54,eup_slw,1.0,28011002,CAN,MB,Winnipeg,24.77.44.140,46,0,,,63,16,DIABETES MELLITUS,WOLFRAM SYNDROME,"DIABETES MELLITUS, optic atrophy.",46-55-176-182,0-8-154-163-176-182,WOLFRAM SYNDROME diabetes mellitus optic atrophy.,"Wolfram syndrome (WS), an infrequent cause of diabetes mellitus, derives its name from the physician who first reported the combination of juvenile-onset diabetes mellitus and optic atrophy.",46 55,0 8,46,0,63,16,1,RO-has_manifestation,906470,"Wolfram syndrome (WS), an infrequent cause of diabetes mellitus, derives its name from the physician who first reported the combination of juvenile-onset diabetes mellitus and optic atrophy",diabetes mellitus,Wolfram syndrome
503545387,7/16/2014 20:37:53,,1324465349,7/16/2014 20:37:39,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,46,0,,,63,16,DIABETES MELLITUS,WOLFRAM SYNDROME,"DIABETES MELLITUS,",46-55,0-8,WOLFRAM SYNDROME,"Wolfram syndrome (WS), an infrequent cause of diabetes mellitus, derives its name from the physician who first reported the combination of juvenile-onset diabetes mellitus and optic atrophy.",46 55,0 8,46,0,63,16,1,RO-has_manifestation,906470,"Wolfram syndrome (WS), an infrequent cause of diabetes mellitus, derives its name from the physician who first reported the combination of juvenile-onset diabetes mellitus and optic atrophy",diabetes mellitus,Wolfram syndrome
503545387,7/16/2014 20:40:02,,1324466285,7/16/2014 20:39:56,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,46,0,,,63,16,DIABETES MELLITUS,WOLFRAM SYNDROME,"DIABETES MELLITUS,",46-55,0-8,WOLFRAM SYNDROME,"Wolfram syndrome (WS), an infrequent cause of diabetes mellitus, derives its name from the physician who first reported the combination of juvenile-onset diabetes mellitus and optic atrophy.",46 55,0 8,46,0,63,16,1,RO-has_manifestation,906470,"Wolfram syndrome (WS), an infrequent cause of diabetes mellitus, derives its name from the physician who first reported the combination of juvenile-onset diabetes mellitus and optic atrophy",diabetes mellitus,Wolfram syndrome
503545387,7/16/2014 20:42:05,,1324467109,7/16/2014 20:42:03,coinworker,1.0,28394550,USA,PA,Marcus Hook,71.175.96.184,46,0,,,63,16,DIABETES MELLITUS,WOLFRAM SYNDROME,"infrequent cause of DIABETES MELLITUS, derives its name",26-37-43-46-55-65-73-77,0-8-23-26,WOLFRAM SYNDROME an infrequent,"Wolfram syndrome (WS), an infrequent cause of diabetes mellitus, derives its name from the physician who first reported the combination of juvenile-onset diabetes mellitus and optic atrophy.",46 55,0 8,46,0,63,16,1,RO-has_manifestation,906470,"Wolfram syndrome (WS), an infrequent cause of diabetes mellitus, derives its name from the physician who first reported the combination of juvenile-onset diabetes mellitus and optic atrophy",diabetes mellitus,Wolfram syndrome
503545387,7/16/2014 20:46:07,,1324468638,7/16/2014 20:45:57,instagc,1.0,13763729,USA,"","",75.182.89.225,46,0,,,63,16,DIABETES MELLITUS,WOLFRAM SYNDROME,"DIABETES MELLITUS,",46-55,0-8,WOLFRAM SYNDROME,"Wolfram syndrome (WS), an infrequent cause of diabetes mellitus, derives its name from the physician who first reported the combination of juvenile-onset diabetes mellitus and optic atrophy.",46 55,0 8,46,0,63,16,1,RO-has_manifestation,906470,"Wolfram syndrome (WS), an infrequent cause of diabetes mellitus, derives its name from the physician who first reported the combination of juvenile-onset diabetes mellitus and optic atrophy",diabetes mellitus,Wolfram syndrome
503545387,7/16/2014 20:46:42,,1324468910,7/16/2014 20:46:39,prodege,1.0,26325260,GBR,"","",79.64.25.64,46,0,,,63,16,DIABETES MELLITUS,WOLFRAM SYNDROME,"infrequent cause of DIABETES MELLITUS, derives its name",26-37-43-46-55-65-73-77,0-8-23-26,WOLFRAM SYNDROME an infrequent,"Wolfram syndrome (WS), an infrequent cause of diabetes mellitus, derives its name from the physician who first reported the combination of juvenile-onset diabetes mellitus and optic atrophy.",46 55,0 8,46,0,63,16,1,RO-has_manifestation,906470,"Wolfram syndrome (WS), an infrequent cause of diabetes mellitus, derives its name from the physician who first reported the combination of juvenile-onset diabetes mellitus and optic atrophy",diabetes mellitus,Wolfram syndrome
503545387,7/16/2014 20:47:32,,1324469289,7/16/2014 20:47:22,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,46,0,,,63,16,DIABETES MELLITUS,WOLFRAM SYNDROME,"infrequent cause of DIABETES MELLITUS, derives its name",26-37-43-46-55-65-73-77,0-8-23-26,WOLFRAM SYNDROME an infrequent,"Wolfram syndrome (WS), an infrequent cause of diabetes mellitus, derives its name from the physician who first reported the combination of juvenile-onset diabetes mellitus and optic atrophy.",46 55,0 8,46,0,63,16,1,RO-has_manifestation,906470,"Wolfram syndrome (WS), an infrequent cause of diabetes mellitus, derives its name from the physician who first reported the combination of juvenile-onset diabetes mellitus and optic atrophy",diabetes mellitus,Wolfram syndrome
503545387,7/16/2014 20:48:27,,1324469717,7/16/2014 20:48:18,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,46,0,,,63,16,DIABETES MELLITUS,WOLFRAM SYNDROME,"DIABETES MELLITUS,",46-55,0-8,WOLFRAM SYNDROME,"Wolfram syndrome (WS), an infrequent cause of diabetes mellitus, derives its name from the physician who first reported the combination of juvenile-onset diabetes mellitus and optic atrophy.",46 55,0 8,46,0,63,16,1,RO-has_manifestation,906470,"Wolfram syndrome (WS), an infrequent cause of diabetes mellitus, derives its name from the physician who first reported the combination of juvenile-onset diabetes mellitus and optic atrophy",diabetes mellitus,Wolfram syndrome
503545387,7/16/2014 20:49:57,,1324470413,7/16/2014 20:49:37,prodege,1.0,9997387,USA,CO,Colorado Springs,75.70.112.31,46,0,,,63,16,DIABETES MELLITUS,WOLFRAM SYNDROME,"cause DIABETES MELLITUS,",37-46-55,0-8-17,"WOLFRAM SYNDROME (WS),","Wolfram syndrome (WS), an infrequent cause of diabetes mellitus, derives its name from the physician who first reported the combination of juvenile-onset diabetes mellitus and optic atrophy.",46 55,0 8,46,0,63,16,1,RO-has_manifestation,906470,"Wolfram syndrome (WS), an infrequent cause of diabetes mellitus, derives its name from the physician who first reported the combination of juvenile-onset diabetes mellitus and optic atrophy",diabetes mellitus,Wolfram syndrome
503545388,7/16/2014 20:37:14,,1324465150,7/16/2014 20:37:05,clixsense,1.0,6610277,CAN,ON,Oshawa,174.117.79.122,134,114,,,138,121,IDDM,INSULIN,insulin dependent ([IDDM] n 53) and,114-122-132-140-144-148,88-103-109-114-122-140,postmenopausal women with INSULIN dependent n,The study aim was to measure body composition and fat distribution in premenopausal and postmenopausal women with insulin-dependent ([IDDM] n = 53) and non-insulin-dependent ([NIDDM] n = 32) diabetes mellitus by dual-energy x-ray absorptiometry.,,114,134,114,138,121,1,RO-may_treat,908277,The study aim was to measure body composition and fat distribution in premenopausal and postmenopausal women with insulin-dependent ([IDDM] n = 53) and non-insulin-dependent ([NIDDM] n = 32) diabetes mellitus by dual-energy x-ray absorptiometry,IDDM,insulin
503545388,7/16/2014 20:39:30,,1324466067,7/16/2014 20:39:08,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,134,114,,,138,121,IDDM,INSULIN,insulin dependent ([IDDM] n = 53),114-122-132-140-144-142,114-122-132-140-142-144,INSULIN dependent ([IDDM] n = 53),The study aim was to measure body composition and fat distribution in premenopausal and postmenopausal women with insulin-dependent ([IDDM] n = 53) and non-insulin-dependent ([NIDDM] n = 32) diabetes mellitus by dual-energy x-ray absorptiometry.,,114,134,114,138,121,1,RO-may_treat,908277,The study aim was to measure body composition and fat distribution in premenopausal and postmenopausal women with insulin-dependent ([IDDM] n = 53) and non-insulin-dependent ([NIDDM] n = 32) diabetes mellitus by dual-energy x-ray absorptiometry,IDDM,insulin
503545388,7/16/2014 20:39:40,,1324466114,7/16/2014 20:39:20,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,134,114,,,138,121,IDDM,INSULIN,insulin dependent,114-122,114-122,INSULIN dependent,The study aim was to measure body composition and fat distribution in premenopausal and postmenopausal women with insulin-dependent ([IDDM] n = 53) and non-insulin-dependent ([NIDDM] n = 32) diabetes mellitus by dual-energy x-ray absorptiometry.,,114,134,114,138,121,1,RO-may_treat,908277,The study aim was to measure body composition and fat distribution in premenopausal and postmenopausal women with insulin-dependent ([IDDM] n = 53) and non-insulin-dependent ([NIDDM] n = 32) diabetes mellitus by dual-energy x-ray absorptiometry,IDDM,insulin
503545388,7/16/2014 20:41:06,,1324466706,7/16/2014 20:40:48,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,134,114,,,138,121,IDDM,INSULIN,insulin - dependent,114-121-122,114-121-122,INSULIN - dependent,The study aim was to measure body composition and fat distribution in premenopausal and postmenopausal women with insulin-dependent ([IDDM] n = 53) and non-insulin-dependent ([NIDDM] n = 32) diabetes mellitus by dual-energy x-ray absorptiometry.,,114,134,114,138,121,1,RO-may_treat,908277,The study aim was to measure body composition and fat distribution in premenopausal and postmenopausal women with insulin-dependent ([IDDM] n = 53) and non-insulin-dependent ([NIDDM] n = 32) diabetes mellitus by dual-energy x-ray absorptiometry,IDDM,insulin
503545388,7/16/2014 20:43:39,,1324467632,7/16/2014 20:43:37,bitcoinget,1.0,24792414,USA,"","",166.181.81.55,134,114,,,138,121,IDDM,INSULIN,insulin dependent ([IDDM] n 53) and,114-122-132-140-144-148,88-103-109-114-122-140,postmenopausal women with INSULIN dependent n,The study aim was to measure body composition and fat distribution in premenopausal and postmenopausal women with insulin-dependent ([IDDM] n = 53) and non-insulin-dependent ([NIDDM] n = 32) diabetes mellitus by dual-energy x-ray absorptiometry.,,114,134,114,138,121,1,RO-may_treat,908277,The study aim was to measure body composition and fat distribution in premenopausal and postmenopausal women with insulin-dependent ([IDDM] n = 53) and non-insulin-dependent ([NIDDM] n = 32) diabetes mellitus by dual-energy x-ray absorptiometry,IDDM,insulin
503545388,7/16/2014 20:44:52,,1324468092,7/16/2014 20:43:40,prodege,1.0,4968858,USA,CA,Corona,99.44.120.153,134,114,,,138,121,IDDM,INSULIN,insulin dependent ([IDDM] n 53),122-132-140-144-114,88-103-109-114-122-140-191,postmenopausal women with INSULIN dependent n diabetes,The study aim was to measure body composition and fat distribution in premenopausal and postmenopausal women with insulin-dependent ([IDDM] n = 53) and non-insulin-dependent ([NIDDM] n = 32) diabetes mellitus by dual-energy x-ray absorptiometry.,,114,134,114,138,121,1,RO-may_treat,908277,The study aim was to measure body composition and fat distribution in premenopausal and postmenopausal women with insulin-dependent ([IDDM] n = 53) and non-insulin-dependent ([NIDDM] n = 32) diabetes mellitus by dual-energy x-ray absorptiometry,IDDM,insulin
503545388,7/16/2014 20:45:28,,1324468339,7/16/2014 20:45:24,prodege,1.0,26325260,GBR,"","",79.64.25.64,134,114,,,138,121,IDDM,INSULIN,insulin dependent ([IDDM] n 53) and,114-122-132-140-144-148,88-103-109-114-122-140,postmenopausal women with INSULIN dependent n,The study aim was to measure body composition and fat distribution in premenopausal and postmenopausal women with insulin-dependent ([IDDM] n = 53) and non-insulin-dependent ([NIDDM] n = 32) diabetes mellitus by dual-energy x-ray absorptiometry.,,114,134,114,138,121,1,RO-may_treat,908277,The study aim was to measure body composition and fat distribution in premenopausal and postmenopausal women with insulin-dependent ([IDDM] n = 53) and non-insulin-dependent ([NIDDM] n = 32) diabetes mellitus by dual-energy x-ray absorptiometry,IDDM,insulin
503545388,7/16/2014 20:45:37,,1324468395,7/16/2014 20:45:19,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,134,114,,,138,121,IDDM,INSULIN,insulin dependent ([IDDM],114-122-132,114-122-132,INSULIN dependent ([IDDM],The study aim was to measure body composition and fat distribution in premenopausal and postmenopausal women with insulin-dependent ([IDDM] n = 53) and non-insulin-dependent ([NIDDM] n = 32) diabetes mellitus by dual-energy x-ray absorptiometry.,,114,134,114,138,121,1,RO-may_treat,908277,The study aim was to measure body composition and fat distribution in premenopausal and postmenopausal women with insulin-dependent ([IDDM] n = 53) and non-insulin-dependent ([NIDDM] n = 32) diabetes mellitus by dual-energy x-ray absorptiometry,IDDM,insulin
503545388,7/16/2014 20:45:40,,1324468409,7/16/2014 20:45:22,instagc,1.0,13763729,USA,"","",75.182.89.225,134,114,,,138,121,IDDM,INSULIN,([IDDM],132,114-122,INSULIN dependent,The study aim was to measure body composition and fat distribution in premenopausal and postmenopausal women with insulin-dependent ([IDDM] n = 53) and non-insulin-dependent ([NIDDM] n = 32) diabetes mellitus by dual-energy x-ray absorptiometry.,,114,134,114,138,121,1,RO-may_treat,908277,The study aim was to measure body composition and fat distribution in premenopausal and postmenopausal women with insulin-dependent ([IDDM] n = 53) and non-insulin-dependent ([NIDDM] n = 32) diabetes mellitus by dual-energy x-ray absorptiometry,IDDM,insulin
503545388,7/16/2014 20:47:10,,1324469124,7/16/2014 20:46:57,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,134,114,,,138,121,IDDM,INSULIN,([IDDM],132,114-122,INSULIN dependent,The study aim was to measure body composition and fat distribution in premenopausal and postmenopausal women with insulin-dependent ([IDDM] n = 53) and non-insulin-dependent ([NIDDM] n = 32) diabetes mellitus by dual-energy x-ray absorptiometry.,,114,134,114,138,121,1,RO-may_treat,908277,The study aim was to measure body composition and fat distribution in premenopausal and postmenopausal women with insulin-dependent ([IDDM] n = 53) and non-insulin-dependent ([NIDDM] n = 32) diabetes mellitus by dual-energy x-ray absorptiometry,IDDM,insulin
503545389,7/16/2014 20:34:23,,1324463962,7/16/2014 20:33:48,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,144,172,,,152,182,PROTEASE,PROTEINASE,P. cyclopium PROTEASE,131-134-144,172-183,PROTEINASE K.,"The greatest variation from the proteinase K polypeptide is in loop 114-134 and is due to the absence of a disulfide bridge in the P. cyclopium protease that is present in proteinase K. A difference was also observed in the orientation of the histidine in the catalytic triad, though this could be due to the presence of PMSF at the active site.",144,172,144,172,152,182,1,RO-has_ingredient,905786,"The greatest variation from the proteinase K polypeptide is in loop 114-134 and is due to the absence of a disulfide bridge in the P. cyclopium protease that is present in proteinase K. A difference was also observed in the orientation of the histidine in the catalytic triad, though this could be due to the presence of PMSF at the active site",protease,proteinase
503545389,7/16/2014 20:40:41,,1324466541,7/16/2014 20:40:20,clixsense,1.0,24896327,GBR,V2,Glasgow,94.2.231.4,144,172,,,152,182,PROTEASE,PROTEINASE,the P. cyclopium PROTEASE,127-131-134-144,172-183,PROTEINASE K.,"The greatest variation from the proteinase K polypeptide is in loop 114-134 and is due to the absence of a disulfide bridge in the P. cyclopium protease that is present in proteinase K. A difference was also observed in the orientation of the histidine in the catalytic triad, though this could be due to the presence of PMSF at the active site.",144,172,144,172,152,182,1,RO-has_ingredient,905786,"The greatest variation from the proteinase K polypeptide is in loop 114-134 and is due to the absence of a disulfide bridge in the P. cyclopium protease that is present in proteinase K. A difference was also observed in the orientation of the histidine in the catalytic triad, though this could be due to the presence of PMSF at the active site",protease,proteinase
503545389,7/16/2014 20:41:56,,1324467063,7/16/2014 20:41:42,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,144,172,,,152,182,PROTEASE,PROTEINASE,P. cyclopium PROTEASE,131-134-144,172-183,PROTEINASE K.,"The greatest variation from the proteinase K polypeptide is in loop 114-134 and is due to the absence of a disulfide bridge in the P. cyclopium protease that is present in proteinase K. A difference was also observed in the orientation of the histidine in the catalytic triad, though this could be due to the presence of PMSF at the active site.",144,172,144,172,152,182,1,RO-has_ingredient,905786,"The greatest variation from the proteinase K polypeptide is in loop 114-134 and is due to the absence of a disulfide bridge in the P. cyclopium protease that is present in proteinase K. A difference was also observed in the orientation of the histidine in the catalytic triad, though this could be due to the presence of PMSF at the active site",protease,proteinase
503545389,7/16/2014 20:42:18,,1324467163,7/16/2014 20:41:55,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,144,172,,,152,182,PROTEASE,PROTEINASE,PROTEASE,144,172-183-186-188,PROTEINASE K. A difference,"The greatest variation from the proteinase K polypeptide is in loop 114-134 and is due to the absence of a disulfide bridge in the P. cyclopium protease that is present in proteinase K. A difference was also observed in the orientation of the histidine in the catalytic triad, though this could be due to the presence of PMSF at the active site.",144,172,144,172,152,182,1,RO-has_ingredient,905786,"The greatest variation from the proteinase K polypeptide is in loop 114-134 and is due to the absence of a disulfide bridge in the P. cyclopium protease that is present in proteinase K. A difference was also observed in the orientation of the histidine in the catalytic triad, though this could be due to the presence of PMSF at the active site",protease,proteinase
503545389,7/16/2014 20:42:29,,1324467243,7/16/2014 20:41:40,prodege,1.0,22360212,GBR,I1,Luton,82.6.41.191,144,172,,,152,182,PROTEASE,PROTEINASE,P. cyclopium PROTEASE,131-134-144,172-183,PROTEINASE K.,"The greatest variation from the proteinase K polypeptide is in loop 114-134 and is due to the absence of a disulfide bridge in the P. cyclopium protease that is present in proteinase K. A difference was also observed in the orientation of the histidine in the catalytic triad, though this could be due to the presence of PMSF at the active site.",144,172,144,172,152,182,1,RO-has_ingredient,905786,"The greatest variation from the proteinase K polypeptide is in loop 114-134 and is due to the absence of a disulfide bridge in the P. cyclopium protease that is present in proteinase K. A difference was also observed in the orientation of the histidine in the catalytic triad, though this could be due to the presence of PMSF at the active site",protease,proteinase
503545389,7/16/2014 20:42:45,,1324467314,7/16/2014 20:42:24,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,144,172,,,152,182,PROTEASE,PROTEINASE,the P. cyclopium PROTEASE,127-131-134-144,172-183,PROTEINASE K.,"The greatest variation from the proteinase K polypeptide is in loop 114-134 and is due to the absence of a disulfide bridge in the P. cyclopium protease that is present in proteinase K. A difference was also observed in the orientation of the histidine in the catalytic triad, though this could be due to the presence of PMSF at the active site.",144,172,144,172,152,182,1,RO-has_ingredient,905786,"The greatest variation from the proteinase K polypeptide is in loop 114-134 and is due to the absence of a disulfide bridge in the P. cyclopium protease that is present in proteinase K. A difference was also observed in the orientation of the histidine in the catalytic triad, though this could be due to the presence of PMSF at the active site",protease,proteinase
503545389,7/16/2014 20:42:48,,1324467331,7/16/2014 20:42:45,bitcoinget,1.0,24792414,USA,"","",166.181.81.55,144,172,,,152,182,PROTEASE,PROTEINASE,the P. cyclopium PROTEASE that is present,127-131-134-144-153-158-161,158-161-169-172-183-186-188,is present in PROTEINASE K. A difference,"The greatest variation from the proteinase K polypeptide is in loop 114-134 and is due to the absence of a disulfide bridge in the P. cyclopium protease that is present in proteinase K. A difference was also observed in the orientation of the histidine in the catalytic triad, though this could be due to the presence of PMSF at the active site.",144,172,144,172,152,182,1,RO-has_ingredient,905786,"The greatest variation from the proteinase K polypeptide is in loop 114-134 and is due to the absence of a disulfide bridge in the P. cyclopium protease that is present in proteinase K. A difference was also observed in the orientation of the histidine in the catalytic triad, though this could be due to the presence of PMSF at the active site",protease,proteinase
503545389,7/16/2014 20:45:04,,1324468163,7/16/2014 20:44:45,prodege,1.0,9997387,USA,CO,Colorado Springs,75.70.112.31,144,172,,,152,182,PROTEASE,PROTEINASE,proteinase K polypeptide P. cyclopium PROTEASE is,32-43-131-134-144-158-45,32-43-45-172-183-186,proteinase K polypeptide PROTEINASE K. A,"The greatest variation from the proteinase K polypeptide is in loop 114-134 and is due to the absence of a disulfide bridge in the P. cyclopium protease that is present in proteinase K. A difference was also observed in the orientation of the histidine in the catalytic triad, though this could be due to the presence of PMSF at the active site.",144,172,144,172,152,182,1,RO-has_ingredient,905786,"The greatest variation from the proteinase K polypeptide is in loop 114-134 and is due to the absence of a disulfide bridge in the P. cyclopium protease that is present in proteinase K. A difference was also observed in the orientation of the histidine in the catalytic triad, though this could be due to the presence of PMSF at the active site",protease,proteinase
503545389,7/16/2014 20:45:57,,1324468529,7/16/2014 20:45:44,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,144,172,,,152,182,PROTEASE,PROTEINASE,PROTEASE,144,172,PROTEINASE,"The greatest variation from the proteinase K polypeptide is in loop 114-134 and is due to the absence of a disulfide bridge in the P. cyclopium protease that is present in proteinase K. A difference was also observed in the orientation of the histidine in the catalytic triad, though this could be due to the presence of PMSF at the active site.",144,172,144,172,152,182,1,RO-has_ingredient,905786,"The greatest variation from the proteinase K polypeptide is in loop 114-134 and is due to the absence of a disulfide bridge in the P. cyclopium protease that is present in proteinase K. A difference was also observed in the orientation of the histidine in the catalytic triad, though this could be due to the presence of PMSF at the active site",protease,proteinase
503545389,7/16/2014 20:47:26,,1324469234,7/16/2014 20:47:06,instagc,1.0,13763729,USA,"","",75.182.89.225,144,172,,,152,182,PROTEASE,PROTEINASE,P. cyclopium PROTEASE,131-134-144,172,PROTEINASE,"The greatest variation from the proteinase K polypeptide is in loop 114-134 and is due to the absence of a disulfide bridge in the P. cyclopium protease that is present in proteinase K. A difference was also observed in the orientation of the histidine in the catalytic triad, though this could be due to the presence of PMSF at the active site.",144,172,144,172,152,182,1,RO-has_ingredient,905786,"The greatest variation from the proteinase K polypeptide is in loop 114-134 and is due to the absence of a disulfide bridge in the P. cyclopium protease that is present in proteinase K. A difference was also observed in the orientation of the histidine in the catalytic triad, though this could be due to the presence of PMSF at the active site",protease,proteinase
503545390,7/16/2014 20:32:26,,1324463241,7/16/2014 20:32:16,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,37,64,,,50,90,BRAIN ABSCESS,RENDU-OSLER-WEBER SYNDROME,BRAIN ABSCESS,37-43,64-70-76-82,RENDU OSLER WEBER SYNDROME,A forty-year-old woman who developed brain abscess was found to Rendu-Osler-weber syndrome with multiple arteriovenous fistulas of the left lung.,37 43,64 70 76 82,37,64,50,90,1,RO-has_manifestation,906053,A forty-year-old woman who developed brain abscess was found to Rendu-Osler-weber syndrome with multiple arteriovenous fistulas of the left lung,brain abscess,Rendu-Osler-weber syndrome
503545390,7/16/2014 20:33:47,,1324463737,7/16/2014 20:33:37,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,37,64,,,50,90,BRAIN ABSCESS,RENDU-OSLER-WEBER SYNDROME,who BRAIN ABSCESS,23-37-43,64-70-76-82,RENDU OSLER WEBER SYNDROME,A forty-year-old woman who developed brain abscess was found to Rendu-Osler-weber syndrome with multiple arteriovenous fistulas of the left lung.,37 43,64 70 76 82,37,64,50,90,1,RO-has_manifestation,906053,A forty-year-old woman who developed brain abscess was found to Rendu-Osler-weber syndrome with multiple arteriovenous fistulas of the left lung,brain abscess,Rendu-Osler-weber syndrome
503545390,7/16/2014 20:36:21,,1324464759,7/16/2014 20:36:00,clixsense,1.0,24896327,GBR,V2,Glasgow,94.2.231.4,37,64,,,50,90,BRAIN ABSCESS,RENDU-OSLER-WEBER SYNDROME,BRAIN ABSCESS,37-43,64-70-76-82,RENDU OSLER WEBER SYNDROME,A forty-year-old woman who developed brain abscess was found to Rendu-Osler-weber syndrome with multiple arteriovenous fistulas of the left lung.,37 43,64 70 76 82,37,64,50,90,1,RO-has_manifestation,906053,A forty-year-old woman who developed brain abscess was found to Rendu-Osler-weber syndrome with multiple arteriovenous fistulas of the left lung,brain abscess,Rendu-Osler-weber syndrome
503545390,7/16/2014 20:38:46,,1324465724,7/16/2014 20:38:45,clixsense,1.0,6610277,CAN,ON,Oshawa,174.117.79.122,37,64,,,50,90,BRAIN ABSCESS,RENDU-OSLER-WEBER SYNDROME,woman who developed BRAIN ABSCESS was found to,17-23-27-37-43-51-55-61,51-55-61-64-70-76-82-91-96-105,was found to RENDU OSLER WEBER SYNDROME with multiple arteriovenous,A forty-year-old woman who developed brain abscess was found to Rendu-Osler-weber syndrome with multiple arteriovenous fistulas of the left lung.,37 43,64 70 76 82,37,64,50,90,1,RO-has_manifestation,906053,A forty-year-old woman who developed brain abscess was found to Rendu-Osler-weber syndrome with multiple arteriovenous fistulas of the left lung,brain abscess,Rendu-Osler-weber syndrome
503545390,7/16/2014 20:41:07,,1324466723,7/16/2014 20:40:55,instagc,1.0,13763729,USA,"","",75.182.89.225,37,64,,,50,90,BRAIN ABSCESS,RENDU-OSLER-WEBER SYNDROME,BRAIN ABSCESS,37-43,64-70-76-82,RENDU OSLER WEBER SYNDROME,A forty-year-old woman who developed brain abscess was found to Rendu-Osler-weber syndrome with multiple arteriovenous fistulas of the left lung.,37 43,64 70 76 82,37,64,50,90,1,RO-has_manifestation,906053,A forty-year-old woman who developed brain abscess was found to Rendu-Osler-weber syndrome with multiple arteriovenous fistulas of the left lung,brain abscess,Rendu-Osler-weber syndrome
503545390,7/16/2014 20:41:22,,1324466835,7/16/2014 20:41:20,coinworker,1.0,28394550,USA,PA,Marcus Hook,71.175.96.184,37,64,,,50,90,BRAIN ABSCESS,RENDU-OSLER-WEBER SYNDROME,woman who developed BRAIN ABSCESS was found to,17-23-27-37-43-51-55-61,51-55-61-64-70-76-82-91-96-105,was found to RENDU OSLER WEBER SYNDROME with multiple arteriovenous,A forty-year-old woman who developed brain abscess was found to Rendu-Osler-weber syndrome with multiple arteriovenous fistulas of the left lung.,37 43,64 70 76 82,37,64,50,90,1,RO-has_manifestation,906053,A forty-year-old woman who developed brain abscess was found to Rendu-Osler-weber syndrome with multiple arteriovenous fistulas of the left lung,brain abscess,Rendu-Osler-weber syndrome
503545390,7/16/2014 20:43:29,,1324467573,7/16/2014 20:43:20,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,37,64,,,50,90,BRAIN ABSCESS,RENDU-OSLER-WEBER SYNDROME,woman who developed BRAIN ABSCESS was found to,17-23-27-37-43-51-55-61,51-55-61-64-70-76-82-91-96-105,was found to RENDU OSLER WEBER SYNDROME with multiple arteriovenous,A forty-year-old woman who developed brain abscess was found to Rendu-Osler-weber syndrome with multiple arteriovenous fistulas of the left lung.,37 43,64 70 76 82,37,64,50,90,1,RO-has_manifestation,906053,A forty-year-old woman who developed brain abscess was found to Rendu-Osler-weber syndrome with multiple arteriovenous fistulas of the left lung,brain abscess,Rendu-Osler-weber syndrome
503545390,7/16/2014 20:43:53,,1324467726,7/16/2014 20:43:51,bitcoinget,1.0,24792414,USA,"","",166.181.81.55,37,64,,,50,90,BRAIN ABSCESS,RENDU-OSLER-WEBER SYNDROME,woman who developed BRAIN ABSCESS was found to,17-23-27-37-43-51-55-61,51-55-61-64-70-76-82-91-96-105,was found to RENDU OSLER WEBER SYNDROME with multiple arteriovenous,A forty-year-old woman who developed brain abscess was found to Rendu-Osler-weber syndrome with multiple arteriovenous fistulas of the left lung.,37 43,64 70 76 82,37,64,50,90,1,RO-has_manifestation,906053,A forty-year-old woman who developed brain abscess was found to Rendu-Osler-weber syndrome with multiple arteriovenous fistulas of the left lung,brain abscess,Rendu-Osler-weber syndrome
503545390,7/16/2014 20:45:41,,1324468419,7/16/2014 20:45:22,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,37,64,,,50,90,BRAIN ABSCESS,RENDU-OSLER-WEBER SYNDROME,BRAIN ABSCESS,37-43,64-70-76-82,RENDU OSLER WEBER SYNDROME,A forty-year-old woman who developed brain abscess was found to Rendu-Osler-weber syndrome with multiple arteriovenous fistulas of the left lung.,37 43,64 70 76 82,37,64,50,90,1,RO-has_manifestation,906053,A forty-year-old woman who developed brain abscess was found to Rendu-Osler-weber syndrome with multiple arteriovenous fistulas of the left lung,brain abscess,Rendu-Osler-weber syndrome
503545390,7/16/2014 20:46:44,,1324468927,7/16/2014 20:46:32,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,37,64,,,50,90,BRAIN ABSCESS,RENDU-OSLER-WEBER SYNDROME,BRAIN ABSCESS,37-43,64-70-76-82,RENDU OSLER WEBER SYNDROME,A forty-year-old woman who developed brain abscess was found to Rendu-Osler-weber syndrome with multiple arteriovenous fistulas of the left lung.,37 43,64 70 76 82,37,64,50,90,1,RO-has_manifestation,906053,A forty-year-old woman who developed brain abscess was found to Rendu-Osler-weber syndrome with multiple arteriovenous fistulas of the left lung,brain abscess,Rendu-Osler-weber syndrome
503545391,7/16/2014 20:33:04,,1324463464,7/16/2014 20:32:49,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,52,0,,,59,11,MYELOMA,THALIDOMIDE,refractory MYELOMA,41-52,0,THALIDOMIDE,Thalidomide was used in 73 patients with refractory myeloma in 15 of 45 institutes participating in the Japan Myeloma Study Group.,52,0,52,0,59,11,1,RO-may_treat,908083,Thalidomide was used in 73 patients with refractory myeloma in 15 of 45 institutes participating in the Japan Myeloma Study Group,myeloma,Thalidomide
503545391,7/16/2014 20:38:05,,1324465419,7/16/2014 20:37:55,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,52,0,,,59,11,MYELOMA,THALIDOMIDE,refractory MYELOMA,41-52,0,THALIDOMIDE,Thalidomide was used in 73 patients with refractory myeloma in 15 of 45 institutes participating in the Japan Myeloma Study Group.,52,0,52,0,59,11,1,RO-may_treat,908083,Thalidomide was used in 73 patients with refractory myeloma in 15 of 45 institutes participating in the Japan Myeloma Study Group,myeloma,Thalidomide
503545391,7/16/2014 20:41:36,,1324466923,7/16/2014 20:41:33,coinworker,1.0,28394550,USA,PA,Marcus Hook,71.175.96.184,52,0,,,59,11,MYELOMA,THALIDOMIDE,patients with refractory MYELOMA in 15 of,27-36-41-52-60-63-66,0-12-16-21,THALIDOMIDE was used in,Thalidomide was used in 73 patients with refractory myeloma in 15 of 45 institutes participating in the Japan Myeloma Study Group.,52,0,52,0,59,11,1,RO-may_treat,908083,Thalidomide was used in 73 patients with refractory myeloma in 15 of 45 institutes participating in the Japan Myeloma Study Group,myeloma,Thalidomide
503545391,7/16/2014 20:41:43,,1324466980,7/16/2014 20:41:02,eup_slw,1.0,28011002,CAN,MB,Winnipeg,24.77.44.140,52,0,,,59,11,MYELOMA,THALIDOMIDE,refractory MYELOMA,52-41,0,THALIDOMIDE,Thalidomide was used in 73 patients with refractory myeloma in 15 of 45 institutes participating in the Japan Myeloma Study Group.,52,0,52,0,59,11,1,RO-may_treat,908083,Thalidomide was used in 73 patients with refractory myeloma in 15 of 45 institutes participating in the Japan Myeloma Study Group,myeloma,Thalidomide
503545391,7/16/2014 20:42:56,,1324467375,7/16/2014 20:42:44,instagc,1.0,13763729,USA,"","",75.182.89.225,52,0,,,59,11,MYELOMA,THALIDOMIDE,refractory MYELOMA,41-52,0,THALIDOMIDE,Thalidomide was used in 73 patients with refractory myeloma in 15 of 45 institutes participating in the Japan Myeloma Study Group.,52,0,52,0,59,11,1,RO-may_treat,908083,Thalidomide was used in 73 patients with refractory myeloma in 15 of 45 institutes participating in the Japan Myeloma Study Group,myeloma,Thalidomide
503545391,7/16/2014 20:44:23,,1324467913,7/16/2014 20:43:53,prodege,1.0,22360212,GBR,I1,Luton,82.6.41.191,52,0,,,59,11,MYELOMA,THALIDOMIDE,refractory MYELOMA,41-52,0,THALIDOMIDE,Thalidomide was used in 73 patients with refractory myeloma in 15 of 45 institutes participating in the Japan Myeloma Study Group.,52,0,52,0,59,11,1,RO-may_treat,908083,Thalidomide was used in 73 patients with refractory myeloma in 15 of 45 institutes participating in the Japan Myeloma Study Group,myeloma,Thalidomide
503545391,7/16/2014 20:44:24,,1324467931,7/16/2014 20:44:09,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,52,0,,,59,11,MYELOMA,THALIDOMIDE,refractory MYELOMA,41-52,0,THALIDOMIDE,Thalidomide was used in 73 patients with refractory myeloma in 15 of 45 institutes participating in the Japan Myeloma Study Group.,52,0,52,0,59,11,1,RO-may_treat,908083,Thalidomide was used in 73 patients with refractory myeloma in 15 of 45 institutes participating in the Japan Myeloma Study Group,myeloma,Thalidomide
503545391,7/16/2014 20:46:54,,1324469012,7/16/2014 20:46:36,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,52,0,,,59,11,MYELOMA,THALIDOMIDE,patients with refractory MYELOMA in 15 of,27-36-41-52-60-63-66,0-12-16-21,THALIDOMIDE was used in,Thalidomide was used in 73 patients with refractory myeloma in 15 of 45 institutes participating in the Japan Myeloma Study Group.,52,0,52,0,59,11,1,RO-may_treat,908083,Thalidomide was used in 73 patients with refractory myeloma in 15 of 45 institutes participating in the Japan Myeloma Study Group,myeloma,Thalidomide
503545391,7/16/2014 20:47:18,,1324469176,7/16/2014 20:46:52,prodege,1.0,9997387,USA,CO,Colorado Springs,75.70.112.31,52,0,,,59,11,MYELOMA,THALIDOMIDE,refractory MYELOMA,41-52,0-52,THALIDOMIDE myeloma,Thalidomide was used in 73 patients with refractory myeloma in 15 of 45 institutes participating in the Japan Myeloma Study Group.,52,0,52,0,59,11,1,RO-may_treat,908083,Thalidomide was used in 73 patients with refractory myeloma in 15 of 45 institutes participating in the Japan Myeloma Study Group,myeloma,Thalidomide
503545391,7/16/2014 20:52:41,,1324471549,7/16/2014 20:52:28,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,52,0,,,59,11,MYELOMA,THALIDOMIDE,refractory MYELOMA,41-52,0,THALIDOMIDE,Thalidomide was used in 73 patients with refractory myeloma in 15 of 45 institutes participating in the Japan Myeloma Study Group.,52,0,52,0,59,11,1,RO-may_treat,908083,Thalidomide was used in 73 patients with refractory myeloma in 15 of 45 institutes participating in the Japan Myeloma Study Group,myeloma,Thalidomide
503545392,7/16/2014 20:34:22,,1324463955,7/16/2014 20:33:58,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,57,63,,,61,71,PAIN,SCIATICA,PAIN (sciatica.,57-62,62,(SCIATICA.,I stay in bed most of the time because of my back or leg pain (sciatica.,57,,57,63,61,71,-1,RO-has_definitional_manifestation,904678,I stay in bed most of the time because of my back or leg pain (sciatica,pain,sciatica
503545392,7/16/2014 20:35:17,,1324464289,7/16/2014 20:34:53,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,57,63,,,61,71,PAIN,SCIATICA,PAIN,57,,,I stay in bed most of the time because of my back or leg pain (sciatica.,57,,57,63,61,71,-1,RO-has_definitional_manifestation,904678,I stay in bed most of the time because of my back or leg pain (sciatica,pain,sciatica
503545392,7/16/2014 20:35:30,,1324464393,7/16/2014 20:35:19,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,57,63,,,61,71,PAIN,SCIATICA,leg PAIN,53-57,53-57-62,leg pain (SCIATICA.,I stay in bed most of the time because of my back or leg pain (sciatica.,57,,57,63,61,71,-1,RO-has_definitional_manifestation,904678,I stay in bed most of the time because of my back or leg pain (sciatica,pain,sciatica
503545392,7/16/2014 20:37:54,,1324465359,7/16/2014 20:37:42,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,57,63,,,61,71,PAIN,SCIATICA,PAIN,57,62,(SCIATICA.,I stay in bed most of the time because of my back or leg pain (sciatica.,57,,57,63,61,71,-1,RO-has_definitional_manifestation,904678,I stay in bed most of the time because of my back or leg pain (sciatica,pain,sciatica
503545392,7/16/2014 20:41:43,,1324466981,7/16/2014 20:41:28,clixsense,1.0,24896327,GBR,V2,Glasgow,94.2.231.4,57,63,,,61,71,PAIN,SCIATICA,leg PAIN,53-57,53-57-62,leg pain (SCIATICA.,I stay in bed most of the time because of my back or leg pain (sciatica.,57,,57,63,61,71,-1,RO-has_definitional_manifestation,904678,I stay in bed most of the time because of my back or leg pain (sciatica,pain,sciatica
503545392,7/16/2014 20:43:23,,1324467539,7/16/2014 20:43:03,prodege,1.0,22360212,GBR,I1,Luton,82.6.41.191,57,63,,,61,71,PAIN,SCIATICA,PAIN,57,62,(SCIATICA.,I stay in bed most of the time because of my back or leg pain (sciatica.,57,,57,63,61,71,-1,RO-has_definitional_manifestation,904678,I stay in bed most of the time because of my back or leg pain (sciatica,pain,sciatica
503545392,7/16/2014 20:43:32,,1324467585,7/16/2014 20:43:16,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,57,63,,,61,71,PAIN,SCIATICA,leg PAIN,53-57,62,(SCIATICA.,I stay in bed most of the time because of my back or leg pain (sciatica.,57,,57,63,61,71,-1,RO-has_definitional_manifestation,904678,I stay in bed most of the time because of my back or leg pain (sciatica,pain,sciatica
503545392,7/16/2014 20:43:50,,1324467705,7/16/2014 20:43:48,bitcoinget,1.0,24792414,USA,"","",166.181.81.55,57,63,,,61,71,PAIN,SCIATICA,back or leg PAIN,45-50-53-57,53-57-62,leg pain (SCIATICA.,I stay in bed most of the time because of my back or leg pain (sciatica.,57,,57,63,61,71,-1,RO-has_definitional_manifestation,904678,I stay in bed most of the time because of my back or leg pain (sciatica,pain,sciatica
503545392,7/16/2014 20:45:16,,1324468263,7/16/2014 20:45:05,prodege,1.0,9997387,USA,CO,Colorado Springs,75.70.112.31,57,63,,,61,71,PAIN,SCIATICA,PAIN,57,57-62,pain (SCIATICA.,I stay in bed most of the time because of my back or leg pain (sciatica.,57,,57,63,61,71,-1,RO-has_definitional_manifestation,904678,I stay in bed most of the time because of my back or leg pain (sciatica,pain,sciatica
503545392,7/16/2014 20:45:20,,1324468284,7/16/2014 20:45:06,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,57,63,,,61,71,PAIN,SCIATICA,PAIN,57,62,(SCIATICA.,I stay in bed most of the time because of my back or leg pain (sciatica.,57,,57,63,61,71,-1,RO-has_definitional_manifestation,904678,I stay in bed most of the time because of my back or leg pain (sciatica,pain,sciatica
503545393,7/16/2014 20:32:32,,1324463278,7/16/2014 20:32:22,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,129,52,,,133,62,SKIN,DERMATITIS,SKIN lesions,129-134,39-44-52,drug induced DERMATITIS,Skin biopsies from eight patients with drug-induced dermatitis have been compared with skin biopsies from 16 patients developing skin lesions (acute graft versus host-reaction and/or drug-induced reaction) after bone marrow transplantation.,129,52,129,52,133,62,1,RO-disease_has_primary_anatomic_site,902348,Skin biopsies from eight patients with drug-induced dermatitis have been compared with skin biopsies from 16 patients developing skin lesions (acute graft versus host-reaction and/or drug-induced reaction) after bone marrow transplantation,skin,dermatitis
503545393,7/16/2014 20:37:51,,1324465319,7/16/2014 20:37:22,clixsense,1.0,24896327,GBR,V2,Glasgow,94.2.231.4,129,52,,,133,62,SKIN,DERMATITIS,SKIN lesions,129-134,39-44-52,drug induced DERMATITIS,Skin biopsies from eight patients with drug-induced dermatitis have been compared with skin biopsies from 16 patients developing skin lesions (acute graft versus host-reaction and/or drug-induced reaction) after bone marrow transplantation.,129,52,129,52,133,62,1,RO-disease_has_primary_anatomic_site,902348,Skin biopsies from eight patients with drug-induced dermatitis have been compared with skin biopsies from 16 patients developing skin lesions (acute graft versus host-reaction and/or drug-induced reaction) after bone marrow transplantation,skin,dermatitis
503545393,7/16/2014 20:38:34,,1324465607,7/16/2014 20:38:32,clixsense,1.0,6610277,CAN,ON,Oshawa,174.117.79.122,129,52,,,133,62,SKIN,DERMATITIS,16 patients developing SKIN lesions graft,106-109-118-129-134-149,34-39-44-52-63-68-73,with drug induced DERMATITIS have been compared,Skin biopsies from eight patients with drug-induced dermatitis have been compared with skin biopsies from 16 patients developing skin lesions (acute graft versus host-reaction and/or drug-induced reaction) after bone marrow transplantation.,129,52,129,52,133,62,1,RO-disease_has_primary_anatomic_site,902348,Skin biopsies from eight patients with drug-induced dermatitis have been compared with skin biopsies from 16 patients developing skin lesions (acute graft versus host-reaction and/or drug-induced reaction) after bone marrow transplantation,skin,dermatitis
503545393,7/16/2014 20:40:35,,1324466503,7/16/2014 20:40:24,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,129,52,,,133,62,SKIN,DERMATITIS,SKIN lesions,129-134,39-44-52,drug induced DERMATITIS,Skin biopsies from eight patients with drug-induced dermatitis have been compared with skin biopsies from 16 patients developing skin lesions (acute graft versus host-reaction and/or drug-induced reaction) after bone marrow transplantation.,129,52,129,52,133,62,1,RO-disease_has_primary_anatomic_site,902348,Skin biopsies from eight patients with drug-induced dermatitis have been compared with skin biopsies from 16 patients developing skin lesions (acute graft versus host-reaction and/or drug-induced reaction) after bone marrow transplantation,skin,dermatitis
503545393,7/16/2014 20:41:51,,1324467028,7/16/2014 20:41:48,coinworker,1.0,28394550,USA,PA,Marcus Hook,71.175.96.184,129,52,,,133,62,SKIN,DERMATITIS,16 patients developing SKIN lesions graft,106-109-118-129-134-149,34-39-44-52-63-68-73,with drug induced DERMATITIS have been compared,Skin biopsies from eight patients with drug-induced dermatitis have been compared with skin biopsies from 16 patients developing skin lesions (acute graft versus host-reaction and/or drug-induced reaction) after bone marrow transplantation.,129,52,129,52,133,62,1,RO-disease_has_primary_anatomic_site,902348,Skin biopsies from eight patients with drug-induced dermatitis have been compared with skin biopsies from 16 patients developing skin lesions (acute graft versus host-reaction and/or drug-induced reaction) after bone marrow transplantation,skin,dermatitis
503545393,7/16/2014 20:42:23,,1324467194,7/16/2014 20:42:08,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,129,52,,,133,62,SKIN,DERMATITIS,SKIN lesions,129-134,39-44-52,drug induced DERMATITIS,Skin biopsies from eight patients with drug-induced dermatitis have been compared with skin biopsies from 16 patients developing skin lesions (acute graft versus host-reaction and/or drug-induced reaction) after bone marrow transplantation.,129,52,129,52,133,62,1,RO-disease_has_primary_anatomic_site,902348,Skin biopsies from eight patients with drug-induced dermatitis have been compared with skin biopsies from 16 patients developing skin lesions (acute graft versus host-reaction and/or drug-induced reaction) after bone marrow transplantation,skin,dermatitis
503545393,7/16/2014 20:43:32,,1324467594,7/16/2014 20:43:30,bitcoinget,1.0,24792414,USA,"","",166.181.81.55,129,52,,,133,62,SKIN,DERMATITIS,16 patients developing SKIN lesions graft,106-109-118-129-134-149,34-39-44-52-63-68-73,with drug induced DERMATITIS have been compared,Skin biopsies from eight patients with drug-induced dermatitis have been compared with skin biopsies from 16 patients developing skin lesions (acute graft versus host-reaction and/or drug-induced reaction) after bone marrow transplantation.,129,52,129,52,133,62,1,RO-disease_has_primary_anatomic_site,902348,Skin biopsies from eight patients with drug-induced dermatitis have been compared with skin biopsies from 16 patients developing skin lesions (acute graft versus host-reaction and/or drug-induced reaction) after bone marrow transplantation,skin,dermatitis
503545393,7/16/2014 20:44:39,,1324468018,7/16/2014 20:44:27,instagc,1.0,13763729,USA,"","",75.182.89.225,129,52,,,133,62,SKIN,DERMATITIS,SKIN lesions,129-134,39-44-52,drug induced DERMATITIS,Skin biopsies from eight patients with drug-induced dermatitis have been compared with skin biopsies from 16 patients developing skin lesions (acute graft versus host-reaction and/or drug-induced reaction) after bone marrow transplantation.,129,52,129,52,133,62,1,RO-disease_has_primary_anatomic_site,902348,Skin biopsies from eight patients with drug-induced dermatitis have been compared with skin biopsies from 16 patients developing skin lesions (acute graft versus host-reaction and/or drug-induced reaction) after bone marrow transplantation,skin,dermatitis
503545393,7/16/2014 20:44:58,,1324468128,7/16/2014 20:44:42,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,129,52,,,133,62,SKIN,DERMATITIS,SKIN lesions,129-134,39-44-52,drug induced DERMATITIS,Skin biopsies from eight patients with drug-induced dermatitis have been compared with skin biopsies from 16 patients developing skin lesions (acute graft versus host-reaction and/or drug-induced reaction) after bone marrow transplantation.,129,52,129,52,133,62,1,RO-disease_has_primary_anatomic_site,902348,Skin biopsies from eight patients with drug-induced dermatitis have been compared with skin biopsies from 16 patients developing skin lesions (acute graft versus host-reaction and/or drug-induced reaction) after bone marrow transplantation,skin,dermatitis
503545393,7/16/2014 20:45:03,,1324468161,7/16/2014 20:44:43,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,129,52,,,133,62,SKIN,DERMATITIS,SKIN lesions,129-134,39-44-52,drug induced DERMATITIS,Skin biopsies from eight patients with drug-induced dermatitis have been compared with skin biopsies from 16 patients developing skin lesions (acute graft versus host-reaction and/or drug-induced reaction) after bone marrow transplantation.,129,52,129,52,133,62,1,RO-disease_has_primary_anatomic_site,902348,Skin biopsies from eight patients with drug-induced dermatitis have been compared with skin biopsies from 16 patients developing skin lesions (acute graft versus host-reaction and/or drug-induced reaction) after bone marrow transplantation,skin,dermatitis
503545394,7/16/2014 20:41:19,,1324466808,7/16/2014 20:41:16,coinworker,1.0,28394550,USA,PA,Marcus Hook,71.175.96.184,77,107,,,85,116,BALDNESS,MINOXIDIL,with male pattern BALDNESS treated with topical,59-64-69-77-86-94-99,86-94-99-107,treated with topical MINOXIDIL.,"Olsen EA, DeLong ER, Weiner MS. Long-term follow-up of men with male pattern baldness treated with topical minoxidil.",77,107,77,107,85,116,1,RO-may_treat,907885,"Olsen EA, DeLong ER, Weiner MS. Long-term follow-up of men with male pattern baldness treated with topical minoxidil",baldness,minoxidil
503545394,7/16/2014 20:41:30,,1324466868,7/16/2014 20:41:21,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,77,107,,,85,116,BALDNESS,MINOXIDIL,male pattern BALDNESS,64-69-77,99-107,topical MINOXIDIL.,"Olsen EA, DeLong ER, Weiner MS. Long-term follow-up of men with male pattern baldness treated with topical minoxidil.",77,107,77,107,85,116,1,RO-may_treat,907885,"Olsen EA, DeLong ER, Weiner MS. Long-term follow-up of men with male pattern baldness treated with topical minoxidil",baldness,minoxidil
503545394,7/16/2014 20:41:59,,1324467075,7/16/2014 20:41:45,bitcoinget,1.0,24792414,USA,"","",166.181.81.55,77,107,,,85,116,BALDNESS,MINOXIDIL,male pattern BALDNESS,64-77-69,99-107,topical MINOXIDIL.,"Olsen EA, DeLong ER, Weiner MS. Long-term follow-up of men with male pattern baldness treated with topical minoxidil.",77,107,77,107,85,116,1,RO-may_treat,907885,"Olsen EA, DeLong ER, Weiner MS. Long-term follow-up of men with male pattern baldness treated with topical minoxidil",baldness,minoxidil
503545394,7/16/2014 20:42:23,,1324467184,7/16/2014 20:42:06,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,77,107,,,85,116,BALDNESS,MINOXIDIL,male pattern BALDNESS,64-77-69,107,MINOXIDIL.,"Olsen EA, DeLong ER, Weiner MS. Long-term follow-up of men with male pattern baldness treated with topical minoxidil.",77,107,77,107,85,116,1,RO-may_treat,907885,"Olsen EA, DeLong ER, Weiner MS. Long-term follow-up of men with male pattern baldness treated with topical minoxidil",baldness,minoxidil
503545394,7/16/2014 20:42:38,,1324467287,7/16/2014 20:42:29,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,77,107,,,85,116,BALDNESS,MINOXIDIL,male pattern BALDNESS,64-69-77,99-107,topical MINOXIDIL.,"Olsen EA, DeLong ER, Weiner MS. Long-term follow-up of men with male pattern baldness treated with topical minoxidil.",77,107,77,107,85,116,1,RO-may_treat,907885,"Olsen EA, DeLong ER, Weiner MS. Long-term follow-up of men with male pattern baldness treated with topical minoxidil",baldness,minoxidil
503545394,7/16/2014 20:45:18,,1324468277,7/16/2014 20:45:08,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,77,107,,,85,116,BALDNESS,MINOXIDIL,male pattern BALDNESS,64-69-77,99-107,topical MINOXIDIL.,"Olsen EA, DeLong ER, Weiner MS. Long-term follow-up of men with male pattern baldness treated with topical minoxidil.",77,107,77,107,85,116,1,RO-may_treat,907885,"Olsen EA, DeLong ER, Weiner MS. Long-term follow-up of men with male pattern baldness treated with topical minoxidil",baldness,minoxidil
503545394,7/16/2014 20:45:46,,1324468488,7/16/2014 20:45:26,prodege,1.0,22360212,GBR,I1,Luton,82.6.41.191,77,107,,,85,116,BALDNESS,MINOXIDIL,male pattern BALDNESS,64-69-77,107,MINOXIDIL.,"Olsen EA, DeLong ER, Weiner MS. Long-term follow-up of men with male pattern baldness treated with topical minoxidil.",77,107,77,107,85,116,1,RO-may_treat,907885,"Olsen EA, DeLong ER, Weiner MS. Long-term follow-up of men with male pattern baldness treated with topical minoxidil",baldness,minoxidil
503545394,7/16/2014 20:47:13,,1324469145,7/16/2014 20:47:10,prodege,1.0,26325260,GBR,"","",79.64.25.64,77,107,,,85,116,BALDNESS,MINOXIDIL,with male pattern BALDNESS treated with topical,59-64-69-77-86-94-99,86-94-99-107,treated with topical MINOXIDIL.,"Olsen EA, DeLong ER, Weiner MS. Long-term follow-up of men with male pattern baldness treated with topical minoxidil.",77,107,77,107,85,116,1,RO-may_treat,907885,"Olsen EA, DeLong ER, Weiner MS. Long-term follow-up of men with male pattern baldness treated with topical minoxidil",baldness,minoxidil
503545394,7/16/2014 20:48:05,,1324469560,7/16/2014 20:47:56,instagc,1.0,13763729,USA,"","",75.182.89.225,77,107,,,85,116,BALDNESS,MINOXIDIL,male pattern BALDNESS,64-69-77,99-107,topical MINOXIDIL.,"Olsen EA, DeLong ER, Weiner MS. Long-term follow-up of men with male pattern baldness treated with topical minoxidil.",77,107,77,107,85,116,1,RO-may_treat,907885,"Olsen EA, DeLong ER, Weiner MS. Long-term follow-up of men with male pattern baldness treated with topical minoxidil",baldness,minoxidil
503545394,7/16/2014 20:49:13,,1324470061,7/16/2014 20:49:04,prodege,1.0,9997387,USA,CO,Colorado Springs,75.70.112.31,77,107,,,85,116,BALDNESS,MINOXIDIL,male pattern BALDNESS,64-69-77,99-107,topical MINOXIDIL.,"Olsen EA, DeLong ER, Weiner MS. Long-term follow-up of men with male pattern baldness treated with topical minoxidil.",77,107,77,107,85,116,1,RO-may_treat,907885,"Olsen EA, DeLong ER, Weiner MS. Long-term follow-up of men with male pattern baldness treated with topical minoxidil",baldness,minoxidil
503545395,7/16/2014 20:37:01,,1324465050,7/16/2014 20:36:38,clixsense,1.0,24896327,GBR,V2,Glasgow,94.2.231.4,82,125,,,93,144,HEPATITIS B,HEPATITIS B VACCINE,HEPATITIS B,82-92,125-135-137,"HEPATITIS B VACCINE,","Sixty-eight patients with renal failure of varying severity who were negative for hepatitis B markers received four doses of hepatitis B vaccine, and anti-HBs titers were determined at 0, 1, 2, 3, 6, 8 and 12 months.",82 92,125 135 137,82,125,93,144,1,RO-may_prevent,907170,"Sixty-eight patients with renal failure of varying severity who were negative for hepatitis B markers received four doses of hepatitis B vaccine, and anti-HBs titers were determined at 0, 1, 2, 3, 6, 8 and 12 months",hepatitis B,hepatitis B vaccine
503545395,7/16/2014 20:37:32,,1324465235,7/16/2014 20:37:21,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,82,125,,,93,144,HEPATITIS B,HEPATITIS B VACCINE,HEPATITIS B markers,82-92-94,125-135-137,"HEPATITIS B VACCINE,","Sixty-eight patients with renal failure of varying severity who were negative for hepatitis B markers received four doses of hepatitis B vaccine, and anti-HBs titers were determined at 0, 1, 2, 3, 6, 8 and 12 months.",82 92,125 135 137,82,125,93,144,1,RO-may_prevent,907170,"Sixty-eight patients with renal failure of varying severity who were negative for hepatitis B markers received four doses of hepatitis B vaccine, and anti-HBs titers were determined at 0, 1, 2, 3, 6, 8 and 12 months",hepatitis B,hepatitis B vaccine
503545395,7/16/2014 20:37:44,,1324465289,7/16/2014 20:37:39,clixsense,1.0,6610277,CAN,ON,Oshawa,174.117.79.122,82,125,,,93,144,HEPATITIS B,HEPATITIS B VACCINE,were negative for HEPATITIS B markers received four,64-69-78-82-92-94-102-111,111-116-122-125-135-137-146-150-155,"four doses of HEPATITIS B VACCINE, and anti HBs","Sixty-eight patients with renal failure of varying severity who were negative for hepatitis B markers received four doses of hepatitis B vaccine, and anti-HBs titers were determined at 0, 1, 2, 3, 6, 8 and 12 months.",82 92,125 135 137,82,125,93,144,1,RO-may_prevent,907170,"Sixty-eight patients with renal failure of varying severity who were negative for hepatitis B markers received four doses of hepatitis B vaccine, and anti-HBs titers were determined at 0, 1, 2, 3, 6, 8 and 12 months",hepatitis B,hepatitis B vaccine
503545395,7/16/2014 20:38:55,,1324465806,7/16/2014 20:38:46,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,82,125,,,93,144,HEPATITIS B,HEPATITIS B VACCINE,HEPATITIS B,82-92,125-135-137,"HEPATITIS B VACCINE,","Sixty-eight patients with renal failure of varying severity who were negative for hepatitis B markers received four doses of hepatitis B vaccine, and anti-HBs titers were determined at 0, 1, 2, 3, 6, 8 and 12 months.",82 92,125 135 137,82,125,93,144,1,RO-may_prevent,907170,"Sixty-eight patients with renal failure of varying severity who were negative for hepatitis B markers received four doses of hepatitis B vaccine, and anti-HBs titers were determined at 0, 1, 2, 3, 6, 8 and 12 months",hepatitis B,hepatitis B vaccine
503545395,7/16/2014 20:41:54,,1324467051,7/16/2014 20:41:21,prodege,1.0,9997387,USA,CO,Colorado Springs,75.70.112.31,82,125,,,93,144,HEPATITIS B,HEPATITIS B VACCINE,HEPATITIS B hepatitis B,82-92-125-135,125-135-137,"HEPATITIS B VACCINE,","Sixty-eight patients with renal failure of varying severity who were negative for hepatitis B markers received four doses of hepatitis B vaccine, and anti-HBs titers were determined at 0, 1, 2, 3, 6, 8 and 12 months.",82 92,125 135 137,82,125,93,144,1,RO-may_prevent,907170,"Sixty-eight patients with renal failure of varying severity who were negative for hepatitis B markers received four doses of hepatitis B vaccine, and anti-HBs titers were determined at 0, 1, 2, 3, 6, 8 and 12 months",hepatitis B,hepatitis B vaccine
503545395,7/16/2014 20:43:07,,1324467465,7/16/2014 20:42:45,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,82,125,,,93,144,HEPATITIS B,HEPATITIS B VACCINE,HEPATITIS B,82-92,125-135-137,"HEPATITIS B VACCINE,","Sixty-eight patients with renal failure of varying severity who were negative for hepatitis B markers received four doses of hepatitis B vaccine, and anti-HBs titers were determined at 0, 1, 2, 3, 6, 8 and 12 months.",82 92,125 135 137,82,125,93,144,1,RO-may_prevent,907170,"Sixty-eight patients with renal failure of varying severity who were negative for hepatitis B markers received four doses of hepatitis B vaccine, and anti-HBs titers were determined at 0, 1, 2, 3, 6, 8 and 12 months",hepatitis B,hepatitis B vaccine
503545395,7/16/2014 20:44:33,,1324467965,7/16/2014 20:44:01,eup_slw,1.0,28011002,CAN,MB,Winnipeg,24.77.44.140,82,125,,,93,144,HEPATITIS B,HEPATITIS B VACCINE,HEPATITIS B,82-92,125-135-137,"HEPATITIS B VACCINE,","Sixty-eight patients with renal failure of varying severity who were negative for hepatitis B markers received four doses of hepatitis B vaccine, and anti-HBs titers were determined at 0, 1, 2, 3, 6, 8 and 12 months.",82 92,125 135 137,82,125,93,144,1,RO-may_prevent,907170,"Sixty-eight patients with renal failure of varying severity who were negative for hepatitis B markers received four doses of hepatitis B vaccine, and anti-HBs titers were determined at 0, 1, 2, 3, 6, 8 and 12 months",hepatitis B,hepatitis B vaccine
503545395,7/16/2014 20:46:26,,1324468785,7/16/2014 20:46:09,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,82,125,,,93,144,HEPATITIS B,HEPATITIS B VACCINE,HEPATITIS B,82-92,125-135-137,"HEPATITIS B VACCINE,","Sixty-eight patients with renal failure of varying severity who were negative for hepatitis B markers received four doses of hepatitis B vaccine, and anti-HBs titers were determined at 0, 1, 2, 3, 6, 8 and 12 months.",82 92,125 135 137,82,125,93,144,1,RO-may_prevent,907170,"Sixty-eight patients with renal failure of varying severity who were negative for hepatitis B markers received four doses of hepatitis B vaccine, and anti-HBs titers were determined at 0, 1, 2, 3, 6, 8 and 12 months",hepatitis B,hepatitis B vaccine
503545395,7/16/2014 20:46:51,,1324468969,7/16/2014 20:46:47,prodege,1.0,26325260,GBR,"","",79.64.25.64,82,125,,,93,144,HEPATITIS B,HEPATITIS B VACCINE,were negative for HEPATITIS B markers received four,64-69-78-82-92-94-102-111,111-116-122-125-135-137-146-150-155,"four doses of HEPATITIS B VACCINE, and anti HBs","Sixty-eight patients with renal failure of varying severity who were negative for hepatitis B markers received four doses of hepatitis B vaccine, and anti-HBs titers were determined at 0, 1, 2, 3, 6, 8 and 12 months.",82 92,125 135 137,82,125,93,144,1,RO-may_prevent,907170,"Sixty-eight patients with renal failure of varying severity who were negative for hepatitis B markers received four doses of hepatitis B vaccine, and anti-HBs titers were determined at 0, 1, 2, 3, 6, 8 and 12 months",hepatitis B,hepatitis B vaccine
503545395,7/16/2014 20:48:24,,1324469702,7/16/2014 20:48:06,instagc,1.0,13763729,USA,"","",75.182.89.225,82,125,,,93,144,HEPATITIS B,HEPATITIS B VACCINE,HEPATITIS B,82-92,125-135-137,"HEPATITIS B VACCINE,","Sixty-eight patients with renal failure of varying severity who were negative for hepatitis B markers received four doses of hepatitis B vaccine, and anti-HBs titers were determined at 0, 1, 2, 3, 6, 8 and 12 months.",82 92,125 135 137,82,125,93,144,1,RO-may_prevent,907170,"Sixty-eight patients with renal failure of varying severity who were negative for hepatitis B markers received four doses of hepatitis B vaccine, and anti-HBs titers were determined at 0, 1, 2, 3, 6, 8 and 12 months",hepatitis B,hepatitis B vaccine
503545396,7/16/2014 20:39:27,,1324466055,7/16/2014 20:39:15,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,98,53,,,106,68,DIABETES,GLUCOSE TESTING,DIABETES,98,53-61,GLUCOSE TESTING,One way to improve the quality of care is to perform glucose testing on patients at high risk for diabetes and to obtain complete lipid profiles.,98,53 61,98,53,106,68,1,RO-may_diagnose,906639,One way to improve the quality of care is to perform glucose testing on patients at high risk for diabetes and to obtain complete lipid profiles,diabetes,glucose testing
503545396,7/16/2014 20:42:07,,1324467122,7/16/2014 20:41:45,clixsense,1.0,24896327,GBR,V2,Glasgow,94.2.231.4,98,53,,,106,68,DIABETES,GLUCOSE TESTING,DIABETES,98,53-61,GLUCOSE TESTING,One way to improve the quality of care is to perform glucose testing on patients at high risk for diabetes and to obtain complete lipid profiles.,98,53 61,98,53,106,68,1,RO-may_diagnose,906639,One way to improve the quality of care is to perform glucose testing on patients at high risk for diabetes and to obtain complete lipid profiles,diabetes,glucose testing
503545396,7/16/2014 20:42:26,,1324467219,7/16/2014 20:42:24,coinworker,1.0,28394550,USA,PA,Marcus Hook,71.175.96.184,98,53,,,106,68,DIABETES,GLUCOSE TESTING,high risk for DIABETES and to obtain,84-89-94-98-107-111-114,39-42-45-53-61-69-72-81,is to perform GLUCOSE TESTING on patients at,One way to improve the quality of care is to perform glucose testing on patients at high risk for diabetes and to obtain complete lipid profiles.,98,53 61,98,53,106,68,1,RO-may_diagnose,906639,One way to improve the quality of care is to perform glucose testing on patients at high risk for diabetes and to obtain complete lipid profiles,diabetes,glucose testing
503545396,7/16/2014 20:43:17,,1324467502,7/16/2014 20:43:07,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,98,53,,,106,68,DIABETES,GLUCOSE TESTING,high risk for DIABETES and to obtain,84-89-94-98-107-111-114,39-42-45-53-61-69-72-81,is to perform GLUCOSE TESTING on patients at,One way to improve the quality of care is to perform glucose testing on patients at high risk for diabetes and to obtain complete lipid profiles.,98,53 61,98,53,106,68,1,RO-may_diagnose,906639,One way to improve the quality of care is to perform glucose testing on patients at high risk for diabetes and to obtain complete lipid profiles,diabetes,glucose testing
503545396,7/16/2014 20:43:29,,1324467572,7/16/2014 20:43:26,bitcoinget,1.0,24792414,USA,"","",166.181.81.55,98,53,,,106,68,DIABETES,GLUCOSE TESTING,high risk for DIABETES and to obtain,84-89-94-98-107-111-114,39-42-45-53-61-69-72-81,is to perform GLUCOSE TESTING on patients at,One way to improve the quality of care is to perform glucose testing on patients at high risk for diabetes and to obtain complete lipid profiles.,98,53 61,98,53,106,68,1,RO-may_diagnose,906639,One way to improve the quality of care is to perform glucose testing on patients at high risk for diabetes and to obtain complete lipid profiles,diabetes,glucose testing
503545396,7/16/2014 20:45:48,,1324468500,7/16/2014 20:45:45,prodege,1.0,26325260,GBR,"","",79.64.25.64,98,53,,,106,68,DIABETES,GLUCOSE TESTING,high risk for DIABETES and to obtain,84-89-94-98-107-111-114,39-42-45-53-61-69-72-81,is to perform GLUCOSE TESTING on patients at,One way to improve the quality of care is to perform glucose testing on patients at high risk for diabetes and to obtain complete lipid profiles.,98,53 61,98,53,106,68,1,RO-may_diagnose,906639,One way to improve the quality of care is to perform glucose testing on patients at high risk for diabetes and to obtain complete lipid profiles,diabetes,glucose testing
503545396,7/16/2014 20:47:34,,1324469302,7/16/2014 20:47:18,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,98,53,,,106,68,DIABETES,GLUCOSE TESTING,DIABETES,98,53-61,GLUCOSE TESTING,One way to improve the quality of care is to perform glucose testing on patients at high risk for diabetes and to obtain complete lipid profiles.,98,53 61,98,53,106,68,1,RO-may_diagnose,906639,One way to improve the quality of care is to perform glucose testing on patients at high risk for diabetes and to obtain complete lipid profiles,diabetes,glucose testing
503545396,7/16/2014 20:48:17,,1324469648,7/16/2014 20:48:08,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,98,53,,,106,68,DIABETES,GLUCOSE TESTING,DIABETES,98,53-61,GLUCOSE TESTING,One way to improve the quality of care is to perform glucose testing on patients at high risk for diabetes and to obtain complete lipid profiles.,98,53 61,98,53,106,68,1,RO-may_diagnose,906639,One way to improve the quality of care is to perform glucose testing on patients at high risk for diabetes and to obtain complete lipid profiles,diabetes,glucose testing
503545396,7/16/2014 20:50:51,,1324470738,7/16/2014 20:50:33,prodege,1.0,4968858,USA,CA,Corona,99.44.120.153,98,53,,,106,68,DIABETES,GLUCOSE TESTING,DIABETES,98,53-61,GLUCOSE TESTING,One way to improve the quality of care is to perform glucose testing on patients at high risk for diabetes and to obtain complete lipid profiles.,98,53 61,98,53,106,68,1,RO-may_diagnose,906639,One way to improve the quality of care is to perform glucose testing on patients at high risk for diabetes and to obtain complete lipid profiles,diabetes,glucose testing
503545396,7/16/2014 20:52:03,,1324471196,7/16/2014 20:51:47,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,98,53,,,106,68,DIABETES,GLUCOSE TESTING,DIABETES,98,53-61,GLUCOSE TESTING,One way to improve the quality of care is to perform glucose testing on patients at high risk for diabetes and to obtain complete lipid profiles.,98,53 61,98,53,106,68,1,RO-may_diagnose,906639,One way to improve the quality of care is to perform glucose testing on patients at high risk for diabetes and to obtain complete lipid profiles,diabetes,glucose testing
503545397,7/16/2014 20:33:36,,1324463630,7/16/2014 20:33:03,clixsense,1.0,24896327,GBR,V2,Glasgow,94.2.231.4,71,36,,,92,52,ARTERIAL HYPERTENSION,PHEOCHROMOCYTOMA,"ARTERIAL HYPERTENSION,",71-80,36,"PHEOCHROMOCYTOMA,","The study involved 12 patients with pheochromocytoma, 17 patients with arterial hypertension, and 9 patients with borderline hypertension.",71 80,36,71,36,92,52,-1,RO-disease_may_have_finding,902900,"The study involved 12 patients with pheochromocytoma, 17 patients with arterial hypertension, and 9 patients with borderline hypertension",arterial hypertension,pheochromocytoma
503545397,7/16/2014 20:38:00,,1324465389,7/16/2014 20:37:52,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,71,36,,,92,52,ARTERIAL HYPERTENSION,PHEOCHROMOCYTOMA,"ARTERIAL HYPERTENSION,",71-80,36,"PHEOCHROMOCYTOMA,","The study involved 12 patients with pheochromocytoma, 17 patients with arterial hypertension, and 9 patients with borderline hypertension.",71 80,36,71,36,92,52,-1,RO-disease_may_have_finding,902900,"The study involved 12 patients with pheochromocytoma, 17 patients with arterial hypertension, and 9 patients with borderline hypertension",arterial hypertension,pheochromocytoma
503545397,7/16/2014 20:38:17,,1324465514,7/16/2014 20:38:11,clixsense,1.0,6610277,CAN,ON,Oshawa,174.117.79.122,71,36,,,92,52,ARTERIAL HYPERTENSION,PHEOCHROMOCYTOMA,"17 patients with ARTERIAL HYPERTENSION, and 9 patients",54-57-66-71-80-94-98-100,19-22-31-36-54-57,"12 patients with PHEOCHROMOCYTOMA, 17 patients","The study involved 12 patients with pheochromocytoma, 17 patients with arterial hypertension, and 9 patients with borderline hypertension.",71 80,36,71,36,92,52,-1,RO-disease_may_have_finding,902900,"The study involved 12 patients with pheochromocytoma, 17 patients with arterial hypertension, and 9 patients with borderline hypertension",arterial hypertension,pheochromocytoma
503545397,7/16/2014 20:38:45,,1324465698,7/16/2014 20:37:52,eup_slw,1.0,28011002,CAN,MB,Winnipeg,24.77.44.140,71,36,,,92,52,ARTERIAL HYPERTENSION,PHEOCHROMOCYTOMA,"pheochromocytoma, ARTERIAL HYPERTENSION,",71-80-36,36-71-80,"PHEOCHROMOCYTOMA, arterial hypertension,","The study involved 12 patients with pheochromocytoma, 17 patients with arterial hypertension, and 9 patients with borderline hypertension.",71 80,36,71,36,92,52,-1,RO-disease_may_have_finding,902900,"The study involved 12 patients with pheochromocytoma, 17 patients with arterial hypertension, and 9 patients with borderline hypertension",arterial hypertension,pheochromocytoma
503545397,7/16/2014 20:39:56,,1324466246,7/16/2014 20:39:37,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,71,36,,,92,52,ARTERIAL HYPERTENSION,PHEOCHROMOCYTOMA,"ARTERIAL HYPERTENSION,",71-80,36-66,"PHEOCHROMOCYTOMA, with","The study involved 12 patients with pheochromocytoma, 17 patients with arterial hypertension, and 9 patients with borderline hypertension.",71 80,36,71,36,92,52,-1,RO-disease_may_have_finding,902900,"The study involved 12 patients with pheochromocytoma, 17 patients with arterial hypertension, and 9 patients with borderline hypertension",arterial hypertension,pheochromocytoma
503545397,7/16/2014 20:40:52,,1324466602,7/16/2014 20:40:30,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,71,36,,,92,52,ARTERIAL HYPERTENSION,PHEOCHROMOCYTOMA,"ARTERIAL HYPERTENSION,",71-80,36,"PHEOCHROMOCYTOMA,","The study involved 12 patients with pheochromocytoma, 17 patients with arterial hypertension, and 9 patients with borderline hypertension.",71 80,36,71,36,92,52,-1,RO-disease_may_have_finding,902900,"The study involved 12 patients with pheochromocytoma, 17 patients with arterial hypertension, and 9 patients with borderline hypertension",arterial hypertension,pheochromocytoma
503545397,7/16/2014 20:41:33,,1324466875,7/16/2014 20:41:30,coinworker,1.0,28394550,USA,PA,Marcus Hook,71.175.96.184,71,36,,,92,52,ARTERIAL HYPERTENSION,PHEOCHROMOCYTOMA,"17 patients with ARTERIAL HYPERTENSION, and 9 patients",54-57-66-71-80-94-98-100,19-22-31-36-54-57-66,"12 patients with PHEOCHROMOCYTOMA, 17 patients with","The study involved 12 patients with pheochromocytoma, 17 patients with arterial hypertension, and 9 patients with borderline hypertension.",71 80,36,71,36,92,52,-1,RO-disease_may_have_finding,902900,"The study involved 12 patients with pheochromocytoma, 17 patients with arterial hypertension, and 9 patients with borderline hypertension",arterial hypertension,pheochromocytoma
503545397,7/16/2014 20:42:11,,1324467128,7/16/2014 20:41:57,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,71,36,,,92,52,ARTERIAL HYPERTENSION,PHEOCHROMOCYTOMA,"17 patients with ARTERIAL HYPERTENSION, and 9 patients",54-57-66-71-80-94-98-100,19-22-31-36-54-57-66,"12 patients with PHEOCHROMOCYTOMA, 17 patients with","The study involved 12 patients with pheochromocytoma, 17 patients with arterial hypertension, and 9 patients with borderline hypertension.",71 80,36,71,36,92,52,-1,RO-disease_may_have_finding,902900,"The study involved 12 patients with pheochromocytoma, 17 patients with arterial hypertension, and 9 patients with borderline hypertension",arterial hypertension,pheochromocytoma
503545397,7/16/2014 20:46:53,,1324468990,7/16/2014 20:46:31,prodege,1.0,22360212,GBR,I1,Luton,82.6.41.191,71,36,,,92,52,ARTERIAL HYPERTENSION,PHEOCHROMOCYTOMA,"ARTERIAL HYPERTENSION,",71-80,36,"PHEOCHROMOCYTOMA,","The study involved 12 patients with pheochromocytoma, 17 patients with arterial hypertension, and 9 patients with borderline hypertension.",71 80,36,71,36,92,52,-1,RO-disease_may_have_finding,902900,"The study involved 12 patients with pheochromocytoma, 17 patients with arterial hypertension, and 9 patients with borderline hypertension",arterial hypertension,pheochromocytoma
503545397,7/16/2014 20:47:00,,1324469049,7/16/2014 20:46:42,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,71,36,,,92,52,ARTERIAL HYPERTENSION,PHEOCHROMOCYTOMA,"ARTERIAL HYPERTENSION,",71-80,36,"PHEOCHROMOCYTOMA,","The study involved 12 patients with pheochromocytoma, 17 patients with arterial hypertension, and 9 patients with borderline hypertension.",71 80,36,71,36,92,52,-1,RO-disease_may_have_finding,902900,"The study involved 12 patients with pheochromocytoma, 17 patients with arterial hypertension, and 9 patients with borderline hypertension",arterial hypertension,pheochromocytoma
503545398,7/16/2014 20:38:20,,1324465536,7/16/2014 20:38:08,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,110,160,,,149,166,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,110-119-132-141,160-176,SEPSIS a,"If they and/or their specific functions are lacking, then immunoparalysis may occur, and severe diseases like systemic inflammatory response syndrome (SIRS) or sepsis can take a fatal course.",110 119 132 141,160,110,160,149,166,-1,RO-cause_of,900232,"If they and/or their specific functions are lacking, then immunoparalysis may occur, and severe diseases like systemic inflammatory response syndrome (SIRS) or sepsis can take a fatal course",systemic inflammatory response syndrome,sepsis
503545398,7/16/2014 20:38:37,,1324465621,7/16/2014 20:38:35,clixsense,1.0,6610277,CAN,ON,Oshawa,174.117.79.122,110,160,,,149,166,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS,severe diseases like SYSTEMIC INFLAMMATORY RESPONSE SYNDROME or sepsis,89-96-105-110-119-132-141-157-160,141-150-157-160-167-171-176,syndrome (SIRS) or SEPSIS can take a,"If they and/or their specific functions are lacking, then immunoparalysis may occur, and severe diseases like systemic inflammatory response syndrome (SIRS) or sepsis can take a fatal course.",110 119 132 141,160,110,160,149,166,-1,RO-cause_of,900232,"If they and/or their specific functions are lacking, then immunoparalysis may occur, and severe diseases like systemic inflammatory response syndrome (SIRS) or sepsis can take a fatal course",systemic inflammatory response syndrome,sepsis
503545398,7/16/2014 20:41:31,,1324466869,7/16/2014 20:41:13,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,110,160,,,149,166,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,110-119-132-141,160,SEPSIS,"If they and/or their specific functions are lacking, then immunoparalysis may occur, and severe diseases like systemic inflammatory response syndrome (SIRS) or sepsis can take a fatal course.",110 119 132 141,160,110,160,149,166,-1,RO-cause_of,900232,"If they and/or their specific functions are lacking, then immunoparalysis may occur, and severe diseases like systemic inflammatory response syndrome (SIRS) or sepsis can take a fatal course",systemic inflammatory response syndrome,sepsis
503545398,7/16/2014 20:41:59,,1324467076,7/16/2014 20:41:58,coinworker,1.0,28394550,USA,PA,Marcus Hook,71.175.96.184,110,160,,,149,166,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS,severe diseases like SYSTEMIC INFLAMMATORY RESPONSE SYNDROME or sepsis,89-96-105-110-119-132-141-157-160,141-150-157-160-167-171-176,syndrome (SIRS) or SEPSIS can take a,"If they and/or their specific functions are lacking, then immunoparalysis may occur, and severe diseases like systemic inflammatory response syndrome (SIRS) or sepsis can take a fatal course.",110 119 132 141,160,110,160,149,166,-1,RO-cause_of,900232,"If they and/or their specific functions are lacking, then immunoparalysis may occur, and severe diseases like systemic inflammatory response syndrome (SIRS) or sepsis can take a fatal course",systemic inflammatory response syndrome,sepsis
503545398,7/16/2014 20:42:54,,1324467367,7/16/2014 20:42:34,clixsense,1.0,24896327,GBR,V2,Glasgow,94.2.231.4,110,160,,,149,166,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,110-119-132-141,141-150-157-160,syndrome (SIRS) or SEPSIS,"If they and/or their specific functions are lacking, then immunoparalysis may occur, and severe diseases like systemic inflammatory response syndrome (SIRS) or sepsis can take a fatal course.",110 119 132 141,160,110,160,149,166,-1,RO-cause_of,900232,"If they and/or their specific functions are lacking, then immunoparalysis may occur, and severe diseases like systemic inflammatory response syndrome (SIRS) or sepsis can take a fatal course",systemic inflammatory response syndrome,sepsis
503545398,7/16/2014 20:44:04,,1324467774,7/16/2014 20:44:01,bitcoinget,1.0,24792414,USA,"","",166.181.81.55,110,160,,,149,166,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS,severe diseases like SYSTEMIC INFLAMMATORY RESPONSE SYNDROME or sepsis,89-96-105-110-119-132-141-157-160,141-150-157-160-167-171-176,syndrome (SIRS) or SEPSIS can take a,"If they and/or their specific functions are lacking, then immunoparalysis may occur, and severe diseases like systemic inflammatory response syndrome (SIRS) or sepsis can take a fatal course.",110 119 132 141,160,110,160,149,166,-1,RO-cause_of,900232,"If they and/or their specific functions are lacking, then immunoparalysis may occur, and severe diseases like systemic inflammatory response syndrome (SIRS) or sepsis can take a fatal course",systemic inflammatory response syndrome,sepsis
503545398,7/16/2014 20:45:45,,1324468457,7/16/2014 20:45:00,eup_slw,1.0,28011002,CAN,MB,Winnipeg,24.77.44.140,110,160,,,149,166,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME (SIRS) sepsis,110-119-132-141-160-150,110-119-141-150-157-160-132,systemic inflammatory response syndrome (SIRS) or SEPSIS,"If they and/or their specific functions are lacking, then immunoparalysis may occur, and severe diseases like systemic inflammatory response syndrome (SIRS) or sepsis can take a fatal course.",110 119 132 141,160,110,160,149,166,-1,RO-cause_of,900232,"If they and/or their specific functions are lacking, then immunoparalysis may occur, and severe diseases like systemic inflammatory response syndrome (SIRS) or sepsis can take a fatal course",systemic inflammatory response syndrome,sepsis
503545398,7/16/2014 20:47:09,,1324469108,7/16/2014 20:47:06,prodege,1.0,26325260,GBR,"","",79.64.25.64,110,160,,,149,166,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS,severe diseases like SYSTEMIC INFLAMMATORY RESPONSE SYNDROME or sepsis,89-96-105-110-119-132-141-157-160,141-150-157-160-167-171-176,syndrome (SIRS) or SEPSIS can take a,"If they and/or their specific functions are lacking, then immunoparalysis may occur, and severe diseases like systemic inflammatory response syndrome (SIRS) or sepsis can take a fatal course.",110 119 132 141,160,110,160,149,166,-1,RO-cause_of,900232,"If they and/or their specific functions are lacking, then immunoparalysis may occur, and severe diseases like systemic inflammatory response syndrome (SIRS) or sepsis can take a fatal course",systemic inflammatory response syndrome,sepsis
503545398,7/16/2014 20:48:22,,1324469688,7/16/2014 20:47:42,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,110,160,,,149,166,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME (SIRS),110-119-132-141-150,160,SEPSIS,"If they and/or their specific functions are lacking, then immunoparalysis may occur, and severe diseases like systemic inflammatory response syndrome (SIRS) or sepsis can take a fatal course.",110 119 132 141,160,110,160,149,166,-1,RO-cause_of,900232,"If they and/or their specific functions are lacking, then immunoparalysis may occur, and severe diseases like systemic inflammatory response syndrome (SIRS) or sepsis can take a fatal course",systemic inflammatory response syndrome,sepsis
503545398,7/16/2014 20:48:50,,1324469913,7/16/2014 20:48:27,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,110,160,,,149,166,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,110-119-132-141,160,SEPSIS,"If they and/or their specific functions are lacking, then immunoparalysis may occur, and severe diseases like systemic inflammatory response syndrome (SIRS) or sepsis can take a fatal course.",110 119 132 141,160,110,160,149,166,-1,RO-cause_of,900232,"If they and/or their specific functions are lacking, then immunoparalysis may occur, and severe diseases like systemic inflammatory response syndrome (SIRS) or sepsis can take a fatal course",systemic inflammatory response syndrome,sepsis
503545399,7/16/2014 20:32:59,,1324463441,7/16/2014 20:32:48,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,99,45,,,104,52,VIRUS,VIREMIA,"VIRUS exposure,",99-105,34-45,persistent VIREMIA,"Efficacious FeLV vaccines prevent persistent viremia and development of FeLV-related disease after virus exposure, but not minimal viral replication and a provirus-positive state as recently demonstrated using sensitive real-time PCR assays.",99,45,99,45,104,52,1,RO-has_causative_agent,903998,"Efficacious FeLV vaccines prevent persistent viremia and development of FeLV-related disease after virus exposure, but not minimal viral replication and a provirus-positive state as recently demonstrated using sensitive real-time PCR assays",virus,viremia
503545399,7/16/2014 20:41:13,,1324466762,7/16/2014 20:40:47,prodege,1.0,22360212,GBR,I1,Luton,82.6.41.191,99,45,,,104,52,VIRUS,VIREMIA,VIRUS,99,45,VIREMIA,"Efficacious FeLV vaccines prevent persistent viremia and development of FeLV-related disease after virus exposure, but not minimal viral replication and a provirus-positive state as recently demonstrated using sensitive real-time PCR assays.",99,45,99,45,104,52,1,RO-has_causative_agent,903998,"Efficacious FeLV vaccines prevent persistent viremia and development of FeLV-related disease after virus exposure, but not minimal viral replication and a provirus-positive state as recently demonstrated using sensitive real-time PCR assays",virus,viremia
503545399,7/16/2014 20:43:08,,1324467471,7/16/2014 20:42:30,prodege,1.0,9997387,USA,CO,Colorado Springs,75.70.112.31,99,45,,,104,52,VIRUS,VIREMIA,Efficacious FeLV persistent viremia FeLV VIRUS,0-34-45-72-99-12,0-12-45-72,Efficacious FeLV VIREMIA FeLV,"Efficacious FeLV vaccines prevent persistent viremia and development of FeLV-related disease after virus exposure, but not minimal viral replication and a provirus-positive state as recently demonstrated using sensitive real-time PCR assays.",99,45,99,45,104,52,1,RO-has_causative_agent,903998,"Efficacious FeLV vaccines prevent persistent viremia and development of FeLV-related disease after virus exposure, but not minimal viral replication and a provirus-positive state as recently demonstrated using sensitive real-time PCR assays",virus,viremia
503545399,7/16/2014 20:44:57,,1324468114,7/16/2014 20:44:49,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,99,45,,,104,52,VIRUS,VIREMIA,"related disease after VIRUS exposure, but not",77-85-93-99-105-115-119,17-26-34-45-53-57-69,vaccines prevent persistent VIREMIA and development of,"Efficacious FeLV vaccines prevent persistent viremia and development of FeLV-related disease after virus exposure, but not minimal viral replication and a provirus-positive state as recently demonstrated using sensitive real-time PCR assays.",99,45,99,45,104,52,1,RO-has_causative_agent,903998,"Efficacious FeLV vaccines prevent persistent viremia and development of FeLV-related disease after virus exposure, but not minimal viral replication and a provirus-positive state as recently demonstrated using sensitive real-time PCR assays",virus,viremia
503545399,7/16/2014 20:46:08,,1324468652,7/16/2014 20:45:51,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,99,45,,,104,52,VIRUS,VIREMIA,"VIRUS exposure,",99-105,45,VIREMIA,"Efficacious FeLV vaccines prevent persistent viremia and development of FeLV-related disease after virus exposure, but not minimal viral replication and a provirus-positive state as recently demonstrated using sensitive real-time PCR assays.",99,45,99,45,104,52,1,RO-has_causative_agent,903998,"Efficacious FeLV vaccines prevent persistent viremia and development of FeLV-related disease after virus exposure, but not minimal viral replication and a provirus-positive state as recently demonstrated using sensitive real-time PCR assays",virus,viremia
503545399,7/16/2014 20:50:11,,1324470486,7/16/2014 20:49:55,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,99,45,,,104,52,VIRUS,VIREMIA,VIRUS,99,45,VIREMIA,"Efficacious FeLV vaccines prevent persistent viremia and development of FeLV-related disease after virus exposure, but not minimal viral replication and a provirus-positive state as recently demonstrated using sensitive real-time PCR assays.",99,45,99,45,104,52,1,RO-has_causative_agent,903998,"Efficacious FeLV vaccines prevent persistent viremia and development of FeLV-related disease after virus exposure, but not minimal viral replication and a provirus-positive state as recently demonstrated using sensitive real-time PCR assays",virus,viremia
503545399,7/16/2014 20:53:09,,1324471681,7/16/2014 20:52:53,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,99,45,,,104,52,VIRUS,VIREMIA,"VIRUS exposure,",99-105,34-45,persistent VIREMIA,"Efficacious FeLV vaccines prevent persistent viremia and development of FeLV-related disease after virus exposure, but not minimal viral replication and a provirus-positive state as recently demonstrated using sensitive real-time PCR assays.",99,45,99,45,104,52,1,RO-has_causative_agent,903998,"Efficacious FeLV vaccines prevent persistent viremia and development of FeLV-related disease after virus exposure, but not minimal viral replication and a provirus-positive state as recently demonstrated using sensitive real-time PCR assays",virus,viremia
503545399,7/16/2014 20:53:18,,1324471704,7/16/2014 20:52:52,instagc,1,24252915,GBR,B7,Bristol,77.98.139.82,99,45,,,104,52,VIRUS,VIREMIA,"VIRUS exposure,",99-105,34-45,persistent VIREMIA,"Efficacious FeLV vaccines prevent persistent viremia and development of FeLV-related disease after virus exposure, but not minimal viral replication and a provirus-positive state as recently demonstrated using sensitive real-time PCR assays.",99,45,99,45,104,52,1,RO-has_causative_agent,903998,"Efficacious FeLV vaccines prevent persistent viremia and development of FeLV-related disease after virus exposure, but not minimal viral replication and a provirus-positive state as recently demonstrated using sensitive real-time PCR assays",virus,viremia
503545399,7/16/2014 20:54:17,,1324472118,7/16/2014 20:53:45,prodege,1.0,4968858,USA,CA,Corona,99.44.120.153,99,45,,,104,52,VIRUS,VIREMIA,"FeLV related disease after VIRUS exposure,",72-77-85-93-99-105,45,VIREMIA,"Efficacious FeLV vaccines prevent persistent viremia and development of FeLV-related disease after virus exposure, but not minimal viral replication and a provirus-positive state as recently demonstrated using sensitive real-time PCR assays.",99,45,99,45,104,52,1,RO-has_causative_agent,903998,"Efficacious FeLV vaccines prevent persistent viremia and development of FeLV-related disease after virus exposure, but not minimal viral replication and a provirus-positive state as recently demonstrated using sensitive real-time PCR assays",virus,viremia
503545399,7/16/2014 20:55:21,,1324472490,7/16/2014 20:55:06,elite,1,28466071,CAN,AB,Edmonton,68.150.39.46,99,45,,,104,52,VIRUS,VIREMIA,VIRUS,99,34-45,persistent VIREMIA,"Efficacious FeLV vaccines prevent persistent viremia and development of FeLV-related disease after virus exposure, but not minimal viral replication and a provirus-positive state as recently demonstrated using sensitive real-time PCR assays.",99,45,99,45,104,52,1,RO-has_causative_agent,903998,"Efficacious FeLV vaccines prevent persistent viremia and development of FeLV-related disease after virus exposure, but not minimal viral replication and a provirus-positive state as recently demonstrated using sensitive real-time PCR assays",virus,viremia
503545400,7/16/2014 20:35:17,,1324464288,7/16/2014 20:34:57,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,98,131,,,113,155,SPLENIC RUPTURE,INFECTIOUS MONONUCLEOSIS,SPLENIC RUPTURE,98-106,131-142,INFECTIOUS MONONUCLEOSIS.,This case-report draws the attention to the possibility of a conservative surgical treatment of a splenic rupture in the course of infectious mononucleosis.,98 106,131 142,98,131,113,155,1,RO-disease_may_have_finding,902861,This case-report draws the attention to the possibility of a conservative surgical treatment of a splenic rupture in the course of infectious mononucleosis,splenic rupture,infectious mononucleosis
503545400,7/16/2014 20:41:21,,1324466812,7/16/2014 20:41:07,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,98,131,,,113,155,SPLENIC RUPTURE,INFECTIOUS MONONUCLEOSIS,SPLENIC RUPTURE,98-106,131-142,INFECTIOUS MONONUCLEOSIS.,This case-report draws the attention to the possibility of a conservative surgical treatment of a splenic rupture in the course of infectious mononucleosis.,98 106,131 142,98,131,113,155,1,RO-disease_may_have_finding,902861,This case-report draws the attention to the possibility of a conservative surgical treatment of a splenic rupture in the course of infectious mononucleosis,splenic rupture,infectious mononucleosis
503545400,7/16/2014 20:43:55,,1324467729,7/16/2014 20:43:38,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,98,131,,,113,155,SPLENIC RUPTURE,INFECTIOUS MONONUCLEOSIS,SPLENIC RUPTURE,98-106,131-142,INFECTIOUS MONONUCLEOSIS.,This case-report draws the attention to the possibility of a conservative surgical treatment of a splenic rupture in the course of infectious mononucleosis.,98 106,131 142,98,131,113,155,1,RO-disease_may_have_finding,902861,This case-report draws the attention to the possibility of a conservative surgical treatment of a splenic rupture in the course of infectious mononucleosis,splenic rupture,infectious mononucleosis
503545400,7/16/2014 20:47:07,,1324469091,7/16/2014 20:46:58,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,98,131,,,113,155,SPLENIC RUPTURE,INFECTIOUS MONONUCLEOSIS,treatment of a SPLENIC RUPTURE in the course,83-93-96-98-106-114-117-121,117-121-128-131-142,the course of INFECTIOUS MONONUCLEOSIS.,This case-report draws the attention to the possibility of a conservative surgical treatment of a splenic rupture in the course of infectious mononucleosis.,98 106,131 142,98,131,113,155,1,RO-disease_may_have_finding,902861,This case-report draws the attention to the possibility of a conservative surgical treatment of a splenic rupture in the course of infectious mononucleosis,splenic rupture,infectious mononucleosis
503545400,7/16/2014 20:47:22,,1324469197,7/16/2014 20:47:19,prodege,1.0,26325260,GBR,"","",79.64.25.64,98,131,,,113,155,SPLENIC RUPTURE,INFECTIOUS MONONUCLEOSIS,treatment of a SPLENIC RUPTURE in the course,83-93-96-98-106-114-117-121,117-121-128-131-142,the course of INFECTIOUS MONONUCLEOSIS.,This case-report draws the attention to the possibility of a conservative surgical treatment of a splenic rupture in the course of infectious mononucleosis.,98 106,131 142,98,131,113,155,1,RO-disease_may_have_finding,902861,This case-report draws the attention to the possibility of a conservative surgical treatment of a splenic rupture in the course of infectious mononucleosis,splenic rupture,infectious mononucleosis
503545400,7/16/2014 20:49:26,,1324470153,7/16/2014 20:49:07,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,98,131,,,113,155,SPLENIC RUPTURE,INFECTIOUS MONONUCLEOSIS,SPLENIC RUPTURE,98-106,131-142,INFECTIOUS MONONUCLEOSIS.,This case-report draws the attention to the possibility of a conservative surgical treatment of a splenic rupture in the course of infectious mononucleosis.,98 106,131 142,98,131,113,155,1,RO-disease_may_have_finding,902861,This case-report draws the attention to the possibility of a conservative surgical treatment of a splenic rupture in the course of infectious mononucleosis,splenic rupture,infectious mononucleosis
503545400,7/16/2014 20:50:32,,1324470586,7/16/2014 20:50:19,prodege,1.0,4968858,USA,CA,Corona,99.44.120.153,98,131,,,113,155,SPLENIC RUPTURE,INFECTIOUS MONONUCLEOSIS,SPLENIC RUPTURE,98-106,131-142,INFECTIOUS MONONUCLEOSIS.,This case-report draws the attention to the possibility of a conservative surgical treatment of a splenic rupture in the course of infectious mononucleosis.,98 106,131 142,98,131,113,155,1,RO-disease_may_have_finding,902861,This case-report draws the attention to the possibility of a conservative surgical treatment of a splenic rupture in the course of infectious mononucleosis,splenic rupture,infectious mononucleosis
503545400,7/16/2014 20:52:19,,1324471291,7/16/2014 20:52:04,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,98,131,,,113,155,SPLENIC RUPTURE,INFECTIOUS MONONUCLEOSIS,SPLENIC RUPTURE,98-106,131-142,INFECTIOUS MONONUCLEOSIS.,This case-report draws the attention to the possibility of a conservative surgical treatment of a splenic rupture in the course of infectious mononucleosis.,98 106,131 142,98,131,113,155,1,RO-disease_may_have_finding,902861,This case-report draws the attention to the possibility of a conservative surgical treatment of a splenic rupture in the course of infectious mononucleosis,splenic rupture,infectious mononucleosis
503545400,7/16/2014 20:52:26,,1324471388,7/16/2014 20:52:05,eup_slw,1.0,28011002,CAN,MB,Winnipeg,24.77.44.140,98,131,,,113,155,SPLENIC RUPTURE,INFECTIOUS MONONUCLEOSIS,SPLENIC RUPTURE,98-106,131-142,INFECTIOUS MONONUCLEOSIS.,This case-report draws the attention to the possibility of a conservative surgical treatment of a splenic rupture in the course of infectious mononucleosis.,98 106,131 142,98,131,113,155,1,RO-disease_may_have_finding,902861,This case-report draws the attention to the possibility of a conservative surgical treatment of a splenic rupture in the course of infectious mononucleosis,splenic rupture,infectious mononucleosis
503545400,7/16/2014 20:52:39,,1324471530,7/16/2014 20:52:18,prodege,1.0,22360212,GBR,I1,Luton,82.6.41.191,98,131,,,113,155,SPLENIC RUPTURE,INFECTIOUS MONONUCLEOSIS,SPLENIC RUPTURE,98-106,131-142,INFECTIOUS MONONUCLEOSIS.,This case-report draws the attention to the possibility of a conservative surgical treatment of a splenic rupture in the course of infectious mononucleosis.,98 106,131 142,98,131,113,155,1,RO-disease_may_have_finding,902861,This case-report draws the attention to the possibility of a conservative surgical treatment of a splenic rupture in the course of infectious mononucleosis,splenic rupture,infectious mononucleosis
503545401,7/16/2014 20:34:45,,1324464108,7/16/2014 20:34:18,clixsense,1.0,24896327,GBR,V2,Glasgow,94.2.231.4,89,52,,,97,68,SEIZURES,PARTIAL EPILEPSY,SEIZURES,89,52-60,PARTIAL EPILEPSY,During therapy of 40 patients (8-57 year-olds) with partial epilepsy the severity of the seizures as well as emotional and cognitive functions of the patients were evaluated.,89,52 60,89,52,97,68,-1,RO-has_definitional_manifestation,904841,During therapy of 40 patients (8-57 year-olds) with partial epilepsy the severity of the seizures as well as emotional and cognitive functions of the patients were evaluated,seizures,partial epilepsy
503545401,7/16/2014 20:37:47,,1324465312,7/16/2014 20:37:32,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,89,52,,,97,68,SEIZURES,PARTIAL EPILEPSY,severity of the SEIZURES,73-82-85-89,52-60,PARTIAL EPILEPSY,During therapy of 40 patients (8-57 year-olds) with partial epilepsy the severity of the seizures as well as emotional and cognitive functions of the patients were evaluated.,89,52 60,89,52,97,68,-1,RO-has_definitional_manifestation,904841,During therapy of 40 patients (8-57 year-olds) with partial epilepsy the severity of the seizures as well as emotional and cognitive functions of the patients were evaluated,seizures,partial epilepsy
503545401,7/16/2014 20:38:49,,1324465757,7/16/2014 20:38:47,clixsense,1.0,6610277,CAN,ON,Oshawa,174.117.79.122,89,52,,,97,68,SEIZURES,PARTIAL EPILEPSY,severity of the SEIZURES as well as,73-82-85-89-98-101-106,36-41-47-52-60-69-73-82,year olds) with PARTIAL EPILEPSY the severity of,During therapy of 40 patients (8-57 year-olds) with partial epilepsy the severity of the seizures as well as emotional and cognitive functions of the patients were evaluated.,89,52 60,89,52,97,68,-1,RO-has_definitional_manifestation,904841,During therapy of 40 patients (8-57 year-olds) with partial epilepsy the severity of the seizures as well as emotional and cognitive functions of the patients were evaluated,seizures,partial epilepsy
503545401,7/16/2014 20:39:06,,1324465896,7/16/2014 20:38:55,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,89,52,,,97,68,SEIZURES,PARTIAL EPILEPSY,SEIZURES,89,52-60,PARTIAL EPILEPSY,During therapy of 40 patients (8-57 year-olds) with partial epilepsy the severity of the seizures as well as emotional and cognitive functions of the patients were evaluated.,89,52 60,89,52,97,68,-1,RO-has_definitional_manifestation,904841,During therapy of 40 patients (8-57 year-olds) with partial epilepsy the severity of the seizures as well as emotional and cognitive functions of the patients were evaluated,seizures,partial epilepsy
503545401,7/16/2014 20:39:07,,1324465899,7/16/2014 20:38:57,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,89,52,,,97,68,SEIZURES,PARTIAL EPILEPSY,SEIZURES,89,52-60,PARTIAL EPILEPSY,During therapy of 40 patients (8-57 year-olds) with partial epilepsy the severity of the seizures as well as emotional and cognitive functions of the patients were evaluated.,89,52 60,89,52,97,68,-1,RO-has_definitional_manifestation,904841,During therapy of 40 patients (8-57 year-olds) with partial epilepsy the severity of the seizures as well as emotional and cognitive functions of the patients were evaluated,seizures,partial epilepsy
503545401,7/16/2014 20:41:25,,1324466850,7/16/2014 20:41:23,coinworker,1.0,28394550,USA,PA,Marcus Hook,71.175.96.184,89,52,,,97,68,SEIZURES,PARTIAL EPILEPSY,severity of the SEIZURES as well as,73-82-85-89-98-101-106,36-41-47-52-60-69-73-82,year olds) with PARTIAL EPILEPSY the severity of,During therapy of 40 patients (8-57 year-olds) with partial epilepsy the severity of the seizures as well as emotional and cognitive functions of the patients were evaluated.,89,52 60,89,52,97,68,-1,RO-has_definitional_manifestation,904841,During therapy of 40 patients (8-57 year-olds) with partial epilepsy the severity of the seizures as well as emotional and cognitive functions of the patients were evaluated,seizures,partial epilepsy
503545401,7/16/2014 20:44:58,,1324468138,7/16/2014 20:44:23,prodege,1.0,22360212,GBR,I1,Luton,82.6.41.191,89,52,,,97,68,SEIZURES,PARTIAL EPILEPSY,SEIZURES,89,52-60,PARTIAL EPILEPSY,During therapy of 40 patients (8-57 year-olds) with partial epilepsy the severity of the seizures as well as emotional and cognitive functions of the patients were evaluated.,89,52 60,89,52,97,68,-1,RO-has_definitional_manifestation,904841,During therapy of 40 patients (8-57 year-olds) with partial epilepsy the severity of the seizures as well as emotional and cognitive functions of the patients were evaluated,seizures,partial epilepsy
503545401,7/16/2014 20:45:44,,1324468451,7/16/2014 20:45:41,prodege,1.0,26325260,GBR,"","",79.64.25.64,89,52,,,97,68,SEIZURES,PARTIAL EPILEPSY,severity of the SEIZURES as well as,73-82-85-89-98-101-106,36-41-47-52-60-69-73-82,year olds) with PARTIAL EPILEPSY the severity of,During therapy of 40 patients (8-57 year-olds) with partial epilepsy the severity of the seizures as well as emotional and cognitive functions of the patients were evaluated.,89,52 60,89,52,97,68,-1,RO-has_definitional_manifestation,904841,During therapy of 40 patients (8-57 year-olds) with partial epilepsy the severity of the seizures as well as emotional and cognitive functions of the patients were evaluated,seizures,partial epilepsy
503545401,7/16/2014 20:45:56,,1324468522,7/16/2014 20:45:40,instagc,1.0,13763729,USA,"","",75.182.89.225,89,52,,,97,68,SEIZURES,PARTIAL EPILEPSY,SEIZURES,89,52-60,PARTIAL EPILEPSY,During therapy of 40 patients (8-57 year-olds) with partial epilepsy the severity of the seizures as well as emotional and cognitive functions of the patients were evaluated.,89,52 60,89,52,97,68,-1,RO-has_definitional_manifestation,904841,During therapy of 40 patients (8-57 year-olds) with partial epilepsy the severity of the seizures as well as emotional and cognitive functions of the patients were evaluated,seizures,partial epilepsy
503545401,7/16/2014 20:48:00,,1324469507,7/16/2014 20:47:39,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,89,52,,,97,68,SEIZURES,PARTIAL EPILEPSY,SEIZURES,89,52-60,PARTIAL EPILEPSY,During therapy of 40 patients (8-57 year-olds) with partial epilepsy the severity of the seizures as well as emotional and cognitive functions of the patients were evaluated.,89,52 60,89,52,97,68,-1,RO-has_definitional_manifestation,904841,During therapy of 40 patients (8-57 year-olds) with partial epilepsy the severity of the seizures as well as emotional and cognitive functions of the patients were evaluated,seizures,partial epilepsy
503545402,7/16/2014 20:36:59,,1324465049,7/16/2014 20:36:35,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,56,128,,,73,139,HODGKIN'S DISEASE,VINCRISTINE,advanced HODGKIN'S DISEASE,47-56-66,128,"VINCRISTINE,","Seventy-six patients with previously untreated advanced Hodgkin's disease have been treated with the MOPP/ABV (mechlorethamine, vincristine, procarbazine, prednisone/doxorubicin, bleomycin, vincristine) hybrid program.",56 66,128,56,128,73,139,1,RO-may_treat,908106,"Seventy-six patients with previously untreated advanced Hodgkin's disease have been treated with the MOPP/ABV (mechlorethamine, vincristine, procarbazine, prednisone/doxorubicin, bleomycin, vincristine) hybrid program",Hodgkin's disease,vincristine
503545402,7/16/2014 20:37:20,,1324465189,7/16/2014 20:37:02,clixsense,1.0,24896327,GBR,V2,Glasgow,94.2.231.4,56,128,,,73,139,HODGKIN'S DISEASE,VINCRISTINE,HODGKIN'S DISEASE,56-66,128,"VINCRISTINE,","Seventy-six patients with previously untreated advanced Hodgkin's disease have been treated with the MOPP/ABV (mechlorethamine, vincristine, procarbazine, prednisone/doxorubicin, bleomycin, vincristine) hybrid program.",56 66,128,56,128,73,139,1,RO-may_treat,908106,"Seventy-six patients with previously untreated advanced Hodgkin's disease have been treated with the MOPP/ABV (mechlorethamine, vincristine, procarbazine, prednisone/doxorubicin, bleomycin, vincristine) hybrid program",Hodgkin's disease,vincristine
503545402,7/16/2014 20:37:38,,1324465247,7/16/2014 20:37:35,clixsense,1.0,6610277,CAN,ON,Oshawa,174.117.79.122,56,128,,,73,139,HODGKIN'S DISEASE,VINCRISTINE,previously untreated advanced HODGKIN'S DISEASE have been treated,26-37-47-56-66-74-79-84,101-106-110-128-141-155-166,"MOPP ABV (mechlorethamine, VINCRISTINE, procarbazine, prednisone doxorubicin,","Seventy-six patients with previously untreated advanced Hodgkin's disease have been treated with the MOPP/ABV (mechlorethamine, vincristine, procarbazine, prednisone/doxorubicin, bleomycin, vincristine) hybrid program.",56 66,128,56,128,73,139,1,RO-may_treat,908106,"Seventy-six patients with previously untreated advanced Hodgkin's disease have been treated with the MOPP/ABV (mechlorethamine, vincristine, procarbazine, prednisone/doxorubicin, bleomycin, vincristine) hybrid program",Hodgkin's disease,vincristine
503545402,7/16/2014 20:40:37,,1324466531,7/16/2014 20:40:19,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,56,128,,,73,139,HODGKIN'S DISEASE,VINCRISTINE,HODGKIN'S DISEASE,56-66,128,"VINCRISTINE,","Seventy-six patients with previously untreated advanced Hodgkin's disease have been treated with the MOPP/ABV (mechlorethamine, vincristine, procarbazine, prednisone/doxorubicin, bleomycin, vincristine) hybrid program.",56 66,128,56,128,73,139,1,RO-may_treat,908106,"Seventy-six patients with previously untreated advanced Hodgkin's disease have been treated with the MOPP/ABV (mechlorethamine, vincristine, procarbazine, prednisone/doxorubicin, bleomycin, vincristine) hybrid program",Hodgkin's disease,vincristine
503545402,7/16/2014 20:44:13,,1324467840,7/16/2014 20:44:02,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,56,128,,,73,139,HODGKIN'S DISEASE,VINCRISTINE,HODGKIN'S DISEASE,56-66,128,"VINCRISTINE,","Seventy-six patients with previously untreated advanced Hodgkin's disease have been treated with the MOPP/ABV (mechlorethamine, vincristine, procarbazine, prednisone/doxorubicin, bleomycin, vincristine) hybrid program.",56 66,128,56,128,73,139,1,RO-may_treat,908106,"Seventy-six patients with previously untreated advanced Hodgkin's disease have been treated with the MOPP/ABV (mechlorethamine, vincristine, procarbazine, prednisone/doxorubicin, bleomycin, vincristine) hybrid program",Hodgkin's disease,vincristine
503545402,7/16/2014 20:45:41,,1324468435,7/16/2014 20:44:53,prodege,1.0,4968858,USA,CA,Corona,99.44.120.153,56,128,,,73,139,HODGKIN'S DISEASE,VINCRISTINE,HODGKIN'S DISEASE,56-66,128,"VINCRISTINE,","Seventy-six patients with previously untreated advanced Hodgkin's disease have been treated with the MOPP/ABV (mechlorethamine, vincristine, procarbazine, prednisone/doxorubicin, bleomycin, vincristine) hybrid program.",56 66,128,56,128,73,139,1,RO-may_treat,908106,"Seventy-six patients with previously untreated advanced Hodgkin's disease have been treated with the MOPP/ABV (mechlorethamine, vincristine, procarbazine, prednisone/doxorubicin, bleomycin, vincristine) hybrid program",Hodgkin's disease,vincristine
503545402,7/16/2014 20:45:52,,1324468504,7/16/2014 20:45:44,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,56,128,,,73,139,HODGKIN'S DISEASE,VINCRISTINE,previously untreated advanced HODGKIN'S DISEASE have been treated,26-37-47-56-66-74-79-84,101-106-110-128-141-155-166,"MOPP ABV (mechlorethamine, VINCRISTINE, procarbazine, prednisone doxorubicin,","Seventy-six patients with previously untreated advanced Hodgkin's disease have been treated with the MOPP/ABV (mechlorethamine, vincristine, procarbazine, prednisone/doxorubicin, bleomycin, vincristine) hybrid program.",56 66,128,56,128,73,139,1,RO-may_treat,908106,"Seventy-six patients with previously untreated advanced Hodgkin's disease have been treated with the MOPP/ABV (mechlorethamine, vincristine, procarbazine, prednisone/doxorubicin, bleomycin, vincristine) hybrid program",Hodgkin's disease,vincristine
503545402,7/16/2014 20:49:47,,1324470350,7/16/2014 20:49:28,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,56,128,,,73,139,HODGKIN'S DISEASE,VINCRISTINE,HODGKIN'S DISEASE,56-66,128,"VINCRISTINE,","Seventy-six patients with previously untreated advanced Hodgkin's disease have been treated with the MOPP/ABV (mechlorethamine, vincristine, procarbazine, prednisone/doxorubicin, bleomycin, vincristine) hybrid program.",56 66,128,56,128,73,139,1,RO-may_treat,908106,"Seventy-six patients with previously untreated advanced Hodgkin's disease have been treated with the MOPP/ABV (mechlorethamine, vincristine, procarbazine, prednisone/doxorubicin, bleomycin, vincristine) hybrid program",Hodgkin's disease,vincristine
503545402,7/16/2014 20:50:53,,1324470740,7/16/2014 20:50:41,prodege,1.0,9997387,USA,CO,Colorado Springs,75.70.112.31,56,128,,,73,139,HODGKIN'S DISEASE,VINCRISTINE,HODGKIN'S DISEASE,56-66,128,"VINCRISTINE,","Seventy-six patients with previously untreated advanced Hodgkin's disease have been treated with the MOPP/ABV (mechlorethamine, vincristine, procarbazine, prednisone/doxorubicin, bleomycin, vincristine) hybrid program.",56 66,128,56,128,73,139,1,RO-may_treat,908106,"Seventy-six patients with previously untreated advanced Hodgkin's disease have been treated with the MOPP/ABV (mechlorethamine, vincristine, procarbazine, prednisone/doxorubicin, bleomycin, vincristine) hybrid program",Hodgkin's disease,vincristine
503545402,7/16/2014 20:52:27,,1324471393,7/16/2014 20:52:07,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,56,128,,,73,139,HODGKIN'S DISEASE,VINCRISTINE,advanced HODGKIN'S DISEASE,47-56-66,128,"VINCRISTINE,","Seventy-six patients with previously untreated advanced Hodgkin's disease have been treated with the MOPP/ABV (mechlorethamine, vincristine, procarbazine, prednisone/doxorubicin, bleomycin, vincristine) hybrid program.",56 66,128,56,128,73,139,1,RO-may_treat,908106,"Seventy-six patients with previously untreated advanced Hodgkin's disease have been treated with the MOPP/ABV (mechlorethamine, vincristine, procarbazine, prednisone/doxorubicin, bleomycin, vincristine) hybrid program",Hodgkin's disease,vincristine
503545403,7/16/2014 20:34:24,,1324463977,7/16/2014 20:34:08,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,132,30,,,138,47,PLAQUE,STANNOUS FLUORIDE,PLAQUE glycolytic,132-139,19-30-39-48,stabilized STANNOUS FLUORIDE dentifrice,Toothbrushing with stabilized stannous fluoride dentifrice in this experiment produced significant and sustained reductions in both plaque glycolytic and regrowth activity as compared to placebo treated plaques.,132,30 39,132,30,138,47,1,RO-may_prevent,907218,Toothbrushing with stabilized stannous fluoride dentifrice in this experiment produced significant and sustained reductions in both plaque glycolytic and regrowth activity as compared to placebo treated plaques,plaque,stannous fluoride
503545403,7/16/2014 20:35:32,,1324464422,7/16/2014 20:35:03,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,132,30,,,138,47,PLAQUE,STANNOUS FLUORIDE,PLAQUE glycolytic,132-139,30-39-48,STANNOUS FLUORIDE dentifrice,Toothbrushing with stabilized stannous fluoride dentifrice in this experiment produced significant and sustained reductions in both plaque glycolytic and regrowth activity as compared to placebo treated plaques.,132,30 39,132,30,138,47,1,RO-may_prevent,907218,Toothbrushing with stabilized stannous fluoride dentifrice in this experiment produced significant and sustained reductions in both plaque glycolytic and regrowth activity as compared to placebo treated plaques,plaque,stannous fluoride
503545403,7/16/2014 20:36:24,,1324464802,7/16/2014 20:36:08,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,132,30,,,138,47,PLAQUE,STANNOUS FLUORIDE,PLAQUE glycolytic,132-139,19-30-39-48,stabilized STANNOUS FLUORIDE dentifrice,Toothbrushing with stabilized stannous fluoride dentifrice in this experiment produced significant and sustained reductions in both plaque glycolytic and regrowth activity as compared to placebo treated plaques.,132,30 39,132,30,138,47,1,RO-may_prevent,907218,Toothbrushing with stabilized stannous fluoride dentifrice in this experiment produced significant and sustained reductions in both plaque glycolytic and regrowth activity as compared to placebo treated plaques,plaque,stannous fluoride
503545403,7/16/2014 20:38:26,,1324465579,7/16/2014 20:38:10,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,132,30,,,138,47,PLAQUE,STANNOUS FLUORIDE,PLAQUE glycolytic,132-139,19-30-39-48,stabilized STANNOUS FLUORIDE dentifrice,Toothbrushing with stabilized stannous fluoride dentifrice in this experiment produced significant and sustained reductions in both plaque glycolytic and regrowth activity as compared to placebo treated plaques.,132,30 39,132,30,138,47,1,RO-may_prevent,907218,Toothbrushing with stabilized stannous fluoride dentifrice in this experiment produced significant and sustained reductions in both plaque glycolytic and regrowth activity as compared to placebo treated plaques,plaque,stannous fluoride
503545403,7/16/2014 20:39:02,,1324465858,7/16/2014 20:38:57,clixsense,1.0,6610277,CAN,ON,Oshawa,174.117.79.122,132,30,,,138,47,PLAQUE,STANNOUS FLUORIDE,reductions in both PLAQUE glycolytic and regrowth,113-124-127-132-139-150-154,0-14-19-30-39-48-59-62,Toothbrushing with stabilized STANNOUS FLUORIDE dentifrice in this,Toothbrushing with stabilized stannous fluoride dentifrice in this experiment produced significant and sustained reductions in both plaque glycolytic and regrowth activity as compared to placebo treated plaques.,132,30 39,132,30,138,47,1,RO-may_prevent,907218,Toothbrushing with stabilized stannous fluoride dentifrice in this experiment produced significant and sustained reductions in both plaque glycolytic and regrowth activity as compared to placebo treated plaques,plaque,stannous fluoride
503545403,7/16/2014 20:43:24,,1324467547,7/16/2014 20:43:22,bitcoinget,1.0,24792414,USA,"","",166.181.81.55,132,30,,,138,47,PLAQUE,STANNOUS FLUORIDE,reductions in both PLAQUE glycolytic and regrowth,113-124-127-132-139-150-154,0-14-19-30-39-48-59-62,Toothbrushing with stabilized STANNOUS FLUORIDE dentifrice in this,Toothbrushing with stabilized stannous fluoride dentifrice in this experiment produced significant and sustained reductions in both plaque glycolytic and regrowth activity as compared to placebo treated plaques.,132,30 39,132,30,138,47,1,RO-may_prevent,907218,Toothbrushing with stabilized stannous fluoride dentifrice in this experiment produced significant and sustained reductions in both plaque glycolytic and regrowth activity as compared to placebo treated plaques,plaque,stannous fluoride
503545403,7/16/2014 20:43:46,,1324467694,7/16/2014 20:43:17,clixsense,1.0,24896327,GBR,V2,Glasgow,94.2.231.4,132,30,,,138,47,PLAQUE,STANNOUS FLUORIDE,PLAQUE,132,30-39-48,STANNOUS FLUORIDE dentifrice,Toothbrushing with stabilized stannous fluoride dentifrice in this experiment produced significant and sustained reductions in both plaque glycolytic and regrowth activity as compared to placebo treated plaques.,132,30 39,132,30,138,47,1,RO-may_prevent,907218,Toothbrushing with stabilized stannous fluoride dentifrice in this experiment produced significant and sustained reductions in both plaque glycolytic and regrowth activity as compared to placebo treated plaques,plaque,stannous fluoride
503545403,7/16/2014 20:45:34,,1324468376,7/16/2014 20:45:29,prodege,1.0,26325260,GBR,"","",79.64.25.64,132,30,,,138,47,PLAQUE,STANNOUS FLUORIDE,reductions in both PLAQUE glycolytic and regrowth,113-124-127-132-139-150-154,0-14-19-30-39-48-59-62,Toothbrushing with stabilized STANNOUS FLUORIDE dentifrice in this,Toothbrushing with stabilized stannous fluoride dentifrice in this experiment produced significant and sustained reductions in both plaque glycolytic and regrowth activity as compared to placebo treated plaques.,132,30 39,132,30,138,47,1,RO-may_prevent,907218,Toothbrushing with stabilized stannous fluoride dentifrice in this experiment produced significant and sustained reductions in both plaque glycolytic and regrowth activity as compared to placebo treated plaques,plaque,stannous fluoride
503545403,7/16/2014 20:46:22,,1324468753,7/16/2014 20:46:13,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,132,30,,,138,47,PLAQUE,STANNOUS FLUORIDE,reductions in both PLAQUE glycolytic and regrowth,113-124-127-132-139-150-154,0-14-19-30-39-48-59-62,Toothbrushing with stabilized STANNOUS FLUORIDE dentifrice in this,Toothbrushing with stabilized stannous fluoride dentifrice in this experiment produced significant and sustained reductions in both plaque glycolytic and regrowth activity as compared to placebo treated plaques.,132,30 39,132,30,138,47,1,RO-may_prevent,907218,Toothbrushing with stabilized stannous fluoride dentifrice in this experiment produced significant and sustained reductions in both plaque glycolytic and regrowth activity as compared to placebo treated plaques,plaque,stannous fluoride
503545403,7/16/2014 20:48:44,,1324469872,7/16/2014 20:46:59,instagc,1,18611009,GBR,Q4,Pershore,31.50.159.84,132,30,,,138,47,PLAQUE,STANNOUS FLUORIDE,reductions in both PLAQUE glycolytic and regrowth,113-124-127-132-139-150-154,0-14-19-30-39-48-59-62,Toothbrushing with stabilized STANNOUS FLUORIDE dentifrice in this,Toothbrushing with stabilized stannous fluoride dentifrice in this experiment produced significant and sustained reductions in both plaque glycolytic and regrowth activity as compared to placebo treated plaques.,132,30 39,132,30,138,47,1,RO-may_prevent,907218,Toothbrushing with stabilized stannous fluoride dentifrice in this experiment produced significant and sustained reductions in both plaque glycolytic and regrowth activity as compared to placebo treated plaques,plaque,stannous fluoride
503545404,7/16/2014 20:32:21,,1324463183,7/16/2014 20:31:59,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,124,144,,,128,154,GVHD,TACROLIMUS,"GVHD prophylaxis of tacrolimus and methylprednisolone,",124-129-141-144-155-159,124-129-141-144-155-159,"GVHD prophylaxis of TACROLIMUS and methylprednisolone,","In minitransplants using a preconditioning regimen consisting of fludarabine, busulfan and anti-T-lymphocyte globulin and a GVHD prophylaxis of tacrolimus and methylprednisolone, we showed that minitransplantation from HLA-haploidentical related donors was possible.",124,144,124,144,128,154,1,RO-may_prevent,907192,"In minitransplants using a preconditioning regimen consisting of fludarabine, busulfan and anti-T-lymphocyte globulin and a GVHD prophylaxis of tacrolimus and methylprednisolone, we showed that minitransplantation from HLA-haploidentical related donors was possible",GVHD,tacrolimus
503545404,7/16/2014 20:35:38,,1324464453,7/16/2014 20:35:16,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,124,144,,,128,154,GVHD,TACROLIMUS,GVHD prophylaxis of tacrolimus,124-129-141-144,124-129-141-144,GVHD prophylaxis of TACROLIMUS,"In minitransplants using a preconditioning regimen consisting of fludarabine, busulfan and anti-T-lymphocyte globulin and a GVHD prophylaxis of tacrolimus and methylprednisolone, we showed that minitransplantation from HLA-haploidentical related donors was possible.",124,144,124,144,128,154,1,RO-may_prevent,907192,"In minitransplants using a preconditioning regimen consisting of fludarabine, busulfan and anti-T-lymphocyte globulin and a GVHD prophylaxis of tacrolimus and methylprednisolone, we showed that minitransplantation from HLA-haploidentical related donors was possible",GVHD,tacrolimus
503545404,7/16/2014 20:37:17,,1324465171,7/16/2014 20:37:15,clixsense,1.0,6610277,CAN,ON,Oshawa,174.117.79.122,124,144,,,128,154,GVHD,TACROLIMUS,globulin and a GVHD prophylaxis of tacrolimus,109-118-122-124-129-141-144,124-129-141-144-155-159-179,"GVHD prophylaxis of TACROLIMUS and methylprednisolone, we","In minitransplants using a preconditioning regimen consisting of fludarabine, busulfan and anti-T-lymphocyte globulin and a GVHD prophylaxis of tacrolimus and methylprednisolone, we showed that minitransplantation from HLA-haploidentical related donors was possible.",124,144,124,144,128,154,1,RO-may_prevent,907192,"In minitransplants using a preconditioning regimen consisting of fludarabine, busulfan and anti-T-lymphocyte globulin and a GVHD prophylaxis of tacrolimus and methylprednisolone, we showed that minitransplantation from HLA-haploidentical related donors was possible",GVHD,tacrolimus
503545404,7/16/2014 20:41:12,,1324466761,7/16/2014 20:41:11,coinworker,1.0,28394550,USA,PA,Marcus Hook,71.175.96.184,124,144,,,128,154,GVHD,TACROLIMUS,globulin and a GVHD prophylaxis of tacrolimus,109-118-122-124-129-141-144,124-129-141-144-155-159-179,"GVHD prophylaxis of TACROLIMUS and methylprednisolone, we","In minitransplants using a preconditioning regimen consisting of fludarabine, busulfan and anti-T-lymphocyte globulin and a GVHD prophylaxis of tacrolimus and methylprednisolone, we showed that minitransplantation from HLA-haploidentical related donors was possible.",124,144,124,144,128,154,1,RO-may_prevent,907192,"In minitransplants using a preconditioning regimen consisting of fludarabine, busulfan and anti-T-lymphocyte globulin and a GVHD prophylaxis of tacrolimus and methylprednisolone, we showed that minitransplantation from HLA-haploidentical related donors was possible",GVHD,tacrolimus
503545404,7/16/2014 20:41:33,,1324466882,7/16/2014 20:40:53,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,124,144,,,128,154,GVHD,TACROLIMUS,"GVHD prophylaxis of tacrolimus and methylprednisolone,",124-129-141-144-155-159,144,TACROLIMUS,"In minitransplants using a preconditioning regimen consisting of fludarabine, busulfan and anti-T-lymphocyte globulin and a GVHD prophylaxis of tacrolimus and methylprednisolone, we showed that minitransplantation from HLA-haploidentical related donors was possible.",124,144,124,144,128,154,1,RO-may_prevent,907192,"In minitransplants using a preconditioning regimen consisting of fludarabine, busulfan and anti-T-lymphocyte globulin and a GVHD prophylaxis of tacrolimus and methylprednisolone, we showed that minitransplantation from HLA-haploidentical related donors was possible",GVHD,tacrolimus
503545404,7/16/2014 20:42:49,,1324467335,7/16/2014 20:42:23,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,124,144,,,128,154,GVHD,TACROLIMUS,GVHD prophylaxis,124-129,144,TACROLIMUS,"In minitransplants using a preconditioning regimen consisting of fludarabine, busulfan and anti-T-lymphocyte globulin and a GVHD prophylaxis of tacrolimus and methylprednisolone, we showed that minitransplantation from HLA-haploidentical related donors was possible.",124,144,124,144,128,154,1,RO-may_prevent,907192,"In minitransplants using a preconditioning regimen consisting of fludarabine, busulfan and anti-T-lymphocyte globulin and a GVHD prophylaxis of tacrolimus and methylprednisolone, we showed that minitransplantation from HLA-haploidentical related donors was possible",GVHD,tacrolimus
503545404,7/16/2014 20:43:56,,1324467730,7/16/2014 20:43:10,prodege,1.0,9997387,USA,CO,Colorado Springs,75.70.112.31,124,144,,,128,154,GVHD,TACROLIMUS,"GVHD prophylaxis of tacrolimus and methylprednisolone,",124-129-141-144-159-155,124-129-141-144-155-159,"GVHD prophylaxis of TACROLIMUS and methylprednisolone,","In minitransplants using a preconditioning regimen consisting of fludarabine, busulfan and anti-T-lymphocyte globulin and a GVHD prophylaxis of tacrolimus and methylprednisolone, we showed that minitransplantation from HLA-haploidentical related donors was possible.",124,144,124,144,128,154,1,RO-may_prevent,907192,"In minitransplants using a preconditioning regimen consisting of fludarabine, busulfan and anti-T-lymphocyte globulin and a GVHD prophylaxis of tacrolimus and methylprednisolone, we showed that minitransplantation from HLA-haploidentical related donors was possible",GVHD,tacrolimus
503545404,7/16/2014 20:43:56,,1324467732,7/16/2014 20:43:54,bitcoinget,1.0,24792414,USA,"","",166.181.81.55,124,144,,,128,154,GVHD,TACROLIMUS,globulin and a GVHD prophylaxis of tacrolimus,109-118-122-124-129-141-144,124-129-141-144-155-159-179,"GVHD prophylaxis of TACROLIMUS and methylprednisolone, we","In minitransplants using a preconditioning regimen consisting of fludarabine, busulfan and anti-T-lymphocyte globulin and a GVHD prophylaxis of tacrolimus and methylprednisolone, we showed that minitransplantation from HLA-haploidentical related donors was possible.",124,144,124,144,128,154,1,RO-may_prevent,907192,"In minitransplants using a preconditioning regimen consisting of fludarabine, busulfan and anti-T-lymphocyte globulin and a GVHD prophylaxis of tacrolimus and methylprednisolone, we showed that minitransplantation from HLA-haploidentical related donors was possible",GVHD,tacrolimus
503545404,7/16/2014 20:45:43,,1324468444,7/16/2014 20:45:32,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,124,144,,,128,154,GVHD,TACROLIMUS,GVHD,124,144,TACROLIMUS,"In minitransplants using a preconditioning regimen consisting of fludarabine, busulfan and anti-T-lymphocyte globulin and a GVHD prophylaxis of tacrolimus and methylprednisolone, we showed that minitransplantation from HLA-haploidentical related donors was possible.",124,144,124,144,128,154,1,RO-may_prevent,907192,"In minitransplants using a preconditioning regimen consisting of fludarabine, busulfan and anti-T-lymphocyte globulin and a GVHD prophylaxis of tacrolimus and methylprednisolone, we showed that minitransplantation from HLA-haploidentical related donors was possible",GVHD,tacrolimus
503545404,7/16/2014 20:46:09,,1324468675,7/16/2014 20:45:53,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,124,144,,,128,154,GVHD,TACROLIMUS,GVHD prophylaxis of tacrolimus,124-129-141-144,124-129-141-144,GVHD prophylaxis of TACROLIMUS,"In minitransplants using a preconditioning regimen consisting of fludarabine, busulfan and anti-T-lymphocyte globulin and a GVHD prophylaxis of tacrolimus and methylprednisolone, we showed that minitransplantation from HLA-haploidentical related donors was possible.",124,144,124,144,128,154,1,RO-may_prevent,907192,"In minitransplants using a preconditioning regimen consisting of fludarabine, busulfan and anti-T-lymphocyte globulin and a GVHD prophylaxis of tacrolimus and methylprednisolone, we showed that minitransplantation from HLA-haploidentical related donors was possible",GVHD,tacrolimus
503545405,7/16/2014 20:34:19,,1324463930,7/16/2014 20:32:06,eup_slw,1.0,28011002,CAN,MB,Winnipeg,24.77.44.140,47,0,,,59,27,HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY,Hypertensive encephalopathy HYPERTENSION,0-13-47,0-13,HYPERTENSIVE ENCEPHALOPATHY,Hypertensive encephalopathy is associated with hypertension from any cause and may occur at any age.,47,0 13,47,0,59,27,1,RO-disease_has_finding,901646,Hypertensive encephalopathy is associated with hypertension from any cause and may occur at any age,hypertension,Hypertensive encephalopathy
503545405,7/16/2014 20:40:19,,1324466362,7/16/2014 20:40:03,clixsense,1.0,24896327,GBR,V2,Glasgow,94.2.231.4,47,0,,,59,27,HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY,HYPERTENSION,47,0-13,HYPERTENSIVE ENCEPHALOPATHY,Hypertensive encephalopathy is associated with hypertension from any cause and may occur at any age.,47,0 13,47,0,59,27,1,RO-disease_has_finding,901646,Hypertensive encephalopathy is associated with hypertension from any cause and may occur at any age,hypertension,Hypertensive encephalopathy
503545405,7/16/2014 20:41:20,,1324466810,7/16/2014 20:41:05,prodege,1.0,9997387,USA,CO,Colorado Springs,75.70.112.31,47,0,,,59,27,HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY,Hypertensive encephalopathy HYPERTENSION,0-13-47,0-13,HYPERTENSIVE ENCEPHALOPATHY,Hypertensive encephalopathy is associated with hypertension from any cause and may occur at any age.,47,0 13,47,0,59,27,1,RO-disease_has_finding,901646,Hypertensive encephalopathy is associated with hypertension from any cause and may occur at any age,hypertension,Hypertensive encephalopathy
503545405,7/16/2014 20:43:45,,1324467684,7/16/2014 20:43:33,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,47,0,,,59,27,HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY,HYPERTENSION,47,0-13,HYPERTENSIVE ENCEPHALOPATHY,Hypertensive encephalopathy is associated with hypertension from any cause and may occur at any age.,47,0 13,47,0,59,27,1,RO-disease_has_finding,901646,Hypertensive encephalopathy is associated with hypertension from any cause and may occur at any age,hypertension,Hypertensive encephalopathy
503545405,7/16/2014 20:46:59,,1324469062,7/16/2014 20:46:34,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,47,0,,,59,27,HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY,HYPERTENSION,47,0-13,HYPERTENSIVE ENCEPHALOPATHY,Hypertensive encephalopathy is associated with hypertension from any cause and may occur at any age.,47,0 13,47,0,59,27,1,RO-disease_has_finding,901646,Hypertensive encephalopathy is associated with hypertension from any cause and may occur at any age,hypertension,Hypertensive encephalopathy
503545405,7/16/2014 20:48:13,,1324469613,7/16/2014 20:48:04,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,47,0,,,59,27,HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY,is associated with HYPERTENSION from any cause,28-31-42-47-60-65-69,0-13-28-31-42,HYPERTENSIVE ENCEPHALOPATHY is associated with,Hypertensive encephalopathy is associated with hypertension from any cause and may occur at any age.,47,0 13,47,0,59,27,1,RO-disease_has_finding,901646,Hypertensive encephalopathy is associated with hypertension from any cause and may occur at any age,hypertension,Hypertensive encephalopathy
503545405,7/16/2014 20:50:18,,1324470524,7/16/2014 20:50:03,prodege,1.0,4968858,USA,CA,Corona,99.44.120.153,47,0,,,59,27,HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY,HYPERTENSION,47,0-13,HYPERTENSIVE ENCEPHALOPATHY,Hypertensive encephalopathy is associated with hypertension from any cause and may occur at any age.,47,0 13,47,0,59,27,1,RO-disease_has_finding,901646,Hypertensive encephalopathy is associated with hypertension from any cause and may occur at any age,hypertension,Hypertensive encephalopathy
503545405,7/16/2014 20:50:26,,1324470561,7/16/2014 20:50:15,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,47,0,,,59,27,HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY,HYPERTENSION,47,0-13,HYPERTENSIVE ENCEPHALOPATHY,Hypertensive encephalopathy is associated with hypertension from any cause and may occur at any age.,47,0 13,47,0,59,27,1,RO-disease_has_finding,901646,Hypertensive encephalopathy is associated with hypertension from any cause and may occur at any age,hypertension,Hypertensive encephalopathy
503545405,7/16/2014 20:51:19,,1324470934,7/16/2014 20:51:01,prodege,1.0,22360212,GBR,I1,Luton,82.6.41.191,47,0,,,59,27,HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY,HYPERTENSION,47,0-13,HYPERTENSIVE ENCEPHALOPATHY,Hypertensive encephalopathy is associated with hypertension from any cause and may occur at any age.,47,0 13,47,0,59,27,1,RO-disease_has_finding,901646,Hypertensive encephalopathy is associated with hypertension from any cause and may occur at any age,hypertension,Hypertensive encephalopathy
503545405,7/16/2014 20:53:08,,1324471672,7/16/2014 20:52:51,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,47,0,,,59,27,HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY,HYPERTENSION,47,0-13,HYPERTENSIVE ENCEPHALOPATHY,Hypertensive encephalopathy is associated with hypertension from any cause and may occur at any age.,47,0 13,47,0,59,27,1,RO-disease_has_finding,901646,Hypertensive encephalopathy is associated with hypertension from any cause and may occur at any age,hypertension,Hypertensive encephalopathy
503545406,7/16/2014 20:32:08,,1324463098,7/16/2014 20:31:48,clixsense,1.0,24896327,GBR,V2,Glasgow,94.2.231.4,81,172,,,90,189,DYSPLASIA,SERRATED ADENOMAS,single crypt DYSPLASIA,68-75-81,172-181,SERRATED ADENOMAS,"Over the 5-year period, the most frequent phenotype encountered was single crypt dysplasia (in all 5 colectomies from familial adenomatous polyposis patients), followed by serrated adenomas (11.2%), hyperplastic polyps (8.4%), dysplasia in UC (6.3%), pure carcinoid tumours (1.7%), signet ring cell carcinoma (1.1%), adenocarcinoid tumours (0.2%) and de novo carcinomas (0.1%.",81,172 181,81,172,90,189,-1,RO-disease_has_finding,901748,"Over the 5-year period, the most frequent phenotype encountered was single crypt dysplasia (in all 5 colectomies from familial adenomatous polyposis patients), followed by serrated adenomas (11.2%), hyperplastic polyps (8.4%), dysplasia in UC (6.3%), pure carcinoid tumours (1.7%), signet ring cell carcinoma (1.1%), adenocarcinoid tumours (0.2%) and de novo carcinomas (0.1%",dysplasia,serrated adenomas
503545406,7/16/2014 20:36:17,,1324464737,7/16/2014 20:36:03,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,81,172,,,90,189,DYSPLASIA,SERRATED ADENOMAS,single crypt DYSPLASIA,68-75-81,172-181,SERRATED ADENOMAS,"Over the 5-year period, the most frequent phenotype encountered was single crypt dysplasia (in all 5 colectomies from familial adenomatous polyposis patients), followed by serrated adenomas (11.2%), hyperplastic polyps (8.4%), dysplasia in UC (6.3%), pure carcinoid tumours (1.7%), signet ring cell carcinoma (1.1%), adenocarcinoid tumours (0.2%) and de novo carcinomas (0.1%.",81,172 181,81,172,90,189,-1,RO-disease_has_finding,901748,"Over the 5-year period, the most frequent phenotype encountered was single crypt dysplasia (in all 5 colectomies from familial adenomatous polyposis patients), followed by serrated adenomas (11.2%), hyperplastic polyps (8.4%), dysplasia in UC (6.3%), pure carcinoid tumours (1.7%), signet ring cell carcinoma (1.1%), adenocarcinoid tumours (0.2%) and de novo carcinomas (0.1%",dysplasia,serrated adenomas
503545406,7/16/2014 20:37:54,,1324465360,7/16/2014 20:37:47,clixsense,1.0,6610277,CAN,ON,Oshawa,174.117.79.122,81,172,,,90,189,DYSPLASIA,SERRATED ADENOMAS,crypt DYSPLASIA all 5,75-81-95-99,149-160-169-172-181-199-212,"patients), followed by SERRATED ADENOMAS hyperplastic polyps","Over the 5-year period, the most frequent phenotype encountered was single crypt dysplasia (in all 5 colectomies from familial adenomatous polyposis patients), followed by serrated adenomas (11.2%), hyperplastic polyps (8.4%), dysplasia in UC (6.3%), pure carcinoid tumours (1.7%), signet ring cell carcinoma (1.1%), adenocarcinoid tumours (0.2%) and de novo carcinomas (0.1%.",81,172 181,81,172,90,189,-1,RO-disease_has_finding,901748,"Over the 5-year period, the most frequent phenotype encountered was single crypt dysplasia (in all 5 colectomies from familial adenomatous polyposis patients), followed by serrated adenomas (11.2%), hyperplastic polyps (8.4%), dysplasia in UC (6.3%), pure carcinoid tumours (1.7%), signet ring cell carcinoma (1.1%), adenocarcinoid tumours (0.2%) and de novo carcinomas (0.1%",dysplasia,serrated adenomas
503545406,7/16/2014 20:40:17,,1324466359,7/16/2014 20:39:59,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,81,172,,,90,189,DYSPLASIA,SERRATED ADENOMAS,DYSPLASIA,81,172-181,SERRATED ADENOMAS,"Over the 5-year period, the most frequent phenotype encountered was single crypt dysplasia (in all 5 colectomies from familial adenomatous polyposis patients), followed by serrated adenomas (11.2%), hyperplastic polyps (8.4%), dysplasia in UC (6.3%), pure carcinoid tumours (1.7%), signet ring cell carcinoma (1.1%), adenocarcinoid tumours (0.2%) and de novo carcinomas (0.1%.",81,172 181,81,172,90,189,-1,RO-disease_has_finding,901748,"Over the 5-year period, the most frequent phenotype encountered was single crypt dysplasia (in all 5 colectomies from familial adenomatous polyposis patients), followed by serrated adenomas (11.2%), hyperplastic polyps (8.4%), dysplasia in UC (6.3%), pure carcinoid tumours (1.7%), signet ring cell carcinoma (1.1%), adenocarcinoid tumours (0.2%) and de novo carcinomas (0.1%",dysplasia,serrated adenomas
503545406,7/16/2014 20:41:29,,1324466867,7/16/2014 20:41:27,coinworker,1.0,28394550,USA,PA,Marcus Hook,71.175.96.184,81,172,,,90,189,DYSPLASIA,SERRATED ADENOMAS,was single crypt DYSPLASIA all 5,64-68-75-81-95-99,149-160-169-172-181-199-212,"patients), followed by SERRATED ADENOMAS hyperplastic polyps","Over the 5-year period, the most frequent phenotype encountered was single crypt dysplasia (in all 5 colectomies from familial adenomatous polyposis patients), followed by serrated adenomas (11.2%), hyperplastic polyps (8.4%), dysplasia in UC (6.3%), pure carcinoid tumours (1.7%), signet ring cell carcinoma (1.1%), adenocarcinoid tumours (0.2%) and de novo carcinomas (0.1%.",81,172 181,81,172,90,189,-1,RO-disease_has_finding,901748,"Over the 5-year period, the most frequent phenotype encountered was single crypt dysplasia (in all 5 colectomies from familial adenomatous polyposis patients), followed by serrated adenomas (11.2%), hyperplastic polyps (8.4%), dysplasia in UC (6.3%), pure carcinoid tumours (1.7%), signet ring cell carcinoma (1.1%), adenocarcinoid tumours (0.2%) and de novo carcinomas (0.1%",dysplasia,serrated adenomas
503545406,7/16/2014 20:42:08,,1324467121,7/16/2014 20:41:46,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,81,172,,,90,189,DYSPLASIA,SERRATED ADENOMAS,single crypt DYSPLASIA,68-75-81,172-181,SERRATED ADENOMAS,"Over the 5-year period, the most frequent phenotype encountered was single crypt dysplasia (in all 5 colectomies from familial adenomatous polyposis patients), followed by serrated adenomas (11.2%), hyperplastic polyps (8.4%), dysplasia in UC (6.3%), pure carcinoid tumours (1.7%), signet ring cell carcinoma (1.1%), adenocarcinoid tumours (0.2%) and de novo carcinomas (0.1%.",81,172 181,81,172,90,189,-1,RO-disease_has_finding,901748,"Over the 5-year period, the most frequent phenotype encountered was single crypt dysplasia (in all 5 colectomies from familial adenomatous polyposis patients), followed by serrated adenomas (11.2%), hyperplastic polyps (8.4%), dysplasia in UC (6.3%), pure carcinoid tumours (1.7%), signet ring cell carcinoma (1.1%), adenocarcinoid tumours (0.2%) and de novo carcinomas (0.1%",dysplasia,serrated adenomas
503545406,7/16/2014 20:42:44,,1324467315,7/16/2014 20:42:41,bitcoinget,1.0,24792414,USA,"","",166.181.81.55,81,172,,,90,189,DYSPLASIA,SERRATED ADENOMAS,was single crypt DYSPLASIA all 5,64-68-75-81-95-99,149-160-169-172-181-199-212,"patients), followed by SERRATED ADENOMAS hyperplastic polyps","Over the 5-year period, the most frequent phenotype encountered was single crypt dysplasia (in all 5 colectomies from familial adenomatous polyposis patients), followed by serrated adenomas (11.2%), hyperplastic polyps (8.4%), dysplasia in UC (6.3%), pure carcinoid tumours (1.7%), signet ring cell carcinoma (1.1%), adenocarcinoid tumours (0.2%) and de novo carcinomas (0.1%.",81,172 181,81,172,90,189,-1,RO-disease_has_finding,901748,"Over the 5-year period, the most frequent phenotype encountered was single crypt dysplasia (in all 5 colectomies from familial adenomatous polyposis patients), followed by serrated adenomas (11.2%), hyperplastic polyps (8.4%), dysplasia in UC (6.3%), pure carcinoid tumours (1.7%), signet ring cell carcinoma (1.1%), adenocarcinoid tumours (0.2%) and de novo carcinomas (0.1%",dysplasia,serrated adenomas
503545406,7/16/2014 20:43:15,,1324467492,7/16/2014 20:43:02,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,81,172,,,90,189,DYSPLASIA,SERRATED ADENOMAS,crypt DYSPLASIA,81-75,172-181,SERRATED ADENOMAS,"Over the 5-year period, the most frequent phenotype encountered was single crypt dysplasia (in all 5 colectomies from familial adenomatous polyposis patients), followed by serrated adenomas (11.2%), hyperplastic polyps (8.4%), dysplasia in UC (6.3%), pure carcinoid tumours (1.7%), signet ring cell carcinoma (1.1%), adenocarcinoid tumours (0.2%) and de novo carcinomas (0.1%.",81,172 181,81,172,90,189,-1,RO-disease_has_finding,901748,"Over the 5-year period, the most frequent phenotype encountered was single crypt dysplasia (in all 5 colectomies from familial adenomatous polyposis patients), followed by serrated adenomas (11.2%), hyperplastic polyps (8.4%), dysplasia in UC (6.3%), pure carcinoid tumours (1.7%), signet ring cell carcinoma (1.1%), adenocarcinoid tumours (0.2%) and de novo carcinomas (0.1%",dysplasia,serrated adenomas
503545406,7/16/2014 20:43:52,,1324467724,7/16/2014 20:43:24,prodege,1.0,22360212,GBR,I1,Luton,82.6.41.191,81,172,,,90,189,DYSPLASIA,SERRATED ADENOMAS,single crypt DYSPLASIA,68-75-81,172-181,SERRATED ADENOMAS,"Over the 5-year period, the most frequent phenotype encountered was single crypt dysplasia (in all 5 colectomies from familial adenomatous polyposis patients), followed by serrated adenomas (11.2%), hyperplastic polyps (8.4%), dysplasia in UC (6.3%), pure carcinoid tumours (1.7%), signet ring cell carcinoma (1.1%), adenocarcinoid tumours (0.2%) and de novo carcinomas (0.1%.",81,172 181,81,172,90,189,-1,RO-disease_has_finding,901748,"Over the 5-year period, the most frequent phenotype encountered was single crypt dysplasia (in all 5 colectomies from familial adenomatous polyposis patients), followed by serrated adenomas (11.2%), hyperplastic polyps (8.4%), dysplasia in UC (6.3%), pure carcinoid tumours (1.7%), signet ring cell carcinoma (1.1%), adenocarcinoid tumours (0.2%) and de novo carcinomas (0.1%",dysplasia,serrated adenomas
503545406,7/16/2014 20:47:05,,1324469078,7/16/2014 20:47:00,prodege,1.0,26325260,GBR,"","",79.64.25.64,81,172,,,90,189,DYSPLASIA,SERRATED ADENOMAS,was single crypt DYSPLASIA all 5,64-68-75-81-95-99,149-160-169-172-181-199-212,"patients), followed by SERRATED ADENOMAS hyperplastic polyps","Over the 5-year period, the most frequent phenotype encountered was single crypt dysplasia (in all 5 colectomies from familial adenomatous polyposis patients), followed by serrated adenomas (11.2%), hyperplastic polyps (8.4%), dysplasia in UC (6.3%), pure carcinoid tumours (1.7%), signet ring cell carcinoma (1.1%), adenocarcinoid tumours (0.2%) and de novo carcinomas (0.1%.",81,172 181,81,172,90,189,-1,RO-disease_has_finding,901748,"Over the 5-year period, the most frequent phenotype encountered was single crypt dysplasia (in all 5 colectomies from familial adenomatous polyposis patients), followed by serrated adenomas (11.2%), hyperplastic polyps (8.4%), dysplasia in UC (6.3%), pure carcinoid tumours (1.7%), signet ring cell carcinoma (1.1%), adenocarcinoid tumours (0.2%) and de novo carcinomas (0.1%",dysplasia,serrated adenomas
503545407,7/16/2014 20:31:58,,1324463011,7/16/2014 20:31:49,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,31,0,,,50,10,PARKINSON'S DISEASE,AMANTADINE,PARKINSON'S DISEASE.,31-43,0,AMANTADINE,Amantadine in the treatment of Parkinson's disease.,31 43,0,31,0,50,10,1,RO-may_treat,907950,Amantadine in the treatment of Parkinson's disease,Parkinson's disease,Amantadine
503545407,7/16/2014 20:35:48,,1324464514,7/16/2014 20:35:40,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,31,0,,,50,10,PARKINSON'S DISEASE,AMANTADINE,PARKINSON'S DISEASE.,31-43,0,AMANTADINE,Amantadine in the treatment of Parkinson's disease.,31 43,0,31,0,50,10,1,RO-may_treat,907950,Amantadine in the treatment of Parkinson's disease,Parkinson's disease,Amantadine
503545407,7/16/2014 20:39:19,,1324465976,7/16/2014 20:39:07,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,31,0,,,50,10,PARKINSON'S DISEASE,AMANTADINE,PARKINSON'S DISEASE.,31-43,0,AMANTADINE,Amantadine in the treatment of Parkinson's disease.,31 43,0,31,0,50,10,1,RO-may_treat,907950,Amantadine in the treatment of Parkinson's disease,Parkinson's disease,Amantadine
503545407,7/16/2014 20:43:36,,1324467622,7/16/2014 20:43:34,bitcoinget,1.0,24792414,USA,"","",166.181.81.55,31,0,,,50,10,PARKINSON'S DISEASE,AMANTADINE,the treatment of PARKINSON'S DISEASE.,14-18-28-31-43,0-11-14-18,AMANTADINE in the treatment,Amantadine in the treatment of Parkinson's disease.,31 43,0,31,0,50,10,1,RO-may_treat,907950,Amantadine in the treatment of Parkinson's disease,Parkinson's disease,Amantadine
503545407,7/16/2014 20:43:42,,1324467649,7/16/2014 20:43:33,instagc,1.0,13763729,USA,"","",75.182.89.225,31,0,,,50,10,PARKINSON'S DISEASE,AMANTADINE,PARKINSON'S DISEASE.,31-43,0,AMANTADINE,Amantadine in the treatment of Parkinson's disease.,31 43,0,31,0,50,10,1,RO-may_treat,907950,Amantadine in the treatment of Parkinson's disease,Parkinson's disease,Amantadine
503545407,7/16/2014 20:45:08,,1324468197,7/16/2014 20:44:26,prodege,1.0,26325260,GBR,"","",79.64.25.64,31,0,,,50,10,PARKINSON'S DISEASE,AMANTADINE,the treatment of PARKINSON'S DISEASE.,14-18-28-31-43,0-11-14-18,AMANTADINE in the treatment,Amantadine in the treatment of Parkinson's disease.,31 43,0,31,0,50,10,1,RO-may_treat,907950,Amantadine in the treatment of Parkinson's disease,Parkinson's disease,Amantadine
503545407,7/16/2014 20:47:55,,1324469450,7/16/2014 20:47:47,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,31,0,,,50,10,PARKINSON'S DISEASE,AMANTADINE,PARKINSON'S DISEASE.,31-43,0,AMANTADINE,Amantadine in the treatment of Parkinson's disease.,31 43,0,31,0,50,10,1,RO-may_treat,907950,Amantadine in the treatment of Parkinson's disease,Parkinson's disease,Amantadine
503545407,7/16/2014 20:50:10,,1324470485,7/16/2014 20:49:57,prodege,1.0,9997387,USA,CO,Colorado Springs,75.70.112.31,31,0,,,50,10,PARKINSON'S DISEASE,AMANTADINE,PARKINSON'S DISEASE.,31-43,0,AMANTADINE,Amantadine in the treatment of Parkinson's disease.,31 43,0,31,0,50,10,1,RO-may_treat,907950,Amantadine in the treatment of Parkinson's disease,Parkinson's disease,Amantadine
503545407,7/16/2014 20:50:24,,1324470554,7/16/2014 20:50:07,prodege,1.0,22360212,GBR,I1,Luton,82.6.41.191,31,0,,,50,10,PARKINSON'S DISEASE,AMANTADINE,PARKINSON'S DISEASE.,31-43,0,AMANTADINE,Amantadine in the treatment of Parkinson's disease.,31 43,0,31,0,50,10,1,RO-may_treat,907950,Amantadine in the treatment of Parkinson's disease,Parkinson's disease,Amantadine
503545407,7/16/2014 20:51:32,,1324471029,7/16/2014 20:50:48,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,31,0,,,50,10,PARKINSON'S DISEASE,AMANTADINE,PARKINSON'S DISEASE.,31-43,0,AMANTADINE,Amantadine in the treatment of Parkinson's disease.,31 43,0,31,0,50,10,1,RO-may_treat,907950,Amantadine in the treatment of Parkinson's disease,Parkinson's disease,Amantadine
503545408,7/16/2014 20:35:02,,1324464200,7/16/2014 20:34:45,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,9,46,,,24,70,LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS,Painless LYMPHADENOPATHY,0-9,46-57,"INFECTIOUS MONONUCLEOSIS,","Painless lymphadenopathy can also result from infectious mononucleosis, toxoplasmosis, cytomegalovirus, or leukemia.",9,46 57,9,46,24,70,1,RO-disease_has_finding,901900,"Painless lymphadenopathy can also result from infectious mononucleosis, toxoplasmosis, cytomegalovirus, or leukemia",lymphadenopathy,infectious mononucleosis
503545408,7/16/2014 20:37:22,,1324465196,7/16/2014 20:37:13,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,9,46,,,24,70,LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS,LYMPHADENOPATHY,9,46-57,"INFECTIOUS MONONUCLEOSIS,","Painless lymphadenopathy can also result from infectious mononucleosis, toxoplasmosis, cytomegalovirus, or leukemia.",9,46 57,9,46,24,70,1,RO-disease_has_finding,901900,"Painless lymphadenopathy can also result from infectious mononucleosis, toxoplasmosis, cytomegalovirus, or leukemia",lymphadenopathy,infectious mononucleosis
503545408,7/16/2014 20:38:43,,1324465694,7/16/2014 20:38:34,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,9,46,,,24,70,LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS,Painless LYMPHADENOPATHY,0-9,46-57,"INFECTIOUS MONONUCLEOSIS,","Painless lymphadenopathy can also result from infectious mononucleosis, toxoplasmosis, cytomegalovirus, or leukemia.",9,46 57,9,46,24,70,1,RO-disease_has_finding,901900,"Painless lymphadenopathy can also result from infectious mononucleosis, toxoplasmosis, cytomegalovirus, or leukemia",lymphadenopathy,infectious mononucleosis
503545408,7/16/2014 20:39:13,,1324465946,7/16/2014 20:39:11,clixsense,1.0,6610277,CAN,ON,Oshawa,174.117.79.122,9,46,,,24,70,LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS,Painless LYMPHADENOPATHY can also result,0-9-25-29-34,29-34-41-46-57-72-87-104,"also result from INFECTIOUS MONONUCLEOSIS, toxoplasmosis, cytomegalovirus, or","Painless lymphadenopathy can also result from infectious mononucleosis, toxoplasmosis, cytomegalovirus, or leukemia.",9,46 57,9,46,24,70,1,RO-disease_has_finding,901900,"Painless lymphadenopathy can also result from infectious mononucleosis, toxoplasmosis, cytomegalovirus, or leukemia",lymphadenopathy,infectious mononucleosis
503545408,7/16/2014 20:41:01,,1324466695,7/16/2014 20:40:45,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,9,46,,,24,70,LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS,LYMPHADENOPATHY,9,46-57,"INFECTIOUS MONONUCLEOSIS,","Painless lymphadenopathy can also result from infectious mononucleosis, toxoplasmosis, cytomegalovirus, or leukemia.",9,46 57,9,46,24,70,1,RO-disease_has_finding,901900,"Painless lymphadenopathy can also result from infectious mononucleosis, toxoplasmosis, cytomegalovirus, or leukemia",lymphadenopathy,infectious mononucleosis
503545408,7/16/2014 20:41:23,,1324466826,7/16/2014 20:41:07,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,9,46,,,24,70,LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS,LYMPHADENOPATHY,9,46-57,"INFECTIOUS MONONUCLEOSIS,","Painless lymphadenopathy can also result from infectious mononucleosis, toxoplasmosis, cytomegalovirus, or leukemia.",9,46 57,9,46,24,70,1,RO-disease_has_finding,901900,"Painless lymphadenopathy can also result from infectious mononucleosis, toxoplasmosis, cytomegalovirus, or leukemia",lymphadenopathy,infectious mononucleosis
503545408,7/16/2014 20:41:45,,1324467000,7/16/2014 20:41:34,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,9,46,,,24,70,LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS,LYMPHADENOPATHY,9,46-57,"INFECTIOUS MONONUCLEOSIS,","Painless lymphadenopathy can also result from infectious mononucleosis, toxoplasmosis, cytomegalovirus, or leukemia.",9,46 57,9,46,24,70,1,RO-disease_has_finding,901900,"Painless lymphadenopathy can also result from infectious mononucleosis, toxoplasmosis, cytomegalovirus, or leukemia",lymphadenopathy,infectious mononucleosis
503545408,7/16/2014 20:42:13,,1324467135,7/16/2014 20:42:12,coinworker,1.0,28394550,USA,PA,Marcus Hook,71.175.96.184,9,46,,,24,70,LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS,Painless LYMPHADENOPATHY can also result,0-9-25-29-34,29-34-41-46-57-72-87-104,"also result from INFECTIOUS MONONUCLEOSIS, toxoplasmosis, cytomegalovirus, or","Painless lymphadenopathy can also result from infectious mononucleosis, toxoplasmosis, cytomegalovirus, or leukemia.",9,46 57,9,46,24,70,1,RO-disease_has_finding,901900,"Painless lymphadenopathy can also result from infectious mononucleosis, toxoplasmosis, cytomegalovirus, or leukemia",lymphadenopathy,infectious mononucleosis
503545408,7/16/2014 20:43:55,,1324467728,7/16/2014 20:43:44,instagc,1.0,13763729,USA,"","",75.182.89.225,9,46,,,24,70,LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS,LYMPHADENOPATHY,9,46-57,"INFECTIOUS MONONUCLEOSIS,","Painless lymphadenopathy can also result from infectious mononucleosis, toxoplasmosis, cytomegalovirus, or leukemia.",9,46 57,9,46,24,70,1,RO-disease_has_finding,901900,"Painless lymphadenopathy can also result from infectious mononucleosis, toxoplasmosis, cytomegalovirus, or leukemia",lymphadenopathy,infectious mononucleosis
503545408,7/16/2014 20:45:23,,1324468294,7/16/2014 20:45:18,prodege,1.0,26325260,GBR,"","",79.64.25.64,9,46,,,24,70,LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS,Painless LYMPHADENOPATHY can also result,0-9-25-29-34,29-34-41-46-57-72-87-104,"also result from INFECTIOUS MONONUCLEOSIS, toxoplasmosis, cytomegalovirus, or","Painless lymphadenopathy can also result from infectious mononucleosis, toxoplasmosis, cytomegalovirus, or leukemia.",9,46 57,9,46,24,70,1,RO-disease_has_finding,901900,"Painless lymphadenopathy can also result from infectious mononucleosis, toxoplasmosis, cytomegalovirus, or leukemia",lymphadenopathy,infectious mononucleosis
503545409,7/16/2014 20:37:27,,1324465216,7/16/2014 20:37:24,clixsense,1.0,6610277,CAN,ON,Oshawa,174.117.79.122,43,100,,,52,104,DYSPLASIA,LSIL,"with HPV, mild DYSPLASIA, and CIN 1",28-33-38-43-54-58-62,84-88-97-100,the category of LSIL.,"Cellular changes consistent with HPV, mild dysplasia, and CIN 1 are combined within the category of LSIL.",43,100,43,100,52,104,1,RO-disease_has_finding,901883,"Cellular changes consistent with HPV, mild dysplasia, and CIN 1 are combined within the category of LSIL",dysplasia,LSIL
503545409,7/16/2014 20:40:45,,1324466582,7/16/2014 20:40:03,prodege,1.0,22360212,GBR,I1,Luton,82.6.41.191,43,100,,,52,104,DYSPLASIA,LSIL,"mild DYSPLASIA,",38-43,100,LSIL.,"Cellular changes consistent with HPV, mild dysplasia, and CIN 1 are combined within the category of LSIL.",43,100,43,100,52,104,1,RO-disease_has_finding,901883,"Cellular changes consistent with HPV, mild dysplasia, and CIN 1 are combined within the category of LSIL",dysplasia,LSIL
503545409,7/16/2014 20:43:22,,1324467532,7/16/2014 20:43:09,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,43,100,,,52,104,DYSPLASIA,LSIL,"mild DYSPLASIA,",38-43,100,LSIL.,"Cellular changes consistent with HPV, mild dysplasia, and CIN 1 are combined within the category of LSIL.",43,100,43,100,52,104,1,RO-disease_has_finding,901883,"Cellular changes consistent with HPV, mild dysplasia, and CIN 1 are combined within the category of LSIL",dysplasia,LSIL
503545409,7/16/2014 20:43:34,,1324467617,7/16/2014 20:43:18,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,43,100,,,52,104,DYSPLASIA,LSIL,"DYSPLASIA,",43,100,LSIL.,"Cellular changes consistent with HPV, mild dysplasia, and CIN 1 are combined within the category of LSIL.",43,100,43,100,52,104,1,RO-disease_has_finding,901883,"Cellular changes consistent with HPV, mild dysplasia, and CIN 1 are combined within the category of LSIL",dysplasia,LSIL
503545409,7/16/2014 20:45:09,,1324468196,7/16/2014 20:44:58,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,43,100,,,52,104,DYSPLASIA,LSIL,"DYSPLASIA,",43,100,LSIL.,"Cellular changes consistent with HPV, mild dysplasia, and CIN 1 are combined within the category of LSIL.",43,100,43,100,52,104,1,RO-disease_has_finding,901883,"Cellular changes consistent with HPV, mild dysplasia, and CIN 1 are combined within the category of LSIL",dysplasia,LSIL
503545409,7/16/2014 20:45:20,,1324468283,7/16/2014 20:45:06,instagc,1.0,13763729,USA,"","",75.182.89.225,43,100,,,52,104,DYSPLASIA,LSIL,"DYSPLASIA,",43,100,LSIL.,"Cellular changes consistent with HPV, mild dysplasia, and CIN 1 are combined within the category of LSIL.",43,100,43,100,52,104,1,RO-disease_has_finding,901883,"Cellular changes consistent with HPV, mild dysplasia, and CIN 1 are combined within the category of LSIL",dysplasia,LSIL
503545409,7/16/2014 20:46:54,,1324469008,7/16/2014 20:46:52,prodege,1.0,26325260,GBR,"","",79.64.25.64,43,100,,,52,104,DYSPLASIA,LSIL,"with HPV, mild DYSPLASIA, and CIN 1",28-33-38-43-54-58-62,84-88-97-100,the category of LSIL.,"Cellular changes consistent with HPV, mild dysplasia, and CIN 1 are combined within the category of LSIL.",43,100,43,100,52,104,1,RO-disease_has_finding,901883,"Cellular changes consistent with HPV, mild dysplasia, and CIN 1 are combined within the category of LSIL",dysplasia,LSIL
503545409,7/16/2014 20:48:19,,1324469660,7/16/2014 20:48:03,prodege,1.0,9997387,USA,CO,Colorado Springs,75.70.112.31,43,100,,,52,104,DYSPLASIA,LSIL,"mild DYSPLASIA,",38-43,100,LSIL.,"Cellular changes consistent with HPV, mild dysplasia, and CIN 1 are combined within the category of LSIL.",43,100,43,100,52,104,1,RO-disease_has_finding,901883,"Cellular changes consistent with HPV, mild dysplasia, and CIN 1 are combined within the category of LSIL",dysplasia,LSIL
503545409,7/16/2014 20:51:07,,1324470830,7/16/2014 20:50:53,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,43,100,,,52,104,DYSPLASIA,LSIL,"mild DYSPLASIA,",38-43,100,LSIL.,"Cellular changes consistent with HPV, mild dysplasia, and CIN 1 are combined within the category of LSIL.",43,100,43,100,52,104,1,RO-disease_has_finding,901883,"Cellular changes consistent with HPV, mild dysplasia, and CIN 1 are combined within the category of LSIL",dysplasia,LSIL
503545409,7/16/2014 20:53:45,,1324471903,7/16/2014 20:53:30,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,43,100,,,52,104,DYSPLASIA,LSIL,"mild DYSPLASIA,",38-43,100,LSIL.,"Cellular changes consistent with HPV, mild dysplasia, and CIN 1 are combined within the category of LSIL.",43,100,43,100,52,104,1,RO-disease_has_finding,901883,"Cellular changes consistent with HPV, mild dysplasia, and CIN 1 are combined within the category of LSIL",dysplasia,LSIL
503545410,7/16/2014 20:33:36,,1324463629,7/16/2014 20:33:14,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,130,143,,,134,148,LUNG,NSCLC,non small cell LUNG cancer,115-119-125-130-135,115-119-125-130-135-142,non small cell lung cancer (NSCLC):,Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): report of Cancer and Leukemia Group B (CALGB) protocol 9633.,130,,130,143,134,148,1,RO-disease_has_primary_anatomic_site,902040,Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): report of Cancer and Leukemia Group B (CALGB) protocol 9633,lung,NSCLC
503545410,7/16/2014 20:38:00,,1324465387,7/16/2014 20:37:56,clixsense,1.0,6610277,CAN,ON,Oshawa,174.117.79.122,130,143,,,134,148,LUNG,NSCLC,non small cell LUNG cancer report,115-119-125-130-135-151,130-135-142-151-158-161,lung cancer (NSCLC): report of Cancer,Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): report of Cancer and Leukemia Group B (CALGB) protocol 9633.,130,,130,143,134,148,1,RO-disease_has_primary_anatomic_site,902040,Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): report of Cancer and Leukemia Group B (CALGB) protocol 9633,lung,NSCLC
503545410,7/16/2014 20:39:48,,1324466180,7/16/2014 20:38:45,eup_slw,1.0,28011002,CAN,MB,Winnipeg,24.77.44.140,130,143,,,134,148,LUNG,NSCLC,LUNG,130,142-189,(NSCLC): (CALGB),Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): report of Cancer and Leukemia Group B (CALGB) protocol 9633.,130,,130,143,134,148,1,RO-disease_has_primary_anatomic_site,902040,Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): report of Cancer and Leukemia Group B (CALGB) protocol 9633,lung,NSCLC
503545410,7/16/2014 20:40:46,,1324466589,7/16/2014 20:40:32,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,130,143,,,134,148,LUNG,NSCLC,non - small cell LUNG cancer,115-118-119-125-130-135,115-118-119-125-130-135,non - small cell lung cancer,Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): report of Cancer and Leukemia Group B (CALGB) protocol 9633.,130,,130,143,134,148,1,RO-disease_has_primary_anatomic_site,902040,Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): report of Cancer and Leukemia Group B (CALGB) protocol 9633,lung,NSCLC
503545410,7/16/2014 20:43:07,,1324467464,7/16/2014 20:41:51,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,130,143,,,134,148,LUNG,NSCLC,non small cell LUNG cancer (NSCLC):,115-119-125-130-135-142,130-135-142,lung cancer (NSCLC):,Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): report of Cancer and Leukemia Group B (CALGB) protocol 9633.,130,,130,143,134,148,1,RO-disease_has_primary_anatomic_site,902040,Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): report of Cancer and Leukemia Group B (CALGB) protocol 9633,lung,NSCLC
503545410,7/16/2014 20:43:09,,1324467477,7/16/2014 20:42:50,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,130,143,,,134,148,LUNG,NSCLC,non small cell LUNG cancer,115-119-125-130-135,142,(NSCLC):,Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): report of Cancer and Leukemia Group B (CALGB) protocol 9633.,130,,130,143,134,148,1,RO-disease_has_primary_anatomic_site,902040,Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): report of Cancer and Leukemia Group B (CALGB) protocol 9633,lung,NSCLC
503545410,7/16/2014 20:44:26,,1324467944,7/16/2014 20:44:10,instagc,1.0,13763729,USA,"","",75.182.89.225,130,143,,,134,148,LUNG,NSCLC,non small cell LUNG cancer,115-119-125-130-135,115-119-125-130-135-142,non small cell lung cancer (NSCLC):,Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): report of Cancer and Leukemia Group B (CALGB) protocol 9633.,130,,130,143,134,148,1,RO-disease_has_primary_anatomic_site,902040,Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): report of Cancer and Leukemia Group B (CALGB) protocol 9633,lung,NSCLC
503545410,7/16/2014 20:45:19,,1324468282,7/16/2014 20:45:10,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,130,143,,,134,148,LUNG,NSCLC,cell LUNG cancer,125-130-135,130-135-158,lung cancer of,Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): report of Cancer and Leukemia Group B (CALGB) protocol 9633.,130,,130,143,134,148,1,RO-disease_has_primary_anatomic_site,902040,Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): report of Cancer and Leukemia Group B (CALGB) protocol 9633,lung,NSCLC
503545410,7/16/2014 20:46:33,,1324468841,7/16/2014 20:46:25,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,130,143,,,134,148,LUNG,NSCLC,non small cell LUNG cancer report,115-119-125-130-135-151,130-135-142-151-158-161,lung cancer (NSCLC): report of Cancer,Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): report of Cancer and Leukemia Group B (CALGB) protocol 9633.,130,,130,143,134,148,1,RO-disease_has_primary_anatomic_site,902040,Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): report of Cancer and Leukemia Group B (CALGB) protocol 9633,lung,NSCLC
503545410,7/16/2014 20:47:40,,1324469345,7/16/2014 20:47:20,prodege,1.0,9997387,USA,CO,Colorado Springs,75.70.112.31,130,143,,,134,148,LUNG,NSCLC,LUNG cancer report,130-135-151,130-135-161,lung cancer Cancer,Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): report of Cancer and Leukemia Group B (CALGB) protocol 9633.,130,,130,143,134,148,1,RO-disease_has_primary_anatomic_site,902040,Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): report of Cancer and Leukemia Group B (CALGB) protocol 9633,lung,NSCLC
503545411,7/16/2014 20:34:36,,1324464065,7/16/2014 20:34:26,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,298,219,,,328,240,NEUROENDOCRINE DIFFERENTIATION,NEUROENDOCRINE TUMORS,NEUROENDOCRINE DIFFERENTIATION,298-313,203-209-214-219-234,large cell type NEUROENDOCRINE TUMORS,KTA7 was considered to be derived from large cell undifferentiated carcinoma with neuroendocrine differentiation (large cell neuroendocrine tumor) and thus may fine use in studies on the pathobiology of large cell-type neuroendocrine tumors since it expresses at the same time marker substances of neuroendocrine differentiation and the hCG alpha-subunit.,298 313,219 234,298,219,328,240,-1,RO-disease_has_finding,901838,KTA7 was considered to be derived from large cell undifferentiated carcinoma with neuroendocrine differentiation (large cell neuroendocrine tumor) and thus may fine use in studies on the pathobiology of large cell-type neuroendocrine tumors since it expresses at the same time marker substances of neuroendocrine differentiation and the hCG alpha-subunit,neuroendocrine differentiation,neuroendocrine tumors
503545411,7/16/2014 20:38:09,,1324465430,7/16/2014 20:37:49,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,298,219,,,328,240,NEUROENDOCRINE DIFFERENTIATION,NEUROENDOCRINE TUMORS,NEUROENDOCRINE DIFFERENTIATION,298-313,203-209-214-219-234,large cell type NEUROENDOCRINE TUMORS,KTA7 was considered to be derived from large cell undifferentiated carcinoma with neuroendocrine differentiation (large cell neuroendocrine tumor) and thus may fine use in studies on the pathobiology of large cell-type neuroendocrine tumors since it expresses at the same time marker substances of neuroendocrine differentiation and the hCG alpha-subunit.,298 313,219 234,298,219,328,240,-1,RO-disease_has_finding,901838,KTA7 was considered to be derived from large cell undifferentiated carcinoma with neuroendocrine differentiation (large cell neuroendocrine tumor) and thus may fine use in studies on the pathobiology of large cell-type neuroendocrine tumors since it expresses at the same time marker substances of neuroendocrine differentiation and the hCG alpha-subunit,neuroendocrine differentiation,neuroendocrine tumors
503545411,7/16/2014 20:41:23,,1324466828,7/16/2014 20:41:08,instagc,1.0,13763729,USA,"","",75.182.89.225,298,219,,,328,240,NEUROENDOCRINE DIFFERENTIATION,NEUROENDOCRINE TUMORS,NEUROENDOCRINE DIFFERENTIATION,298-313,219-234,NEUROENDOCRINE TUMORS,KTA7 was considered to be derived from large cell undifferentiated carcinoma with neuroendocrine differentiation (large cell neuroendocrine tumor) and thus may fine use in studies on the pathobiology of large cell-type neuroendocrine tumors since it expresses at the same time marker substances of neuroendocrine differentiation and the hCG alpha-subunit.,298 313,219 234,298,219,328,240,-1,RO-disease_has_finding,901838,KTA7 was considered to be derived from large cell undifferentiated carcinoma with neuroendocrine differentiation (large cell neuroendocrine tumor) and thus may fine use in studies on the pathobiology of large cell-type neuroendocrine tumors since it expresses at the same time marker substances of neuroendocrine differentiation and the hCG alpha-subunit,neuroendocrine differentiation,neuroendocrine tumors
503545411,7/16/2014 20:42:02,,1324467080,7/16/2014 20:42:00,coinworker,1.0,28394550,USA,PA,Marcus Hook,71.175.96.184,298,219,,,328,240,NEUROENDOCRINE DIFFERENTIATION,NEUROENDOCRINE TUMORS,marker substances of NEUROENDOCRINE DIFFERENTIATION and the hCG,277-284-295-298-313-329-333-337,203-209-214-219-234-241-247-250,large cell type NEUROENDOCRINE TUMORS since it expresses,KTA7 was considered to be derived from large cell undifferentiated carcinoma with neuroendocrine differentiation (large cell neuroendocrine tumor) and thus may fine use in studies on the pathobiology of large cell-type neuroendocrine tumors since it expresses at the same time marker substances of neuroendocrine differentiation and the hCG alpha-subunit.,298 313,219 234,298,219,328,240,-1,RO-disease_has_finding,901838,KTA7 was considered to be derived from large cell undifferentiated carcinoma with neuroendocrine differentiation (large cell neuroendocrine tumor) and thus may fine use in studies on the pathobiology of large cell-type neuroendocrine tumors since it expresses at the same time marker substances of neuroendocrine differentiation and the hCG alpha-subunit,neuroendocrine differentiation,neuroendocrine tumors
503545411,7/16/2014 20:42:28,,1324467245,7/16/2014 20:41:51,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,298,219,,,328,240,NEUROENDOCRINE DIFFERENTIATION,NEUROENDOCRINE TUMORS,NEUROENDOCRINE DIFFERENTIATION,298-313,203-209-213-214-219-234,large cell - type NEUROENDOCRINE TUMORS,KTA7 was considered to be derived from large cell undifferentiated carcinoma with neuroendocrine differentiation (large cell neuroendocrine tumor) and thus may fine use in studies on the pathobiology of large cell-type neuroendocrine tumors since it expresses at the same time marker substances of neuroendocrine differentiation and the hCG alpha-subunit.,298 313,219 234,298,219,328,240,-1,RO-disease_has_finding,901838,KTA7 was considered to be derived from large cell undifferentiated carcinoma with neuroendocrine differentiation (large cell neuroendocrine tumor) and thus may fine use in studies on the pathobiology of large cell-type neuroendocrine tumors since it expresses at the same time marker substances of neuroendocrine differentiation and the hCG alpha-subunit,neuroendocrine differentiation,neuroendocrine tumors
503545411,7/16/2014 20:44:45,,1324468052,7/16/2014 20:44:35,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,298,219,,,328,240,NEUROENDOCRINE DIFFERENTIATION,NEUROENDOCRINE TUMORS,NEUROENDOCRINE DIFFERENTIATION,298-313,219-234,NEUROENDOCRINE TUMORS,KTA7 was considered to be derived from large cell undifferentiated carcinoma with neuroendocrine differentiation (large cell neuroendocrine tumor) and thus may fine use in studies on the pathobiology of large cell-type neuroendocrine tumors since it expresses at the same time marker substances of neuroendocrine differentiation and the hCG alpha-subunit.,298 313,219 234,298,219,328,240,-1,RO-disease_has_finding,901838,KTA7 was considered to be derived from large cell undifferentiated carcinoma with neuroendocrine differentiation (large cell neuroendocrine tumor) and thus may fine use in studies on the pathobiology of large cell-type neuroendocrine tumors since it expresses at the same time marker substances of neuroendocrine differentiation and the hCG alpha-subunit,neuroendocrine differentiation,neuroendocrine tumors
503545411,7/16/2014 20:48:06,,1324469568,7/16/2014 20:47:41,prodege,1.0,22360212,GBR,I1,Luton,82.6.41.191,298,219,,,328,240,NEUROENDOCRINE DIFFERENTIATION,NEUROENDOCRINE TUMORS,NEUROENDOCRINE DIFFERENTIATION,298-313,219-234,NEUROENDOCRINE TUMORS,KTA7 was considered to be derived from large cell undifferentiated carcinoma with neuroendocrine differentiation (large cell neuroendocrine tumor) and thus may fine use in studies on the pathobiology of large cell-type neuroendocrine tumors since it expresses at the same time marker substances of neuroendocrine differentiation and the hCG alpha-subunit.,298 313,219 234,298,219,328,240,-1,RO-disease_has_finding,901838,KTA7 was considered to be derived from large cell undifferentiated carcinoma with neuroendocrine differentiation (large cell neuroendocrine tumor) and thus may fine use in studies on the pathobiology of large cell-type neuroendocrine tumors since it expresses at the same time marker substances of neuroendocrine differentiation and the hCG alpha-subunit,neuroendocrine differentiation,neuroendocrine tumors
503545411,7/16/2014 20:50:31,,1324470584,7/16/2014 20:50:12,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,298,219,,,328,240,NEUROENDOCRINE DIFFERENTIATION,NEUROENDOCRINE TUMORS,NEUROENDOCRINE DIFFERENTIATION,298-313,219-234,NEUROENDOCRINE TUMORS,KTA7 was considered to be derived from large cell undifferentiated carcinoma with neuroendocrine differentiation (large cell neuroendocrine tumor) and thus may fine use in studies on the pathobiology of large cell-type neuroendocrine tumors since it expresses at the same time marker substances of neuroendocrine differentiation and the hCG alpha-subunit.,298 313,219 234,298,219,328,240,-1,RO-disease_has_finding,901838,KTA7 was considered to be derived from large cell undifferentiated carcinoma with neuroendocrine differentiation (large cell neuroendocrine tumor) and thus may fine use in studies on the pathobiology of large cell-type neuroendocrine tumors since it expresses at the same time marker substances of neuroendocrine differentiation and the hCG alpha-subunit,neuroendocrine differentiation,neuroendocrine tumors
503545411,7/16/2014 20:53:14,,1324471689,7/16/2014 20:52:41,prodege,1.0,4968858,USA,CA,Corona,99.44.120.153,298,219,,,328,240,NEUROENDOCRINE DIFFERENTIATION,NEUROENDOCRINE TUMORS,NEUROENDOCRINE DIFFERENTIATION,298-313,203-209-214-219-234,large cell type NEUROENDOCRINE TUMORS,KTA7 was considered to be derived from large cell undifferentiated carcinoma with neuroendocrine differentiation (large cell neuroendocrine tumor) and thus may fine use in studies on the pathobiology of large cell-type neuroendocrine tumors since it expresses at the same time marker substances of neuroendocrine differentiation and the hCG alpha-subunit.,298 313,219 234,298,219,328,240,-1,RO-disease_has_finding,901838,KTA7 was considered to be derived from large cell undifferentiated carcinoma with neuroendocrine differentiation (large cell neuroendocrine tumor) and thus may fine use in studies on the pathobiology of large cell-type neuroendocrine tumors since it expresses at the same time marker substances of neuroendocrine differentiation and the hCG alpha-subunit,neuroendocrine differentiation,neuroendocrine tumors
503545411,7/16/2014 20:53:35,,1324471812,7/16/2014 20:53:20,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,298,219,,,328,240,NEUROENDOCRINE DIFFERENTIATION,NEUROENDOCRINE TUMORS,NEUROENDOCRINE DIFFERENTIATION,298-313,203-209-214-219-234,large cell type NEUROENDOCRINE TUMORS,KTA7 was considered to be derived from large cell undifferentiated carcinoma with neuroendocrine differentiation (large cell neuroendocrine tumor) and thus may fine use in studies on the pathobiology of large cell-type neuroendocrine tumors since it expresses at the same time marker substances of neuroendocrine differentiation and the hCG alpha-subunit.,298 313,219 234,298,219,328,240,-1,RO-disease_has_finding,901838,KTA7 was considered to be derived from large cell undifferentiated carcinoma with neuroendocrine differentiation (large cell neuroendocrine tumor) and thus may fine use in studies on the pathobiology of large cell-type neuroendocrine tumors since it expresses at the same time marker substances of neuroendocrine differentiation and the hCG alpha-subunit,neuroendocrine differentiation,neuroendocrine tumors
503545412,7/16/2014 20:33:57,,1324463788,7/16/2014 20:33:34,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,32,0,,,49,11,POLYCYTHEMIA VERA,HYDROXYUREA,POLYCYTHEMIA VERA:,32-45,0,HYDROXYUREA,Hydroxyurea in the treatment of polycythemia vera: a prospective study of 100 patients over a 20-year period.,32 45,0,32,0,49,11,1,RO-may_treat,907569,Hydroxyurea in the treatment of polycythemia vera: a prospective study of 100 patients over a 20-year period,polycythemia vera,Hydroxyurea
503545412,7/16/2014 20:37:09,,1324465095,7/16/2014 20:37:00,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,32,0,,,49,11,POLYCYTHEMIA VERA,HYDROXYUREA,POLYCYTHEMIA VERA:,32-45,0,HYDROXYUREA,Hydroxyurea in the treatment of polycythemia vera: a prospective study of 100 patients over a 20-year period.,32 45,0,32,0,49,11,1,RO-may_treat,907569,Hydroxyurea in the treatment of polycythemia vera: a prospective study of 100 patients over a 20-year period,polycythemia vera,Hydroxyurea
503545412,7/16/2014 20:38:56,,1324465800,7/16/2014 20:38:51,clixsense,1.0,6610277,CAN,ON,Oshawa,174.117.79.122,32,0,,,49,11,POLYCYTHEMIA VERA,HYDROXYUREA,the treatment of POLYCYTHEMIA VERA: a prospective study,15-19-29-32-45-51-53-65,0-12-15-19,HYDROXYUREA in the treatment,Hydroxyurea in the treatment of polycythemia vera: a prospective study of 100 patients over a 20-year period.,32 45,0,32,0,49,11,1,RO-may_treat,907569,Hydroxyurea in the treatment of polycythemia vera: a prospective study of 100 patients over a 20-year period,polycythemia vera,Hydroxyurea
503545412,7/16/2014 20:40:21,,1324466369,7/16/2014 20:39:57,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,32,0,,,49,11,POLYCYTHEMIA VERA,HYDROXYUREA,POLYCYTHEMIA VERA:,32-45,0,HYDROXYUREA,Hydroxyurea in the treatment of polycythemia vera: a prospective study of 100 patients over a 20-year period.,32 45,0,32,0,49,11,1,RO-may_treat,907569,Hydroxyurea in the treatment of polycythemia vera: a prospective study of 100 patients over a 20-year period,polycythemia vera,Hydroxyurea
503545412,7/16/2014 20:40:22,,1324466398,7/16/2014 20:40:13,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,32,0,,,49,11,POLYCYTHEMIA VERA,HYDROXYUREA,POLYCYTHEMIA VERA:,32-45,0,HYDROXYUREA,Hydroxyurea in the treatment of polycythemia vera: a prospective study of 100 patients over a 20-year period.,32 45,0,32,0,49,11,1,RO-may_treat,907569,Hydroxyurea in the treatment of polycythemia vera: a prospective study of 100 patients over a 20-year period,polycythemia vera,Hydroxyurea
503545412,7/16/2014 20:41:39,,1324466946,7/16/2014 20:41:37,coinworker,1.0,28394550,USA,PA,Marcus Hook,71.175.96.184,32,0,,,49,11,POLYCYTHEMIA VERA,HYDROXYUREA,the treatment of POLYCYTHEMIA VERA: a prospective study,15-19-29-32-45-51-53-65,0-12-15-19,HYDROXYUREA in the treatment,Hydroxyurea in the treatment of polycythemia vera: a prospective study of 100 patients over a 20-year period.,32 45,0,32,0,49,11,1,RO-may_treat,907569,Hydroxyurea in the treatment of polycythemia vera: a prospective study of 100 patients over a 20-year period,polycythemia vera,Hydroxyurea
503545412,7/16/2014 20:41:41,,1324466972,7/16/2014 20:41:32,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,32,0,,,49,11,POLYCYTHEMIA VERA,HYDROXYUREA,POLYCYTHEMIA VERA:,32-45,0,HYDROXYUREA,Hydroxyurea in the treatment of polycythemia vera: a prospective study of 100 patients over a 20-year period.,32 45,0,32,0,49,11,1,RO-may_treat,907569,Hydroxyurea in the treatment of polycythemia vera: a prospective study of 100 patients over a 20-year period,polycythemia vera,Hydroxyurea
503545412,7/16/2014 20:43:18,,1324467505,7/16/2014 20:43:16,bitcoinget,1.0,24792414,USA,"","",166.181.81.55,32,0,,,49,11,POLYCYTHEMIA VERA,HYDROXYUREA,the treatment of POLYCYTHEMIA VERA: a prospective study,15-19-29-32-45-51-53-65,0-12-15-19,HYDROXYUREA in the treatment,Hydroxyurea in the treatment of polycythemia vera: a prospective study of 100 patients over a 20-year period.,32 45,0,32,0,49,11,1,RO-may_treat,907569,Hydroxyurea in the treatment of polycythemia vera: a prospective study of 100 patients over a 20-year period,polycythemia vera,Hydroxyurea
503545412,7/16/2014 20:46:07,,1324468635,7/16/2014 20:45:46,eup_slw,1.0,28011002,CAN,MB,Winnipeg,24.77.44.140,32,0,,,49,11,POLYCYTHEMIA VERA,HYDROXYUREA,POLYCYTHEMIA VERA:,32-45,0,HYDROXYUREA,Hydroxyurea in the treatment of polycythemia vera: a prospective study of 100 patients over a 20-year period.,32 45,0,32,0,49,11,1,RO-may_treat,907569,Hydroxyurea in the treatment of polycythemia vera: a prospective study of 100 patients over a 20-year period,polycythemia vera,Hydroxyurea
503545412,7/16/2014 20:52:12,,1324471260,7/16/2014 20:51:08,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,32,0,,,49,11,POLYCYTHEMIA VERA,HYDROXYUREA,POLYCYTHEMIA VERA:,32-45,0,HYDROXYUREA,Hydroxyurea in the treatment of polycythemia vera: a prospective study of 100 patients over a 20-year period.,32 45,0,32,0,49,11,1,RO-may_treat,907569,Hydroxyurea in the treatment of polycythemia vera: a prospective study of 100 patients over a 20-year period,polycythemia vera,Hydroxyurea
503545413,7/16/2014 20:38:41,,1324465678,7/16/2014 20:38:37,clixsense,1.0,6610277,CAN,ON,Oshawa,174.117.79.122,60,109,,,65,118,JOINT,ARTHROSIS,the patello femoral JOINT after upper tibial,40-44-52-60-66-72-78,85-95-105-109-119-122-126,osteotomy performed for ARTHROSIS of the knee,The progressive radiological changes in the patello-femoral joint after upper tibial osteotomy performed for arthrosis of the knee were studied more than 10 years after the surgical procedure.,60,109,60,109,65,118,1,RO-disease_has_primary_anatomic_site,902308,The progressive radiological changes in the patello-femoral joint after upper tibial osteotomy performed for arthrosis of the knee were studied more than 10 years after the surgical procedure,joint,arthrosis
503545413,7/16/2014 20:39:58,,1324466253,7/16/2014 20:39:42,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,60,109,,,65,118,JOINT,ARTHROSIS,patello femoral JOINT,44-52-60,109,ARTHROSIS,The progressive radiological changes in the patello-femoral joint after upper tibial osteotomy performed for arthrosis of the knee were studied more than 10 years after the surgical procedure.,60,109,60,109,65,118,1,RO-disease_has_primary_anatomic_site,902308,The progressive radiological changes in the patello-femoral joint after upper tibial osteotomy performed for arthrosis of the knee were studied more than 10 years after the surgical procedure,joint,arthrosis
503545413,7/16/2014 20:40:29,,1324466467,7/16/2014 20:40:10,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,60,109,,,65,118,JOINT,ARTHROSIS,patello femoral JOINT,44-52-60,109-119-122-126,ARTHROSIS of the knee,The progressive radiological changes in the patello-femoral joint after upper tibial osteotomy performed for arthrosis of the knee were studied more than 10 years after the surgical procedure.,60,109,60,109,65,118,1,RO-disease_has_primary_anatomic_site,902308,The progressive radiological changes in the patello-femoral joint after upper tibial osteotomy performed for arthrosis of the knee were studied more than 10 years after the surgical procedure,joint,arthrosis
503545413,7/16/2014 20:41:39,,1324466949,7/16/2014 20:41:29,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,60,109,,,65,118,JOINT,ARTHROSIS,patello - femoral JOINT,44-51-52-60,109,ARTHROSIS,The progressive radiological changes in the patello-femoral joint after upper tibial osteotomy performed for arthrosis of the knee were studied more than 10 years after the surgical procedure.,60,109,60,109,65,118,1,RO-disease_has_primary_anatomic_site,902308,The progressive radiological changes in the patello-femoral joint after upper tibial osteotomy performed for arthrosis of the knee were studied more than 10 years after the surgical procedure,joint,arthrosis
503545413,7/16/2014 20:44:00,,1324467758,7/16/2014 20:43:57,bitcoinget,1.0,24792414,USA,"","",166.181.81.55,60,109,,,65,118,JOINT,ARTHROSIS,the patello femoral JOINT after upper tibial,40-44-52-60-66-72-78,85-95-105-109-119-122-126,osteotomy performed for ARTHROSIS of the knee,The progressive radiological changes in the patello-femoral joint after upper tibial osteotomy performed for arthrosis of the knee were studied more than 10 years after the surgical procedure.,60,109,60,109,65,118,1,RO-disease_has_primary_anatomic_site,902308,The progressive radiological changes in the patello-femoral joint after upper tibial osteotomy performed for arthrosis of the knee were studied more than 10 years after the surgical procedure,joint,arthrosis
503545413,7/16/2014 20:44:57,,1324468118,7/16/2014 20:44:46,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,60,109,,,65,118,JOINT,ARTHROSIS,JOINT,60,109,ARTHROSIS,The progressive radiological changes in the patello-femoral joint after upper tibial osteotomy performed for arthrosis of the knee were studied more than 10 years after the surgical procedure.,60,109,60,109,65,118,1,RO-disease_has_primary_anatomic_site,902308,The progressive radiological changes in the patello-femoral joint after upper tibial osteotomy performed for arthrosis of the knee were studied more than 10 years after the surgical procedure,joint,arthrosis
503545413,7/16/2014 20:45:53,,1324468505,7/16/2014 20:45:35,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,60,109,,,65,118,JOINT,ARTHROSIS,patello femoral JOINT,44-52-60,109-119-122-126,ARTHROSIS of the knee,The progressive radiological changes in the patello-femoral joint after upper tibial osteotomy performed for arthrosis of the knee were studied more than 10 years after the surgical procedure.,60,109,60,109,65,118,1,RO-disease_has_primary_anatomic_site,902308,The progressive radiological changes in the patello-femoral joint after upper tibial osteotomy performed for arthrosis of the knee were studied more than 10 years after the surgical procedure,joint,arthrosis
503545413,7/16/2014 20:46:33,,1324468861,7/16/2014 20:46:30,prodege,1.0,26325260,GBR,"","",79.64.25.64,60,109,,,65,118,JOINT,ARTHROSIS,the patello femoral JOINT after upper tibial,40-44-52-60-66-72-78,85-95-105-109-119-122-126,osteotomy performed for ARTHROSIS of the knee,The progressive radiological changes in the patello-femoral joint after upper tibial osteotomy performed for arthrosis of the knee were studied more than 10 years after the surgical procedure.,60,109,60,109,65,118,1,RO-disease_has_primary_anatomic_site,902308,The progressive radiological changes in the patello-femoral joint after upper tibial osteotomy performed for arthrosis of the knee were studied more than 10 years after the surgical procedure,joint,arthrosis
503545413,7/16/2014 20:46:53,,1324469016,7/16/2014 20:45:42,prodege,1.0,4968858,USA,CA,Corona,99.44.120.153,60,109,,,65,118,JOINT,ARTHROSIS,patello femoral JOINT,44-52-60,109-119-122-126,ARTHROSIS of the knee,The progressive radiological changes in the patello-femoral joint after upper tibial osteotomy performed for arthrosis of the knee were studied more than 10 years after the surgical procedure.,60,109,60,109,65,118,1,RO-disease_has_primary_anatomic_site,902308,The progressive radiological changes in the patello-femoral joint after upper tibial osteotomy performed for arthrosis of the knee were studied more than 10 years after the surgical procedure,joint,arthrosis
503545413,7/16/2014 20:48:30,,1324469731,7/16/2014 20:48:07,prodege,1.0,22360212,GBR,I1,Luton,82.6.41.191,60,109,,,65,118,JOINT,ARTHROSIS,patello femoral JOINT,44-52-60,109,ARTHROSIS,The progressive radiological changes in the patello-femoral joint after upper tibial osteotomy performed for arthrosis of the knee were studied more than 10 years after the surgical procedure.,60,109,60,109,65,118,1,RO-disease_has_primary_anatomic_site,902308,The progressive radiological changes in the patello-femoral joint after upper tibial osteotomy performed for arthrosis of the knee were studied more than 10 years after the surgical procedure,joint,arthrosis
503545414,7/16/2014 20:34:34,,1324464031,7/16/2014 20:34:24,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,110,28,,,118,38,MENINGES,MENINGITIS,MENINGES,110,28,MENINGITIS,"We report two patients with meningitis due to spirochaetal infection, both of whom showed diffusely enhancing meninges around the brain and spinal cord.",110,28,110,28,118,38,1,RO-disease_has_primary_anatomic_site,902231,"We report two patients with meningitis due to spirochaetal infection, both of whom showed diffusely enhancing meninges around the brain and spinal cord",meninges,meningitis
503545414,7/16/2014 20:34:45,,1324464105,7/16/2014 20:33:58,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,110,28,,,118,38,MENINGES,MENINGITIS,MENINGES,110,28,MENINGITIS,"We report two patients with meningitis due to spirochaetal infection, both of whom showed diffusely enhancing meninges around the brain and spinal cord.",110,28,110,28,118,38,1,RO-disease_has_primary_anatomic_site,902231,"We report two patients with meningitis due to spirochaetal infection, both of whom showed diffusely enhancing meninges around the brain and spinal cord",meninges,meningitis
503545414,7/16/2014 20:37:31,,1324465234,7/16/2014 20:35:23,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,110,28,,,118,38,MENINGES,MENINGITIS,diffusely enhancing MENINGES,90-100-110,28-39-43-46-59,"MENINGITIS due to spirochaetal infection,","We report two patients with meningitis due to spirochaetal infection, both of whom showed diffusely enhancing meninges around the brain and spinal cord.",110,28,110,28,118,38,1,RO-disease_has_primary_anatomic_site,902231,"We report two patients with meningitis due to spirochaetal infection, both of whom showed diffusely enhancing meninges around the brain and spinal cord",meninges,meningitis
503545414,7/16/2014 20:38:25,,1324465553,7/16/2014 20:37:53,clixsense,1.0,24896327,GBR,V2,Glasgow,94.2.231.4,110,28,,,118,38,MENINGES,MENINGITIS,MENINGES,110,28,MENINGITIS,"We report two patients with meningitis due to spirochaetal infection, both of whom showed diffusely enhancing meninges around the brain and spinal cord.",110,28,110,28,118,38,1,RO-disease_has_primary_anatomic_site,902231,"We report two patients with meningitis due to spirochaetal infection, both of whom showed diffusely enhancing meninges around the brain and spinal cord",meninges,meningitis
503545414,7/16/2014 20:38:32,,1324465594,7/16/2014 20:38:27,clixsense,1.0,6610277,CAN,ON,Oshawa,174.117.79.122,110,28,,,118,38,MENINGES,MENINGITIS,showed diffusely enhancing MENINGES around the brain,83-90-100-110-119-126-130,10-14-23-28-39-43-46,two patients with MENINGITIS due to spirochaetal,"We report two patients with meningitis due to spirochaetal infection, both of whom showed diffusely enhancing meninges around the brain and spinal cord.",110,28,110,28,118,38,1,RO-disease_has_primary_anatomic_site,902231,"We report two patients with meningitis due to spirochaetal infection, both of whom showed diffusely enhancing meninges around the brain and spinal cord",meninges,meningitis
503545414,7/16/2014 20:40:52,,1324466624,7/16/2014 20:40:36,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,110,28,,,118,38,MENINGES,MENINGITIS,diffusely enhancing MENINGES,90-110-100,28,MENINGITIS,"We report two patients with meningitis due to spirochaetal infection, both of whom showed diffusely enhancing meninges around the brain and spinal cord.",110,28,110,28,118,38,1,RO-disease_has_primary_anatomic_site,902231,"We report two patients with meningitis due to spirochaetal infection, both of whom showed diffusely enhancing meninges around the brain and spinal cord",meninges,meningitis
503545414,7/16/2014 20:42:35,,1324467270,7/16/2014 20:42:25,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,110,28,,,118,38,MENINGES,MENINGITIS,showed diffusely enhancing MENINGES around the brain,83-90-100-110-119-126-130,10-14-23-28-39-43-46,two patients with MENINGITIS due to spirochaetal,"We report two patients with meningitis due to spirochaetal infection, both of whom showed diffusely enhancing meninges around the brain and spinal cord.",110,28,110,28,118,38,1,RO-disease_has_primary_anatomic_site,902231,"We report two patients with meningitis due to spirochaetal infection, both of whom showed diffusely enhancing meninges around the brain and spinal cord",meninges,meningitis
503545414,7/16/2014 20:43:17,,1324467498,7/16/2014 20:43:00,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,110,28,,,118,38,MENINGES,MENINGITIS,MENINGES,110,28,MENINGITIS,"We report two patients with meningitis due to spirochaetal infection, both of whom showed diffusely enhancing meninges around the brain and spinal cord.",110,28,110,28,118,38,1,RO-disease_has_primary_anatomic_site,902231,"We report two patients with meningitis due to spirochaetal infection, both of whom showed diffusely enhancing meninges around the brain and spinal cord",meninges,meningitis
503545414,7/16/2014 20:43:21,,1324467519,7/16/2014 20:43:19,bitcoinget,1.0,24792414,USA,"","",166.181.81.55,110,28,,,118,38,MENINGES,MENINGITIS,showed diffusely enhancing MENINGES around the brain,83-90-100-110-119-126-130,10-14-23-28-39-43-46,two patients with MENINGITIS due to spirochaetal,"We report two patients with meningitis due to spirochaetal infection, both of whom showed diffusely enhancing meninges around the brain and spinal cord.",110,28,110,28,118,38,1,RO-disease_has_primary_anatomic_site,902231,"We report two patients with meningitis due to spirochaetal infection, both of whom showed diffusely enhancing meninges around the brain and spinal cord",meninges,meningitis
503545414,7/16/2014 20:44:22,,1324467906,7/16/2014 20:43:57,prodege,1.0,9997387,USA,CO,Colorado Springs,75.70.112.31,110,28,,,118,38,MENINGES,MENINGITIS,MENINGES,110,28,MENINGITIS,"We report two patients with meningitis due to spirochaetal infection, both of whom showed diffusely enhancing meninges around the brain and spinal cord.",110,28,110,28,118,38,1,RO-disease_has_primary_anatomic_site,902231,"We report two patients with meningitis due to spirochaetal infection, both of whom showed diffusely enhancing meninges around the brain and spinal cord",meninges,meningitis
503545415,7/16/2014 20:37:20,,1324465182,7/16/2014 20:37:10,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,82,59,,,89,77,DENTURE,DENTURE STOMATITIS,DENTURE plaque.,82-90,59-67,DENTURE STOMATITIS,Soaking dentures in denture cleanser reduced the degree of denture stomatitis and denture plaque.,82,59 67,82,59,89,77,-1,RO-has_causative_agent,903515,Soaking dentures in denture cleanser reduced the degree of denture stomatitis and denture plaque,denture,denture stomatitis
503545415,7/16/2014 20:37:22,,1324465193,7/16/2014 20:37:14,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,82,59,,,89,77,DENTURE,DENTURE STOMATITIS,DENTURE plaque.,82-90,59-67,DENTURE STOMATITIS,Soaking dentures in denture cleanser reduced the degree of denture stomatitis and denture plaque.,82,59 67,82,59,89,77,-1,RO-has_causative_agent,903515,Soaking dentures in denture cleanser reduced the degree of denture stomatitis and denture plaque,denture,denture stomatitis
503545415,7/16/2014 20:45:00,,1324468146,7/16/2014 20:44:34,eup_slw,1.0,28011002,CAN,MB,Winnipeg,24.77.44.140,82,59,,,89,77,DENTURE,DENTURE STOMATITIS,DENTURE,82,59-67,DENTURE STOMATITIS,Soaking dentures in denture cleanser reduced the degree of denture stomatitis and denture plaque.,82,59 67,82,59,89,77,-1,RO-has_causative_agent,903515,Soaking dentures in denture cleanser reduced the degree of denture stomatitis and denture plaque,denture,denture stomatitis
503545415,7/16/2014 20:47:05,,1324469086,7/16/2014 20:46:52,instagc,1.0,13763729,USA,"","",75.182.89.225,82,59,,,89,77,DENTURE,DENTURE STOMATITIS,DENTURE plaque.,82-90,59-67,DENTURE STOMATITIS,Soaking dentures in denture cleanser reduced the degree of denture stomatitis and denture plaque.,82,59 67,82,59,89,77,-1,RO-has_causative_agent,903515,Soaking dentures in denture cleanser reduced the degree of denture stomatitis and denture plaque,denture,denture stomatitis
503545415,7/16/2014 20:51:48,,1324471100,7/16/2014 20:51:36,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,82,59,,,89,77,DENTURE,DENTURE STOMATITIS,DENTURE plaque.,82-90,59-67,DENTURE STOMATITIS,Soaking dentures in denture cleanser reduced the degree of denture stomatitis and denture plaque.,82,59 67,82,59,89,77,-1,RO-has_causative_agent,903515,Soaking dentures in denture cleanser reduced the degree of denture stomatitis and denture plaque,denture,denture stomatitis
503545415,7/16/2014 20:51:49,,1324471102,7/16/2014 20:51:21,prodege,1.0,22360212,GBR,I1,Luton,82.6.41.191,82,59,,,89,77,DENTURE,DENTURE STOMATITIS,DENTURE plaque.,82-90,59-67,DENTURE STOMATITIS,Soaking dentures in denture cleanser reduced the degree of denture stomatitis and denture plaque.,82,59 67,82,59,89,77,-1,RO-has_causative_agent,903515,Soaking dentures in denture cleanser reduced the degree of denture stomatitis and denture plaque,denture,denture stomatitis
503545415,7/16/2014 20:52:40,,1324471533,7/16/2014 20:52:02,prodege,1.0,4968858,USA,CA,Corona,99.44.120.153,82,59,,,89,77,DENTURE,DENTURE STOMATITIS,DENTURE plaque.,82-90,59-67,DENTURE STOMATITIS,Soaking dentures in denture cleanser reduced the degree of denture stomatitis and denture plaque.,82,59 67,82,59,89,77,-1,RO-has_causative_agent,903515,Soaking dentures in denture cleanser reduced the degree of denture stomatitis and denture plaque,denture,denture stomatitis
503545415,7/16/2014 20:52:49,,1324471582,7/16/2014 20:52:35,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,82,59,,,89,77,DENTURE,DENTURE STOMATITIS,DENTURE plaque.,82-90,59-67,DENTURE STOMATITIS,Soaking dentures in denture cleanser reduced the degree of denture stomatitis and denture plaque.,82,59 67,82,59,89,77,-1,RO-has_causative_agent,903515,Soaking dentures in denture cleanser reduced the degree of denture stomatitis and denture plaque,denture,denture stomatitis
503545415,7/16/2014 20:54:03,,1324472045,7/16/2014 20:53:46,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,82,59,,,89,77,DENTURE,DENTURE STOMATITIS,DENTURE plaque.,82-90,59-67,DENTURE STOMATITIS,Soaking dentures in denture cleanser reduced the degree of denture stomatitis and denture plaque.,82,59 67,82,59,89,77,-1,RO-has_causative_agent,903515,Soaking dentures in denture cleanser reduced the degree of denture stomatitis and denture plaque,denture,denture stomatitis
503545415,7/16/2014 20:55:05,,1324472428,7/16/2014 20:54:45,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,82,59,,,89,77,DENTURE,DENTURE STOMATITIS,DENTURE,82,59-67,DENTURE STOMATITIS,Soaking dentures in denture cleanser reduced the degree of denture stomatitis and denture plaque.,82,59 67,82,59,89,77,-1,RO-has_causative_agent,903515,Soaking dentures in denture cleanser reduced the degree of denture stomatitis and denture plaque,denture,denture stomatitis
503545416,7/16/2014 20:32:30,,1324463265,7/16/2014 20:32:19,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,53,11,,,68,18,TYPE 2 DIABETES,INSULIN,TYPE 2 DIABETES.,53-58-60,11-19,INSULIN secretagogues,The use of insulin secretagogues in the treatment of type 2 diabetes.,53 58 60,11,53,11,68,18,1,RO-may_treat,907897,The use of insulin secretagogues in the treatment of type 2 diabetes,type 2 diabetes,insulin
503545416,7/16/2014 20:38:55,,1324465797,7/16/2014 20:38:43,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,53,11,,,68,18,TYPE 2 DIABETES,INSULIN,TYPE 2 DIABETES.,53-58-60,11,INSULIN,The use of insulin secretagogues in the treatment of type 2 diabetes.,53 58 60,11,53,11,68,18,1,RO-may_treat,907897,The use of insulin secretagogues in the treatment of type 2 diabetes,type 2 diabetes,insulin
503545416,7/16/2014 20:41:47,,1324467001,7/16/2014 20:41:32,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,53,11,,,68,18,TYPE 2 DIABETES,INSULIN,TYPE 2 DIABETES.,53-58-60,11,INSULIN,The use of insulin secretagogues in the treatment of type 2 diabetes.,53 58 60,11,53,11,68,18,1,RO-may_treat,907897,The use of insulin secretagogues in the treatment of type 2 diabetes,type 2 diabetes,insulin
503545416,7/16/2014 20:45:29,,1324468349,7/16/2014 20:45:12,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,53,11,,,68,18,TYPE 2 DIABETES,INSULIN,the treatment of TYPE 2 DIABETES.,36-40-50-53-58-60,0-4-8-11-19-33-36,The use of INSULIN secretagogues in the,The use of insulin secretagogues in the treatment of type 2 diabetes.,53 58 60,11,53,11,68,18,1,RO-may_treat,907897,The use of insulin secretagogues in the treatment of type 2 diabetes,type 2 diabetes,insulin
503545416,7/16/2014 20:46:50,,1324468975,7/16/2014 20:46:39,prodege,1.0,9997387,USA,CO,Colorado Springs,75.70.112.31,53,11,,,68,18,TYPE 2 DIABETES,INSULIN,TYPE 2 DIABETES.,53-58-60,11-19,INSULIN secretagogues,The use of insulin secretagogues in the treatment of type 2 diabetes.,53 58 60,11,53,11,68,18,1,RO-may_treat,907897,The use of insulin secretagogues in the treatment of type 2 diabetes,type 2 diabetes,insulin
503545416,7/16/2014 20:47:22,,1324469198,7/16/2014 20:46:54,prodege,1.0,4968858,USA,CA,Corona,99.44.120.153,53,11,,,68,18,TYPE 2 DIABETES,INSULIN,TYPE 2 DIABETES.,53-58-60,11-19,INSULIN secretagogues,The use of insulin secretagogues in the treatment of type 2 diabetes.,53 58 60,11,53,11,68,18,1,RO-may_treat,907897,The use of insulin secretagogues in the treatment of type 2 diabetes,type 2 diabetes,insulin
503545416,7/16/2014 20:47:42,,1324469360,7/16/2014 20:47:02,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,53,11,,,68,18,TYPE 2 DIABETES,INSULIN,TYPE 2 DIABETES.,53-58-60,11-19,INSULIN secretagogues,The use of insulin secretagogues in the treatment of type 2 diabetes.,53 58 60,11,53,11,68,18,1,RO-may_treat,907897,The use of insulin secretagogues in the treatment of type 2 diabetes,type 2 diabetes,insulin
503545416,7/16/2014 20:48:07,,1324469574,7/16/2014 20:47:56,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,53,11,,,68,18,TYPE 2 DIABETES,INSULIN,TYPE 2 DIABETES.,53-58-60,11,INSULIN,The use of insulin secretagogues in the treatment of type 2 diabetes.,53 58 60,11,53,11,68,18,1,RO-may_treat,907897,The use of insulin secretagogues in the treatment of type 2 diabetes,type 2 diabetes,insulin
503545416,7/16/2014 20:48:46,,1324469899,7/16/2014 20:48:32,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,53,11,,,68,18,TYPE 2 DIABETES,INSULIN,TYPE 2 DIABETES.,53-58-60,11-19,INSULIN secretagogues,The use of insulin secretagogues in the treatment of type 2 diabetes.,53 58 60,11,53,11,68,18,1,RO-may_treat,907897,The use of insulin secretagogues in the treatment of type 2 diabetes,type 2 diabetes,insulin
503545416,7/16/2014 20:50:40,,1324470645,7/16/2014 20:50:27,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,53,11,,,68,18,TYPE 2 DIABETES,INSULIN,TYPE 2 DIABETES.,53-58-60,11-19,INSULIN secretagogues,The use of insulin secretagogues in the treatment of type 2 diabetes.,53 58 60,11,53,11,68,18,1,RO-may_treat,907897,The use of insulin secretagogues in the treatment of type 2 diabetes,type 2 diabetes,insulin
503545417,7/16/2014 20:34:45,,1324464115,7/16/2014 20:34:35,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,106,84,,,122,96,PHEOCHROMOCYTOMA,PHENTOLAMINE,PHEOCHROMOCYTOMA;,106,84,PHENTOLAMINE,"177 ,   a  Sudden and marked reduction in BP following parenteral administration of phentolamine suggests pheochromocytoma;  a   however, false-negative and false-positive responses are frequent.",106,84,106,84,122,96,1,RO-may_diagnose,906704,"177 ,   a  Sudden and marked reduction in BP following parenteral administration of phentolamine suggests pheochromocytoma;  a   however, false-negative and false-positive responses are frequent",pheochromocytoma,phentolamine
503545417,7/16/2014 20:35:05,,1324464237,7/16/2014 20:34:44,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,106,84,,,122,96,PHEOCHROMOCYTOMA,PHENTOLAMINE,PHEOCHROMOCYTOMA;,106,84,PHENTOLAMINE,"177 ,   a  Sudden and marked reduction in BP following parenteral administration of phentolamine suggests pheochromocytoma;  a   however, false-negative and false-positive responses are frequent.",106,84,106,84,122,96,1,RO-may_diagnose,906704,"177 ,   a  Sudden and marked reduction in BP following parenteral administration of phentolamine suggests pheochromocytoma;  a   however, false-negative and false-positive responses are frequent",pheochromocytoma,phentolamine
503545417,7/16/2014 20:38:50,,1324465751,7/16/2014 20:38:24,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,106,84,,,122,96,PHEOCHROMOCYTOMA,PHENTOLAMINE,PHEOCHROMOCYTOMA;,106,84,PHENTOLAMINE,"177 ,   a  Sudden and marked reduction in BP following parenteral administration of phentolamine suggests pheochromocytoma;  a   however, false-negative and false-positive responses are frequent.",106,84,106,84,122,96,1,RO-may_diagnose,906704,"177 ,   a  Sudden and marked reduction in BP following parenteral administration of phentolamine suggests pheochromocytoma;  a   however, false-negative and false-positive responses are frequent",pheochromocytoma,phentolamine
503545417,7/16/2014 20:40:31,,1324466479,7/16/2014 20:40:15,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,106,84,,,122,96,PHEOCHROMOCYTOMA,PHENTOLAMINE,PHEOCHROMOCYTOMA;,106,84,PHENTOLAMINE,"177 ,   a  Sudden and marked reduction in BP following parenteral administration of phentolamine suggests pheochromocytoma;  a   however, false-negative and false-positive responses are frequent.",106,84,106,84,122,96,1,RO-may_diagnose,906704,"177 ,   a  Sudden and marked reduction in BP following parenteral administration of phentolamine suggests pheochromocytoma;  a   however, false-negative and false-positive responses are frequent",pheochromocytoma,phentolamine
503545417,7/16/2014 20:41:21,,1324466811,7/16/2014 20:41:09,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,106,84,,,122,96,PHEOCHROMOCYTOMA,PHENTOLAMINE,PHEOCHROMOCYTOMA;,106,84,PHENTOLAMINE,"177 ,   a  Sudden and marked reduction in BP following parenteral administration of phentolamine suggests pheochromocytoma;  a   however, false-negative and false-positive responses are frequent.",106,84,106,84,122,96,1,RO-may_diagnose,906704,"177 ,   a  Sudden and marked reduction in BP following parenteral administration of phentolamine suggests pheochromocytoma;  a   however, false-negative and false-positive responses are frequent",pheochromocytoma,phentolamine
503545417,7/16/2014 20:41:26,,1324466856,7/16/2014 20:41:03,clixsense,1.0,24896327,GBR,V2,Glasgow,94.2.231.4,106,84,,,122,96,PHEOCHROMOCYTOMA,PHENTOLAMINE,PHEOCHROMOCYTOMA;,106,84,PHENTOLAMINE,"177 ,   a  Sudden and marked reduction in BP following parenteral administration of phentolamine suggests pheochromocytoma;  a   however, false-negative and false-positive responses are frequent.",106,84,106,84,122,96,1,RO-may_diagnose,906704,"177 ,   a  Sudden and marked reduction in BP following parenteral administration of phentolamine suggests pheochromocytoma;  a   however, false-negative and false-positive responses are frequent",pheochromocytoma,phentolamine
503545417,7/16/2014 20:41:53,,1324467041,7/16/2014 20:41:25,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,106,84,,,122,96,PHEOCHROMOCYTOMA,PHENTOLAMINE,PHEOCHROMOCYTOMA;,106,84,PHENTOLAMINE,"177 ,   a  Sudden and marked reduction in BP following parenteral administration of phentolamine suggests pheochromocytoma;  a   however, false-negative and false-positive responses are frequent.",106,84,106,84,122,96,1,RO-may_diagnose,906704,"177 ,   a  Sudden and marked reduction in BP following parenteral administration of phentolamine suggests pheochromocytoma;  a   however, false-negative and false-positive responses are frequent",pheochromocytoma,phentolamine
503545417,7/16/2014 20:43:32,,1324467602,7/16/2014 20:43:10,instagc,1.0,13763729,USA,"","",75.182.89.225,106,84,,,122,96,PHEOCHROMOCYTOMA,PHENTOLAMINE,PHEOCHROMOCYTOMA;,106,84,PHENTOLAMINE,"177 ,   a  Sudden and marked reduction in BP following parenteral administration of phentolamine suggests pheochromocytoma;  a   however, false-negative and false-positive responses are frequent.",106,84,106,84,122,96,1,RO-may_diagnose,906704,"177 ,   a  Sudden and marked reduction in BP following parenteral administration of phentolamine suggests pheochromocytoma;  a   however, false-negative and false-positive responses are frequent",pheochromocytoma,phentolamine
503545417,7/16/2014 20:44:34,,1324467985,7/16/2014 20:44:27,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,106,84,,,122,96,PHEOCHROMOCYTOMA,PHENTOLAMINE,"of phentolamine suggests PHEOCHROMOCYTOMA; a however, false",81-84-97-106-125-129-138,55-66-81-84-97-106-125,parenteral administration of PHENTOLAMINE suggests pheochromocytoma; a,"177 ,   a  Sudden and marked reduction in BP following parenteral administration of phentolamine suggests pheochromocytoma;  a   however, false-negative and false-positive responses are frequent.",106,84,106,84,122,96,1,RO-may_diagnose,906704,"177 ,   a  Sudden and marked reduction in BP following parenteral administration of phentolamine suggests pheochromocytoma;  a   however, false-negative and false-positive responses are frequent",pheochromocytoma,phentolamine
503545417,7/16/2014 20:46:37,,1324468887,7/16/2014 20:46:16,prodege,1.0,9997387,USA,CO,Colorado Springs,75.70.112.31,106,84,,,122,96,PHEOCHROMOCYTOMA,PHENTOLAMINE,phentolamine PHEOCHROMOCYTOMA;,84-106,84-106-125,PHENTOLAMINE pheochromocytoma; a,"177 ,   a  Sudden and marked reduction in BP following parenteral administration of phentolamine suggests pheochromocytoma;  a   however, false-negative and false-positive responses are frequent.",106,84,106,84,122,96,1,RO-may_diagnose,906704,"177 ,   a  Sudden and marked reduction in BP following parenteral administration of phentolamine suggests pheochromocytoma;  a   however, false-negative and false-positive responses are frequent",pheochromocytoma,phentolamine
503545418,7/16/2014 20:33:20,,1324463528,7/16/2014 20:33:05,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,73,210,,,106,250,HUMAN IMMUNODEFICIENCY VIRUS (HIV,ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS,HUMAN IMMUNODEFICIENCY VIRUS (HIV),73-79-96-102,210-219-236-245,ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS.,An understanding of the biologic characteristics and cellular tropism of human immunodeficiency virus (HIV) is critical to appreciate the diverse neurologic manifestations of HIV infection in patients with the acquired immunodeficiency syndrome (AIDS.,73 79 96 102,210 219 236 245,73,210,106,250,-1,RO-has_causative_agent,903835,An understanding of the biologic characteristics and cellular tropism of human immunodeficiency virus (HIV) is critical to appreciate the diverse neurologic manifestations of HIV infection in patients with the acquired immunodeficiency syndrome (AIDS,human immunodeficiency virus (HIV,acquired immunodeficiency syndrome (AIDS
503545418,7/16/2014 20:34:55,,1324464165,7/16/2014 20:34:46,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,73,210,,,106,250,HUMAN IMMUNODEFICIENCY VIRUS (HIV,ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS,HUMAN IMMUNODEFICIENCY VIRUS (HIV),73-79-96-102,210-219-236-245,ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS.,An understanding of the biologic characteristics and cellular tropism of human immunodeficiency virus (HIV) is critical to appreciate the diverse neurologic manifestations of HIV infection in patients with the acquired immunodeficiency syndrome (AIDS.,73 79 96 102,210 219 236 245,73,210,106,250,-1,RO-has_causative_agent,903835,An understanding of the biologic characteristics and cellular tropism of human immunodeficiency virus (HIV) is critical to appreciate the diverse neurologic manifestations of HIV infection in patients with the acquired immunodeficiency syndrome (AIDS,human immunodeficiency virus (HIV,acquired immunodeficiency syndrome (AIDS
503545418,7/16/2014 20:39:10,,1324465919,7/16/2014 20:39:03,clixsense,1.0,6610277,CAN,ON,Oshawa,174.117.79.122,73,210,,,106,250,HUMAN IMMUNODEFICIENCY VIRUS (HIV,ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS,cellular tropism of HUMAN IMMUNODEFICIENCY VIRUS (HIV) is critical,53-62-70-73-79-96-102-108-111,192-201-206-210-219-236-245,patients with the ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS.,An understanding of the biologic characteristics and cellular tropism of human immunodeficiency virus (HIV) is critical to appreciate the diverse neurologic manifestations of HIV infection in patients with the acquired immunodeficiency syndrome (AIDS.,73 79 96 102,210 219 236 245,73,210,106,250,-1,RO-has_causative_agent,903835,An understanding of the biologic characteristics and cellular tropism of human immunodeficiency virus (HIV) is critical to appreciate the diverse neurologic manifestations of HIV infection in patients with the acquired immunodeficiency syndrome (AIDS,human immunodeficiency virus (HIV,acquired immunodeficiency syndrome (AIDS
503545418,7/16/2014 20:39:55,,1324466233,7/16/2014 20:39:40,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,73,210,,,106,250,HUMAN IMMUNODEFICIENCY VIRUS (HIV,ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS,HUMAN IMMUNODEFICIENCY VIRUS (HIV),73-79-96-102,210-219-236-245,ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS.,An understanding of the biologic characteristics and cellular tropism of human immunodeficiency virus (HIV) is critical to appreciate the diverse neurologic manifestations of HIV infection in patients with the acquired immunodeficiency syndrome (AIDS.,73 79 96 102,210 219 236 245,73,210,106,250,-1,RO-has_causative_agent,903835,An understanding of the biologic characteristics and cellular tropism of human immunodeficiency virus (HIV) is critical to appreciate the diverse neurologic manifestations of HIV infection in patients with the acquired immunodeficiency syndrome (AIDS,human immunodeficiency virus (HIV,acquired immunodeficiency syndrome (AIDS
503545418,7/16/2014 20:42:28,,1324467231,7/16/2014 20:41:56,prodege,1.0,9997387,USA,CO,Colorado Springs,75.70.112.31,73,210,,,106,250,HUMAN IMMUNODEFICIENCY VIRUS (HIV,ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS,HUMAN IMMUNODEFICIENCY VIRUS (HIV) HIV,73-79-96-102-175,210-219-236-245,ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS.,An understanding of the biologic characteristics and cellular tropism of human immunodeficiency virus (HIV) is critical to appreciate the diverse neurologic manifestations of HIV infection in patients with the acquired immunodeficiency syndrome (AIDS.,73 79 96 102,210 219 236 245,73,210,106,250,-1,RO-has_causative_agent,903835,An understanding of the biologic characteristics and cellular tropism of human immunodeficiency virus (HIV) is critical to appreciate the diverse neurologic manifestations of HIV infection in patients with the acquired immunodeficiency syndrome (AIDS,human immunodeficiency virus (HIV,acquired immunodeficiency syndrome (AIDS
503545418,7/16/2014 20:43:06,,1324467452,7/16/2014 20:42:25,eup_slw,1.0,28011002,CAN,MB,Winnipeg,24.77.44.140,73,210,,,106,250,HUMAN IMMUNODEFICIENCY VIRUS (HIV,ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS,HUMAN IMMUNODEFICIENCY VIRUS (HIV) immunodeficiency syndrome (AIDS.,73-79-96-102-219-236-245,79-96-210-219-236-245-102,immunodeficiency virus (HIV) ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS.,An understanding of the biologic characteristics and cellular tropism of human immunodeficiency virus (HIV) is critical to appreciate the diverse neurologic manifestations of HIV infection in patients with the acquired immunodeficiency syndrome (AIDS.,73 79 96 102,210 219 236 245,73,210,106,250,-1,RO-has_causative_agent,903835,An understanding of the biologic characteristics and cellular tropism of human immunodeficiency virus (HIV) is critical to appreciate the diverse neurologic manifestations of HIV infection in patients with the acquired immunodeficiency syndrome (AIDS,human immunodeficiency virus (HIV,acquired immunodeficiency syndrome (AIDS
503545418,7/16/2014 20:46:24,,1324468767,7/16/2014 20:46:19,prodege,1.0,26325260,GBR,"","",79.64.25.64,73,210,,,106,250,HUMAN IMMUNODEFICIENCY VIRUS (HIV,ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS,cellular tropism of HUMAN IMMUNODEFICIENCY VIRUS (HIV) is critical to,53-62-70-73-79-96-102-108-111-120,192-201-206-210-219-236-245,patients with the ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS.,An understanding of the biologic characteristics and cellular tropism of human immunodeficiency virus (HIV) is critical to appreciate the diverse neurologic manifestations of HIV infection in patients with the acquired immunodeficiency syndrome (AIDS.,73 79 96 102,210 219 236 245,73,210,106,250,-1,RO-has_causative_agent,903835,An understanding of the biologic characteristics and cellular tropism of human immunodeficiency virus (HIV) is critical to appreciate the diverse neurologic manifestations of HIV infection in patients with the acquired immunodeficiency syndrome (AIDS,human immunodeficiency virus (HIV,acquired immunodeficiency syndrome (AIDS
503545418,7/16/2014 20:47:17,,1324469153,7/16/2014 20:47:02,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,73,210,,,106,250,HUMAN IMMUNODEFICIENCY VIRUS (HIV,ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS,HUMAN IMMUNODEFICIENCY VIRUS (HIV),73-79-96-102,210-219-236-245,ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS.,An understanding of the biologic characteristics and cellular tropism of human immunodeficiency virus (HIV) is critical to appreciate the diverse neurologic manifestations of HIV infection in patients with the acquired immunodeficiency syndrome (AIDS.,73 79 96 102,210 219 236 245,73,210,106,250,-1,RO-has_causative_agent,903835,An understanding of the biologic characteristics and cellular tropism of human immunodeficiency virus (HIV) is critical to appreciate the diverse neurologic manifestations of HIV infection in patients with the acquired immunodeficiency syndrome (AIDS,human immunodeficiency virus (HIV,acquired immunodeficiency syndrome (AIDS
503545418,7/16/2014 20:48:55,,1324469975,7/16/2014 20:48:31,prodege,1.0,22360212,GBR,I1,Luton,82.6.41.191,73,210,,,106,250,HUMAN IMMUNODEFICIENCY VIRUS (HIV,ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS,HUMAN IMMUNODEFICIENCY VIRUS (HIV),73-79-96-102,210-219-236-245,ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS.,An understanding of the biologic characteristics and cellular tropism of human immunodeficiency virus (HIV) is critical to appreciate the diverse neurologic manifestations of HIV infection in patients with the acquired immunodeficiency syndrome (AIDS.,73 79 96 102,210 219 236 245,73,210,106,250,-1,RO-has_causative_agent,903835,An understanding of the biologic characteristics and cellular tropism of human immunodeficiency virus (HIV) is critical to appreciate the diverse neurologic manifestations of HIV infection in patients with the acquired immunodeficiency syndrome (AIDS,human immunodeficiency virus (HIV,acquired immunodeficiency syndrome (AIDS
503545418,7/16/2014 20:50:52,,1324470739,7/16/2014 20:50:32,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,73,210,,,106,250,HUMAN IMMUNODEFICIENCY VIRUS (HIV,ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS,HUMAN IMMUNODEFICIENCY VIRUS (HIV),73-79-96-102,210-219-236-245,ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS.,An understanding of the biologic characteristics and cellular tropism of human immunodeficiency virus (HIV) is critical to appreciate the diverse neurologic manifestations of HIV infection in patients with the acquired immunodeficiency syndrome (AIDS.,73 79 96 102,210 219 236 245,73,210,106,250,-1,RO-has_causative_agent,903835,An understanding of the biologic characteristics and cellular tropism of human immunodeficiency virus (HIV) is critical to appreciate the diverse neurologic manifestations of HIV infection in patients with the acquired immunodeficiency syndrome (AIDS,human immunodeficiency virus (HIV,acquired immunodeficiency syndrome (AIDS
503545419,7/16/2014 20:37:11,,1324465118,7/16/2014 20:36:36,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,83,17,,,92,22,NON-LUPUS,LUPUS,NON LUPUS,83-87,17,LUPUS,We conclude that lupus transplant recipients have outcomes generally equivalent to non-lupus transplant recipients.,83 87,17,83,17,92,22,-1,RO-has_manifestation,906376,We conclude that lupus transplant recipients have outcomes generally equivalent to non-lupus transplant recipients,non-lupus,lupus
503545419,7/16/2014 20:41:06,,1324466710,7/16/2014 20:40:47,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,83,17,,,92,22,NON-LUPUS,LUPUS,NON LUPUS,83-87,17,LUPUS,We conclude that lupus transplant recipients have outcomes generally equivalent to non-lupus transplant recipients.,83 87,17,83,17,92,22,-1,RO-has_manifestation,906376,We conclude that lupus transplant recipients have outcomes generally equivalent to non-lupus transplant recipients,non-lupus,lupus
503545419,7/16/2014 20:42:29,,1324467236,7/16/2014 20:42:10,instagc,1.0,13763729,USA,"","",75.182.89.225,83,17,,,92,22,NON-LUPUS,LUPUS,NON LUPUS transplant recipients.,83-87-93-104,17-23-34,LUPUS transplant recipients,We conclude that lupus transplant recipients have outcomes generally equivalent to non-lupus transplant recipients.,83 87,17,83,17,92,22,-1,RO-has_manifestation,906376,We conclude that lupus transplant recipients have outcomes generally equivalent to non-lupus transplant recipients,non-lupus,lupus
503545419,7/16/2014 20:43:00,,1324467415,7/16/2014 20:41:42,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,83,17,,,92,22,NON-LUPUS,LUPUS,NON LUPUS,83-87,17,LUPUS,We conclude that lupus transplant recipients have outcomes generally equivalent to non-lupus transplant recipients.,83 87,17,83,17,92,22,-1,RO-has_manifestation,906376,We conclude that lupus transplant recipients have outcomes generally equivalent to non-lupus transplant recipients,non-lupus,lupus
503545419,7/16/2014 20:45:06,,1324468177,7/16/2014 20:44:52,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,83,17,,,92,22,NON-LUPUS,LUPUS,NON LUPUS transplant recipients.,83-87-93-104,17-23-34,LUPUS transplant recipients,We conclude that lupus transplant recipients have outcomes generally equivalent to non-lupus transplant recipients.,83 87,17,83,17,92,22,-1,RO-has_manifestation,906376,We conclude that lupus transplant recipients have outcomes generally equivalent to non-lupus transplant recipients,non-lupus,lupus
503545419,7/16/2014 20:45:50,,1324468496,7/16/2014 20:45:34,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,83,17,,,92,22,NON-LUPUS,LUPUS,NON LUPUS,83-87,17,LUPUS,We conclude that lupus transplant recipients have outcomes generally equivalent to non-lupus transplant recipients.,83 87,17,83,17,92,22,-1,RO-has_manifestation,906376,We conclude that lupus transplant recipients have outcomes generally equivalent to non-lupus transplant recipients,non-lupus,lupus
503545419,7/16/2014 20:46:00,,1324468535,7/16/2014 20:45:56,prodege,1.0,26325260,GBR,"","",79.64.25.64,83,17,,,92,22,NON-LUPUS,LUPUS,generally equivalent to NON LUPUS transplant recipients.,59-69-80-83-87-93-104,0-3-12-17-23-34-45,We conclude that LUPUS transplant recipients have,We conclude that lupus transplant recipients have outcomes generally equivalent to non-lupus transplant recipients.,83 87,17,83,17,92,22,-1,RO-has_manifestation,906376,We conclude that lupus transplant recipients have outcomes generally equivalent to non-lupus transplant recipients,non-lupus,lupus
503545419,7/16/2014 20:50:54,,1324470747,7/16/2014 20:50:35,eup_slw,1.0,28011002,CAN,MB,Winnipeg,24.77.44.140,83,17,,,92,22,NON-LUPUS,LUPUS,NON LUPUS,83-87,17,LUPUS,We conclude that lupus transplant recipients have outcomes generally equivalent to non-lupus transplant recipients.,83 87,17,83,17,92,22,-1,RO-has_manifestation,906376,We conclude that lupus transplant recipients have outcomes generally equivalent to non-lupus transplant recipients,non-lupus,lupus
503545419,7/16/2014 20:51:34,,1324471031,7/16/2014 20:50:54,prodege,1.0,9997387,USA,CO,Colorado Springs,75.70.112.31,83,17,,,92,22,NON-LUPUS,LUPUS,NON LUPUS transplant,83-87-93,17-23,LUPUS transplant,We conclude that lupus transplant recipients have outcomes generally equivalent to non-lupus transplant recipients.,83 87,17,83,17,92,22,-1,RO-has_manifestation,906376,We conclude that lupus transplant recipients have outcomes generally equivalent to non-lupus transplant recipients,non-lupus,lupus
503545419,7/16/2014 20:52:05,,1324471204,7/16/2014 20:51:49,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,83,17,,,92,22,NON-LUPUS,LUPUS,NON LUPUS transplant recipients.,83-87-93-104,17-23-34,LUPUS transplant recipients,We conclude that lupus transplant recipients have outcomes generally equivalent to non-lupus transplant recipients.,83 87,17,83,17,92,22,-1,RO-has_manifestation,906376,We conclude that lupus transplant recipients have outcomes generally equivalent to non-lupus transplant recipients,non-lupus,lupus
503545420,7/16/2014 20:35:41,,1324464469,7/16/2014 20:35:31,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,236,153,,,254,174,AMYLOID DEPOSITION,SECONDARY AMYLOIDOSIS,transthyretin AMYLOID DEPOSITION.,222-236-244,141-149-153-163,primary and SECONDARY AMYLOIDOSIS,"Marked, widespread enlargement of the thyroid gland with amyloid deposits or amyloid goiter is a rare condition reported in association with primary and secondary amyloidosis but has not been described in association with transthyretin amyloid deposition.",236 244,153 163,236,153,254,174,-1,RO-disease_has_finding,901669,"Marked, widespread enlargement of the thyroid gland with amyloid deposits or amyloid goiter is a rare condition reported in association with primary and secondary amyloidosis but has not been described in association with transthyretin amyloid deposition",amyloid deposition,secondary amyloidosis
503545420,7/16/2014 20:38:41,,1324465674,7/16/2014 20:38:26,clixsense,1.0,24896327,GBR,V2,Glasgow,94.2.231.4,236,153,,,254,174,AMYLOID DEPOSITION,SECONDARY AMYLOIDOSIS,transthyretin AMYLOID DEPOSITION.,222-236-244,141-149-153-163,primary and SECONDARY AMYLOIDOSIS,"Marked, widespread enlargement of the thyroid gland with amyloid deposits or amyloid goiter is a rare condition reported in association with primary and secondary amyloidosis but has not been described in association with transthyretin amyloid deposition.",236 244,153 163,236,153,254,174,-1,RO-disease_has_finding,901669,"Marked, widespread enlargement of the thyroid gland with amyloid deposits or amyloid goiter is a rare condition reported in association with primary and secondary amyloidosis but has not been described in association with transthyretin amyloid deposition",amyloid deposition,secondary amyloidosis
503545420,7/16/2014 20:41:09,,1324466763,7/16/2014 20:41:07,coinworker,1.0,28394550,USA,PA,Marcus Hook,71.175.96.184,236,153,,,254,174,AMYLOID DEPOSITION,SECONDARY AMYLOIDOSIS,association with transthyretin AMYLOID DEPOSITION.,205-217-222-236-244,136-141-149-153-163-175-179-183,with primary and SECONDARY AMYLOIDOSIS but has not,"Marked, widespread enlargement of the thyroid gland with amyloid deposits or amyloid goiter is a rare condition reported in association with primary and secondary amyloidosis but has not been described in association with transthyretin amyloid deposition.",236 244,153 163,236,153,254,174,-1,RO-disease_has_finding,901669,"Marked, widespread enlargement of the thyroid gland with amyloid deposits or amyloid goiter is a rare condition reported in association with primary and secondary amyloidosis but has not been described in association with transthyretin amyloid deposition",amyloid deposition,secondary amyloidosis
503545420,7/16/2014 20:43:46,,1324467692,7/16/2014 20:43:43,bitcoinget,1.0,24792414,USA,"","",166.181.81.55,236,153,,,254,174,AMYLOID DEPOSITION,SECONDARY AMYLOIDOSIS,association with transthyretin AMYLOID DEPOSITION.,205-217-222-236-244,136-141-149-153-163-175-179-183,with primary and SECONDARY AMYLOIDOSIS but has not,"Marked, widespread enlargement of the thyroid gland with amyloid deposits or amyloid goiter is a rare condition reported in association with primary and secondary amyloidosis but has not been described in association with transthyretin amyloid deposition.",236 244,153 163,236,153,254,174,-1,RO-disease_has_finding,901669,"Marked, widespread enlargement of the thyroid gland with amyloid deposits or amyloid goiter is a rare condition reported in association with primary and secondary amyloidosis but has not been described in association with transthyretin amyloid deposition",amyloid deposition,secondary amyloidosis
503545420,7/16/2014 20:43:55,,1324467727,7/16/2014 20:43:36,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,236,153,,,254,174,AMYLOID DEPOSITION,SECONDARY AMYLOIDOSIS,AMYLOID DEPOSITION.,236-244,153-163,SECONDARY AMYLOIDOSIS,"Marked, widespread enlargement of the thyroid gland with amyloid deposits or amyloid goiter is a rare condition reported in association with primary and secondary amyloidosis but has not been described in association with transthyretin amyloid deposition.",236 244,153 163,236,153,254,174,-1,RO-disease_has_finding,901669,"Marked, widespread enlargement of the thyroid gland with amyloid deposits or amyloid goiter is a rare condition reported in association with primary and secondary amyloidosis but has not been described in association with transthyretin amyloid deposition",amyloid deposition,secondary amyloidosis
503545420,7/16/2014 20:43:59,,1324467741,7/16/2014 20:43:06,eup_slw,1.0,28011002,CAN,MB,Winnipeg,24.77.44.140,236,153,,,254,174,AMYLOID DEPOSITION,SECONDARY AMYLOIDOSIS,amyloidosis AMYLOID DEPOSITION.,236-244-163,153-163-222-236,SECONDARY AMYLOIDOSIS transthyretin amyloid,"Marked, widespread enlargement of the thyroid gland with amyloid deposits or amyloid goiter is a rare condition reported in association with primary and secondary amyloidosis but has not been described in association with transthyretin amyloid deposition.",236 244,153 163,236,153,254,174,-1,RO-disease_has_finding,901669,"Marked, widespread enlargement of the thyroid gland with amyloid deposits or amyloid goiter is a rare condition reported in association with primary and secondary amyloidosis but has not been described in association with transthyretin amyloid deposition",amyloid deposition,secondary amyloidosis
503545420,7/16/2014 20:44:45,,1324468059,7/16/2014 20:44:38,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,236,153,,,254,174,AMYLOID DEPOSITION,SECONDARY AMYLOIDOSIS,association with transthyretin AMYLOID DEPOSITION.,205-217-222-236-244,136-141-149-153-163-175-179-183,with primary and SECONDARY AMYLOIDOSIS but has not,"Marked, widespread enlargement of the thyroid gland with amyloid deposits or amyloid goiter is a rare condition reported in association with primary and secondary amyloidosis but has not been described in association with transthyretin amyloid deposition.",236 244,153 163,236,153,254,174,-1,RO-disease_has_finding,901669,"Marked, widespread enlargement of the thyroid gland with amyloid deposits or amyloid goiter is a rare condition reported in association with primary and secondary amyloidosis but has not been described in association with transthyretin amyloid deposition",amyloid deposition,secondary amyloidosis
503545420,7/16/2014 20:45:24,,1324468299,7/16/2014 20:45:00,prodege,1.0,22360212,GBR,I1,Luton,82.6.41.191,236,153,,,254,174,AMYLOID DEPOSITION,SECONDARY AMYLOIDOSIS,transthyretin AMYLOID DEPOSITION.,222-236-244,153-163,SECONDARY AMYLOIDOSIS,"Marked, widespread enlargement of the thyroid gland with amyloid deposits or amyloid goiter is a rare condition reported in association with primary and secondary amyloidosis but has not been described in association with transthyretin amyloid deposition.",236 244,153 163,236,153,254,174,-1,RO-disease_has_finding,901669,"Marked, widespread enlargement of the thyroid gland with amyloid deposits or amyloid goiter is a rare condition reported in association with primary and secondary amyloidosis but has not been described in association with transthyretin amyloid deposition",amyloid deposition,secondary amyloidosis
503545420,7/16/2014 20:46:18,,1324468719,7/16/2014 20:46:09,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,236,153,,,254,174,AMYLOID DEPOSITION,SECONDARY AMYLOIDOSIS,AMYLOID DEPOSITION.,236-244,153-163,SECONDARY AMYLOIDOSIS,"Marked, widespread enlargement of the thyroid gland with amyloid deposits or amyloid goiter is a rare condition reported in association with primary and secondary amyloidosis but has not been described in association with transthyretin amyloid deposition.",236 244,153 163,236,153,254,174,-1,RO-disease_has_finding,901669,"Marked, widespread enlargement of the thyroid gland with amyloid deposits or amyloid goiter is a rare condition reported in association with primary and secondary amyloidosis but has not been described in association with transthyretin amyloid deposition",amyloid deposition,secondary amyloidosis
503545420,7/16/2014 20:47:40,,1324469348,7/16/2014 20:47:27,instagc,1.0,13763729,USA,"","",75.182.89.225,236,153,,,254,174,AMYLOID DEPOSITION,SECONDARY AMYLOIDOSIS,transthyretin AMYLOID DEPOSITION.,222-236-244,153-163,SECONDARY AMYLOIDOSIS,"Marked, widespread enlargement of the thyroid gland with amyloid deposits or amyloid goiter is a rare condition reported in association with primary and secondary amyloidosis but has not been described in association with transthyretin amyloid deposition.",236 244,153 163,236,153,254,174,-1,RO-disease_has_finding,901669,"Marked, widespread enlargement of the thyroid gland with amyloid deposits or amyloid goiter is a rare condition reported in association with primary and secondary amyloidosis but has not been described in association with transthyretin amyloid deposition",amyloid deposition,secondary amyloidosis
503545421,7/16/2014 20:35:17,,1324464283,7/16/2014 20:34:47,clixsense,1.0,24896327,GBR,V2,Glasgow,94.2.231.4,93,7,,,118,14,HYPERSENSITIVITY REACTION,ALLERGY,HYPERSENSITIVITY REACTION,93-110,7,ALLERGY,SEE:   allergy ;  anaphylaxis  ETIOLOGY: The condition is the result of a type I allergic or hypersensitivity reaction during which the allergen is absorbed into the blood directly or through the mucosa.,93 110,7,93,7,118,14,-1,RO-cause_of,900292,SEE:   allergy ;  anaphylaxis  ETIOLOGY: The condition is the result of a type I allergic or hypersensitivity reaction during which the allergen is absorbed into the blood directly or through the mucosa,hypersensitivity reaction,allergy
503545421,7/16/2014 20:39:15,,1324465956,7/16/2014 20:39:00,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,93,7,,,118,14,HYPERSENSITIVITY REACTION,ALLERGY,HYPERSENSITIVITY REACTION,93-110,7,ALLERGY,SEE:   allergy ;  anaphylaxis  ETIOLOGY: The condition is the result of a type I allergic or hypersensitivity reaction during which the allergen is absorbed into the blood directly or through the mucosa.,93 110,7,93,7,118,14,-1,RO-cause_of,900292,SEE:   allergy ;  anaphylaxis  ETIOLOGY: The condition is the result of a type I allergic or hypersensitivity reaction during which the allergen is absorbed into the blood directly or through the mucosa,hypersensitivity reaction,allergy
503545421,7/16/2014 20:41:07,,1324466725,7/16/2014 20:40:54,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,93,7,,,118,14,HYPERSENSITIVITY REACTION,ALLERGY,HYPERSENSITIVITY REACTION,93-110,7,ALLERGY,SEE:   allergy ;  anaphylaxis  ETIOLOGY: The condition is the result of a type I allergic or hypersensitivity reaction during which the allergen is absorbed into the blood directly or through the mucosa.,93 110,7,93,7,118,14,-1,RO-cause_of,900292,SEE:   allergy ;  anaphylaxis  ETIOLOGY: The condition is the result of a type I allergic or hypersensitivity reaction during which the allergen is absorbed into the blood directly or through the mucosa,hypersensitivity reaction,allergy
503545421,7/16/2014 20:41:57,,1324467065,7/16/2014 20:41:54,coinworker,1.0,28394550,USA,PA,Marcus Hook,71.175.96.184,93,7,,,118,14,HYPERSENSITIVITY REACTION,ALLERGY,I allergic or HYPERSENSITIVITY REACTION during which the,79-81-90-93-110-119-126-132,0-7-18-31-41,SEE: ALLERGY anaphylaxis ETIOLOGY: The,SEE:   allergy ;  anaphylaxis  ETIOLOGY: The condition is the result of a type I allergic or hypersensitivity reaction during which the allergen is absorbed into the blood directly or through the mucosa.,93 110,7,93,7,118,14,-1,RO-cause_of,900292,SEE:   allergy ;  anaphylaxis  ETIOLOGY: The condition is the result of a type I allergic or hypersensitivity reaction during which the allergen is absorbed into the blood directly or through the mucosa,hypersensitivity reaction,allergy
503545421,7/16/2014 20:46:06,,1324468617,7/16/2014 20:45:43,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,93,7,,,118,14,HYPERSENSITIVITY REACTION,ALLERGY,HYPERSENSITIVITY REACTION,93-110,7,ALLERGY,SEE:   allergy ;  anaphylaxis  ETIOLOGY: The condition is the result of a type I allergic or hypersensitivity reaction during which the allergen is absorbed into the blood directly or through the mucosa.,93 110,7,93,7,118,14,-1,RO-cause_of,900292,SEE:   allergy ;  anaphylaxis  ETIOLOGY: The condition is the result of a type I allergic or hypersensitivity reaction during which the allergen is absorbed into the blood directly or through the mucosa,hypersensitivity reaction,allergy
503545421,7/16/2014 20:46:27,,1324468781,7/16/2014 20:46:10,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,93,7,,,118,14,HYPERSENSITIVITY REACTION,ALLERGY,HYPERSENSITIVITY REACTION,93-110,7,ALLERGY,SEE:   allergy ;  anaphylaxis  ETIOLOGY: The condition is the result of a type I allergic or hypersensitivity reaction during which the allergen is absorbed into the blood directly or through the mucosa.,93 110,7,93,7,118,14,-1,RO-cause_of,900292,SEE:   allergy ;  anaphylaxis  ETIOLOGY: The condition is the result of a type I allergic or hypersensitivity reaction during which the allergen is absorbed into the blood directly or through the mucosa,hypersensitivity reaction,allergy
503545421,7/16/2014 20:47:19,,1324469172,7/16/2014 20:47:10,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,93,7,,,118,14,HYPERSENSITIVITY REACTION,ALLERGY,I allergic or HYPERSENSITIVITY REACTION during which the,79-81-90-93-110-119-126-132,0-7-18-31-41,SEE: ALLERGY anaphylaxis ETIOLOGY: The,SEE:   allergy ;  anaphylaxis  ETIOLOGY: The condition is the result of a type I allergic or hypersensitivity reaction during which the allergen is absorbed into the blood directly or through the mucosa.,93 110,7,93,7,118,14,-1,RO-cause_of,900292,SEE:   allergy ;  anaphylaxis  ETIOLOGY: The condition is the result of a type I allergic or hypersensitivity reaction during which the allergen is absorbed into the blood directly or through the mucosa,hypersensitivity reaction,allergy
503545421,7/16/2014 20:49:37,,1324470263,7/16/2014 20:49:13,prodege,1.0,9997387,USA,CO,Colorado Springs,75.70.112.31,93,7,,,118,14,HYPERSENSITIVITY REACTION,ALLERGY,type I allergic HYPERSENSITIVITY REACTION,74-79-81-93-110,7-18-31,ALLERGY anaphylaxis ETIOLOGY:,SEE:   allergy ;  anaphylaxis  ETIOLOGY: The condition is the result of a type I allergic or hypersensitivity reaction during which the allergen is absorbed into the blood directly or through the mucosa.,93 110,7,93,7,118,14,-1,RO-cause_of,900292,SEE:   allergy ;  anaphylaxis  ETIOLOGY: The condition is the result of a type I allergic or hypersensitivity reaction during which the allergen is absorbed into the blood directly or through the mucosa,hypersensitivity reaction,allergy
503545421,7/16/2014 20:51:33,,1324471033,7/16/2014 20:50:55,eup_slw,1.0,28011002,CAN,MB,Winnipeg,24.77.44.140,93,7,,,118,14,HYPERSENSITIVITY REACTION,ALLERGY,HYPERSENSITIVITY REACTION,93-110,0-7-18-31,SEE: ALLERGY anaphylaxis ETIOLOGY:,SEE:   allergy ;  anaphylaxis  ETIOLOGY: The condition is the result of a type I allergic or hypersensitivity reaction during which the allergen is absorbed into the blood directly or through the mucosa.,93 110,7,93,7,118,14,-1,RO-cause_of,900292,SEE:   allergy ;  anaphylaxis  ETIOLOGY: The condition is the result of a type I allergic or hypersensitivity reaction during which the allergen is absorbed into the blood directly or through the mucosa,hypersensitivity reaction,allergy
503545421,7/16/2014 20:52:52,,1324471585,7/16/2014 20:52:34,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,93,7,,,118,14,HYPERSENSITIVITY REACTION,ALLERGY,HYPERSENSITIVITY REACTION,93-110,7,ALLERGY,SEE:   allergy ;  anaphylaxis  ETIOLOGY: The condition is the result of a type I allergic or hypersensitivity reaction during which the allergen is absorbed into the blood directly or through the mucosa.,93 110,7,93,7,118,14,-1,RO-cause_of,900292,SEE:   allergy ;  anaphylaxis  ETIOLOGY: The condition is the result of a type I allergic or hypersensitivity reaction during which the allergen is absorbed into the blood directly or through the mucosa,hypersensitivity reaction,allergy
503545422,7/16/2014 20:38:45,,1324465702,7/16/2014 20:38:18,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,102,133,,,131,137,CONGENITAL MUSCULAR DYSTROPHY,FCMD,CONGENITAL MUSCULAR DYSTROPHY,102-113-122,102-113-122,congenital muscular dystrophy,"This study included 15 patients with Duchenne muscular dystrophy (DMD), 8 patients with Fukuyama type congenital muscular dystrophy (FCMD) and 2 sisters with non-Fukuyama type congenital muscular dystrophy (nFCMD.",102 113 122,,102,133,131,137,-1,RO-has_manifestation,906216,"This study included 15 patients with Duchenne muscular dystrophy (DMD), 8 patients with Fukuyama type congenital muscular dystrophy (FCMD) and 2 sisters with non-Fukuyama type congenital muscular dystrophy (nFCMD",congenital muscular dystrophy,FCMD
503545422,7/16/2014 20:42:32,,1324467257,7/16/2014 20:42:11,bitcoinget,1.0,24792414,USA,"","",166.181.81.55,102,133,,,131,137,CONGENITAL MUSCULAR DYSTROPHY,FCMD,Fukuyama type CONGENITAL MUSCULAR DYSTROPHY,88-97-102-113-122,88-97-102-113-122,Fukuyama type congenital muscular dystrophy,"This study included 15 patients with Duchenne muscular dystrophy (DMD), 8 patients with Fukuyama type congenital muscular dystrophy (FCMD) and 2 sisters with non-Fukuyama type congenital muscular dystrophy (nFCMD.",102 113 122,,102,133,131,137,-1,RO-has_manifestation,906216,"This study included 15 patients with Duchenne muscular dystrophy (DMD), 8 patients with Fukuyama type congenital muscular dystrophy (FCMD) and 2 sisters with non-Fukuyama type congenital muscular dystrophy (nFCMD",congenital muscular dystrophy,FCMD
503545422,7/16/2014 20:44:06,,1324467794,7/16/2014 20:43:25,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,102,133,,,131,137,CONGENITAL MUSCULAR DYSTROPHY,FCMD,CONGENITAL MUSCULAR DYSTROPHY,102-113-122,88-97-102-113-122-132,Fukuyama type congenital muscular dystrophy (FCMD),"This study included 15 patients with Duchenne muscular dystrophy (DMD), 8 patients with Fukuyama type congenital muscular dystrophy (FCMD) and 2 sisters with non-Fukuyama type congenital muscular dystrophy (nFCMD.",102 113 122,,102,133,131,137,-1,RO-has_manifestation,906216,"This study included 15 patients with Duchenne muscular dystrophy (DMD), 8 patients with Fukuyama type congenital muscular dystrophy (FCMD) and 2 sisters with non-Fukuyama type congenital muscular dystrophy (nFCMD",congenital muscular dystrophy,FCMD
503545422,7/16/2014 20:45:18,,1324468266,7/16/2014 20:45:09,prodege,1.0,26325260,GBR,"","",79.64.25.64,102,133,,,131,137,CONGENITAL MUSCULAR DYSTROPHY,FCMD,with Fukuyama type CONGENITAL MUSCULAR DYSTROPHY and 2,83-88-97-102-113-122-139-143,113-122-132-139-143-145,muscular dystrophy (FCMD) and 2 sisters,"This study included 15 patients with Duchenne muscular dystrophy (DMD), 8 patients with Fukuyama type congenital muscular dystrophy (FCMD) and 2 sisters with non-Fukuyama type congenital muscular dystrophy (nFCMD.",102 113 122,,102,133,131,137,-1,RO-has_manifestation,906216,"This study included 15 patients with Duchenne muscular dystrophy (DMD), 8 patients with Fukuyama type congenital muscular dystrophy (FCMD) and 2 sisters with non-Fukuyama type congenital muscular dystrophy (nFCMD",congenital muscular dystrophy,FCMD
503545422,7/16/2014 20:46:08,,1324468646,7/16/2014 20:45:58,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,102,133,,,131,137,CONGENITAL MUSCULAR DYSTROPHY,FCMD,CONGENITAL MUSCULAR DYSTROPHY,102-113-122,132,(FCMD),"This study included 15 patients with Duchenne muscular dystrophy (DMD), 8 patients with Fukuyama type congenital muscular dystrophy (FCMD) and 2 sisters with non-Fukuyama type congenital muscular dystrophy (nFCMD.",102 113 122,,102,133,131,137,-1,RO-has_manifestation,906216,"This study included 15 patients with Duchenne muscular dystrophy (DMD), 8 patients with Fukuyama type congenital muscular dystrophy (FCMD) and 2 sisters with non-Fukuyama type congenital muscular dystrophy (nFCMD",congenital muscular dystrophy,FCMD
503545422,7/16/2014 20:46:51,,1324468965,7/16/2014 20:46:36,instagc,1.0,13763729,USA,"","",75.182.89.225,102,133,,,131,137,CONGENITAL MUSCULAR DYSTROPHY,FCMD,CONGENITAL MUSCULAR DYSTROPHY,102-113-122,132,(FCMD),"This study included 15 patients with Duchenne muscular dystrophy (DMD), 8 patients with Fukuyama type congenital muscular dystrophy (FCMD) and 2 sisters with non-Fukuyama type congenital muscular dystrophy (nFCMD.",102 113 122,,102,133,131,137,-1,RO-has_manifestation,906216,"This study included 15 patients with Duchenne muscular dystrophy (DMD), 8 patients with Fukuyama type congenital muscular dystrophy (FCMD) and 2 sisters with non-Fukuyama type congenital muscular dystrophy (nFCMD",congenital muscular dystrophy,FCMD
503545422,7/16/2014 20:47:54,,1324469453,7/16/2014 20:47:37,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,102,133,,,131,137,CONGENITAL MUSCULAR DYSTROPHY,FCMD,Fukuyama type CONGENITAL MUSCULAR DYSTROPHY (FCMD),88-97-102-113-122-132,88-97-102-113-122-132,Fukuyama type congenital muscular dystrophy (FCMD),"This study included 15 patients with Duchenne muscular dystrophy (DMD), 8 patients with Fukuyama type congenital muscular dystrophy (FCMD) and 2 sisters with non-Fukuyama type congenital muscular dystrophy (nFCMD.",102 113 122,,102,133,131,137,-1,RO-has_manifestation,906216,"This study included 15 patients with Duchenne muscular dystrophy (DMD), 8 patients with Fukuyama type congenital muscular dystrophy (FCMD) and 2 sisters with non-Fukuyama type congenital muscular dystrophy (nFCMD",congenital muscular dystrophy,FCMD
503545422,7/16/2014 20:49:33,,1324470232,7/16/2014 20:48:56,prodege,1.0,22360212,GBR,I1,Luton,82.6.41.191,102,133,,,131,137,CONGENITAL MUSCULAR DYSTROPHY,FCMD,CONGENITAL MUSCULAR DYSTROPHY (FCMD),102-113-122-132,113-122-132-102,congenital muscular dystrophy (FCMD),"This study included 15 patients with Duchenne muscular dystrophy (DMD), 8 patients with Fukuyama type congenital muscular dystrophy (FCMD) and 2 sisters with non-Fukuyama type congenital muscular dystrophy (nFCMD.",102 113 122,,102,133,131,137,-1,RO-has_manifestation,906216,"This study included 15 patients with Duchenne muscular dystrophy (DMD), 8 patients with Fukuyama type congenital muscular dystrophy (FCMD) and 2 sisters with non-Fukuyama type congenital muscular dystrophy (nFCMD",congenital muscular dystrophy,FCMD
503545422,7/16/2014 20:51:13,,1324470894,7/16/2014 20:50:58,instagc,1,24252915,GBR,B7,Bristol,77.98.139.82,102,133,,,131,137,CONGENITAL MUSCULAR DYSTROPHY,FCMD,Fukuyama type CONGENITAL MUSCULAR DYSTROPHY (FCMD) 2,88-97-102-113-122-132-143,88-97-102-113-122-132,Fukuyama type congenital muscular dystrophy (FCMD),"This study included 15 patients with Duchenne muscular dystrophy (DMD), 8 patients with Fukuyama type congenital muscular dystrophy (FCMD) and 2 sisters with non-Fukuyama type congenital muscular dystrophy (nFCMD.",102 113 122,,102,133,131,137,-1,RO-has_manifestation,906216,"This study included 15 patients with Duchenne muscular dystrophy (DMD), 8 patients with Fukuyama type congenital muscular dystrophy (FCMD) and 2 sisters with non-Fukuyama type congenital muscular dystrophy (nFCMD",congenital muscular dystrophy,FCMD
503545422,7/16/2014 20:52:04,,1324471207,7/16/2014 20:51:33,eup_slw,1.0,28011002,CAN,MB,Winnipeg,24.77.44.140,102,133,,,131,137,CONGENITAL MUSCULAR DYSTROPHY,FCMD,Fukuyama CONGENITAL MUSCULAR DYSTROPHY (FCMD),88-102-113-122-132,113-122-132,muscular dystrophy (FCMD),"This study included 15 patients with Duchenne muscular dystrophy (DMD), 8 patients with Fukuyama type congenital muscular dystrophy (FCMD) and 2 sisters with non-Fukuyama type congenital muscular dystrophy (nFCMD.",102 113 122,,102,133,131,137,-1,RO-has_manifestation,906216,"This study included 15 patients with Duchenne muscular dystrophy (DMD), 8 patients with Fukuyama type congenital muscular dystrophy (FCMD) and 2 sisters with non-Fukuyama type congenital muscular dystrophy (nFCMD",congenital muscular dystrophy,FCMD
503545423,7/16/2014 20:33:58,,1324463791,7/16/2014 20:33:35,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,41,20,,,45,28,HAIR,ALOPECIA,HAIR stem cells,41-46-51,20,ALOPECIA,Chemotherapy causes alopecia by damaging hair stem cells and hair follicles making the hair brittle and causing scalp hair to break off or fall out.,41,20,41,20,45,28,1,RO-disease_has_primary_anatomic_site,902066,Chemotherapy causes alopecia by damaging hair stem cells and hair follicles making the hair brittle and causing scalp hair to break off or fall out,hair,alopecia
503545423,7/16/2014 20:35:59,,1324464625,7/16/2014 20:35:38,clixsense,1.0,24896327,GBR,V2,Glasgow,94.2.231.4,41,20,,,45,28,HAIR,ALOPECIA,HAIR,41,20,ALOPECIA,Chemotherapy causes alopecia by damaging hair stem cells and hair follicles making the hair brittle and causing scalp hair to break off or fall out.,41,20,41,20,45,28,1,RO-disease_has_primary_anatomic_site,902066,Chemotherapy causes alopecia by damaging hair stem cells and hair follicles making the hair brittle and causing scalp hair to break off or fall out,hair,alopecia
503545423,7/16/2014 20:41:12,,1324466752,7/16/2014 20:40:55,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,41,20,,,45,28,HAIR,ALOPECIA,HAIR stem cells,41-46-51,20,ALOPECIA,Chemotherapy causes alopecia by damaging hair stem cells and hair follicles making the hair brittle and causing scalp hair to break off or fall out.,41,20,41,20,45,28,1,RO-disease_has_primary_anatomic_site,902066,Chemotherapy causes alopecia by damaging hair stem cells and hair follicles making the hair brittle and causing scalp hair to break off or fall out,hair,alopecia
503545423,7/16/2014 20:41:53,,1324467046,7/16/2014 20:41:51,coinworker,1.0,28394550,USA,PA,Marcus Hook,71.175.96.184,41,20,,,45,28,HAIR,ALOPECIA,alopecia by damaging HAIR stem cells and,20-29-32-41-46-51-57,0-13-20-29-32-41,Chemotherapy causes ALOPECIA by damaging hair,Chemotherapy causes alopecia by damaging hair stem cells and hair follicles making the hair brittle and causing scalp hair to break off or fall out.,41,20,41,20,45,28,1,RO-disease_has_primary_anatomic_site,902066,Chemotherapy causes alopecia by damaging hair stem cells and hair follicles making the hair brittle and causing scalp hair to break off or fall out,hair,alopecia
503545423,7/16/2014 20:44:23,,1324467920,7/16/2014 20:44:15,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,41,20,,,45,28,HAIR,ALOPECIA,alopecia by damaging HAIR stem cells and,20-29-32-41-46-51-57,0-13-20-29-32-41,Chemotherapy causes ALOPECIA by damaging hair,Chemotherapy causes alopecia by damaging hair stem cells and hair follicles making the hair brittle and causing scalp hair to break off or fall out.,41,20,41,20,45,28,1,RO-disease_has_primary_anatomic_site,902066,Chemotherapy causes alopecia by damaging hair stem cells and hair follicles making the hair brittle and causing scalp hair to break off or fall out,hair,alopecia
503545423,7/16/2014 20:45:40,,1324468412,7/16/2014 20:45:17,prodege,1.0,9997387,USA,CO,Colorado Springs,75.70.112.31,41,20,,,45,28,HAIR,ALOPECIA,Chemotherapy HAIR and hair,0-41-57-61,0-20,Chemotherapy ALOPECIA,Chemotherapy causes alopecia by damaging hair stem cells and hair follicles making the hair brittle and causing scalp hair to break off or fall out.,41,20,41,20,45,28,1,RO-disease_has_primary_anatomic_site,902066,Chemotherapy causes alopecia by damaging hair stem cells and hair follicles making the hair brittle and causing scalp hair to break off or fall out,hair,alopecia
503545423,7/16/2014 20:46:13,,1324468700,7/16/2014 20:46:10,prodege,1.0,26325260,GBR,"","",79.64.25.64,41,20,,,45,28,HAIR,ALOPECIA,alopecia by damaging HAIR stem cells and,20-29-32-41-46-51-57,0-13-20-29-32-41,Chemotherapy causes ALOPECIA by damaging hair,Chemotherapy causes alopecia by damaging hair stem cells and hair follicles making the hair brittle and causing scalp hair to break off or fall out.,41,20,41,20,45,28,1,RO-disease_has_primary_anatomic_site,902066,Chemotherapy causes alopecia by damaging hair stem cells and hair follicles making the hair brittle and causing scalp hair to break off or fall out,hair,alopecia
503545423,7/16/2014 20:48:34,,1324469772,7/16/2014 20:47:59,eup_slw,1.0,28011002,CAN,MB,Winnipeg,24.77.44.140,41,20,,,45,28,HAIR,ALOPECIA,HAIR follicles,41-66,20,ALOPECIA,Chemotherapy causes alopecia by damaging hair stem cells and hair follicles making the hair brittle and causing scalp hair to break off or fall out.,41,20,41,20,45,28,1,RO-disease_has_primary_anatomic_site,902066,Chemotherapy causes alopecia by damaging hair stem cells and hair follicles making the hair brittle and causing scalp hair to break off or fall out,hair,alopecia
503545423,7/16/2014 20:51:46,,1324471085,7/16/2014 20:51:34,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,41,20,,,45,28,HAIR,ALOPECIA,HAIR stem cells,41-46-51,20,ALOPECIA,Chemotherapy causes alopecia by damaging hair stem cells and hair follicles making the hair brittle and causing scalp hair to break off or fall out.,41,20,41,20,45,28,1,RO-disease_has_primary_anatomic_site,902066,Chemotherapy causes alopecia by damaging hair stem cells and hair follicles making the hair brittle and causing scalp hair to break off or fall out,hair,alopecia
503545423,7/16/2014 21:03:40,,1324476651,7/16/2014 21:02:56,prodege,1,27186457,USA,HI,Waipahu,70.95.131.43,41,20,,,45,28,HAIR,ALOPECIA,alopecia by damaging HAIR stem cells and hair follicles,20-29-32-41-46-51-57-61-66,0-13-20-29-32-41-46-51-57-61-66,Chemotherapy causes ALOPECIA by damaging hair stem cells and hair follicles,Chemotherapy causes alopecia by damaging hair stem cells and hair follicles making the hair brittle and causing scalp hair to break off or fall out.,41,20,41,20,45,28,1,RO-disease_has_primary_anatomic_site,902066,Chemotherapy causes alopecia by damaging hair stem cells and hair follicles making the hair brittle and causing scalp hair to break off or fall out,hair,alopecia
503545424,7/16/2014 20:37:04,,1324465071,7/16/2014 20:36:56,clixsense,1.0,6610277,CAN,ON,Oshawa,174.117.79.122,56,96,,,65,110,HEMATURIA,BLADDER CANCER,"HEMATURIA, which is often",56-67-73-76,76-82-91-96-104,often confused with BLADDER CANCER.,"Localized amyloidosis of the bladder is a rare cause of hematuria, which is often confused with bladder cancer.",56,96 104,56,96,65,110,-1,RO-disease_may_have_finding,902626,"Localized amyloidosis of the bladder is a rare cause of hematuria, which is often confused with bladder cancer",hematuria,bladder cancer
503545424,7/16/2014 20:41:44,,1324466997,7/16/2014 20:41:42,coinworker,1.0,28394550,USA,PA,Marcus Hook,71.175.96.184,56,96,,,65,110,HEMATURIA,BLADDER CANCER,"rare cause of HEMATURIA, which is often",42-47-53-56-67-73-76,76-82-91-96-104,often confused with BLADDER CANCER.,"Localized amyloidosis of the bladder is a rare cause of hematuria, which is often confused with bladder cancer.",56,96 104,56,96,65,110,-1,RO-disease_may_have_finding,902626,"Localized amyloidosis of the bladder is a rare cause of hematuria, which is often confused with bladder cancer",hematuria,bladder cancer
503545424,7/16/2014 20:42:10,,1324467125,7/16/2014 20:41:59,bitcoinget,1.0,24792414,USA,"","",166.181.81.55,56,96,,,65,110,HEMATURIA,BLADDER CANCER,"HEMATURIA,",56,96-104,BLADDER CANCER.,"Localized amyloidosis of the bladder is a rare cause of hematuria, which is often confused with bladder cancer.",56,96 104,56,96,65,110,-1,RO-disease_may_have_finding,902626,"Localized amyloidosis of the bladder is a rare cause of hematuria, which is often confused with bladder cancer",hematuria,bladder cancer
503545424,7/16/2014 20:44:34,,1324467982,7/16/2014 20:44:25,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,56,96,,,65,110,HEMATURIA,BLADDER CANCER,"HEMATURIA,",56,96-104,BLADDER CANCER.,"Localized amyloidosis of the bladder is a rare cause of hematuria, which is often confused with bladder cancer.",56,96 104,56,96,65,110,-1,RO-disease_may_have_finding,902626,"Localized amyloidosis of the bladder is a rare cause of hematuria, which is often confused with bladder cancer",hematuria,bladder cancer
503545424,7/16/2014 20:45:53,,1324468515,7/16/2014 20:45:41,prodege,1.0,9997387,USA,CO,Colorado Springs,75.70.112.31,56,96,,,65,110,HEMATURIA,BLADDER CANCER,"amyloidosis HEMATURIA,",10-56,96-104-56,"hematuria, BLADDER CANCER.","Localized amyloidosis of the bladder is a rare cause of hematuria, which is often confused with bladder cancer.",56,96 104,56,96,65,110,-1,RO-disease_may_have_finding,902626,"Localized amyloidosis of the bladder is a rare cause of hematuria, which is often confused with bladder cancer",hematuria,bladder cancer
503545424,7/16/2014 20:46:06,,1324468630,7/16/2014 20:45:47,prodege,1.0,22360212,GBR,I1,Luton,82.6.41.191,56,96,,,65,110,HEMATURIA,BLADDER CANCER,"HEMATURIA,",56,96-104,BLADDER CANCER.,"Localized amyloidosis of the bladder is a rare cause of hematuria, which is often confused with bladder cancer.",56,96 104,56,96,65,110,-1,RO-disease_may_have_finding,902626,"Localized amyloidosis of the bladder is a rare cause of hematuria, which is often confused with bladder cancer",hematuria,bladder cancer
503545424,7/16/2014 20:46:18,,1324468709,7/16/2014 20:46:15,prodege,1.0,26325260,GBR,"","",79.64.25.64,56,96,,,65,110,HEMATURIA,BLADDER CANCER,"rare cause of HEMATURIA, which is often",42-47-53-56-67-73-76,76-82-91-96-104,often confused with BLADDER CANCER.,"Localized amyloidosis of the bladder is a rare cause of hematuria, which is often confused with bladder cancer.",56,96 104,56,96,65,110,-1,RO-disease_may_have_finding,902626,"Localized amyloidosis of the bladder is a rare cause of hematuria, which is often confused with bladder cancer",hematuria,bladder cancer
503545424,7/16/2014 20:47:00,,1324469045,7/16/2014 20:45:38,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,56,96,,,65,110,HEMATURIA,BLADDER CANCER,"HEMATURIA,",56,96-104,BLADDER CANCER.,"Localized amyloidosis of the bladder is a rare cause of hematuria, which is often confused with bladder cancer.",56,96 104,56,96,65,110,-1,RO-disease_may_have_finding,902626,"Localized amyloidosis of the bladder is a rare cause of hematuria, which is often confused with bladder cancer",hematuria,bladder cancer
503545424,7/16/2014 20:48:24,,1324469701,7/16/2014 20:48:16,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,56,96,,,65,110,HEMATURIA,BLADDER CANCER,"rare cause of HEMATURIA, which is often",42-47-53-56-67-73-76,76-82-91-96-104,often confused with BLADDER CANCER.,"Localized amyloidosis of the bladder is a rare cause of hematuria, which is often confused with bladder cancer.",56,96 104,56,96,65,110,-1,RO-disease_may_have_finding,902626,"Localized amyloidosis of the bladder is a rare cause of hematuria, which is often confused with bladder cancer",hematuria,bladder cancer
503545424,7/16/2014 20:50:35,,1324470610,7/16/2014 20:50:06,eup_slw,1.0,28011002,CAN,MB,Winnipeg,24.77.44.140,56,96,,,65,110,HEMATURIA,BLADDER CANCER,"amyloidosis HEMATURIA,",56-10,96-104-10,amyloidosis BLADDER CANCER.,"Localized amyloidosis of the bladder is a rare cause of hematuria, which is often confused with bladder cancer.",56,96 104,56,96,65,110,-1,RO-disease_may_have_finding,902626,"Localized amyloidosis of the bladder is a rare cause of hematuria, which is often confused with bladder cancer",hematuria,bladder cancer
503545425,7/16/2014 20:31:46,,1324462953,7/16/2014 20:31:26,clixsense,1.0,24896327,GBR,V2,Glasgow,94.2.231.4,170,96,,,178,112,FLUORIDE,DENTAL FLUOROSIS,FLUORIDE,170,96-103,DENTAL FLUOROSIS,"Recent studies indicate, however, that the prevalence and, to a lesser extent, the intensity of dental fluorosis have increased in schoolchildren in both fluoridated and fluoride-deficient areas.",170,96 103,170,96,178,112,-1,RO-has_causative_agent,903698,"Recent studies indicate, however, that the prevalence and, to a lesser extent, the intensity of dental fluorosis have increased in schoolchildren in both fluoridated and fluoride-deficient areas",fluoride,dental fluorosis
503545425,7/16/2014 20:32:47,,1324463359,7/16/2014 20:32:33,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,170,96,,,178,112,FLUORIDE,DENTAL FLUOROSIS,FLUORIDE deficient areas.,170-179-189,96-103,DENTAL FLUOROSIS,"Recent studies indicate, however, that the prevalence and, to a lesser extent, the intensity of dental fluorosis have increased in schoolchildren in both fluoridated and fluoride-deficient areas.",170,96 103,170,96,178,112,-1,RO-has_causative_agent,903698,"Recent studies indicate, however, that the prevalence and, to a lesser extent, the intensity of dental fluorosis have increased in schoolchildren in both fluoridated and fluoride-deficient areas",fluoride,dental fluorosis
503545425,7/16/2014 20:38:07,,1324465448,7/16/2014 20:38:04,clixsense,1.0,6610277,CAN,ON,Oshawa,174.117.79.122,170,96,,,178,112,FLUORIDE,DENTAL FLUOROSIS,both fluoridated and FLUORIDE deficient areas.,149-154-166-170-179-189,79-83-93-96-103-113-118-128,the intensity of DENTAL FLUOROSIS have increased in,"Recent studies indicate, however, that the prevalence and, to a lesser extent, the intensity of dental fluorosis have increased in schoolchildren in both fluoridated and fluoride-deficient areas.",170,96 103,170,96,178,112,-1,RO-has_causative_agent,903698,"Recent studies indicate, however, that the prevalence and, to a lesser extent, the intensity of dental fluorosis have increased in schoolchildren in both fluoridated and fluoride-deficient areas",fluoride,dental fluorosis
503545425,7/16/2014 20:41:16,,1324466784,7/16/2014 20:41:14,coinworker,1.0,28394550,USA,PA,Marcus Hook,71.175.96.184,170,96,,,178,112,FLUORIDE,DENTAL FLUOROSIS,both fluoridated and FLUORIDE deficient areas.,149-154-166-170-179-189,79-83-93-96-103-113-118-128,the intensity of DENTAL FLUOROSIS have increased in,"Recent studies indicate, however, that the prevalence and, to a lesser extent, the intensity of dental fluorosis have increased in schoolchildren in both fluoridated and fluoride-deficient areas.",170,96 103,170,96,178,112,-1,RO-has_causative_agent,903698,"Recent studies indicate, however, that the prevalence and, to a lesser extent, the intensity of dental fluorosis have increased in schoolchildren in both fluoridated and fluoride-deficient areas",fluoride,dental fluorosis
503545425,7/16/2014 20:41:50,,1324467026,7/16/2014 20:41:37,instagc,1.0,13763729,USA,"","",75.182.89.225,170,96,,,178,112,FLUORIDE,DENTAL FLUOROSIS,FLUORIDE deficient,170-179,96-103,DENTAL FLUOROSIS,"Recent studies indicate, however, that the prevalence and, to a lesser extent, the intensity of dental fluorosis have increased in schoolchildren in both fluoridated and fluoride-deficient areas.",170,96 103,170,96,178,112,-1,RO-has_causative_agent,903698,"Recent studies indicate, however, that the prevalence and, to a lesser extent, the intensity of dental fluorosis have increased in schoolchildren in both fluoridated and fluoride-deficient areas",fluoride,dental fluorosis
503545425,7/16/2014 20:43:43,,1324467653,7/16/2014 20:43:33,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,170,96,,,178,112,FLUORIDE,DENTAL FLUOROSIS,both fluoridated and FLUORIDE deficient areas.,149-154-166-170-179-189,79-83-93-96-103-113-118-128,the intensity of DENTAL FLUOROSIS have increased in,"Recent studies indicate, however, that the prevalence and, to a lesser extent, the intensity of dental fluorosis have increased in schoolchildren in both fluoridated and fluoride-deficient areas.",170,96 103,170,96,178,112,-1,RO-has_causative_agent,903698,"Recent studies indicate, however, that the prevalence and, to a lesser extent, the intensity of dental fluorosis have increased in schoolchildren in both fluoridated and fluoride-deficient areas",fluoride,dental fluorosis
503545425,7/16/2014 20:44:44,,1324468051,7/16/2014 20:44:23,prodege,1.0,9997387,USA,CO,Colorado Springs,75.70.112.31,170,96,,,178,112,FLUORIDE,DENTAL FLUOROSIS,dental fluorosis FLUORIDE deficient,96-103-170-179,96-103-113-154-179-170,DENTAL FLUOROSIS have fluoridated fluoride deficient,"Recent studies indicate, however, that the prevalence and, to a lesser extent, the intensity of dental fluorosis have increased in schoolchildren in both fluoridated and fluoride-deficient areas.",170,96 103,170,96,178,112,-1,RO-has_causative_agent,903698,"Recent studies indicate, however, that the prevalence and, to a lesser extent, the intensity of dental fluorosis have increased in schoolchildren in both fluoridated and fluoride-deficient areas",fluoride,dental fluorosis
503545425,7/16/2014 20:46:09,,1324468674,7/16/2014 20:46:06,prodege,1.0,26325260,GBR,"","",79.64.25.64,170,96,,,178,112,FLUORIDE,DENTAL FLUOROSIS,both fluoridated and FLUORIDE deficient areas.,149-154-166-170-179-189,79-83-93-96-103-113-118-128,the intensity of DENTAL FLUOROSIS have increased in,"Recent studies indicate, however, that the prevalence and, to a lesser extent, the intensity of dental fluorosis have increased in schoolchildren in both fluoridated and fluoride-deficient areas.",170,96 103,170,96,178,112,-1,RO-has_causative_agent,903698,"Recent studies indicate, however, that the prevalence and, to a lesser extent, the intensity of dental fluorosis have increased in schoolchildren in both fluoridated and fluoride-deficient areas",fluoride,dental fluorosis
503545425,7/16/2014 20:47:39,,1324469323,7/16/2014 20:47:20,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,170,96,,,178,112,FLUORIDE,DENTAL FLUOROSIS,FLUORIDE,170,96-103,DENTAL FLUOROSIS,"Recent studies indicate, however, that the prevalence and, to a lesser extent, the intensity of dental fluorosis have increased in schoolchildren in both fluoridated and fluoride-deficient areas.",170,96 103,170,96,178,112,-1,RO-has_causative_agent,903698,"Recent studies indicate, however, that the prevalence and, to a lesser extent, the intensity of dental fluorosis have increased in schoolchildren in both fluoridated and fluoride-deficient areas",fluoride,dental fluorosis
503545425,7/16/2014 20:49:08,,1324470045,7/16/2014 20:48:35,eup_slw,1.0,28011002,CAN,MB,Winnipeg,24.77.44.140,170,96,,,178,112,FLUORIDE,DENTAL FLUOROSIS,FLUORIDE,170,96-103,DENTAL FLUOROSIS,"Recent studies indicate, however, that the prevalence and, to a lesser extent, the intensity of dental fluorosis have increased in schoolchildren in both fluoridated and fluoride-deficient areas.",170,96 103,170,96,178,112,-1,RO-has_causative_agent,903698,"Recent studies indicate, however, that the prevalence and, to a lesser extent, the intensity of dental fluorosis have increased in schoolchildren in both fluoridated and fluoride-deficient areas",fluoride,dental fluorosis
503545426,7/16/2014 20:32:49,,1324463368,7/16/2014 20:32:31,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,169,122,,,177,132,ASBESTOS,ASBESTOSIS,ASBESTOS associated fibrosis,169-178-189,122,ASBESTOSIS,Proceesing from the epidemiologic survey higher risk of malignant neoplasms of the lungs was established in patients with asbestosis in comparison with those exposed to asbestos-associated fibrosis were studied in 110 patients.,169,122,169,122,177,132,-1,RO-has_causative_agent,903974,Proceesing from the epidemiologic survey higher risk of malignant neoplasms of the lungs was established in patients with asbestosis in comparison with those exposed to asbestos-associated fibrosis were studied in 110 patients,asbestos,asbestosis
503545426,7/16/2014 20:33:33,,1324463605,7/16/2014 20:32:56,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,169,122,,,177,132,ASBESTOS,ASBESTOSIS,ASBESTOS - associated fibrosis,169-177-178-189,122,ASBESTOSIS,Proceesing from the epidemiologic survey higher risk of malignant neoplasms of the lungs was established in patients with asbestosis in comparison with those exposed to asbestos-associated fibrosis were studied in 110 patients.,169,122,169,122,177,132,-1,RO-has_causative_agent,903974,Proceesing from the epidemiologic survey higher risk of malignant neoplasms of the lungs was established in patients with asbestosis in comparison with those exposed to asbestos-associated fibrosis were studied in 110 patients,asbestos,asbestosis
503545426,7/16/2014 20:36:16,,1324464727,7/16/2014 20:36:02,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,169,122,,,177,132,ASBESTOS,ASBESTOSIS,ASBESTOS,169,122,ASBESTOSIS,Proceesing from the epidemiologic survey higher risk of malignant neoplasms of the lungs was established in patients with asbestosis in comparison with those exposed to asbestos-associated fibrosis were studied in 110 patients.,169,122,169,122,177,132,-1,RO-has_causative_agent,903974,Proceesing from the epidemiologic survey higher risk of malignant neoplasms of the lungs was established in patients with asbestosis in comparison with those exposed to asbestos-associated fibrosis were studied in 110 patients,asbestos,asbestosis
503545426,7/16/2014 20:42:17,,1324467160,7/16/2014 20:42:14,coinworker,1.0,28394550,USA,PA,Marcus Hook,71.175.96.184,169,122,,,177,132,ASBESTOS,ASBESTOSIS,those exposed to ASBESTOS associated fibrosis were,152-158-166-169-178-189-198,105-108-117-122-133-136-147,in patients with ASBESTOSIS in comparison with,Proceesing from the epidemiologic survey higher risk of malignant neoplasms of the lungs was established in patients with asbestosis in comparison with those exposed to asbestos-associated fibrosis were studied in 110 patients.,169,122,169,122,177,132,-1,RO-has_causative_agent,903974,Proceesing from the epidemiologic survey higher risk of malignant neoplasms of the lungs was established in patients with asbestosis in comparison with those exposed to asbestos-associated fibrosis were studied in 110 patients,asbestos,asbestosis
503545426,7/16/2014 20:42:51,,1324467345,7/16/2014 20:42:49,bitcoinget,1.0,24792414,USA,"","",166.181.81.55,169,122,,,177,132,ASBESTOS,ASBESTOSIS,those exposed to ASBESTOS associated fibrosis were,152-158-166-169-178-189-198,105-108-117-122-133-136-147,in patients with ASBESTOSIS in comparison with,Proceesing from the epidemiologic survey higher risk of malignant neoplasms of the lungs was established in patients with asbestosis in comparison with those exposed to asbestos-associated fibrosis were studied in 110 patients.,169,122,169,122,177,132,-1,RO-has_causative_agent,903974,Proceesing from the epidemiologic survey higher risk of malignant neoplasms of the lungs was established in patients with asbestosis in comparison with those exposed to asbestos-associated fibrosis were studied in 110 patients,asbestos,asbestosis
503545426,7/16/2014 20:44:11,,1324467830,7/16/2014 20:44:01,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,169,122,,,177,132,ASBESTOS,ASBESTOSIS,those exposed to ASBESTOS associated fibrosis were,152-158-166-169-178-189-198,105-108-117-122-133-136-147,in patients with ASBESTOSIS in comparison with,Proceesing from the epidemiologic survey higher risk of malignant neoplasms of the lungs was established in patients with asbestosis in comparison with those exposed to asbestos-associated fibrosis were studied in 110 patients.,169,122,169,122,177,132,-1,RO-has_causative_agent,903974,Proceesing from the epidemiologic survey higher risk of malignant neoplasms of the lungs was established in patients with asbestosis in comparison with those exposed to asbestos-associated fibrosis were studied in 110 patients,asbestos,asbestosis
503545426,7/16/2014 20:44:42,,1324468045,7/16/2014 20:44:19,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,169,122,,,177,132,ASBESTOS,ASBESTOSIS,ASBESTOS,169,122,ASBESTOSIS,Proceesing from the epidemiologic survey higher risk of malignant neoplasms of the lungs was established in patients with asbestosis in comparison with those exposed to asbestos-associated fibrosis were studied in 110 patients.,169,122,169,122,177,132,-1,RO-has_causative_agent,903974,Proceesing from the epidemiologic survey higher risk of malignant neoplasms of the lungs was established in patients with asbestosis in comparison with those exposed to asbestos-associated fibrosis were studied in 110 patients,asbestos,asbestosis
503545426,7/16/2014 20:45:34,,1324468368,7/16/2014 20:45:04,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,169,122,,,177,132,ASBESTOS,ASBESTOSIS,ASBESTOS associated fibrosis,169-178-189,122,ASBESTOSIS,Proceesing from the epidemiologic survey higher risk of malignant neoplasms of the lungs was established in patients with asbestosis in comparison with those exposed to asbestos-associated fibrosis were studied in 110 patients.,169,122,169,122,177,132,-1,RO-has_causative_agent,903974,Proceesing from the epidemiologic survey higher risk of malignant neoplasms of the lungs was established in patients with asbestosis in comparison with those exposed to asbestos-associated fibrosis were studied in 110 patients,asbestos,asbestosis
503545426,7/16/2014 20:52:47,,1324471580,7/16/2014 20:52:27,eup_slw,1.0,28011002,CAN,MB,Winnipeg,24.77.44.140,169,122,,,177,132,ASBESTOS,ASBESTOSIS,ASBESTOS,169,122,ASBESTOSIS,Proceesing from the epidemiologic survey higher risk of malignant neoplasms of the lungs was established in patients with asbestosis in comparison with those exposed to asbestos-associated fibrosis were studied in 110 patients.,169,122,169,122,177,132,-1,RO-has_causative_agent,903974,Proceesing from the epidemiologic survey higher risk of malignant neoplasms of the lungs was established in patients with asbestosis in comparison with those exposed to asbestos-associated fibrosis were studied in 110 patients,asbestos,asbestosis
503545426,7/16/2014 20:53:05,,1324471646,7/16/2014 20:52:40,prodege,1.0,22360212,GBR,I1,Luton,82.6.41.191,169,122,,,177,132,ASBESTOS,ASBESTOSIS,ASBESTOS associated fibrosis,169-178-189,122,ASBESTOSIS,Proceesing from the epidemiologic survey higher risk of malignant neoplasms of the lungs was established in patients with asbestosis in comparison with those exposed to asbestos-associated fibrosis were studied in 110 patients.,169,122,169,122,177,132,-1,RO-has_causative_agent,903974,Proceesing from the epidemiologic survey higher risk of malignant neoplasms of the lungs was established in patients with asbestosis in comparison with those exposed to asbestos-associated fibrosis were studied in 110 patients,asbestos,asbestosis
503545427,7/16/2014 20:36:34,,1324464870,7/16/2014 20:36:25,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,77,105,,,90,113,VARIOLA VIRUS,SMALLPOX,"VARIOLA VIRUS,",77-85,105,SMALLPOX.,"Each comparison gave the same conclusion: CMPV is the closest known virus to variola virus, the cause of smallpox.",77 85,105,77,105,90,113,1,RO-has_causative_agent,903571,"Each comparison gave the same conclusion: CMPV is the closest known virus to variola virus, the cause of smallpox",variola virus,smallpox
503545427,7/16/2014 20:37:34,,1324465239,7/16/2014 20:37:32,clixsense,1.0,6610277,CAN,ON,Oshawa,174.117.79.122,77,105,,,90,113,VARIOLA VIRUS,SMALLPOX,"known virus to VARIOLA VIRUS, the cause of",62-68-74-77-85-92-96-102,92-96-102-105,the cause of SMALLPOX.,"Each comparison gave the same conclusion: CMPV is the closest known virus to variola virus, the cause of smallpox.",77 85,105,77,105,90,113,1,RO-has_causative_agent,903571,"Each comparison gave the same conclusion: CMPV is the closest known virus to variola virus, the cause of smallpox",variola virus,smallpox
503545427,7/16/2014 20:38:17,,1324465513,7/16/2014 20:38:07,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,77,105,,,90,113,VARIOLA VIRUS,SMALLPOX,"VARIOLA VIRUS,",77-85,105,SMALLPOX.,"Each comparison gave the same conclusion: CMPV is the closest known virus to variola virus, the cause of smallpox.",77 85,105,77,105,90,113,1,RO-has_causative_agent,903571,"Each comparison gave the same conclusion: CMPV is the closest known virus to variola virus, the cause of smallpox",variola virus,smallpox
503545427,7/16/2014 20:39:00,,1324465856,7/16/2014 20:38:47,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,77,105,,,90,113,VARIOLA VIRUS,SMALLPOX,"VARIOLA VIRUS,",77-85,105,SMALLPOX.,"Each comparison gave the same conclusion: CMPV is the closest known virus to variola virus, the cause of smallpox.",77 85,105,77,105,90,113,1,RO-has_causative_agent,903571,"Each comparison gave the same conclusion: CMPV is the closest known virus to variola virus, the cause of smallpox",variola virus,smallpox
503545427,7/16/2014 20:41:47,,1324467007,7/16/2014 20:41:46,coinworker,1.0,28394550,USA,PA,Marcus Hook,71.175.96.184,77,105,,,90,113,VARIOLA VIRUS,SMALLPOX,"known virus to VARIOLA VIRUS, the cause of",62-68-74-77-85-92-96-102,92-96-102-105,the cause of SMALLPOX.,"Each comparison gave the same conclusion: CMPV is the closest known virus to variola virus, the cause of smallpox.",77 85,105,77,105,90,113,1,RO-has_causative_agent,903571,"Each comparison gave the same conclusion: CMPV is the closest known virus to variola virus, the cause of smallpox",variola virus,smallpox
503545427,7/16/2014 20:43:15,,1324467493,7/16/2014 20:43:12,bitcoinget,1.0,24792414,USA,"","",166.181.81.55,77,105,,,90,113,VARIOLA VIRUS,SMALLPOX,"known virus to VARIOLA VIRUS, the cause of",62-68-74-77-85-92-96-102,92-96-102-105,the cause of SMALLPOX.,"Each comparison gave the same conclusion: CMPV is the closest known virus to variola virus, the cause of smallpox.",77 85,105,77,105,90,113,1,RO-has_causative_agent,903571,"Each comparison gave the same conclusion: CMPV is the closest known virus to variola virus, the cause of smallpox",variola virus,smallpox
503545427,7/16/2014 20:44:24,,1324467925,7/16/2014 20:44:14,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,77,105,,,90,113,VARIOLA VIRUS,SMALLPOX,"VARIOLA VIRUS,",77-85,105,SMALLPOX.,"Each comparison gave the same conclusion: CMPV is the closest known virus to variola virus, the cause of smallpox.",77 85,105,77,105,90,113,1,RO-has_causative_agent,903571,"Each comparison gave the same conclusion: CMPV is the closest known virus to variola virus, the cause of smallpox",variola virus,smallpox
503545427,7/16/2014 20:45:09,,1324468199,7/16/2014 20:45:01,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,77,105,,,90,113,VARIOLA VIRUS,SMALLPOX,"known virus to VARIOLA VIRUS, the cause of",62-68-74-77-85-92-96-102,92-96-102-105,the cause of SMALLPOX.,"Each comparison gave the same conclusion: CMPV is the closest known virus to variola virus, the cause of smallpox.",77 85,105,77,105,90,113,1,RO-has_causative_agent,903571,"Each comparison gave the same conclusion: CMPV is the closest known virus to variola virus, the cause of smallpox",variola virus,smallpox
503545427,7/16/2014 20:45:55,,1324468510,7/16/2014 20:45:50,prodege,1.0,26325260,GBR,"","",79.64.25.64,77,105,,,90,113,VARIOLA VIRUS,SMALLPOX,"known virus to VARIOLA VIRUS, the cause of",62-68-74-77-85-92-96-102,92-96-102-105,the cause of SMALLPOX.,"Each comparison gave the same conclusion: CMPV is the closest known virus to variola virus, the cause of smallpox.",77 85,105,77,105,90,113,1,RO-has_causative_agent,903571,"Each comparison gave the same conclusion: CMPV is the closest known virus to variola virus, the cause of smallpox",variola virus,smallpox
503545427,7/16/2014 20:47:28,,1324469243,7/16/2014 20:46:54,eup_slw,1.0,28011002,CAN,MB,Winnipeg,24.77.44.140,77,105,,,90,113,VARIOLA VIRUS,SMALLPOX,"CMPV VARIOLA VIRUS,",77-85-42,105-42,CMPV SMALLPOX.,"Each comparison gave the same conclusion: CMPV is the closest known virus to variola virus, the cause of smallpox.",77 85,105,77,105,90,113,1,RO-has_causative_agent,903571,"Each comparison gave the same conclusion: CMPV is the closest known virus to variola virus, the cause of smallpox",variola virus,smallpox
503545428,7/16/2014 20:36:49,,1324464969,7/16/2014 20:35:33,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,13,53,,,25,62,ASSOCIATIONS,ALLERGIES,clinical ASSOCIATIONS,4-13,53,ALLERGIES,The clinical associations of kiwi fruit allergy with allergies to pollens or latex are reviewed.,13,53,13,53,25,62,-1,RO-cause_of,900309,The clinical associations of kiwi fruit allergy with allergies to pollens or latex are reviewed,associations,allergies
503545428,7/16/2014 20:42:05,,1324467091,7/16/2014 20:41:48,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,13,53,,,25,62,ASSOCIATIONS,ALLERGIES,ASSOCIATIONS,13,53,ALLERGIES,The clinical associations of kiwi fruit allergy with allergies to pollens or latex are reviewed.,13,53,13,53,25,62,-1,RO-cause_of,900309,The clinical associations of kiwi fruit allergy with allergies to pollens or latex are reviewed,associations,allergies
503545428,7/16/2014 20:42:11,,1324467129,7/16/2014 20:42:09,coinworker,1.0,28394550,USA,PA,Marcus Hook,71.175.96.184,13,53,,,25,62,ASSOCIATIONS,ALLERGIES,The clinical ASSOCIATIONS of kiwi fruit,0-4-13-26-29-34,34-40-48-53-63-66-74,fruit allergy with ALLERGIES to pollens or,The clinical associations of kiwi fruit allergy with allergies to pollens or latex are reviewed.,13,53,13,53,25,62,-1,RO-cause_of,900309,The clinical associations of kiwi fruit allergy with allergies to pollens or latex are reviewed,associations,allergies
503545428,7/16/2014 20:42:43,,1324467310,7/16/2014 20:42:30,instagc,1.0,13763729,USA,"","",75.182.89.225,13,53,,,25,62,ASSOCIATIONS,ALLERGIES,ASSOCIATIONS,13,53,ALLERGIES,The clinical associations of kiwi fruit allergy with allergies to pollens or latex are reviewed.,13,53,13,53,25,62,-1,RO-cause_of,900309,The clinical associations of kiwi fruit allergy with allergies to pollens or latex are reviewed,associations,allergies
503545428,7/16/2014 20:42:59,,1324467399,7/16/2014 20:42:43,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,13,53,,,25,62,ASSOCIATIONS,ALLERGIES,ASSOCIATIONS,13,53,ALLERGIES,The clinical associations of kiwi fruit allergy with allergies to pollens or latex are reviewed.,13,53,13,53,25,62,-1,RO-cause_of,900309,The clinical associations of kiwi fruit allergy with allergies to pollens or latex are reviewed,associations,allergies
503545428,7/16/2014 20:43:02,,1324467434,7/16/2014 20:42:31,prodege,1.0,22360212,GBR,I1,Luton,82.6.41.191,13,53,,,25,62,ASSOCIATIONS,ALLERGIES,ASSOCIATIONS,13,53,ALLERGIES,The clinical associations of kiwi fruit allergy with allergies to pollens or latex are reviewed.,13,53,13,53,25,62,-1,RO-cause_of,900309,The clinical associations of kiwi fruit allergy with allergies to pollens or latex are reviewed,associations,allergies
503545428,7/16/2014 20:46:46,,1324468951,7/16/2014 20:46:43,prodege,1.0,26325260,GBR,"","",79.64.25.64,13,53,,,25,62,ASSOCIATIONS,ALLERGIES,The clinical ASSOCIATIONS of kiwi fruit,0-4-13-26-29-34,34-40-48-53-63-66-74,fruit allergy with ALLERGIES to pollens or,The clinical associations of kiwi fruit allergy with allergies to pollens or latex are reviewed.,13,53,13,53,25,62,-1,RO-cause_of,900309,The clinical associations of kiwi fruit allergy with allergies to pollens or latex are reviewed,associations,allergies
503545428,7/16/2014 20:48:16,,1324469647,7/16/2014 20:47:22,prodege,1.0,4968858,USA,CA,Corona,99.44.120.153,13,53,,,25,62,ASSOCIATIONS,ALLERGIES,clinical ASSOCIATIONS,4-13,34-40-48-53-63-66-74-77,fruit allergy with ALLERGIES to pollens or latex,The clinical associations of kiwi fruit allergy with allergies to pollens or latex are reviewed.,13,53,13,53,25,62,-1,RO-cause_of,900309,The clinical associations of kiwi fruit allergy with allergies to pollens or latex are reviewed,associations,allergies
503545428,7/16/2014 20:50:06,,1324470454,7/16/2014 20:49:37,eup_slw,1.0,28011002,CAN,MB,Winnipeg,24.77.44.140,13,53,,,25,62,ASSOCIATIONS,ALLERGIES,ASSOCIATIONS,13,53,ALLERGIES,The clinical associations of kiwi fruit allergy with allergies to pollens or latex are reviewed.,13,53,13,53,25,62,-1,RO-cause_of,900309,The clinical associations of kiwi fruit allergy with allergies to pollens or latex are reviewed,associations,allergies
503545428,7/16/2014 20:50:14,,1324470500,7/16/2014 20:50:00,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,13,53,,,25,62,ASSOCIATIONS,ALLERGIES,clinical ASSOCIATIONS,4-13,53,ALLERGIES,The clinical associations of kiwi fruit allergy with allergies to pollens or latex are reviewed.,13,53,13,53,25,62,-1,RO-cause_of,900309,The clinical associations of kiwi fruit allergy with allergies to pollens or latex are reviewed,associations,allergies
